Robert G. Gish, MD Full Curriculum Vitae & Biography - Updated January 2015

Table of Contents Page GOOGLE CITATION & IMPACT SCORE

A. GOOGLE CITATION & IMPACT SCORE .................................................................. 1

PROFESSIONAL INFORMATION A. LICENSURE & CERTIFICATIONS ............................................................................ 1 B. EDUCATION ............................................................................................................. 2

C. POST GRADUATE EDUCATION .............................................................................. 2 D. HONORS ................................................................................................................... 2 E. NATIONAL FOUNDATION HONORS ........................................................................ 2 F. SOCIETY MEMBERSHIPS ........................................................................................ 2 G. LANGUAGES ............................................................................................................ 2 BIOGRAPHY ...........................................................................................................................3-6

A. PERSONAL STATEMENT ......................................................................................... 5 B. EXPANDED RESEARCH .......................................................................................... 5

C. PRESS RELEASE - HEPATITIS B FOUNDATION .................................................... 6 D. FACULTY APPOINTMENTS ..................................................................................7-8 E. EMPLOYMENT AND STAFF POSITIONS ............................................................ 8-10 F. STATE OF CALIFORNIA CONSULTANT POSITIONS ............................................ 10 G. CONSULTANT POSITIONS .................................................................................... 11 H. BUSINESS POSITIONS .......................................................................................... 11 I. RESEARCH SUPPORT...................................................................................... 12-30 J. UCSD RESEARCH / ADVISORY ....................................................................... 31-32 K. COINVESTIGATOR: GASTROINTESTINAL TRIALS ......................................... 32-33

TEACHING ACTIVITIES ...................................................................................................... 34-35 B. COMMITTEES .................................................................................................... 36-41 C. BOARD ACTIVITIES ........................................................................................... 42-44 D. EDITORIAL ACTIVITIES .......................................................................................... 45 E. MENTEE LIST .................................................................................................... 46-48 F. CLINICAL EXAM SESSIONS ................................................................................... 48 G. FACULTY REVIEW AND ASSESSMENT ................................................................ 48 PUBLICATIONS A. PEER REVIEW ORIGINAL PUBLICATIONS ...................................................... 49-64 B. SUBMITTED FOR PUBLICATION ...................................................................... 65-67 C. REVIEW ARTICLES ........................................................................................... 68-71 D. PUBLIC POLICY ORIGINAL MANUSCRIPT ............................................................ 71 E. NEWLETTERS......................................................................................................... 72 F. BOOK CHAPTER & EDITORIALS....................................................................... 72-76 G. CASE REPORTS & LETTER TO THE EDITORS .................................................... 76 H. EDITOR / REVIEWER ........................................................................................ 78-81 I. UCSD ...................................................................................................................... 82 J. ABSTRACTS ..................................................................................................... 83-115

i

............................................................................................................................................ Page OTHER CME PRESENTATIONS AND PUBLICATIONS ............................................................... 116-122 FEDERAL AND STATE HEARINGS ....................................................................................... 123 EDUCATIONAL EVENTS ....................................................................................................... 124 SPECIAL COURSES ATTENDED ................................................................................... 124-125 COMMUNITY SERVICE and MEDIA APPEARANCES .................................................... 126-134 INTERNATIONAL COMMUNITY PROGRAMS ....................................................................... 135 INTERNET SITES AND PUBLICATIONS ............................................................................... 136 INVITED LECTURES: NATIONAL AND INTERNATIONAL .............................................. 137-147 INVITED LECTURES: REGIONAL ................................................................................... 147-199 AWARDS, CERTIFICATES, AND HONORS .................................................................... 200-201 CONSULTANT: ACKNOWLEDGEMENT AS A CONTRIBUTOR / CME ACTIVITIES ...... 202-221 CHARITABLE AND PHILANTHROPIC ACTIVITIES ............................................................... 222 HISTORICAL PRACTICE ADDRESSES AND OUTREACH SITES ................................. 223-224 RESEARCH SUMMARY .................................................................................................. 225-226 FORMER PRACTICE LEADERSHIP ...................................................................................... 227 DISCLOSURES ...................................................................................................................... 228 PHARMACEUTICAL COMPANY RELATIONSHIPS ............................................................... 228 SPEAKERS BUREAU ............................................................................................................. 228

ii

Curriculum Vitae

ROBERT G. GISH, M.D.

GOOGLE CITATION & IMPACT SCORE

August 20 2014: Google Citations: 11,423 All-Time H-Index Score: 55 Impact 10-index Score: 135

PROFESSIONAL INFORMATION

8/31/2013 – Present Robert G. Gish MD, Principal Robert G. Gish, Consultants LLC 6022 La Jolla Mesa Drive La Jolla, California 92037 Cell phone: 1 858 229 9865 Fax: 1 858 886 7093 Email: [email protected] Web address: robertgish.com LLC EIN: Available upon request

10/1/2013 – Present (Adjunct) Professor of Clinical Medicine University of Nevada, Las Vegas

10/1/2013 – Present Senior Medical Director St. Josephs Hospital and Medical Center Phoenix, Arizona

1/31/2014 – Present Medical Director Hepatitis B Foundation http://hepb.org/index.html

5/1/2014 – Present Clincial Professor of Medicine (Consultant) Stanford Hospital and Medical Center Stanford, California

PERSONAL INFORMATION

Date of Birth: September 18, 1955 SSN: Available upon request Marital Status: Married Home Address: San Diego, California Birthplace: Chicago, Illinois Citizenship: U.S.A.

tel:1%20858%20229%209865

tel:1%20858%20886%207093

mailto:[email protected]

http://robertgish.com/

Curriculum Vitae

ROBERT G. GISH, M.D. 2

LICENSURE

State of California, G-045632

State of Nevada, 772112 State of Arizona, 48551 DEA number: Available upon request

BOARD CERTIFICATION

1984 Internal Medicine – ABIM 90181 1987 Gastroenterology – ABIM 90181 (MOC active) 2007 CAQ Liver Transplantation – ABIM 90181

EDUCATION

9/1/1973 – 6/15/1977 Pharmaceutical Sciences University of Kansas Lawrence, Kansas 9/1/1977 – 6/15/1980 Medical Doctor University of Kansas School of Medicine Kansas City, Kansas

POSTGRADUATE EDUCATION

6/1/1980 – 5/30/1981 Internship in Internal Medicine University of California, San Diego San Diego, California 6/1/1981 – 6/30/1983 Residency in Internal Medicine University of California, San Diego San Diego, California 7/1/1984 – 5/30/1988 Fellowship in Gastroenterology and Hepatology University of California, Los Angeles Los Angeles, California

NATIONAL HONORS

Alpha Omega Alpha

NATIONAL FOUNDATION HONORS

2002 Salute to Excellence: American Liver Foundation, 2/9/2002

Curriculum Vitae


SOCIETY MEMBERSHIPS

American Association for the Study of Liver Disease American Gastroenterological Association American Society of Transplant Physicians American College of Physicians Asia Pacific Association for the Study of the Liver California Medical Association (25 years) European Association for the Study of the Liver International Liver Cancer Association American Liver Foundation American Transplant Society International Coalition of Hepatology Educators San Diego County Medical Society (25 years)

LANGUAGES

English Spanish Vietnamese French

Curriculum Vitae ROBERT G. GISH, M.D. 4

BIOGRAPHY

Dr. Robert G. Gish began his medical training in 1974 when he was enrolled into the Pharmacy School at the University of Kansas. He transferred to the University of Kansas Medical School in 1977 and finished his MD degree in 1980. Dr. Gish went on to complete a 3 year Internal Medicine residency at the University of California, San Diego and a 4 year Gastroenterology and Hepatology fellowship at the University of California Los Angeles during which time he was awarded the NIH Physician Scientist Award to study cal-cium signaling in liver cells. After completing his training, Dr. Gish moved to San Francisco and took a position at the California Pacific Medical Center (formerly known as Pacific Presbyterian Hospital, Presbyterian, Stanford Hospital, and Cooper-Lane). He became the Co-Medical Director of the Liver Transplant Program in 1988 and then the Medical Director of the Liver Transplant Program in 1994. In that role he developed an outreach program that built 15 clinics that eventually served over 35,000 patients in the Northern California and Nevada regions, and made the CPMC a leading liver transplant center in the nation for both volume and quality . Dr. Gish has had and continues to have an active research program in viral hepatitis (HBV,HCV, HDV and HEV) liver transplant, bioartificial liver, and public policy especially related to liver can-cer, liver transplantation and viral hepatitis. Although his primary research focus is clinical re-search, he frequently collaborates with basic scientists in his research activities. He has published more than 600 original articles, review articles, abstracts and book chapters with a Google Scholar score of over 45 . Dr. Gish is also actively involved in numerous professional societies, and is a long-term member of the American Association for the Study of Liver Disease, European Association for the Study of Liver Disease, Asian Pacific Association for the Study of the Liver, and the American Society of Transplant Physicians. He is a fellow of both the American College of Physicians and a long-term member of the Ameri-can Association for the Study of Liver Disease since 1984 and is now a Fellow of the AASLD (as part of the first group to enter the AASLD fellow program 2014). Dr. Gish has served on the edi-torial boards of American Journal of Gastroenterology, Journal of Hepatology, Digestive Diseases and Sciences, Gastroenterology, Hepatology, Liver Transplantation and Surgery, and Journal of Viral Hepatitis. He has co-authored a public health policy for liver health in Vietnam and is also assisting with the development of health care policies in Armenia and the Philippines. In December 2010, Dr. Gish moved to San Diego to join the faculty of UCSD as a Clinical Profes-sor of Medicine, Section Chief of Hepatology, and Director of the Center of Excellence for Hepato-biliary Disease and Abdominal Transplantation (C.H.A.T.). In September of 2013, Dr. Gish left UCSD to form a consulting company, Robert G. Gish Consultants LLC to provide consultative support to Hepatology Centers and Liver Transplant Programs who wish to start or grow their programs through pathways of quality and optimal pa-tient care that is integrated with research and education. In September of 2013, Dr Gish joined Dr Manch at St Josephs Hospital and Medical Center to start a liver and liver transplant center which continues to be an ogoing venture. On April 1, 2014, Dr Gish joined the Stanford

BIOGRAPHY: Continued

Curriculum Vitae


Department of Medicine, Division of Gastroenterology and Hepatology and Liver Transplant Ser-vice Line as a Staff Physician with major roles in inreach and outreach as well as program devel-opment. Over the years of 2012 to 2014, Dr Gish has been and continues to be very active with the National Viral Hepatitis Round Table (NVHR) a patient and community advocacy non-profit organization. In February of 2014, Dr Gish joined the Hepatitis B Foundation, (HBF) as their Med-ical Director to lend his policy, advocacy and clinical science skills to their armamentarium. Today, Dr. Gish is also a Clinical Professor of Medicine (Adjunct) at the University of Nevada in Las Vegas where he continues to teach and is a senior consultant at St Joseph’s Medical Center in Phoenix. And Clinical Professor of Medicine at Stanford University (Consultant). LIVER CENTERS AND LIVER TRANSPLANT PROGRAMS Dr. Gish became the Co-Medical Director of the Liver Transplant Program at the California Pacific Medical Center in 1988. He developed an outreach program that now serves over 35,000 patients in Northern California and Nevada, making CPMC a leading liver transplant center. Dr. Gish joined the faculty of University of California San Diego in several capacities, including Director of the Center for Hepatobiliary Disease and Abdominal Transplantation. He also became Director of Clinical Hepatology at UCSD in 2010. His research on Regional Review Boards may also change public policies on liver transplants in the United States. This research supports the replacement of the current RRB system with a national review board that uses clinical expertise to assign priorities. The goal of this system is to allocate organs equitably while improving compliance with the HHS Final Rule. His appointment with the Liver Transplant Program and Department of Med-icine at Stanford University began on April 30, 2014. RESEARCH Dr. Gish’s pharmaceutical research includes a 2011 Phase III study on the effects of BI 201335, pegylated interferon-a and ribavirin on patients infected with genotype 1 chronic hepatitis C. He is also the principle investigator in an ongoing study on screening for viral hepatitis and its eco-nomic effects on healthcare. Another study currently being conducted by Dr. Gish involves the analysis of liver patients at UCSD. Dr. Gish was the principle investigator in a study that was started in 2012 to investigate the effects of PSI-352938, PSE-7977 and Ribavirin in patients with Chronic HCV. He is also currently inves-tigating the challenges of educating Asians in San Diego County on Hepatitis B in a study that began in 2012. Dr. Gish was an investigator in studies that led to the development of tests for HBV and HCV and most recently a 2005 study on DNA HBV genotyping and molecular profiling in newly recruited, HBV and HCV patients. He was also an investigator in a 2006 study that used molecular signa-tures to predict interferon response in patients infected with Hepatitis C.

Curriculum Vitae


BIOGRAPHY: Continued HEALTH POLICY AND PATIENT ADVOCACY Dr. Gish’s research now includes co-leading a research program with Arrowhead Pharmaceuti-cals on iRNA treatment of HBV infection. Dr. Gish has been involved with patient care and patient advocacy groups dating back to 1988 when he became involved with the American Liver Foundation. Since that time, he has been active with a number of organizations including the National Viral Hepatitis Roundtable, Viral Hep-atitis Action Coalition, the Fair Foundation, Center for Eradication of Viral Hepatitis/Asia Pacific Organization (CEVHAP), HEP- DART, World Health Organization, Centers for Disease Control, Hepatitis B Free (San Francisco and San Diego), Hepatitis B Foundation, Hepatitis C Caring Am-bassadors, Vietnam Viral Hepatitis Foundation (VVHF), and Hepatitis Foundation for Vietnam.

Dr. Gish’s international advocacy career focuses on public policy in Vietnam, Philippines, and Armenia. His team wrote a white paper on Health Care and Liver Health in Vietnam that was published in a peer-reviewed publication. Additional projects in Vietnam and the Philippines in-clude protocols that advance screening for viral hepatitis and linkage to care, as well as global liver health issues including obesity, fatty liver, and alcohol induced liver disease. The newest addition to Dr. Gish’s global health policy work is in Armenia, where he is developing a white paper for that country’s 5-year Liver Health Policy. PERSONAL STATEMENT My clinical research and studies focus on viral hepatitis, liver transplant, bioartificial liver, public policy especially related to liver transplantation and viral hepatitis. Clinical trials for a variety of antiviral therapies and new bioartificial livers systems will continue to be a major focus of my practice. We will use databases to help uncover associations between liver cancer and certain cancer biomarkers. In addition we will be building a multidisciplinary liver cancer program and will integrate models of HCC signaling into our program. My background includes training in viral hepatitis clinical trials and liver cancer trials. I plan to have a focus on biomarkers for liver cancer to help guide treatment decisions and therapies. I have 25 years of experience as a clinician and clinical investigator in the realm of liver disease, liver transplant and liver cancer. I do a variety of educational programs for Pharma including “promotional” talks that are highly regulated by the FDA and the Pharma Code: these funds are all donated or expensed into research, education, policy, philanthropy and supporting international liver health care. EXPANDED RESEARCH Dr. Gish’s work focuses on the epidemiology of liver disease, biomarkers for liver disease and multi-targeted therapies for liver cancer such as protein kinase inhibitors, fibroblast growth factors and iRNA technologies to treat viral hepatitis. His research also includes the diagnosis and treat-ment of liver failure, liver transplantation, and viral hepatitis, both B and C variants. Recent clinical studies have focused on the Hepatitis B Virus within the Asian population at large as well as exosomes, liver failure, bioartifical livers and international health policy.

Curriculum Vitae


BIOGRAPHY: Continued PRESS RELEASE – February 2014 Hepatitis B Foundation Welcomes Dr. Robert Gish as Medical Director Renowned leader in the field of liver disease takes on new role leading advocacy and research DOYLESTOWN, Pa. (February 2014) – The Hepatitis B Foundation (www.hepb.org), the only national nonprofit organization solely dedicated to finding a cure for hepatitis B, is pleased to announce that Robert G. Gish, M.D., became the foundation’s medical director on Jan. 30, 2014. An internationally renowned medical researcher in the field of viral hepatitis, Dr. Gish has made invaluable contributions to the understanding and treatment of hepatitis B, which is the world’s leading cause of liver cancer. A longtime supporter of the foundation’s mission and a member of the Scientific Advisory Board, Dr. Gish’s new role will further strengthen its research and advocacy efforts worldwide. “We are delighted to welcome Dr. Gish to our board,” said Dr. W. Thomas London, senior member emeritus of Fox Chase Cancer Center and vice president of the board of directors of the Hepatitis B Foundation. “He has long been a leader in the field and has extensive experience in the conduct of clinical trials of new drugs to combat chronic hepatitis B. His leader-ship as medical director will help us advance the treatment and prevent the severe consequences of this potentially deadly disease.” After receiving his medical degree in 1980, Dr. Gish quickly developed a keen interest in liver health, focusing his research on investigation of viral hepatitis B and C. He went on to become medical director of the liver transplant program at California Pacific Medical Center in 1994, developing an outreach program that eventually served more than 35,000 patients in northern California and Nevada and made the medical center a leading liver transplant center. Over the course of his career, Dr. Gish has published more than 600 original articles, abstracts and book chapters and more than 120 peer-reviewed publications. Today, he is a clinical professor of Medicine at the University of Nevada in Las Vegas, where he continues to teach, and is a senior consultant at St. Joseph’s Medical Center in Phoenix. In 2013, he formed Robert G. Gish Consultants LLC to support liver health and transplant programs with operations, outreach, compliance, financial planning and program development in the U.S. and Asia. “Dr. Gish’s background is a perfect fit for the work we do here at the Foundation and our Baruch S. Blumberg Institute,” said Dr. Timothy Block, president of the Hepatitis B Foundation and also a professor of Microbiology at Drexel University. “We are honored that Dr. Gish has agreed to be-come our medical director and look forward to many years of collaboration so we can finally put an end to this serious liver infection.” To learn more about Dr. Robert Gish, visit his website.

Curriculum Vitae


FACULTY APPOINTMENTS

* Please note: Some of the following dates are best estimates due to lack of complete historical documentation:

*7/1/1983 – 6/30/1984 Emergency Room Associate Claremont Hospital Claremont, California

6/1/1985 – 5/30/1988 Research Associate Division of Gastroenterology University of California, Los Angeles Los Angeles, California 9/11988 – 6/1/1993 Research Associate Medical Research Institute California Pacific Medical Center University of the Pacific San Francisco, California 9/1/1991 – 7/2/1996 Assistant Clinical Professor of Medicine University of California, Davis Sacramento, California *7/1/1991 – 6/30/1996 Valley Children's Hospital Liver Disease Program Fresno, California 7/1/1993 – 6/30/1998 Merced Community Hospital Family Medicine Program University of California, Davis Sacramento, California 7/1/1994 – 6/30/1998 Assistant Clinical Professor of Medicine University of Nevada, Reno Reno, Nevada 7/1/1998 – 6/30/2005 Associate Clinical Professor of Medicine University of Nevada, Reno Reno, Nevada 7/1/2005 – 6/30/2006 Clinical Professor of Medicine University of Nevada, Las Vegas, Nevada 8/11/988-7/30/1995 Co-Medical Director

The Liver Transplant Program California Pacific Medical Center San Francisco, California

Curriculum Vitae


FACULTY APPOINTMENTS: Continued

8/1/1995 – 1/1/2010 Medical Director of The Liver Transplant Program California Pacific Medical Center San Francisco, California 9/1/1996 – 6/1/1999 Assistant Clinical Professor of Medicine

University of California, San Francisco San Francisco, California 7/30/1999 – 6/30/2009 Associate Clinical Professor of Medicine University of California, San Francisco San Francisco, California 7/1/2009 – 8/30/2010 Clinical Professor of Medicine University of California, San Francisco San Francisco, California 9/1/2010 – 8/30/2013 Clinical Professor of Medicine University of California, School of Medicine San Diego, California 1/1/2014 – Present Clinical Professor, Department of Internal Medicine, Adjucnt University of Nevada School of Medicine, Las Vegas, Nevada 2014 – Present Clinical Professor of Medicine Stanford Hospital and Medical Center Stanford, CA

EMPLOYMENT AND STAFF POSITIONS

1975 – 1977 Research Associate McCollum Laboratories

University of Kansas Lawrence, Kansas 1982 – 1983 Per diem Physician Medicus Medical Group San Diego, California 1982 – 1983 Per diem Physician Kaiser Permanente San Diego, California

Curriculum Vitae


EMPLOYMENT AND STAFF POSITIONS: Continued

1982 – 1983 On call MD: Life Flight-Critical Air Transport San Diego, California 1983 – 1984 Per diem Physician Pioneer Memorial Hospital Brawley, California 1983 – 1984 Emergency Clinic and Medical Doctor at Clarmmont Hospital Industrial Medical Centers San Diego, California

1984 – 1986 Emergency Physician: Serra Memorial Hospital Emergency Medicine Sun Valley, California

1986 – 1988 Consultant

Sherman Oaks Community Hospital Sherman Oaks, California 1987 Consultant Phillip Edelman, M.D. Occupational Medicine Orange, California 1987 Consultant Washington Medical Center Culver City, California 1987 – 1988 Consultant Valley Presbyterian Van Nuys, California 1988 Staff Physician Oliveview Medical Center Sylmar, California

1988 Consultant West Hills Medical Center Conoga Park, California 1988 – 1989 Consultant Mt. Zion Medical Center San Francisco, California 1990 – 1991 Consultant Seton Medical Center Daly City, California

Curriculum Vitae



1990 – 1995 Consultant Valley Children's Hospital Fresno, California 1993 – 2006 Consultant Enloe Hospital, Chico, California

2002 – 2009 Consultant Sunrise Hospital Las Vegas, Nevada 1988 – 2010 Staff Physician California Pacific Medical Center San Francisco, California

2009 – 2010 Physician

St. Luke’s Hospital San Francisco, California

1991 – 2010 Consultant Highland Hospital Oakland, California 1996 – 2010 Consultant Medical Staff, Department of Medicine John Muir Medical Center Walnut Creek, California 1997 – 2006 Consultant Alta Bates Medical Center Medicine and Family Practice Berkeley, California

2003 – 2010 Physician Saint Mary’s Medical Center San Francisco, California

2010 – 2013 Medical Director of Center for Hepatobiliary Disease and Abdominal Transplantation (CHAT) Chief of Hepatology University of California, San Diego San Diego, California

2014 – Present Medical Director, Staff Physician Stanford Hospital and Medical Center Stanford, CA

Curriculum Vitae



2014 – Present Contractor, Best Doctors, Inc. Boston, MA

STATE OF CALIFORNIA CONSULTANT POSITIONS 1996 State of California Department of Corrections Infectious Disease Advisory Board CONSULTANT POSITIONS

2010 – Present Founding Member CEVHAP (Coalition to Eradicate Viral Hepatitis in Asia Pacific). Singapore

2012 – 2014 Advisory Board/Steering Committee, National Viral Hepatitis Roundtable

2013 – 2014 Executive Committee Vice Chair, National Viral Hepatitis Roundtable

BUSINESS POSITIONS

1999 – 2000 President and Treasurer Pacific Hepatology and Gastroenterology Medical Group, P.C. San Francisco, California

1999 – 2001 President and CEO Hepahope Corporation San Francisco, California

2000 – 2005 President Pacific Hepatology and Gastroenterology Medical Group, P.C. San Francisco, California

2009 – Present President, Pacific Health Consortium LLC 1988 – 2010 Office address:

California Pacific Medical Center 2340 Clay Street San Francisco, California 94115

Curriculum Vitae


BUSINESS POSITIONS: Continued

2010 – 2013 U.C. San Diego

Medical Director of Center for Hepatobiliary Disease and Abdominal Transplantation (CHAT) Chief of Hepatology Professor of Medicine 350 Dickinson Street, Suite 342 San Diego, California

8/31/2013 – Robert G. Gish MD Present Robert G. Gish Consultants, LLC

Business address: 6022 La Jolla Mesa Drive San Diego, CA 92037 Cell phone: 1 858 229 9865 Email: [email protected] Website: robertgish.com

mailto:[email protected]


RESEARCH SUPPORT

1975 – 1977 Co-Investigator: NIH Grant #GM 22357. “Ionization Kinetics of Carbon Acids.” University of Kansas. Grant award: $70,000.

1985 – 1988 Principle Investigator: National Institute of Environmental Health

Sciences Physician Scientist Award. Grant award: $210,000.

1993 – 1995 Co-Investigator: Amgen grant. A Phase III, Randomized, Double-Blind Controlled Trial of Recombinant Methionyl Interferon Consensus (r-tetIFN-Con1) in Patients with Chronic Hepatitis C Virus (HCV) Infection. California Pacific Medical Center.

Grant award: $187,604. 1993 –1994 Co-Investigator: Loewy Fund grant. Development and Validation

of a Standardized Interview for the Detection of Alcoholism in Patients Referred for Liver Transplantation. California Pacific Medical Center. Grant award: $6,487.

1993 – 1998 Co-Investigator: NIH grant. Cytokines and Human Autoimmune

Liver Disease. Grant award: $579,800. 1994 Principle Investigator: Syntex grant. Ganciclovir for the Treatment

of Hepatitis B after Organ Transplantation. Grant award: $10,000. 1994 Principle Investigator: Schering Corporation grant. Interferon alfa-

2b: Dose Escalation and Taper for the Treatment of Hepatitis C. Grant award: $15,000.

1995 Principle Investigator: PRI grant. Natural History of Hepatitis B.

Grant award: $10,000. 1995 Co-Investigator: Chiron grant. Beta-Interferon for Retreatment of

Hepatitis C. Grant award: $30,000. 1995 – 1997 Principle Investigator: Schering-Plough grant. Hepatitis C

Treatment with Interferon with or without Phlebotomy. Grant award: $25,000. 1995 – 1997 Co-investigator: GlaxoWellcome grant. Study P110-008-

Tucaresol Dose Escalation Drug Study for Hepatitis B. Grant award: $35,000. 1996 – 1997 Co-Investigator: GlaxoWellcome grant. Study NUCA 3011- A

Placebo-Controlled Study of Lamivudine and Intron-A® in Patients with Chronic Hepatitis B Infection who are Interferon Non-Responders. Grant award: $8,000.

Curriculum Vitae


RESEARCH SUPPORT: Continued

1996 – 1997 Co-Investigator: GlaxoWellcome grant. Study NUCA3010- A Study of Lamivudine or Placebo in Patients with Chronic Hepatitis B Infection who are Treatment Naive. Grant award: $10,000.

1996 – 1997 Co-Investigator: GlaxoWellcome grant. Study NUCA3005-

Lamivudine Open Label Program for Treatment of Patients with Hepatitis B Viral Infection Post-Liver Transplantation.

Grant award: $20,000. 1996 – 1997 Co-Investigator: GlaxoWellcome grant. Study NUCA2006- A Pilot

Study to Assess the Safety and Efficacy of Lamivudine During the Course of Liver Transplantation for Patients with Chronic Hepatitis B Infection (naïve study). Grant award: $35,000.

1996 – 2001 Principle Investigator: GlaxoWellcome grant. Study NUCA3017- A

Study of Extended LamivudineTtreatment for Hepatitis B Patients Previously Enrolled in Phase II or Phase III Lamivudine Trials. Grant award: $80,000.

1996 – 1997 Co-Investigator: Schering-Plough grant. Study C95-144- Interferon

with or without Ribavirin in Hepatitis C Patients with Relapse after Interferon. Grant award: $158,000.

1996 – 1997 Co-Investigator: Schering-Plough grant. Study C95-132- IntronA

Monotherapy vs. IntronA + Ribavirin for Treatment of Chronic Hepatitis C in Interferon-naive Patients. Grant award: $178,000.

1996 – 1998 Principle Investigator: Schering-Plough grant. Interferon with

Ribavirin for Interferon Failure in Hepatitis C Patients. Grant award: $550,000. 1996 – 1997 Principle Investigator: Ciba Corning grant. Lab study of Mx protein

as a Marker for Injection Therapy. Grant award: $5,000. 1996 – 1999 Principle Investigator: GlaxoWellcome grant. Study NUCA3021-

Lamivudine Compassionate Use Treatment Program for Subjects of Three Life-Threatening Forms of Hepatitis B Infection.

1997 – 2000 Principle Investigator: Otsuka America Pharmaceutical Inc. Grant.

Study 156-96-203; Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy, Safety and Pharmacokinetics Study of OPC 41061 in Hospitalized Patients with Hyponatremia, Secondary to Liver Disease.

Grant award: $150,000.

Curriculum Vitae



1997 – 2002 Co-investigator: Roche BioScience grant. Study MYCO 2642- A Randomized, Double-Blind, Comparative Study of the Efficacy and Safety of Intravenous and Oral Mycophenolate Mofetil and Azathioprine, Each in Combination with Cyclosporine (Neoral) and Corticosteroids in Liver Transplant Recipients.

Grant award: $176,000. 1997 – 2002 Principle Investigator: GlaxoWellcome grant. Study NUCA 3016- A

Long-term Epidemiologic Study of Patients who have Evidence of Possible Durable Response to Lamivudine in Phase II or Phase III Trials of Lamivudine. Grant award: $21,000.

1998 – 2000 Principle Investigator: Triangle Pharmaceuticals grant. Phase I

Clinical Trial of FTC for Patients who have Chronic HBV Infection. Grant award: $300,000.

1998 – 2001 Principle Investigator: Triangle Pharmaceuticals grant. Phase II

Rollover Clinical Trial of FTC for Patients who have Chronic HBV Infection. Grant award: $200,000.

1998 – 1999 Principle Investigator: Bristol-Myers Squibb grant. Lobucavir vs.

Interferon for patients who have not undergone previous Treatment with Interferon Therapy. Grant award: $75,000.

1999 – 2000 Principle Investigator: Bristol-Myers Squibb grant. 200475 vs. Interferon for patients who have not undergone

previous treatment with Interferon therapy. Grant award: $85,000. 1998 – 1999 Co-investigator: Bristol-Myers Squibb grant. Lobucavir for Patients

who have Failed Previous Treatment with Interferon Therapy. Grant award: $75,000. 1997 – 1998 Co-investigator: Matrix Pharmaceuticals grant. Intratumoral

Injection of Cis-Platinum/Bovine Collagen for theTreatment of Hepatocellular Carcinoma and Metastatic Colon Cancer.

Grant award: $30,000. 1998 – Present Principal Investigator: Schering-Plough grant. Interferon/Ribavirin

Treatment of Non-Responders and Relapsers. Grant award: $750,000.

1998 – 2000 Principle Investigator: Schering-Plough grant. Study C98-169-

Comparison of Intron A Induction Therapy + Rebetol vs. Intron

A + Rebetol for the Treatment of Adult Naive Subjects with Chronic Hepatitis C Infected with HCV Genotypes 1, 2, 3, or 2/3. Grant award: $59,000.

Curriculum Vitae



1998 – 2001 Principle Investigator: Hoffmann-LaRoche grant. Study NV15496C- A Phase III Open-label, Randomized, Multicenter, Parallel Dose Efficacy and Safety Study Comparing Pegylated-

Interferon -2a (RO 25-8310) to a Standard Regimen of Roferon A in the Treatment of Patients with Chronic Hepatitis C. Grant award: $148,000.


Treatment of Relapse in Patients with Chronic Hepatitis C

Comparing Intron A Monotherapy vs. IntronA + Ribavirin. Grant award: $20,000.

1998 – 2001 Principle Investigator: An open-label, single arm Study to Evaluate

the Combination of Zenapax (daclizumab) and CellCept (mycophenolate mofetil) with Corticosteroids in the Prevention of Acute Rejection in Primary Liver transplant Recipients. Roche Pharmaceuticals. Grant award: $17,500.


Comparison of Peg-interferon vs. Intron A for Treatment of Adult Subjects with Chronic Hepatitis C not Previously Treated with Interferon: Dose-finding study. Grant award: $105,000.

1999 – 2002 Principle Investigator: Hoffmann-LaRoche grant. Study #

NV15801- A phase III,Rrandomized, Multicenter, Efficacy and Safety Study Comparing the Combination of Pegylated-interferon

-2a (Ro 25-8310) and Ribavirin with Rebetron™ A in the Treatment of Patients with Chronic Hepatitis C. Grant award: $68,000.

1999 – 2002 Principle Investigator: Hoffmann-LaRoche grant. Study NR15994-

A randomized, open-label, multicenter, efficacy and safety Study of Pegasys™ plus Ribavirin, Pegasys™ plus CellCept®, Pegasys™ plus Amantadine, or Pegasys™ plus Amantadine plus Ribavirin in Patients with Chronic HCV Infection who have not

Responded to at least 12 Weeks of Treatment with Rebetron. Grant award: $75,000.

1999 – 2002 Principle Investigator: Gilead grant. Study GS98-437- A double-

blind, randomized, placebo-controlled Study of Adefovir Dipivoxil for the Treatment of Patients with HBeAg+ Chronic Hepatitis B Vi-rus Infection. Grant award: $106,000.

Curriculum Vitae



1999 – 2006 Principle Investigator: Gilead Pharmaceuticals grant. Phase III & Rollover, Double-blind, randomized, placebo-controlled Study of Adefovir Dipivoxil for Treatment of Patients with HBeAg+ Chronic Hepatitis B Virus Infection with Open Label Long Term Follow Up of Safety, Efficacy, and Resistance of Adefovir.

Grant award: $143,323. 2000 – 2001 Principle Investigator: Gilead grant. Study 472- Pharmacokinetics

study (PK) of 48 weeks treatment with adefovir 10mg/day for HBV infected, nucleoside treatment-naïve patients with compensated liver disease.

2000 Sub-Investigator: Bristol-Meyers Squibb grant. Long-Term

rollover, assessment of safety and antiviral activity of open-label entecavir plus lamivudine in chronic hepatitis B patients who have viremia on monotherapy in other entecavir trials.

Grant award: $32,571. 2000 – 2005 Sub-Investigator: Bristol-Meyers Squibb grant. A phase III study of

the Safety and Antiviral Activity of Entecavir vs. Lamivudine in Adults with Chronic Hepatitis B Infection who are Positive for Hepatitis B E Antigen. Grant award: $75,867.

2000 – 2005 Sub-Investigator: Bristol-Meyers Squibb grant. A Phase III Study

of the Safety and Antiviral Activity of Entecavir vs. Lamivudine in Adults with Chronic Hepatitis B Infection who are Negative for Hepatitis B E-Antigen. Grant award: $29,911.

2000 – 2005 Sub-Investigator: Bristol-Meyers Squibb grant. A Phase III Study

of the Safety and Antiviral Activity of Entecavir vs. Lamivudine in Adults with Chronic Hepatitis B Infection who are Negative for Hepatitis B E-Antigen. Grant award: $40,048.

2000 – 2005 Sub-Investigator: Bristol-Meyers Squibb. Long-term Assessment

of Treatment Outcomes with Entecavir and Lamivudine for Chronic Hepatitis B Infection in Patients who have Enrolled in Phase III Entecavir Trials. Grant award: $3,524.

2000 – 2005 Principle Investigator: Bristol-Meyers Squibb. Decompensated,

Comparison of the Efficacy and Safety of Entecavir vs. Adefovir in Subjects Chronically Infected with Hepatitis B virus with Evidence of Lamivudine Resistance and Hepatic Decompensation.

Grant award: $80,150. 2001 Principle Investigator: GlaxoSmithKline grant. Study Nuc2094 -

Lamivudine and Adefovir Combination for the Treatment of Chronic HBV Infection.

Curriculum Vitae



2001 – 2002 Principle Investigator: Scripps Consortium grant. Hepatitis C Registry. Grant award: $5,000.

2001 – 2002 Principle Investigator: Bayer Pharmaceuticals grant. HCV 3.0

assay development. Grant award: $6,000. 2001 – 2002 Co-Investigator: BioMeasure, Inc., grant. Lanreotide Study for the

Study of Acute GI Bleeding in Portal Hypertension. Grant award: $40,000.

2001 – 2002 Principle Investigator: Bristol-Meyers Squibb grant. Study 014-

020- Entecavir vs. Lamivudine (52 weeks therapy) in Adult Patients with Chronic Hepatitis B who are Positive for Hepatitis B e-Antigen and Naïve to Previous Therapy.

2001 – 2002 Principle Investigator: Roceh Pharmaceuticals: 8 weeks of Peg-

Interferon +/- Ribavirin vs. Roferon 3 MU TIW + Ribavirin for Patients with Chronic Hepatitis C Co-infected with HIV, Naïve to Interferon Therapy.

2001 – 2002 Sub-Investigator: Physician initiated study: Hepatitis Resource

Network. Peg-interferon -2b + Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-infected Persons not Previously Treated with Interferon.

2001 – 2002 Sub-Investigator: National Hemochromatosis Transplant Registry

grant. Prevalence of Hepatic Iron Overload and HFE Mutations among Patients Undergoing Orthotopic Liver Transplantation (OLT): Interim Results from the National Hemochromatosis Transplant Registry (NHTR) NIH.

2001 – 2006 Sub-Investigator: SciClone Pharmaceuticals grant. A multicenter,

double-blinded study in patients with compensated non-cirrhosis due to chronic hepatitis C who are non-responders to prior interferon alfa + ribaviron therapy, comparing treatment with thymosin + peg-interferon with peg-interferon + placebo.

Grant award: $289,756. 2001 – 2008 Sub-Investigator: SciClone Pharmaceuticals grant. A multicenter,

double-blinded study in patients with compensated cirrhosis due to chronic hepatitis C who are non-responders to prior interferon alfa + ribaviron therapy, comparing treatment with thymosin + peg-interferon with peg-interferon + placebo. Grant award: $240,869.

Curriculum Vitae



2001 – 2005 Sub-Investigator: Hoffman-LaRoche grant. A Phase III partially double-blind study Evaluating the Efficacy and Safety of 40kD Branched Pegylated Interferon Combined withPlacebo or Lamivu-dine vs. Lamivudine in HBeAg- Positive Patients with Chronic Hepatitis B. Grant award: $45,579.

2001 – 2006 Principle Investigator: Schering-Plough grant. Long term follow up

Protocol to Assess Subjects after Completing 24 weeks of Schering-Plough Research Institute (SPRI) Clinical Trial for Chronic Hepatitis C. Grant award: $19,200.

2001 – 2005 Principle Investigator: Schering-Plough grant. Comparison of peg-

interferon plus ribavirin given as a fixed dose or on a weight optimized basis for treatment of chronic hepatitis C in previously untreated adult subjects. Grant award: $41,950.

2002 – 2004 Principle Investigator: Roche Pharmaceuticals grant. A phase III

partially double-blinded Study Evaluating the Efficacy and Safety of Pegasys with Placebo or Lamivudine Versus Lamivudine in HBeAg-PositivePpatients with Chronic Hepatitis B.

2002 Principle Investigator: Ortho-Biotech grant. Procrit vs. Placebo

weekly to treat anemia for patients taking ribavirin + interferon or peg-interferon.

2002 Principle Investigator: Akros Pharma grant. A randomized,

double-blind placebo-controlled, ascending dose Study of the Safety, Tolerability, Pharmacokinetics, andPpharmacodynamics of JTK-003 inPpatients with Chronic Hepatitis C Infection for Non-responders to Previous Therapy.

2002 – 2003 Principle Investigator: ICN pharmaceuticals/Ribapharm grant. A Phase I multiple-dose astudy to evaluate safety, tolerability, and pharmacokinetics of viramidine for patients with compensated HCV.

2002 Principle Investigator: Chiron grant. Randomized, placebo-

controlled study of the safety and efficacy of HBV/MF59 (vaccine) alone or in combination with lamivudine.

2002 – 2003 Principle Investigator: Bristol-Meyers Squibb grant. Entecavir vs.

Lamivudine (52 weeks therapy) in Adult Patients with Chronic Pepatitis B who have had an Incomplete Response to Lamivudine Therapy.

Curriculum Vitae



2002 – 2005 Principle Investigator: SciClone Pharmaceuticals grant. Thymosin for HCV Non-responders Comparing Treatment with Thymosin Alpha 1 + Peg-interferon Alpha-2a with Peg-interferon Alpha-2a + Placebo (Study 1: noncirrhotic; Study 2: cirrhotic).

2002 – 2005 Co-Investigator: NIH grant. Recurrent Hepatitis B after Liver

Transplant. Grant award: $32,705. 2002 – 2005 Sub-Investigator: Roche Pharmaceuticals. A randomized, open

label, multi-center, pilot study of Pegasys and Epivir-HBV as Initial Treatment of HBeAg- Negative Chronic Hepatitis B Infection.

Grant award: $29,644. 2002 – 2003 Principle Investigator: Intermune grant. Double-blind, randomized,

placebo-controlled Study of the Safety and Anti-fibrotic Efficacy of Gamma Interferon in Patients with Severe Liver Fibrosis or Cirrhosis due to HCV.

2002 – 2003 Sub-investigator: Schering Corp. Comparison of Peg-interferon

Alfa-2b plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis in Previously Untreated Adult Patients.

2002 – 2004 Principle Investigator: SciClone Pharmaceuticals grant. Trial of

zadaxin with transarterial chemoembolization in patients with unresectable hepatocellular chemoembolization with or without zadaxin therapy for 6 months. Award $240,000

2002 – 2003 Principle Investigator: ICN pharmaceuticals/Ribapharm grant. A

Phase II randomized Study to Evaluate the Efficacy of Viramidine for Patients with Compensated HCV.

2002 – 2003 Principle Investigator: Eximias Pharmaceuticals. Thymataq vs.

Doxorubicin for the Treatment of HCC. Grant award: $240,000 2002 – 2005 Principle Investigator: Valeant Pharmaceuticals grant. Phase II

dose-ranging Study of Viramidine in Combination with Pegasys in Treatment-naïve Subjects with Chronic Hepatitis C Infection. Grant award: $292,559.

2002 – 2005 Sub-Investigator: Idenix Pharmaceuticals grant. A randomized,

double-blind trial of Telbivudine vs.Llamivudine in Adults with Compensated Chronic Hepatitis B. Grant award: $106,427.

Curriculum Vitae



2002 – 2009 Sub-Investigator: XTL Pharmaceuticals grant. A pilot phase II, multi-center, randomized, double-blind, placebo-controlled, dose escalation Study of the Safety and Efficacy of Human HCV-antibody (HCV-AB 68) for Prevention of Hepatitis C Disease Recurrence in Patients who have Received Hepatic Allografts for Treatment of End-stage Liver Disease due to Hepatitis C Virus Infection. Grant award: $10,000.

2003 – 2004 Principle Investigator: Bristol-Meyers Squibb. Entecavir vs. Lamiv-

udine (52 weeks therapy) in Adult patients with Chronic Hepatitis B who have had an Incomplete Response to Lamivudine Therapy: Rollover study.

2003 Sub-investigator: Medtronic grant. Interstim sacral nerve

stimulation therapy for bowel control: Fecal incontinence study. 2003 Principle Investigator: Roche Pharmaceuticals grant. Randomized,

open-label study of Pegasys and Epivir-HBV as initial treatment of HBeAg negative HBV.

2003 Sub-investigator: Two-week randomized, double-blind, placebo-

controlled study of PRN, BID and fixed dosing regimens of alosetron in female subjects with severe diarrhea-predominant irritable bowel syndrome who have failed conventional therapy.

2003 Principle Investigator: Idun Pharmaceuticals grant. Caspase study

for the treatment of chronic liver disease including chronic HCV infection.

2003 Principle Investigator: United Therapeutics grant. Phase II study of

UT 231, including PK assessment, in patients with chronic HCV who were non-responders to previous interferon and ribavirin therapy.

2003 Principle Investigator: Actelion Pharmaceuticals. Phase II Study

of tezosentan for the treatment of portal hypertension. 2003 SubInvestigator: Celera grant. Natural history of fibrosis in

patients who had undergone treatment for HCV. 2003 – 2004 Principle Investigator: Chiron grant. Evaluation of the Procleix™

HIV-1/HCV RNA qualitative assay in detecting HCV RNA from whole blood from HCV infected patients.

Curriculum Vitae



2003 – 2006 Sub-Investigator: Hoffman-LaRoche grant. Rrandomized, multi-center, open-label, phase IV study evaluating efficacy and safety of 16 week vs. 24 week treatment with Pegasys in combination with Copegus in interferon-naïve patients with chronic hepatitis C genotype 2 or 3 virus infection. Grant award: $136,513.

2003 – 2006 Principle Investigator: Gilead Pharmaceuticals grant. Long-term

study of durability of seroconversion in patients with chronic hepatitis B virus infection who have seroconverted while participating in the previous Gilead-sponsored study of adefovir dipivoxil. Grant award: $1,000.

2003 – 2005 Principle Investigator: Celera grant. DNA genotyping and mRNA profiling

of newly recruited, treatment-naïve HCV patients.

Grant award: $120,300. 2003 – 2004 Principle Investigator: XTL Pharmaceuticals grant. Phase II, multi-

center, randomized, open-label, dose ranging, parallel group study of the antiviral effects, pharmacokinetics and safety of HepeX-B as compared to hepatitis B immune globulin in patients who have received hepatic allografts for hepatitis B virus infection.

Grant award: $7,400. 2004 Principle investigator (CPMC): Amgen grant. Treatment of

ribavirin-induced anemia during the treatment of chronic HCV with darbopoietin (ADHERENCE trial).

2004 Principle investigator: (CPMC) Ortho Biotech grant. Prospective

treatment trial using erythropoietin to treat anemia due to ribavirin during interferon treatment for chronic HCV infection.

2004 Principle Investigator: Eximias Pharmaceutical Corp. grant.

Phase III Evaluation of THYMITAQ(R) nolatrexed dihydrochloride, in unresectable hepatocellular carcinoma (ETHECC[C]) trial.

2004 Co-Principle Investigator: WEAVE (WEST EAST ANTIVIRAL

EFFICACY) protocol- Randomized trial of Pegasys/ribavirin vs. Pegasys/ribavirin and CAM therapy.

2004 – 2005 Principle Investigator: Idun Pharmaceuticals grant. A phase III

dose-response study of caspase inhibitor in hepatitis C patients. Grant award: $62,100.

2004 – 2005 Sub-Investigator: Boehringer Ingleheim grant. A pharmacokinetic

study to assess nevirapine levels in HIV-infected patients with impaired hepatic function. Grant award: $19,929.

Curriculum Vitae



2004 – 2006 Sub-Principle Investigator: Ortho Biotech grant. Procrit for the treatment of post-transplant anemia. Grant award: $50,000.

2004 – 2006 Principle Investigator: eXagen Diagnostics grant. Identification of a

molecular signature from peripheral blood that predicts interferon response in hepatitis C infection. Grant award: $30,000.

2004 – 2006 Sub-Investigator: Hoffman-LaRoche grant. Prospective,

randomized, multi-center, open-label, comparative safety and efficacy study of prophylactically administered pegylated interferon plus ribavirin vs. no prophylaxis following liver transplantation for hepatitis C. Grant award: $246,608.

2004 – 2007 Principle Investigator: Valeant Pharmaceuticals grant. Phase II

randomized, double-blind, multi-center study to compare safety and efficacy of viramidine to ribarivin in treatment-naïve patients with chronic hepatitis C. Grant award: $202,395.

2004 – 2007 Sub-Investigator: Vertex Pharmaceuticals grant. Phase 2b study

of merimepodib in combination with interferon and ribavirin in subjects with chronic hepatitis C genotype 1 non-responsive to prior therapy and interferon. Grant award: $96,740.

2004 – 2009 Co-Investigator: NIH grant. Early detection of liver cancer. Grant award: $50,694.

2005 – 2007 Principle Investigator: Stanford University grant. CPMC/Stanford

keratin study of liver disease in African Americans. Grant award: $2,000. 2005 – 2007 Sub-Investigator: Idenix Pharmaceuticals grant. A randomized,

double blind trial of telbivudine vs. adefovir dipivoxil in adults with HBeAg-positive, compensated chronic hepatitis B.

Grant award: $28,380.

2005 – 2008 Sub-Investigator: Idenix Pharmaceuticals grant. Open-label study of telbivudine in adults with chronic hepatitis B previously treated in Idenix-sponsored telbivudine studies. Grant award: $126,005.

2005 – 2007 Sub-Investigator: Idenix Pharmaceuticals grant. Randomized,

phase IIb clinical trial to evaluate the safety and antiviral activity of NM283 and the combination of interferon plus NM283 in patients with chronic hepatitis C who have previously failed to respond to standard therapy. Grant award: $69,883.

Curriculum Vitae



2005 Sub-Investigator: Hemolife Medical grant. Continuous plasma filtration with sorbent adsorbent detoxification utilizing the HemoLife Medical Inc. HLM 100 column and the HLM-200 plasma filter for the treatment of episodic type C hepatic encephalopathy in subjects with decompensated cirrhosis. Grant award: $86,790.

2005 Sub-Investigator: Orphan Therapeutics grant. A double-blind,

randomized, placebo-controlled, multi-center phase III study of intravenous terlipressin in patients with hepatorenal syndrome Type 1. Grant award: $34,791.

2007 – 2008 Principle investigator: Nucleonics siRNA therapy for the treatment

of chronic hepatitis B. Grant award: $124,000. 2008 – 2010 PROTOCOL GS-US-174-0108 “A Phase II, Double-Blind, Multi-

Center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir In The Treatment Of Chronic Hepatitis B Subjects With Decompensated Liver Disease And In The Prevention Of Hepatitis B Recurrence Post-Transplantation.” Budget $26,642

2010 Sub-Investigator: Study of the Antiviral Activity of Entecavir in

Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection.

2010 Sub-Investigator: Ph 2 rollover protocol of Telaprevir (VX-950) in

combination with Peginterferon Alfa-2a and Ribavirin in subjects enrolled in the controlled group (Group A) of study VX06-950-106, VX05-950-104 and VX05-650-104EU who did not achieve or maintain an undetectable HCV RNA level through sustained viral response.

2010 Sub-Investigator: A Randomized, Placebo-Controlled, Dose-

Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients with BK Virus Nephropathy (CASG209).

2010 Sub-Investigator: Multicenter, randomized, double-blind, placebo

controlled, multiple dose study of the safety, tolerability and population pharmacokinetics of CMX001 in post transplant subjects with BK virus viruria.

2010 Sub-Investigator: A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation.

Curriculum Vitae



2010 Sub-Investigator: A Phase II randomized, double-blind, placebo-controlled study of Sorafenib or Placebo in combination with transarterial chemoembolization (TACE) performed with DC bead and doxorubicin for intermediate stage hepatocellular carcimoma (HCC).

2010 Principle-Investigator: A Randomized, Double-blind, Multi-center

Phase II Study of Brivanib plus Best Supportive Care (BCD) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib. Budget amount $244,105.00

2010 Sub-Investigator: A Phase I, Open-Label, Multi-center, Dose-

escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination with Sorafenib (Nexavar) in Patients with Advanced or Metastic Hepatocellular Carcinoma (HCC).

2010 Sub-Investigator: Global Investigation of Therapeutic Decisions in

Hepatocellular Carcinoma and of its Treatment with Sorafenib. 2010 Principle-Investigator: Randomized, Controlled Phase 2a/b Study

of the Efficacy and Safety of PEG-rIL-29 Administed in Combination with Ribavirin to Treatment-Naïve Subjects with Chronic Hepatitis C Virus Infection. Budget $48,950.00

2010 Sub-Investigator: A Rollover Protocol to Provide Open-Label

Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product to Subjects Completing the GS-US-203-0107 Study.

2010 Principle-Investigator: A Phase 2, Randomized, Double-Blind

Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated with Adefovir Dipiivoxil for Chronic Hepatitis B and having Persistent Viral Replication.

2010 Sub-Investigator: An Open Label Trial of Telbivudine (LdT) in

Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies. NV-02B-022.

2010 Sub-Investigator: A Phase 2, Open-Label, Multi-Center,

Randomized Trial to Demonstrate the Pharmacokinetics of LCP-TACRO Tablets Once Daily and Program Capsules Twice Daily in Adult De Novo Liver Transplant Patients.

Curriculum Vitae



2010 Sub-Investigator: A Phase 2, Randomized, Double-Blind, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys and Copegus versus the Currently Approved Combination of Pegasys and Copegus in Treatment Naïve Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection.

2010 Sub-Investigator: Salix Pharmaceuticals, Inc./A Multi-Center,

Open-Label, Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 BID in Subjects with a History of Hepatic Encephalopathy.

2010 Sub-Investigator: Long-Term Follow-Up of Subjects in a Phase 2

or 3 Clinical Trial in which SCH 503034 was Administered for the Treatment of Chronic Hepatitis C.

2010 Sub-Investigator: Ph2, Open label randomized study to evaluate

the efficacy and safety of the combination product, Emtricitabine/Tenofovir (Truvada) in the presence of absence of Hepatitis B immunoglobulin (CHB) post-orthotopic liver transplant (OLT).

2010 Sub-Investigator: An open-level, single-arm, roll-over trial of

telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C216 trail who failed therapy for virologic reasons.

2010 Sub-Investigator: Phase III, 24 dose regimens of Telaprevir in

combination with Peginterferon alfa 2a and Ribavirin in treatment naïve subjects with genotype 1 chronic hepatitis C.

2010 Sub-Investigator: Randomized study of stopping treatment at

24wks vs. continuing treatment to 48 weeks in treatment-naïve subjects with Genotype 1 CHC who achieve an extended RVR while receiving Telaprevir, Peginterferon (Peasys) and Ribavirin (Copegus).

2010 Sub-Investigator: A 3-Year, Virology Follow up Study in Subjects

Previously Treated WithTelaprevir in Select Clinical Studies. 2010 Sub-Investigator: Efficacy and Safety of the Extracorporeal Liver

Assist Device (ELAD) in Subjects with Fulminant Hepatic Failure (FHF).

Curriculum Vitae



2010 Sub-Investigator: Efficacy and Safety of the Extravorporeal Liver Assist Device (ELAD) in Subjects with Acute on Chronic Hepatitis (AOCH).

2010 Sub-Investigator: A multi-center randomized, double-blind,

placebo-controlled trial to evaluate the efficacy, safety and tolerability of Rifaximin 550 mg bid for 6 months in preventing hepatic encephalopaty.

2010 ILCS Horizon Scanning Protocol “International and National

Priorities for Liver Cancer Control.” Johns Hopkins Bloomberg School of Public Health IRB.

4/2010 – 8/2013 Co-Primary Investigator: NV20536. A Roche Study: A Random-

ized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combi-nation of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection. Grant Award: $214,336.60.

11/2010 – 8/2013 Co-Primary Investigator: NV22688. A Roche Study: A Long-Term

Monitoring Study To Evaluate The Persistence Of Direct Acting Antiviral (DAA) Treatment-Resistant Mutations Or The Durability Of Sustained Virological Response (SVR) In Patients Treated With DAA-Containing Regimens For Chronic Hepatitis C Infection (CHC). Grant Award: $21,273.00.

4/2011 – 8/2013 Co-Primary Investigator: P7977-0724. A Gilead Sciences & Phar-

masett study: A Multicenter, Open-label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacoki-netics and Pharmacodynamics following Oral Administration of PSI-7977 in Combination with Pegylated Interferon and Ribavirin in Treatment-Naïve Patients with Chronic HCV Infection Genotype 1,4,5, or 6. Grant Award: $117,872.

2011 Co-Primary Investigator: WV21913C. A Roche Study: A Random-

ized, Open-Label, Multicenter Study to Evaluate the Sustained Vi-rologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (DNV/r) and Copegus, in Combi-nation with the HCV Polymerase Inhibitor Prodrug RO 5024048 and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients who have Failed a Previous Course of Peginterferon Alfa Plus Ribavi-rin Combination Therapy. Grant Award: $141,986.

Curriculum Vitae



6/2011 – 8/2013 Co-Primary Investigator: GS-US-248-0120. A Gilead Sciences, Inc. Study: A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Geno-type 1 HCV Infection. Grant Award: $213,102.

9/2011 – 8/2013 Co-Primary Investigator: GS-US-248-0121. A Gilead Sciences,

Inc. Study: A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 with Peginterferon Alfa 2a (PEG) and Rib-avirin (RBV) in Treatment-Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype. Grant Award: $59,742.

2011 – 8/2013 Primary Investigator: BIPI 1220.48. A Boehringer Ingelheim

Study: A Phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-a (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN / RBV treatment [Version 3.0] Grant Award: $89,739.

2011 – 8/2013 Co-Primary Investigator: AI444038. A Bristol-Myers Squibb Study:

Open-Label, Single Arm Evaluation of BMS-790052 in Combina-tion with Peg-Interferon Alfa-2a and Ribavirin in Black-African Americans, Latinos, and White-Caucasians with Chronic Hepatitis C Genotype 1 Infection. Grant Award: $92,572.

2011 – 8/2013 Co-Primary Investigator: GS-US-248-0123. A Gilead Sciences,

Inc. Study: A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection. Grant Award: $33,491.

2011 – 8/2013 Co-Primary Investigator: GS-US-248-0122 . A Gilead Sciences,

Inc. Study: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection. Grant Award: $33,491.

2011 – 8/2013 Co-Primary Investigator: NV27779. A Roche Study: A Phase II,

Randomized, Double-Blind, Multicenter, Parallel Group Study To Evaluate The Sustained Virologic Response Of The HCV Poly-merase Inhibitor Prodrug Ro5024048 In Combination With Telaprevir And Pegasys®/Copegus® In Patients With Chronic Hepatitis C Genotype 1 Virus Infection Who Were Prior Null Re-sponders To Treatment With Pegylated Interferon/Ribavirin. Grant Award: $95,089.

Curriculum Vitae



2011 – 8/2013 Primary Investigator: P2938-0721. A Gilead Sciences / Pharma-sett, Inc. Study: An International, Multi-center, Blinded, Random-ized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients with Chronic HCV Infection. Grant Award: $273,564.

2012 – 8/2013 Primary Investigator: BMS AI444-043. A Brstol-Myers Squib

Study: A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg- Interferon Alfa 2a and Ribavirin in Previ-ously Untreated HCV Patients Coinfected with Human Immunode-ficiency Virus (HIV) and Hepatitis C Virus (HCV). Grant Award: $73,976.

2012 – 8/2013 Co-Primary Investigator: VX11-950-114. A Vertex Study: A Phase

3b Study of 2 Treatment Durations of Telaprevir, PEG-INF (Pega-sys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects with Genotype 1 Chronic Hepatitis C and IL28B CC Genotype [Version 2.0]. Grant Award: $58,092.

2012 – 8/2013 Co-Primary Investigator: P7977-2025. A Gilead Sciences / Phar-

masett, Inc. Study: An Open-Label Study to Explore the Clinical Efficacy of GS-7977 with Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant. Grant Award: $80,722.

2012 – 8/2013 Co-Primary Investigator: GS-US-334-0107 . A Gilead Sciences,

Inc. Study: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Subjects with Chronic Geno-type 2 or 3 HCV Infection who are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon. Grant Award: $102,037.

2012 – 8/2013 Co-Primary Investigator: GS-US-334-0109, A Gilead Sciences,

Inc. Study: An Open-Label Study of GS-7977+ Ribavirin with or without Peginterferon Alfa-2a in Subjects with Chronic HCV Infec-tion who Participated in Prior Gilead HCV Studies Grant Award: $94,440.

2012 – 8/2013 Co-Primary Investigator: GS-US-334-0108, A Gilead Sciences,

Inc. Study: A Phase 3, Multicenter, Randomized, Double-Blind, Study to Investigate the Efficacy and Safety of GS-7977 + Ribavi-rin for 12 or 16 Weeks in Treatment Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection. Grant Award: $100,831.

Curriculum Vitae



2012 – 8/2013 Primary Investigator: P7977-1231, A Gilead Sciences / Pharma-sett, Inc. Study: A Phase 3, Multicenter, Randomized, Active-Con-trolled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients with Chronic Genotype 2 or 3 HCV Infection. Grant Award: $43,041.

2012 – 8/2013 Primary Investigator: GS-US-283-0102, A Gilead Sciences, Inc.

Study: A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging, Study Evaluating the Safety, Tolera-bility, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects with Chronic Hepatitis B Virus Infection. Grant Award: $43,041.

2012 Primary Investigator: GS-US-283-0106, A Gilead Sciences, Inc.

Study: A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects with Chronic Hepatitis B Virus Infection. Grant Award: $178,385. 6/1/12 – 8/2013.

2012 Primary Investigator: GS-US-243-0102., A Gilead Sciences, Inc.

Study: A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerabil-ity, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naïve Subjects with Chronic Hepatitis C Virus Infection. Grant Award: $183,441. 6/1/12 – 8/2013.

2012 Primary Investigator: GS-US-283-0110, A Gilead Sciences, Inc.

Study: A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Loss of S Antigen (HBsAg) and Sustained HBV Viral Load Reduction Below the Limit of Quantitation (BLQ) in Gil-ead-Sponsored Trials of GS-9620 in Subjects with Chronic Hepati-tis B Infection. Grant Award: $139,400. 7/1/12 – 8/2013.

2012 Co-Primary Investigator: GS-US-334-0110, A Gilead Sciences,

Inc. Study: A Phase 3, Multicenter, Open-Label Study to Investi-gate the Efficacy and Safety of GS-7977 with Peginterferon Alfa2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects with Chronic Genotype 1, 4, 5, or 6 HCV Infection. Grant Award: $102,411. 7/1/12 – 8/2013.

Curriculum Vitae



2013 Co-Primary Investigator: GS-US-337-0109, A Gilead Sciences, Inc. Study: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects with Chronic Genotype 1 HCV Infection. Gilead Sciences, Inc. Grant Award: $116,799. 1/1/13 – 8/2013.

2013 Co-Primary Investigator: GS M14-002. An AbbVie Study: A Ran-

domized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepa-titis C Virus (HCV) Infection (PEARL-IV). Grant Award: $126,539.00. 3/1/13 – 8/2013.

2013 Co-Primary Investigator: GS-US-337-0108, A Gilead Sciences, Inc. Study: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir / Ledi-pasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infec-tion. Grant Award: $104,650. 5/1/13 – 8/2013.

2013 GS-US-342-0102, A Gilead Sciences, Inc. Study: A Phase 2, Mul-

ticenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Subjects with Chronic HCV Infection . Grant Award: $46,551. 5/1/13 – 8/2013.


UCSD: RESEARCH / ADVISORY

2012 Co-Principal Investigator: “Biological Markers and Outcomes in

Hepatitis C and Other Liver Diseases. All UCSD Health Systems. Other Co-Principal Investigator: Julio Gutierrez, MD.

2013 Co-Principal Investigator: STOPC Biobank Genetics Consortium (UCSD Unit). Other Co-Principal Investigator: Alexander Kuo, MD.

2012 Principal Investigator: “Retrospective Analysis of UCSD Liver Pa-tient Population,” UCSD Medical Center, 5-Year Study. UCSD Liver Center.

2011 Principal Investigator: “POC Hepatitis B and Hepatitis C:

Screening for Viral Hepatitis, Its Role in Linkage to Care and Economic Ramification in Healthcare,” Asian Pacific Health Foundation (APHF) Community Outreach Events. In Process.

2011 Principal Investigator: “Retrospective Analysis of UCSD Liver

Patient Population.” UCSD Human Research Protections Program. UCSD Medical Center. Study is for 5 years,

In Process. 2011 – 2013 Principal Investigator: “UCSD Liver Research Biorepository. UCSD Health Systems.

2012 Principal Investigator: “An International Multi-Center, Blinded,

Randomized Study to Investigate Safety, Tolerability, PK and PD Following Administration of Regimens Containing PSI-352938, PSE-7977, and Ribavirin in Patients with Chronic HCV,” AVRC at UCSD.

2012 – 2013 Principal Investigator: “Barriers to Hepatitis B Screening and

Hepatitis B Knowledge Among Asian Population in San Diego County.” All UCSD Health Systems.

2012 – 2013 Study to Improve Early Identification of Hepatitis B (HBV) and C (HCV) Infections in Clinical and Community Settings and to En-hance Linkage to Care, Treatment, and Preventive Services for Infected Persons. Grant submitted by Hepatitis Free San Diego in collaboration with the Antiviral Research Center, University of Cal-ifornia, San Diego. Approved by Centers for Disease Control and Prevention (CDC), September 2012 for 1 year.

2013 – Present Co-investigator: A University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences study; Cost-Effectiveness of Hepatitis C Screening: Point of Care (POC) vs. Standard of Care Tests.


UCSD: RESEARCH / ADVISORY: Continued

2012 – Present Co-investigator: A University of California, San Diego Skaggs

School of Pharmacy and Pharmaceutical Sciences study. Cost Ef-ficiency Analysis of Point-of-Care versus Standard of Care Tests for Hepatitis B in Asian Americans in San Diego County.

8/31/2013 – Robert G. Gish MD Present Robert G. Gish Consultants, LLC

Business address: 6022 La Jolla Mesa Drive San Diego, CA 92037 Cell phone: 1 858 229 9865 Email: [email protected] Website: robertgish.com

COINVESTIGATOR: GASTROINTESTINAL TRIALS

2002 Tegaserod vs. Placebo, for functional dyspepsia with documented delayed gastric emptying. (Novartis).

2002 A phase III, double-blind, multicenter, randomized, placebo-

controlled study of the effects of a somatostatin analogue - lanreotide as an adjuvant to endoscopic band ligation of patients with acute bleeding from oesophageal varies secondary to cirrhosis and portal hypertension (Biomeasure).

2002 Performance evaluation of the given diagnostic imaging system in

the upper gastrointestinal tract (given imaging). 2002 An efficacy and safety study of intravenous pantoprazole in the

prevention of recurrent peptic ulcer bleeding after successful hemostasis (Wyeth-Ayerst).

2002 Prospective comparison of air contrast barium enema (ACBE)

computed tomographic colonography (virtual colonoscopy) and colonoscopy for evaluation of the colon.

2002 Evaluation of investigational sclerotherapy-type needle for tissue

identification (Enterics). 2002 A pilot Phase II, muliticenter, randomized, double-blind, placebo-

controlled, dose escalation study of the safety and efficacy of human HCV-antibody (HCV-Ab XTL 68) for prevention of hepatitis C disease recurrence in patients who have received hepatic allografts for treatment of end-stage liver disease due to hepatitis C virus infection.

Curriculum Vitae


COINVESTIGATOR: GASTROINTESTINAL TRIALS: Continued

2010 Moving towards comprehensive liver cancer control: A qualitative study.

2010 Applying conjoint analysis to develop a comprehensive liver

cancer control plan in Asia. 2011 Predicting the future impact of emerging technologies on

Hepatocellular carcinoma (HCC): Measuring stakeholders preferences with best-worst scaling.

2011 Stakeholder involvement in priority setting of strategies to improve

hepatocellular carcinoma policy (EU data). 2011 Predicting the future impact of emerging technologies on

Hepatocellular carcinoma (HCC): Measuring stakeholders preferences with best-worst scaling.

2011 Predicting the future impact of emerging technologies on

hepatocellular carcinoma (HCC): Using best-worst scaling to explore clinicians’ views.

2011 Controlling liver cancer internationally: A qualitative study of

clinicians’ perceptions of current public policy needs. 2011 Stakeholder involvement in priority setting of strategies to improve

liver cancer control policy in Asia. 2011 Focus will be all Asian data results vs. USA - performance needs

and discussion around country-level differences (possible publication in special supplement of ONCOLOGY, tbc).

2011 Evaluation of the Merits of the Evidence Regarding the

Identification of Hepatitis C Virus (HCV) and HCV-Related Chronic Disease Among Persons Born from 1945 to 1965.

2012 Associate Member, Moores UCSD Cancer Center. 2013 Editorial Advisory Board, Gastroenterology & Hepatology Journal,

Digestive Disease Week Breakfast, Orlando, FL.; May 19, 2013. 2011 – 2013 STOPSC Genetics Recruitment; Studies of Primary Sclerosing

Cholangitis (STOPSC) is a multi-center joining effort to understand the possible causes and treatment of Primary Slerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) as well as the effects of the disease on the liver over time


TEACHING ACTIVITIES

1987–1988 Consult Attending Gastroenterology and Liver Services Wadsworth Veterans Hospital Los Angeles, California 1987–1988 Clinical Toxicology UCLA School of Medicine Los Angeles, California 1989–1991 UC Davis Liver Conference Martinez VA, University of California, Davis Martinez, California 1991–1995 Gastroenterology and Liver Clinic University of California, Davis Sacramento, California 1994 Visiting Professor University of Florida Gainesville, Florida 1996 Visiting Professor University of Iowa Iowa 1996, 1997 & 2003 Visiting Professor University of California, Los Angeles Los Angeles, CA 2003 Visiting Professor University of Colorado Denver, Colorado 2006 Visiting Professor University of Southern California Los Angeles, California 1988 – 2010 Gastroenterology Teaching Service Highland General Hospital, Alameda County Medical Center Oakland, California 1988 – 2010 Gastroenterology and Liver Teaching Service California Pacific Medical Center San Francisco, California 1993 – 1999 Merced Community Hospital Teaching Faculty

Family Medicine Program Merced, California

University of California, Davis Sacramento, California


TEACHING ACTIVITIES: Continued

1996 – 2010 Department of Medicine University of California, San Francisco San Francisco, California OSCE 1995-2002 Medicine Teaching Service at CPMC Housestaff Teaching Service at Highland Hospital 50 hours per year of teaching service (minimum) 2008 – 2010 Department of Medicine University of California, San Francisco San Francisco, California Medicine Teaching Service (a total of 88 hours of preceptorship) 2010 – 2013 Department of Medicine University of California, San Diego San Diego, California 2013 Consultant to Hepatitis Free San Diego Elective Course,

UCSD Skaggs School of Pharmacy and Pharmaceutical Sci-ences, San Diego, California

2013 Developed and Funded New Graduate Training Program

Committee approval for Transplant Hepatology fellow for one year, Dr. Heather Patton, Department of Medicine, University of California, San Diego

San Diego, California June 2013 Review of Dr. Tami Daugherty for Clinical Associate Professor

Department of Medicine, Stanford University School of Medicine, Division of Gastroenterology and Hepatology Stanford, California

Curriculum Vitae


COMMITTEES

1989 – 1992 Member, Human Liver Cell Culture Facility SRI International Menlo Park, California 1989 – 1992 Member, Executive Committee Pacific Transplant Institute San Francisco, California 1990 – 1992 Executive Vice President, S.F. Bay Area Chapter American Liver Foundation San Francisco, California 1990 – 1992 Chairman, Fundraising Committee S.F. Bay Area Chapter American Liver Foundation San Francisco, California 1991 – 1993 Member, Scientific Exhibits Committee American Society for Gastrointestinal Endoscopy 1992 – 1993 Chairman, Nominating committee S.F. Bay Area Chapter American Liver Foundation San Francisco, California 1992 – 1993 Chairman, Public Education Committee S.F. Bay Area Chapter American Liver Foundation San Francisco, California 1993 Member, Committee for Test Question Development American Board of Internal Medicine 1993 – 1996 Chairman, Medical Advisory Committee

S.F. Bay Area Chapter American Liver Foundation San Francisco, California

1994 – 1997 Member, Committee on Liver and Intra-abdominal Organ

Transplantation American Society of Transplant Physicians 1996 Member, Abstract Review Committee American Society of Transplant Physicians 1997 – 1998 Member, Hepatitis Task Force State of California Public Awareness and Department of

Corrections, under direction of Senator Polanco

Curriculum Vitae


COMMITTEES: Continued

1997 – 2001 Member, Clinical Research Committeer American Association for the Study of Liver Diseases 1999 Secretary Hepatitis Resource Network 1999 – 2000 Chairman, Search Committee California Pacific Medical Center Pathologist San Francisco, CA 1999 – 2013 Member, Governing Council Abstract Reviewer American Association for the Study of Liver Diseases (AASLD) 1999 – 2001 Co-Chair, Membership Committee American Society of Transplantation 2001 – 2002 Medical Adivsory Committee

American Liver Foundation San Francisco, California 2001 – 2002 Member, HCV Advocate Medical Writers Circle 2002 – 2004 Member, Abstract Review Committee AASLD 2003 Chair AASLD Topic Forum

2003 Faculty Member AASLD Expert Consensus Conference 2003 Task Force Member Santa Barbara County HCV Strategic Plan 2003 – 2006 Member, Liver and Intestinal Transplantation Committee Organ Procurement and Transplantation Network (OPTN)/UNOS 2004 Member, Health Liver Alert Screening Committee American Liver Foundation 2004 Expert Council Member Advancing Clinical Treatment of Hepatitis B Virus (ACT-HBV) Initi-

ative 2004 – 2006 Member, Fund Development Committee AASLD

Curriculum Vitae


COMMITTEES: Continued 2005 – 2007 Member, Public Policy Committee

AASLD 2004 – 2010 Member, Research Development Committee California Pacific Medical Center 2006 – Present Member, Scientific Committee Hep Dart Conference 1994 – 2007 Director, Department of Transplantation Serum and Tissue Bank California Pacific Medical Center 1995 – 2007 Liver Center Member University of California, San Francisco 1996 – 1998 Member, National Scientific Review Committee American Liver Foundation 1997 – 2000 Member, Membership Committee American Society of Transplant Physicians 1997 – 2003 Medical Review Subcommittee American Liver Foundation 1997 Member, Southern China Hepatitis Study Group Guangzhou, China and Hong Kong 1998 – 2010 Member, Committee on Information Technology California Pacific Medical Center San Francisco, California 2004 – 2005 Member, Hepatitis Plan Workgroup State of Nevada 2007 Member, Fund Raising Study Task Force AASLD 2007 Abstract Reviewer American Transplant Congress 2007 – 2008 Member, Organizing Committee Hong Kong-Shanghai International Liver Congress 2007 – 2010 San Francisco Hep B Free Campaign

2008 – 2010 Board Member, American Liver Foundation, San Francisco Chapter

Curriculum Vitae



2008 – 2010 Advisor, LASH Local Area Support for Hepatitis, Inc. (L.A.S.H.) 2008 – Present Board Member, FAIR Foundation 2008 – Present Scientific Advisory Committee, Global Antiviral Journal 2009 Program of comprehensive research actions: Hepatocellular carci-

noma. French National Cancer Institute. Grant Review. 2009 2009 – 2010 Member at large, Nominating Committee American Society of Transplantation (AST) 2009 – Present Board Member Hepatitis C Oversight Partnership (HepCop) 2009 – Present Group Membership, AASLD Special Interest Group on Hepatitis B (SIG) 2010 – Present Scientific Board Member Asian Pacific Association for the Study of Liver Disease (APASL) 2010 Abstract Reviewer Asian Pacific Association for the Study of Liver Disease

(ASPASL), Beijing, China 2009 – 2013 Co-Chair of and Memberof Steering Committee AASLD Hepatitis B Special Interest Group (SIG) 2010 Nomination Committee San Francisco Medical Society

2010 – Present Member, Hepatitis D International Network 2011 – Present LI-RADS (Liver Imaging Reporting and Data System) 2011 Abstract review panel: AASLD Fall meeting 2011– Present San Diego County Medical Society 2011 – Present Member, Philippines Viral Hepatitis Project

Curriculum Vitae



2012 – 2013 Graduate Medical Education Enrollment Committee, Transplant Hepatology Program University of California, San Diego.

2012 – Present Member, International Coalition of Hepatology Educators 2012 Abstract Review Committee, American Association for the Study

of Liver Disease 2012 – 2013 Vice President, Steering committee of the National Viral Hepatitis

Round Table 2012 – 2015 Member, National Viral Hepatitis Round Table 2012 – Present Member, Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP)

2011 & 2012 Faculty Interviewer Committee, Internal Medicine Residency Ap-plicants, University of California, San Diego Department of Internal Medicine.

2013 AASLD Abstract Review Committee 2013 Member, Editorial Advisory Board, Gastroenterology & Hepatology

Journal, Digestive Disease Week Breakfast, Orlando, FL., May 19, 2013. 2011 – 2013 EMR Provider Optimization Group (POG) EPIC Commitee 2013 Planning and Steering Committee Member for Imaging and Surveillance, Liver Cancer Roundtable 2013 Executive Vice-Chair, National Viral Hepatitis Roundtable Committee 2013 – Present Founding Member, Liver Cancer Roundtable 2010 Co-Chair, the 2nd Biannual International Conference of Armenian

Hepatological Forum.

2013 Finance Review Committee, American Association for the Study of Liver Diseases (AASLD), Annual Business Meeting

2014 Committee Member Nominee, Centers for Disease Control and Prevention (CDC)/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT).

Curriculum Vitae



2014 – Present Medical Director Hepatitis B Foundation, Doylestown, PA

2014 – Present Member

Global Hepatitis Community, www.hepcomm.com 2014 – Present Vice President & Member, Board of Directors

FAIR Foundation, Palm Desert, CA

2014 – Present Chair, Safety Monitoring Board Review Novira Therapeutics, Doylestown, PA

2014 – Present Member, Editorial Board

BMJ Open Gastroenterology (in association with British Society of Gastroenterology)

2014 – Present Fellow, American Associations for the Study of Liver Disease

September 2014 Organizing Committee, 1st Transcaucasus International Confer ence on Liver Disease 2014; Presented by Georgian, Armenian and Azerbaijani Hepatology Associations, Tibilisi, Georgia.

2014 – Present Secretary, Vietnam Viral Hepatitis Alliance 2014 – Present Chair, Clinic Research Committee, Vietnam Viral Hepatitis Alliance

http://www.hepcomm.com/

Curriculum Vitae


BOARD ACTIVITIES

1999 – 2002 Member, Medical Advisory Board Schering-Plough InforMed Hepatology 1999 – 2002 Cheng Si Yaun, Hong Kong and Beijing, Research and Education

in Liver Disease, Board Member, Peoples Republic of China 2001 – 2003 Member, Data Safety Monitoring Board Department of Health and Human Services, National Institutes of

Health Civacir HCV immunoglobulin protocol 2002 – 2010 Chair, U.S. Hepatitis B Advisory Board Bristol-Meyers Squibb Corporation 2002 – 2006 At-large Member, Region 5 Organ Allocation Listing Committee Regional Review Board United Network for Organ Sharing (UNOS) 2003 – 2004 Member, Data Safety Monitoring Board Civicir Research protocol to prevent recurrent HCV after liver

transplantation 1999 – Present Board Member, Hepatitis C Caring Ambassadors 2007 Editorial Board, Antiviral Therapy – Manuscript Central 2003 – 2006 Member, Advisory Board Liver Institute for Education and Research (L.I.F.E.R.) Foundation

2004 – Present Member, Editorial Board Liver Transplantation 2005 – Present Member, Editorial Advisory Board Gastroenterology & Hepatology 2007– Present Hepatitis B Foundation Medical and Scientific Advisory 2009 – Present Member, Board of Directors HepaHope 2009 Member, International Advisory Board Egyptian Society of Liver Cancer (ESLC) 2011 Member, Advisory Board, Pharmasset

Curriculum Vitae ROBERT G. GISH, M.D. 45 BOARD ACTIVITIES: Continued

1992 Member, Academic Review Board University of Florida Gainesville, Florida 1992 – 1994 Member, Advisory Board Hepatitis B Demonstration Project City of San Francisco, Children's Immunization San Francisco, California 1999 – 2002 Medical Director, Board of Directors HCV Global Foundation 1999 – 2000 Editorial Board The Practical Hepatitis Newsletter (PHN) 2011 – Present Member, Philippines Viral Hepatitis Project 2011 Southern Nevada Health District (SNHD) 21st Ho’loaule’a Festival (Pure Aloha Festival). (September 2011)

hosted by Las Vegas Hawaiian Civic Club Leadership 2012 – Present Member, Liver Imaging Radiology Committee (LI-RADS)

University of California, San Diego. 2012 – Present Member, Abstract Review Committee

American Transplant Congress (ATC), Review Program Live.

2012 At Large, Board Nominations Nominee, American Association for the Study of Liver Diseases, Governing Board, May 2012.

2013 At Large, Nominee, American Association for the Study of Liver Diseases, Governing Board, and Treasurer, May 2013. 2013 – Present National Hepatitis B Task Force, Advisory Board. 2013 – Present Advisory Board Member

North American Journal of Medicine and Science (NAJMS). 2013 – Present Member, Gastroenterology & Hepatology Editorial Advisory Board. 2013 – Present Advisor, National Viral Hepatitis Task Force (NVHTF) 2013 – Present Advisor, Viral Hepatitis Foundation (VHF)

2013 – Present Advisor, Hepatology Society of the Philippines

Curriculum Vitae


BOARD ACTIVITIES: Continued

2013 Advisor, Abstract Review Committee, American Association for the Study of Liver Disease Annual Conference Committee, Wash-ington, D.C., November 1-5, 2013

2013 Advisory Board Member, Tan Tao School of Medicine, Ho Chi

Minh City, Vietnam

2013 Academic Peer Review Surakit Pungpapong, M.D., Associate Professor of Medicine, College of Medicine, Mayo Clinic, October 8, 2013. 2014 – 2015 Member, Drug Safety Monitoring Board, Isis Pharmaceuticals HBV Phase 2 Drug Development 2014 – Present Member, Editorial Advisory Board, Gastroenterology & Hepatology


EDITORIAL ACTIVITIES

Alimentary Pharmacology & Therapeutics Archives of Medical Research ASTP Abstract Review Committee American Journal of Gastroenterology Biodrugs Diabetes Care Digestive Diseases and Sciences European Journal of Gastroenterology & Hepatology Gastroenterology Gastrointestinal Endoscopy Gut Hepatology Journal of Clinical Investigation Journal of Gastrointestinal Endoscopy Journal of Hepatology Journal of Infectious Disease Liver Transplantation and Surgery Liver International Mayo Clinic Proceedings Obstetrics and Gynecology Transplantation Proceedings Transplantation Journal of AIDS Section Editor, Current Hepatitis Reports, Vol. 1, No. 1, November 2007 Peer View/in Focus Gastroenterology Clinics of North America Journal of Virology Review 2005 Edition European Journal of Gastroenterology & Hepatology Associate Editor: Chinese Hepatology 2005 Thesis Advisor: PhD in Psychology Louise I. Bertman, 1999 Compliance, noncompliance and comparative MMPI-2 profiles of alcohol-dependent and non-alcohol-dependent patients evaluated for orthotopic liver transplantation


MENTEE LIST

NAME ETHNICITY MENTOR RELATIONSHIP POSITION NOW (Dates, How mentored)

Debbie Hana-Yi Korean 2008-2010 research associate

NYU Residency

Michael Mangahas Filipino 2008-2010 research associate

Med student; UCSF/UC Berkeley

Sumbella F. Baqai, MD

Pakistani 2008-2010 research associate

Resident and Chief Resi-dent Department of Internal Medicine; Alameda County Medical Center, Oakland, CA

Javaheri Shahram Persian 1999-2000: GI Fellow Fellowship mentor

Aris Mendiola Pilipino 2000-2001: GI Fellow Fellowship mentor

Sheila Savur Indonesian 2001-2001: GI Fellow Fellowship mentor

Tammy Daugherty Caucasian 2000-2003: GI Fellow Fellowship mentor

Linda Nguyen Vietnamese 2000-2003: GI Fellow Fellowship mentor

Daniel Rengstorff Caucasian 2001-2004: GI Fellow Fellowship mentor

Ann Chen Chinese 2003-2004: GI Fellow Fellowship mentor

Christine Pizzute Caucasian 2004-2005: GI Fellow Fellowship mentor

Jessie Liu Chinese 2005-2006: GI Fellow Fellowship mentor

Katerina Shetler Russian/Ukrainian 2005-2006: GI Fellow Fellowship mentor

Mimi Lin Chinese 2006-2007: GI Fellow Fellowship mentor

Liz Clark Chinese/Hawaiian 2007-2008: GI Fellow Fellowship mentor

Michele Tana Chinese 2008-2009: GI Fellow Fellowship mentor

Cathy Cabansag Filapina 2008-2009: GI Fellow Fellowship mentor

Edward Holt Caucasian 2009-2010: GI Fellow Fellowship mentor


MENTEE LIST: Continued


Irene Vodkin Caucasian 2007-2008: Preceptor for student’s Longitudinal Clini-cal Experience (LCE)

UCSF Med Student

Iris Ma Chinese 2008-2009: Preceptor for student’s Longitudinal Clini-cal Experience (LCE)

UCSF Med Student

Arlene Vazquez Hispanic 2009-1010: Preceptor for student’s Longitudinal Clini-cal Experience (LCE)

UCSF Med Student

Patricia Zheng Chinese 2010-2011: Preceptor for student’s Longitudinal Clini-cal Experience (LCE)

UCSF Med Student

Steve Kane Caucasian 2010-2013 Premed student, re-search associate

Margaret Clark Caucasian 2010-2013 Premed student, re-search associate

Erica Boettcher Caucasian 2010 – 2013 GI Fellow

Brigid Boland Caucasian 2010 – 2013 GI Fellow

Imad Elkhatib Middle Eastern 2010 – 2013 GI Fellow

Wilson Kwong Asian 2011 – 2013 GI Fellow

Michael McTigue Caucasian 2011 – 2013 GI Fellow

Mazen Nourredin Caucasian 2010 – 2013 GI Fellow

Suresh Pola Asian Indian 2010 – 2013 GI Fellow

Ashish Shah Asian Indian 2011 – 2013 GI Fellow

Amir Zarrinpar Persian 2011 – 2013 GI Fellow

Ingrid Gonzalez Hispanic 2011 – 2013 GI Fellow

Thuy Anh Le Asian 2010 – 2013 GI Fellow

Julio Guttierrez Hispanic 2010 – 2013 GI Fellow

Fred Park Asian 2011 – 2013 GI Fellow

Toritsesan Boyo (Tosan)

Nigerian 2011-2013 Business Resident


MENTEE LIST: Continued


Lilly Nguyen Vietnamese 2013 – 2013 Pharmacy Student

Thuy Nguyen Vietnamese 2013 Pharmacy Student

Xuan Phan Vietnamese 2013 Pharmacy Student

Laura Stinton Caucasian June 2013 Fellowship mentor

My Traing Vietnamee August 2014 Pharmacy Student

CLINICAL EXAM SESSIONS

Participant / Proctor, GI Focused clinical exam session, UCSD, November 2011 Participant, Clinical Exam Sessions, University of California, San Diego School of Internal Medi-cine, November 21, 2011. FACULTY REVIEW AND ASSESSMENT Yngve Falck-Ytter, MD, AGAF, Associate Professor of Medicine, Case Western Reserve Uni-versity Chief, Division of Gastroenterology, December 2, 2014. Chinese University of Hong Kong, Professor Lai Hung Wong, professorship candidate assess-ment, December 19, 2014.


PUBLICATIONS: PEER REVIEW ORIGINAL PUBLICATIONS

1979 – 1994 1. Stella VJ, Gish RG. Ionization kinetics of the carbon acid phenindione. J Pharm Sci. Au-

gust 1979; 68(8):1042-1047.

2. Stella VJ, Gish RG. Kinetics and mechanism of ionization of the carbon acids 4’-substi-tuted 2-phenyl-1, 3-indanediones. J Pharm Sci. August 1979; 68(8):1047-1049.

3. Gish RG, Garcia C, Reedy T, Kaplowitz N, Langer GA. Calcium compartmentation and exchange rates in primary hepatocyte culture. Anal Biochem. May 1990; 187(1):187-196.

4. Zeldis JB, Depner TA, Kuramoto RK, Gish RG, Holland PV. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med. Jun 1990;112(12):958-960.

5. Linton MF, Gish RG, Hubl ST, Butler E, Esquivel CO, Boyles JK, Wardell MR, Young SG. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest. Jul 1991;88(1):270-281.

6. Nakazato P, Cox K, Concepcion W, Gish RG, Berquist W, Imperial J, Esquivel C. Early experience with FK506 induction immunosuppression – suggestion for using oral FK506. Transplant Proc. Dec 1991;23(6):3019-3020.

7. Gish RG, Warmerdam M, Zeldis J, Keeffe EB, Nakazato P, Lim J, Cox K, Kuramoto IK, Fry KE, Yarbough P, Moeckli R, Yun-cho K, Reyes G. Variation in antibody reactivity to the hepatitis C virus by comparative immunoscreening and enzyme immunoassay. Viral Immunology. Spring 1993;6(1):49-54.

8. Gish RG, Lee AH, Keeffe EB, Rome H, Concepcion W, Esquivel CO. Liver transplanta-tion for patients with alcoholism and end-stage liver disease. Am J Gastroenterol. Sep 1993;88(9):1337-1342.

9. Gonzalez-Peralta RP, Fang JW, Davis GL, Gish RG, Tsukiyama-Kohara K, Kohara M, Mondelli MU, Lesniewski R, Phillips MI, Mizokami M, et al. Optimization for the detection of viral hepatitis C (HCV) antigens in liver. J Hepatology. Jan 1994;20(1):143-147.

10. Lang T, Berquist W, Rich E, Cox K, De Vries P, Cahill J, Baker E, Gish R. Treatment of recurrent pancreatitis by endoscopic drainage of a duodenal duplication. J Pediatr Gas-troenterol Nutr. May 1994;18(4):494-496.

1995 11. Martinez OM, Villanueva JC, Lawrence-Miyasaki L, Quinn MB, Gish RG, Cox K, So S,

Esquivel CO, Krams SM. Molecular markers of Epstein-Barr virus infection in the circula-tion of transplant recipients. Transplant Proc. Feb 1995;27(1):1211-1212.

12. Gish RG, Krams S, Martinez OM. Interleukin 12 (IL-12): A possible cytotoxic T-lympho-cyte (CTL) differentiation factor in allograft recipients. Transplant Proceed. Feb 1995;27(1):459-460.


PUBLICATIONS: PEER REVIEW ORIGINAL PUBLICATIONS: Continued

13. Lau JY, Mizokami M, Kolberg JA, Davis GL, Prescott LE, Ohno T, Perrill RP, Lindsay

KL, Gish RG, Qian KP, Kohara M, Simmonds P, and Urdea MS. Application of six hepa-titis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Inf Dis. Feb 1995;171(2):281-289.

14. Gish RG, Keeffe EB, Lim J, Brooks LJ, Esquivel CO. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. J Hepatol. Mar 1995;22(3):257-262.

15. Gonzalez-Peralta RP, Fang JW, Davis GL, Gish RG, Kohara M, Mondelli MU, Urdea MS, Mizokami M, Lau JY. Significance of hepatic expression of hepatitis C viral (HCV) antigens in chronic hepatitis C. Dig Dis Sci. Dec 1995;40(12):2595-2601.

1996

16. Gish RG, Lau JY, Brooks L, Fang JW, Steady SL, Imperial JC, Garcia-Kennedy R, Es-quivel CO, Keeffe EB. Ganciclovir treatment of hepatitis B virus infection in liver trans-plant recipients. Hepatology. Jan 1996;23(1):1-7.

17. Lau GK, Davis GL, Wu SP, Gish RG, Balart LA, Lau JY. Hepatic expression of hepatitis C virus RNA in chronic hepatitis C: a study by in situ reverse-transcription polymerase chain reaction. Hepatology. Jun 1996;23(6):1318-1323.

18. Cacciarelli T, Martinez OM, Gish RG, Villaneuva JC, Krams SM. Immunoregulatory cy-tokines in chronic hepatitis C virus infection: pre- and post-treatment with interferon alfa. Hepatology. Jul 1996;24(1):6-9.

19. Lau JY, Davis GL, Prescott LE, Maertens G, Lindsay KL, Qian K, Mizokami M, Sim-monds P; Hepatitis Interventional Therapy Group (Gish RG). Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med. May 1996;124(10):868-876.

1997

20. Gish RG, Qian KP, Quan S, Xu YL, Pike I, Polito A, DiNello R, Lau JY. Concordance be-tween hepatitis C virus serotyping assays. J Viral Hepat. 1997;4(6):421-422.

21. Ku NO, Wright TL, Terrault NA, Gish RG, Omary MB. Mutation of human keratin 18 in association with cryptogenic cirrhosis. J Clin Invest. Jan 1997;99(1):19-23.

22. Gish RG. Hepatitis C virus: Seven years old. Viral Hepatitis Reviews. 1997;3(1):17-37.Gish RG, Lau JYN. Hepatitis C Virus: Eight Years Old. Viral Hepatitis Reviews. Mar 1997;3(1):17-37.

23. Gish RG and Olden K. Alcohol and liver disease – should transplantation be of-fered? Practical Gastroenterology. December 1997.



24. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish RG, Keeffe EB, Kneteman NM, Lake

JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH. Minimal crite-ria for placement of adults on the liver transplant waiting list: a report of a national con-ference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg. Nov 1997;3(6):628-637.

25. Gish RG. Review of computer program "A simplified approach to the management of patients with chronic hepatitis B and C infections." Gastroenterology. Dec1997.

1998

26. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B im-mune globulin prophylaxis. Hepatology. Jan 1998;27(1):213-222.

27. Xiang J, Klinzman D, McLinden J, Schmidt WN, LaBrecque DR, Gish RG, Stapleton JT. Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J Virol. Apr 1998;72(4):2738-2744.

28. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, Kneteman NM, Lake JR, Martin P, Rakela J, Shiffman ML, So S, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Transplantation. Oct 1998;66(7):956-962.

29. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J; International Hepatitis Interventional Therapy Group (Gish RG). Interferon alfa-2b alone or in combination with ribavirin for the treat-ment of relapse of chronic hepatitis C. N Engl J Med. Nov 1998;339(21):1493-1499

30. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK; Hepatitis Interventional Therapy Group (Gish RG). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. Nov 1998;339(21):1485-1492.

31. Gish RG. Longer, Longer, Longer. Advances in Gastroenterology, Hepatology and Clini-cal Nutrition. 1998;3:83-85.

1999

32. Poordad FF, Gish RG. Evolving therapies for the treatment of viral hepatitis. Expert Opinion on Emerging Drugs. Jan 1999;4(1):15-34.

33. Fischer L, Sterneck M, Muller-Ruchholtz C, Gish R, Will H. Hepatitis B virus variants as-sociated with clinically severe recurrence after liver transplantation. Transplant Proc. Feb-Mar 1999;31(1-2):492-493.

Curriculum Vitae



34. Gish RG, Qian K, Brooks L, Leung J, Xu Y, Pike I, Lau JY. Characterization of anti-hep-atitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serology. J Gastroenterol Hepatol. Apr 1999;14(4):339-344.

35. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, Schiff E, Gish R, Villeneuve JP, Farr G, Anschuetz G, Crowther L, Brown N. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation, Lamivudine Transplant Group. Hepatology. May 1999;29(5):1581-1586.

36. Elkayam O, Hassoba HM, Ferrell LD, Garcia-Kennedy R, Gish RG, Wright TL, Laffler T, Traylor D, Hunt G, Rosenthal P. GB virus C (GBV-C/HGV) and E2 antibodies in children preliver and postliver transplant. Pediatr Res. Jun 1999;45(6):795-798.

37. Tung BY, Farrell FJ, McCashland TM, Gish RG, Bacon BR, Keeffe EB, Kowdley KV. Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver Transpl Surg. Sep 1999;5(5):369-374.

38. Ware JE Jr., Bayliss MS, Mannocchia M, Davis GL; The Interventional Therapy Group (Gish RG). Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology. Aug 1999;30(2):550-555.

39. Nalbandian G, Van de Water J, Gish R, Manns M, Coppel RL, Rudich SM, Prindiville T, Gershwin ME. Is there a serological difference between men and women with primary biliary cirrhosis? Am J Gastroenterol. Sep 1999;94(9):2482-2486.

40. Tanaka A, Prindiville TP, Gish R, Solnick JV, Coppel RL, Keeffe EB, Ansari A, Gershwin ME. Are infectious agents involved in primary biliary cirrhosis? A PCR approach. J Hepatol. Oct 1999;31(4):664-671.

41. Tanaka A, Lindor K, Gish R, Batts K, Shiratori Y, Omata M, Omata M, Nelson JL, Ansari A, Coppel R, Newsome M, Gershwin ME. Fetal microchimerism alone does not contrib-ute to the induction of primary biliary cirrhosis. Hepatology. Oct 1999;30(4):833-38.

42. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, Gish RG. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl and Surg. Nov 1999;5(6):491-496.

43. Gish, RG, Wakil AE. Combination interferon-alfa 2B plus ribavirin for treatment of chronic hepatitis C. Current Practice of Medicine. 1999;2(4-10).

2000 44. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T,

Yao R, Albrecht; International Hepatitis Interventional Therapy Group (Gish RG). The Impact of Interferon Plus Ribavirin on Response to Therapy in Black Patients With Chronic Hepatitis C. Gastroenterology. Nov 2000;119(5):1317-1323.

Curriculum Vitae



2001 45. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish RG, Martin P, Dienstag J, Adams

P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N; Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine mon-otherapy before and after liver transplantation for chronic hepatitis B. Hepatology. Feb 2001;33(2):424-432.

46. Ku NO, Gish R., Omary M, Wright TL. Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med. May 2001;344(21):1580-1587.

47. Gish RG, Lee A, Brooks L, Leung J, Lau JY, Moore DH. Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver trans-plantation. Liver Transpl. Jul 2001;7(7):581-87.

48. Hadlock KG, Gish RG, Rowe J, Rajyaguru SS, Newsom M, Warford A, Foung SK. Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2). J Med Virol. Sep 2001;65(1):23-29.

49. Kato H, Orito E, Sugauchi F, Ueda R, Gish RG, Usuada S, Miyakawa Y, Mizokami M. Determination of hepatitis B genotype by polymerase chain reaction with hemi-nested primers. J Med Virol Methods. Nov 2001;98(2):153-159.

2002 50. Kato H, Orito E, Gish RG, Bzowej N, Newsom M, Sugauchi F, Suzuki S, Ueda R,

Miyakawa Y, Mizokami M. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology. Apr 2002;35(4):922-9.

51. Kato H, Orito E, Gish RG, et al. Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F). Journal of Virology. Jun 2002;76(12):6313-6137.

52. Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Dele-hanty J, Rigney A, Mondou E, Snow A, Rousseau F. Dose range study of pharmacoki-netics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother. Jun 2002;46(6):1734-40.

53. Shakil AO, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeevaram H, Gish R, Kwo P, Balan V, Wright TL, Brass C, Rakela J. A pilot study of interferon alfa and ribavi-rin combination in liver transplant recipients with recurrent hepatitis C. Hepatology. Nov 2002;36(5):1253-8.

54. Mao TK, Kimura Y, Kenny TP, Branchi A, Gish RG, Van de Water J, Kung HJ, Friedman SL, Gershwin ME. Elevated expression of tyrosine kinase DDR2 in primary biliary cirrho-sis. Autoimmunity. Dec 2002;35(8):521-529.

55. Kato H, Orito E, Sugauchi F, Ueda R, Koshizaka T, Yanaka S, Gish RG, Mizokami M. New hepatitis B virus genotyping system that allows for identification of mixed genotype infection. Submitted 2002.

Curriculum Vitae



2003 56. Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G,

Gardner SD, Brown N, Griffiths D; United States Lamivudine Compassionate Use Study Group (Gish RG). A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. Jan 2003;9(1):49-56.

57. Marcellin P, Chang TT, Lim SG, Tong M, Sievert W, Shiffman, M, Jeffers L, Goodman Z, Wulfsohn MS, Xion S, Fry J, Brosgart C, for the Adefovir Dipivoxil 437 Study Group (Gish RG). Adefovir Dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. Feb 2003;348(9):808-816.

58. Zarski JP, Mc Hutchison J, Bronowicki JP, Sturm N, Garcia-Kennedy R, Hodaj E, Truta B, Wright T, Gish R. Rate of natural disease progression in patients with chronic hepati-tis C. J Hepatol. Mar 2003;38(3):307-314.

59. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Gish RG, Ueda R, Miyakawa Y, Mizokami M. Epidemiological and virological characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology. Apr 2003;124(4):925-932.

60. Kato H, Orito E, Sugauchi F, Ueda R, Koshizaka T, Yanaka S, Gish RG, Kurbanov F, Ruzibakiev R, Kramvis A, Kew MC, Ahmad N, Khan M, Usuda S, Miyakawa Y, Mizokami M. Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. J Virol Methods. Jun 2003;110(1):29-35.

61. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, Alonzo J, Garcia-Kennedy R, Rayon JM, Wright TL. A model to predict severe HCV-related disease following liver transplantation. Hepatology. Jul 2003;38(1):34-41.

62. Westland C, Delaney W 4th, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. Hepatitis B virus genotypes and virologic re-sponse in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. Jul 2003;125(1):107-116.

63. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain KB, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS; Liver Cancer Network. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol, Sep 2003;98(9):2060-2063.

64. Poordad F, Gish R, Wakil A, Garcia-Kennedy R, Martin P, Yao FY. De novo non-alco-holic fatty liver disease following orthotopic liver transplantation. Am J Transplant. Nov 2003;3(11):1413-1417.

Curriculum Vitae



2004 65. Sugauchi F, Kumada H, Acharya SA, Shrestha SM, Gamutan MT, Khan M, Gish RG,

Tanaka Y, Kato T, Orito E, Ueda R, Miyakawa Y, Mizokami M. Epidemiological and se-quence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. J Gen Virol. Apr 2004;85(Pt 4):811-820.

66. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat. May 2004;11(3):243-250.

67. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ; Proactive Study Group (Gish RG). Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, ran-domized controlled study. Gastroenterology. May 2004;126(5):1302-1311.

68. Kato H, Gish RG, Bzowej N, Newsom M, Sugauchi F, Tanaka Y, Kato T, Orito E, Usuda S, Ueda R, Miyakawa Y, Mizokami M. Eight genotypes (A-H) of hepatitis B virus infect-ing patients from San Francisco and their demographic, clinical, and virological charac-teristics. J Med Virol. Aug 2004;73(4):516-21.

69. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, Gordon SC, Wright HI, Zweiban B, Podda M, Gershwin ME. Primary biliary cirrhosis in monozygotic and dizy-gotic twins: genetics, epigenetics, and environment. Gastroenterology. Aug 2004;127(2):485-92.

70. Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, Acharya SK, Gish RG, Kramvis A, Kew MC, Yoshihara N, Shrestha SM, Khan M, Miyakawa Y, Mizokami M. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology. Sep 2004;40(3):747-55.

71. Jazayeri M, Basuni AA, Sran N, Gish R, Cooksley G, Locarnini S, Carman WF. HBV core sequence: definition of genotype-specific variability and correlation with geograph-ical origin. J Viral Hepat. Nov 2004;11(6):488-501.

2005

72. Aora S, Xu C, Teng A, Peterson J, Yeh LT, Gish R, Lau D, Rossi S, Lin CC. Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. J Clin Pharmacol. Mar 2005;45(3):275-285.

73. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F. Severe hepatotoxicity associated with nevi-rapine use in HIV-infected subjects. J Infect Dis. Mar 2005;191(6):825-829.

74. Savur S, Bonacini M, Bzowej N, Gish R, Wakil A, Osorio R. Erythropoietin is approved for the treatment of anemia associated with renal failure, chemotherapy, preoperative anemia, and human immunodeficiency virus disease. Liver Transpl. Mar 2005;11(3):366.

Curriculum Vitae



75. Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL, Wang C, Anderson J, Mondou E, Snow A, Sorbel J, Rousseau F, Corey L. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol. Jul 2005;43(1):60-66..

76. Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, Fontana RJ, McCashland T, Cotler SJ, Bacon BR, Keeffe EB, Gordon F, Polissar N; National He-mochromatosis Transplant Registry. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterol-ogy. Aug 2005;129(2):494-503.

77. Terrault NA, Pawlotsky JM, McHutchison J, Anderson F, Krajden M, Gordon S, Zitron I, Perrillo R, Gish R, Holodniy M, Friesenhahn M. Clinical utility of viral load measure-ments in individuals with chronic hepatitis C infection on antiviral therapy. J Viral Hepat. Sep 2005;12(5):465-472.

78. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Ba-con BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes RG; BEHoLD Study Group. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. Oct 2005;129(4):1198-1209.

79. Kato H, Fujiwara K, Gish RG, Sakugawa H, Yoshizawa H, Sugauchi F, Orito E, Ueda R, Tanaka Y, Kato T, Miyakawa Y, Mizokami M. Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. World J Gastroenterol. Oct 2005;11(40):6295-6304.

80. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM; USA PBC Epidemiology Group (Gish RG). Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. Nov 2005;42(5):1194-1202.

81. Colquhoun S, Gish R, Runyon B. “MELD Exception Guidelines for Candidates with Asci-tes.” www.unos.org November 21, 2005.

82. Washburn K, Gish R, Kamath P. “MELD Exception Guidelines for Candidates with Budd-Chiari Syndrome.” www.unos.org November 21, 2005.

83. Gores G, Gish R, Sudan D. “MELD Exception Guidelines for Candidates with Cholangi-ocarcinoma.” www.unos.org November 21, 2005.

84. Horseln S, Sweet S, Gish R, Shepherd R. “MELD Exception Guidelines for Candidates with Cystic Fibrosis and Coexistent Chronic Liver Disease.” www.unos.org November 21, 2005.

85. Ham J, Gish R, Mullen K. “MELD Exception Guidelines for Candidates with Hepatic En-cephalopathy.” www.unos.org November 21, 2005.

86. Pomfret E, Gish R, Brandhagen D. “MELD Exception Guidelines for Candidates with Fa-milial Amyloidotic Polyneuropathy (FAP).” www.unos.org November 21, 2005.

87. Mulligan DC, Gish RG, Krowka MJ. “MELD Exception Guidelines for Candidates with Hepato-pulmonary Syndrome.” www.unos.org November 21, 2005.

https://webmail.service.emory.edu/horde/services/go.php?url=http%3A%2F%2Fwww.unos.org%2F







Curriculum Vitae



88. Garcia-Tsao G, Gish RG, Punch J. “MELD Exception Guidelines for Candidates with Hereditary Hemorrhagic Telangiectasia.” www.unos.org November 21, 2005

89. Horslen S, Gish RG, McDonald R. “MELD Exception Guidelines for Candidates with Pri-mary Hyperoxaluria.” www.unos.org November 21, 2005.

90. Arrazola L, Gish RG, Everson GT. “MELD Exception Guidelines for Candidates with Pol-ycystic Liver Disease.” www.unos.org November 21, 2005.

91. Mulligan DC, Gish R, Krowka MJ. “MELD Exception Guidelines for Candidates with Por-topulmonary Hypertension.” www.unos.org November 21, 2005.

92. Washburn WK, Gish R. “MELD Exception Guidelines for Candidates with Severe Pruri-tus.” www.unos.org November 21, 2005.

93. Gores G, Gish R, Roshan Shrestha, “MELD Exception Guidelines for Candidates with Recurrent Bacterial Cholangitis associated with Structural Biliary Dis-ease.” www.unos.org November 21, 2005.

94. Sheiner P, Gish R, Sunyal A. “MELD Exception Guidelines for Candidates with Portal Hypertensive GI Bleeding.” www.unos.org November 21, 2005.

95. Sheiner P, Gish R, Miller C. “MELD Exception Guidelines for Candidates with Small for Size Syndrome after Liver Transplantation.” www.unos.org November 21, 2005.

96. Punch J, Gish R.“MELD Exception Guidelines for Candidates with Uncommon Hepatic Tumors.” www.unos.org November 21, 2005.

97. McDiarmid S, Gish R, Horslen S. “MELD Exception Guidelines for Candidates with Unu-sual Metabolic Liver Diseases That Would be Cured by Liver. Transplanta-tion.” www.unos.org November 21, 2005.

2006 98. Ito K, Tanaka Y, Orito E, Sugiyama M, Fujiwara K, Sugauchi F, Kato T, Tokita H, Izumi

N, Kato M, Yuen MF, Lai CL, Gish RG, Ueda R, Mizokami M. T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin Infect Dis. Jan 2006;42(1):1-7. Epub 2005 Nov 29.

99. Perrillo RP, Gish RG, Peters M, Keeffe EB, Alberti A, Buti M, Cooksley WG, Fried MW, Hadziyannis SJ, Liaw YF, Naoumov NV, Schiff ER, Thio CL, Tsai N, Schalm S. Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol Hepatol. Feb 2006;4(2):233-248.

100. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. Mar 2006;354(10):1001-1010.

101. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group (Gish RG). Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. Mar 2006;354(10):1011-1020.











Curriculum Vitae



102. Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, Butter-worth L, Cooksley G, Gish RG, Beaugrand M, Fay F, Fay O, Gonzalez JE, Martins RM, Dhumeaux D, Vanderborght B, Stuyver L, Sablon E, de Lamballerie X, Pawlotsky JM. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Vi-rol. Oct 2006;78(10):1296-1303.

103. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A, Shi-mada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. Influence of hepatitis B virus geno-types on the intra- and extracellular expression of viral DNA and antigens. Hepatology. Oct 2006;44(4):915-924.

104. Arrazola L, Moonka D, Gish RG, Everson GT. Model for end-stage liver disease (MELD) exception for polycystic liver disease. Liver Transpl 2006; 12 Suppl 3:S110-S111.

105. Biggins SW, Colquhoun S, Gish RG, Runyon BA. Model for end-stage liver disease (MELD) exception for ascites. Liver Transpl 2006; 12 Suppl 3:S88-S90.

106. Freeman RB, Jr., Gish RG, Harper A, Davis GL, Vierling J, Lieblein L et al. Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006; 12 Suppl 3:S128-S136.

107. Garcia-Tsao G, Gish RG, Punch J. Model for end-stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia. Liver Transpl 2006; 12 Suppl 3:S108-S109.

108. Gores GJ, Gish RG, Shrestha R, Wiesner RH. Model for end-stage liver disease (MELD) exception for bacterial cholangitis. Liver Transpl 2006; 12 Suppl 3:S91-S92.

109. Gores GJ, Gish RG, Sudan D, Rosen CB. Model for end-stage liver disease (MELD) ex-ception for cholangiocarcinoma or biliary dysplasia. Liver Transpl 2006; 12 Suppl 3:S95-S97.

110. Ham J, Gish RG, Mullen K. Model for end-stage liver disease (MELD) exception for he-patic encephalopathy. Liver Transpl 2006; 12 Suppl 3:S102-S104.

111. Horslen S, Sweet S, Gish RG, Shepherd R. Model for end-stage liver disease (MELD) exception for cystic fibrosis. Liver Transpl 2006; 12 Suppl 3:S98-S99.

112. Horslen S, Gish RG, McDonald R. Model for end-stage liver disease (MELD) exception for primary hyperoxaluria. Liver Transpl 2006; 12 Suppl 3:S117-S118.

113. Krowka MJ, Fallon MB, Mulligan DC, Gish RG. Model for end-stage liver disease (MELD) exception for portopulmonary hypertension. Liver Transpl 2006; 12 Suppl 3:S114-S116.

114. McDiarmid S, Gish RG, Horslen S, Mazariegos GV. Model for end-stage liver disease (MELD) exception for unusual metabolic liver diseases. Liver Transpl 2006; 12 Suppl 3:S124-S127.

Curriculum Vitae



115. Pomfret E, Gish RG, Brandhagen D. Model for end-stage liver disease (MELD) excep-tion for familial amyloidotic polyneuropathy. Liver Transpl 2006; 12 Suppl 3:S100-S101.

116. Punch J, Gish RG. Model for end-stage liver disease (MELD) exception for uncommon hepatic tumors. Liver Transpl 2006; 12 Suppl 3:S122-S123.

117. Sheiner P, Gish RG, Sanyal A. Model for end-stage liver disease (MELD) exception for portal hypertensive gastrointestinal bleeding. Liver Transpl 2006; 12 Suppl 3:S112-S113.

118. Sheiner P, Belghiti J, Gish RG, Miller C. Model for end-stage liver disease (MELD) ex-ception small-for-size syndrome. Liver Transpl 2006; 12 Suppl 3:S120-S121.

119. Washburn WK, Gish RG, Kamath PS. Model for end-stage liver disease (MELD) excep-tion for Budd-Chiari syndrome. Liver Transpl 2006; 12 Suppl 3:S93-S94.

120. Washburn WK, Gish RG. Model for end-stage liver disease (MELD) exception for se-vere pruritus. Liver Transpl 2006; 12 Suppl 3:S119.

121. Wiesner R, Lake JR, Freeman RB, Gish RG. Model for end-stage liver disease (MELD) exception guidelines. Liver Transpl 2006; 12 Suppl 3:S85-S87.

2007 122. Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV,

Gish RG. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2007;25(11):963-977.

123. Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, Reddy KR, Reindol-lar R, Rodriguez-Torres M, Sullivan S, Blatt LM, Faris-Young S. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology. Mar 2007;45(3):569-578.

124. Gish RG. Do we need to MEND the MELD? Liver Transpl. Apr 2007;13(4):486-487.

125. Gish RG, Arora S, Rajender Reddy K, Nelson DR, O'Brien C, Xu Y, Murphy B. Virologi-cal response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a random-ized, phase 2 study. J Hepatol. Jul 2007;47(1):51-59. Epub 2007 Mar 12.

126. Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, Frederick RT, Bonacini M. My-cophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol. Jul 2007;5(7):799-802.

127. Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-ef-fectiveness analysis. Aliment Pharmacol Ther. 2008; Epub 2007 Mar 27.

Curriculum Vitae



128. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubi-cin. J Clin Oncol. Jul 2007;25(21):3069-3075.

129. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Ma-khviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA. Oral IDN-6556, an antiapop-totic caspase inhibitor, may lower aminotransferase activity in patients with chronic hep-atitis C. Hepatology. Aug 2007;46(2):324-329.

130. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. Nov 2007;133(5):1437-1444. Epub 2007 Aug 14.

131. Carr C, Blaine Hollinger F, Yoffe B, Wakil A, Phillips J, Bzowej N, Leung J, Mirro K, Poordad F, Moore DH, Gish RG. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. Liver Int. Oct 2007;27(8):1111-1118.

132. Ko C, Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling RK, Cotler SJ, Fontana RJ, McCashland TM, Han SH, Gordon FD, Schilsky ML, Kowdley KV. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: re-sults from the National Hemochromatosis Transplant Registry. Liver Int. Dec 2007;27(10):1394-1401.

133. Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastro-enterol. Dec 2007;102(12):2718-23. Epub 2007 Jul 27.

134. Selmi C, Gershwin ME, Lindor KD, Worman HJ, Gold EB, Watnik M, Utts J, Invernizzi P, Kaplan MM, Vierling JM, Bowlus CL, Silveira MG, Bossi I; USA PBC Epidemiology Group (Gish RG). Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology. 2007 Dec;46(6):1836-43.

135. Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH. The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. Value Health. 2007; Epub 2007 Dec 17.

2008 136. Gish RG, Jacobson I, Pockros P. Improving HBV Treatment: Early Screening and Sus-

tained Control for Improved Outcomes. Clinical Roundtable Monograph. Gastroenterol-ogy and Hepatology. January 2008.

137. Gish RG. Comment: Entecavir therapy provides long-term benefit for chronic hepatitis B. Contemporary Dental Assisting. Reuters Health, 2008.

138. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC; Public Policy Committee of the American Association for the Study of Liver Disease (Gish RG). Serum activity of ala-nine aminotransferase (ALT) as an indicator of health and disease. Hepatology. Apr 2008;47(4):1363-1370.

Curriculum Vitae



139. Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. May-Jun 2008;11(3):527-38.

140. Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-ef-fectiveness analysis. Aliment Pharmacol Ther. Jun 2008;27(12):1240-1252.

2009

141. Xu L, Guo L, Shen Z, Loss G, Gish R, Wasilenko S, Mason AL. Duplication of MER115 on chromosome 4 in patients with primary biliary cirrhosis. Liver Int. Mar 2009;29(3):375-383.

142. Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. A randomized controlled trial of thy-malfasin plus transarterial chemoembolization for unresectable hepatocellular carci-noma. Hepatol Int. Sept 2009; 3(3):480-489.

143. Chang TT, Chao YC, Gorbakov VV, Han KH, Gish RG, de Man R, Cheinquer H, Bes-sone F, Brett-Smith H, Tamez R. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. Nov 2009;16(11):784-789.

144. Marcellin P, Gish RG, Gitlin N, Heise J, Halliman DG, Chun E et al. Safety and efficacy of viramidine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-na-ive hepatitis C patients. J Hepatol 2009.

2010 145. Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H,

Tamez R. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucle-oside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. Jan 2010;17(1):16-22.

146. Marcellin P, Gish RG, Gitlin N, Heise J, Halliman DG, Chun E, Rodriguez-Torees M. Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. J Hepatol. Jan 2010;52(1):32-38.

147. Gish RG, Cooper SL. Hepatitis B in the greater San Francisco bay area: an integrated program to respond to a diverse local epidemic. Aug. 2010: J Viral Hep.

148. Gish R, Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma, Cancer Epidemiology, Biomarkers & Prevention, Dec 2010

2011

149. Gish RG, Satishchandran C, Young M, Pachuk C. RNA Interference and its Potential Applications to Chronic HBV Treatment: Results Of A Phase 1 Safety And Tolerability Study. Antivir Ther. 2011;16(4):547-554.

Curriculum Vitae



150. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. “Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients. A Case Series”. Dig Dis Sci. 2011 Feb:56(2): 578-585.

151. Wong RJ, Gish R, Schilsky M, Frenette C. “A Clinical Assessment of Wilson Disease in Patients with Concurrent Liver Disease”. J Clin Gastroenterol. 2011 Mar;45(3):267-273.

152. Frei R, Gish R, Boceprevir Studies Suggest Addition to Hepatitis-C Cocktail Increases

Efficacy in Genotype 1 Individuals, NEJM, March 2011

153. Gish RG, Cooper SL, “Hepatitis B in the Greater San Francisco Bay Area: An Integrated Programme to Respond to a Diverse Local Epidemic,” Journal of Viral Hepa Apr; 18(4): e40-51, April 2011.

154. Han SH, Reddy KR, Keefe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekin B, Lok A and the NIH HBV OLT study group. “Clinical Outcomes Of Liver Transplantation For Hbv-Related Hepatocellular Carcinoma: Data From The NIH HBV OLT Study”. Clin Transplant. 2011 Mar-Apr;25(2):E152-E162.

155. Comunale MA, Wang M, Rodemich-Betesh L, Hafner J, Lamontagne A, Klein A, Marrero J, Di Bisceglie AM, Gish R, Block T, Mehta A. Novel Changes in Glycosylation of Serum Apo-J in Patients with Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1222-1229.

156. Cohen C, Holmberg SD, McMahon Bi, Block JM, Brosgart CL, Gish RG, London WT, Block TM, “Is Chronic Hepatitis B Being Undertreated in the United States?,” Journal of Viral Hepatitis, Jun;18(6):377-83. June 18, 2011.

157. Cachey ER, Wyles DL, Goiceochea M, Torriani FJ, Ballard C, Colwell B, Gish RG, Mathews WC. Reliability And Predictive Validity Of A Hepatitis-Related Symptom Inven-tory In HIV-Infected Individuals Referred for Hepatitis C Treatment. AIDS Res & Ther. 2011 Aug 10;8:29.

158. Gish, RG, Kaveh H. HBV screening in asians and pacific islanders: interim cost-effec-tiveness analysis of a single-enter San Francisco program”; Journal of Epide and Com Health. 2011 Sept (1).

2012

159. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. The Impact of Race/Ethnicity on the Clinical Epidemiology of Autoimmune Hepatitis. J Clin Gastroenterol. 2012 Feb;46(2):155-161.

160. Patton H, Misel M, Gish RG. Acute Liver Failure in Adults: An Evidence-based Manage-

ment Protocol for Clinicians. Gastroenterol Hepatol. 2012 Mar;8(3):161-212. 161. Kuo A, Gish R. Chronic Hepatitis B Infection. Clin Liver Dis. 2012 May;16(2):347-369.

Curriculum Vitae



162. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar Risk of Renal Events among Patients Treated with Tenofovir or Entecavir for Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2012 Aug; 10(8):941-946.

2013

163. Gish RG, Chang, Lai CL, Ade Man R. Quantitative Hepatitis B surface antigen analysis i Hepatitis B E-antigen in positive, nucleoside-naïve patients treated with encantavir,” anti-viral therapy, AVT-12-OA-2806.R1, 2013 Mar(6):

164. Gish RG, Hana YD, Kane S, Clark M, Mangahas M, Baqai S, Winters M, Proudfoot, J, Glenn JS,. Coinfection with Hepatitis B and D: epidemiology, prevalence and disease in patients in northern California.

165. Gish RG, et al, “One-Step Real-Time PCR Assay for Detection and Quantitation of Hep-atitis D Virus RNA"; Journal of Virological Methods, # VIRMET-D-13-00111R1

2014

166. Kim S, Syed G, Khan M , Chiu W, Sohail M, Gish R, Siddiqui A, "Hepatitis C Virus Trig-gers Mitochondrial Fission and Attenuates Apoptosis to Promote Viral Persistence Proc Natl Acad Sc,#:2013-21114RR 19Mar-2014.

166. Wong RJ, Gish RG; Implementing Best Practices When Initiating Hepatitis B Virus Ther-

apy, Clin in Liv Dis, Apr-2014.

167. Gish RG, Gutierrez JA, Navarro-Cazarez N, Giang K, Adler D, Tran B, Locarnini S, Hammond R, Bowden S; A simple and inexpensive point-of-care test for hepatitis B sur-face antigen detection: serological and molecular evaluation, Journal of Viral Hep, doi:10.1111/jvh.12257, accepted for publication, 15 March 2014.

168. Wong RJ, Gish, RG, Aijaz, A; Hepatic Encephalopathy is Associated with Significantly Increased Mortality Among Patients Awaiting Liver Transplantation, Journal of Liver Transplant, accepted for publication, 8 June 2014.

169. Ahn J, Gish, RG., Hepatitis D in 2014- a Call to Screening, accepted for publication, Gastroenterology Hepatology, accepted for publication, 8 June, 2014.

170. Gish RG, Kono Y, Kartik J, Loomba R, Patton H , Alexander K, Mendler M; Hepatocellu-lar Carcinoma Surveillance: A National Survey of Current Practices in the United States, Digestive Disease Science Journal, manuscript ID# DDSJ-D-14-00596R, accepted for publication, 14June 2014.

171. Gish RG, Lands L, et al; Immunosuppression in Patients with Chronic Hepatitis B, Cur-rent Hepatology Reports, Article 238, DOI: 10.1007/s11901-014-0238-2, Editorial manu-script number: HEPS-D-14-00018.0, accepted for publication, 11 June 2014.

Curriculum Vitae



172. Seetharam A, Perillo RP, Gish RG; Immunosuppression in Patients with Chronic Hepati-tis B, DOI 10.1007/s11901-014-0238-2; Curr Hepatology Rep; 21 June 2014.

173. Perillo RP, Gish RG, Seetharam A, Lands L; Medical Interventions Associated with HBV Reactivation: Common and Less Common, Clinical Liver Disease, Manuscript ID CLD-14-0060, 10 July 2014 Perillo RP, Gish RG, Falck‐Ytter YT; American Gastroenter-ological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation during Immunosuppressive Drug Therapy; Gastroenterology Press, 2014.

174. Donald G. Mitchell DG, Bruix J, Sherman M, Sirlin CB; LI-RADS (Liver Imaging Report-ing and Data System): Summary, Discussion, and Consensus of the LI-RADS Manage-ment Working Group and Future Directions; Manuscript ID HEP-14-0736.R1.27304; Heptalology 18July, 2014; co-author via the study consortium and acknowledgements.

175. Wong RJ, Gish RG; “Implementing Best Practices When Initiating Hepatitis B Virus Therapy”, Critical Issues in HBV, Volume I Number I, Aug 2014. Also available through VINDICO medical education, OpenCME.org and the Healio.com/Infectious-Disease/Edu-cation-Lab.

176. Baqai S, Proudfoot J, Yi D, Mangahas M, Gish RG, “High rate of core promoter and pre-core mutations in patients with chronic hepatitis B and their impact on the liver disease,”, DOI: 10.1007/s12072-014-9598-5, Editorial manuscript #HEPI-D-14-00200.2, Hepatol-ogy International, 12Dec 2014.

Curriculum Vitae ROBERT G. GISH, M.D. 67 SUBMITTED FOR PUBLICATION

1. Gish RG. Successful domino liver transplantation from a patient with methylmalonic acidemia: first ever report. American Association for the Study of Liver Dis ease, Liver Transplantation, Manuscript ID LT-12-522.R1; 2013 Mar(6):

2. Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. “HCC: Surveillance: An Inquiry into Current Practices in the United States”, American Journ of Gastroentrol, Submitted for publication; 18 Dec-2013. Manuscript ID: AJG-13-2307. This was pub-lished can you find on pubmed ?

3. Wong RF, Gish RG, hmed, Aijaz: Hepatic Encephalopathy is Associated with Signifi-cantly Increased Mortality Among Patients Awaiting Liver Transplantation”, 5 Mar-2014. submitted for publication.

4. Baqai SF, Hana D, Zeng L, Gish RG. “Entecavir Effective for Both Treatment-Experi-enced and Treatment-Naïve Chronic Hepatitis B Patients in ‘Real Life’ Settings,” Lark Scientific, Mar-2014.

5. Gish RG, Wong, et al., Etiology of Underlying Liver Disease Impacts Post-Liver Trans-plantation Survival among Patients with Hepatocellular Carcinoma, Hepatology, Manu-script ID HEP-14-1069, 7 May 2014.

6. Gish RG, Brosgart CL, Clary R, Block JM, Block TM, Lelt, Knowdley KV; The CDC Un-derestimates the Prevalence of Chronic Hepatitis B in the U.S., advocacy letter submit-ted for publication, Hepatology, 11 June 2014.

7. Gish RG, Brosgart CL, Clary R, Block JM, Block TM, Lelt, Knowdley KV; The CDC Un-derestimates the Prevalence of Chronic Hepatitis c in the U.S., advocacy letter submit-ted for publication, American Association for the Study of Liver Disease (AASLD), 11 June 2014.

8. Gish RG, Wong, et al., Etiology of Underlying Liver Disease Impacts Post-Liver Trans-

plantation Survival among Patients with Hepatocellular Carcinoma, American Associa-tion for the Study of Liver Disease, manuscript ID# LT-14-348, submitted for publication, 24 June 2014.

Curriculum Vitae


PUBLICATIONS – SUBBITTED FOR PUBLICATION: Continued

9. Wong RJ, Gish, RG, Aijaz, A., Hepatic Encephalopathy is Associated with Significantly Increased Mortality Among Patients Awaiting Liver Transplantation" American Associa-tion for the Study of Liver Disease, manuscript ID# LT-14-198.R3, submitted for publica-tion, 26 June 2014.

10. Reddy KR, Beavers KL, Hammond SP, Lim JK, Lim, Falck-Ytter YT, et al., American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy, Gastroenterology, submitted for publication, 26 June 2014. published

11. Wong RJ, Gish RG, Implementing Best Practices When Initiating Hepatitis B Virus Ther-apy, Vindico Medical Education; http://www.vindicomeded.com, monograph submitted for publication; 11 July 2014. published

12. Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, De Man RA, Llamoso C, Tang H; Entecavir Versus Lamivudine on Hepatic Covalently Closed-Circular DNA in Chronic Hepatitis B, submitted for publication, World Journal of Gastroenterology, 1Aug2014.accepted

13. Yu K, Tran B, Gish RG; “Expanding Hepatitis B Screening in Asian and Pacific Islander Americans in San Diego County: Needs Assessment and Linkage to Care”, Abstract Poster presented for California Pharmacists Association, San Diego, 10April, 2015.

14. Nguyen L, Tran B, Fontanesi J, Gish RG, “Cost effectiveness Analysis of Point-of-care versus Standard of Care Tests for Hepatitis B in Asian and Pacific Islanders,” submitted for publication, Amer Journ Pub Health, Oct2014.

15. Nguyen CT, Tran B, Fontanesi J, Gish RG, “Point-of-care testing for hepatitis C screen-ing at Community-Based-Organizations facilitates disease control,” submitted for publi-cation, Amer Journ Pub Health, Oct2014.

16. Phan X, Tran B, Tang G, Fontanesi J, Gish RG, “Targeting populations at risk for hepati-tis B: Demographic Considerations,” submitted for publication, Amer Journ Pub Health, Oct2014.

17. Chong S, Nguyen C, Tran B, Tsunoda S, Taylor P, Gish RG, “Collaborative Efforts to screen at risk populations for hepatitis B and C in San Diego County,” submitted for pub-lication, Amer Journ Pub Health, Oct2014.

18. Tran B, Nguyen K, Adler D, Gish RG, “ Pearls gained from hepatitis B screening in the Community setting,” submitted for publication, Amer Journ Pub Health, Oct2014.

19. Fontanesi J, Martinez A, Gish RG, Boyo TO, “A Case Study of Quality Improvement Methods for Complex Adaptive Systems Applied to an Academic Hepatology Program,” submitted for publication, Journal of Medical Practice Management, 14Oct, 2014.

Curriculum Vitae


PUBLICATIONS – SUBBITTED FOR PUBLICATION: Continued

20. Kohla MAS, Abu Zeid MI, El-Warraky M, Taha H, Gish RG, “Predictors of Hepatic De-compensation after TACE for Hepatocellular Carcinoma,” ESPS #15772, World Journ of Gastroenterology, 9Dec. 2014, submitted for publication.

21. Gish RG, Ahmed A, Wong RJ, “"Elevated Alpha-fetoprotein: Differential Diagnosis,” sub-mitted for publication. Accepted Feb is pub date

22. Baqai S Proudfoot J, Xu R, Kane S, Clark M, Gish RG; “Comparable Efficacy with Entecavir Monotherapy and Tenofovir + Entecavir Combination in Chronic Hepatitis B Patients,” submitted for publications Manuscript #JVH-00550-2014, Journal of Vir Hep, 10Dec 2014. published

23. Mixson-Hayden T, Kodan M, Gish RG, Perrillo R, Kamili S, “Passive Hepatitis Delta Sur-veillance in the United States: 2012-2014,” submitted for presentation, International Conference on Emerging Infectious Diseases 2015.

24. Aguilar M, Smith A, Woo G, Bhuket T, Liu B, Gish RG, Ahmed A, Wong RJ, “Real-World Outcomes of Sofosbuvir-Based Treatment in Chronic HCV Infection: A Community-Based Urban Safety-Net Hospital Experience in the United States,” Submitted for publi-cations ID# RS-1639, International Liver Congress 2015, 50th Annual Meeting of the Eu-ropean Association for the Study of the Liver (EASL), Vienna, Austria, 22April 2015.

25. Wong R, Gish RG, “Race/Ethnicity-Specific Disparities in Cancer Incidence, Burden of Disease, and Overall Survival among Patients with Hepatocellular Carcinoma in the U.S.: An Updated Analysis of the Surveillance, Epidemiology, and End Results Cancer Registry,” submitted for publication, ID#2155032, Digestive Disease Week 2015, Wash-ington DC, 17May 2015.


PUBLICATIONS – REVIEW ARTICLES

1. Glassman P, Wong C, Gish R. A review of liver transplantation for the dentist and guide-

lines for dental management. Spec Care Dentist. Mar-Apr 1993;13(2):74-80. Review.

2. Gish RG, Ascher NL. Transmission of hepatitis B virus through allotransplantation. Liver

Transpl Surg. Mar 1996;2(2):161-164.

3. Gish RG. Standards of treatment in chronic hepatitis C. Semin Liver Dis. 1999;19 Supl 1:35-47. Review.

4. Gish RG. Future directions in the treatment of patients with chronic hepatitis C virus in-fection. Can J Gastroenterol. Jan-Feb 1999;13(1):57-62. Review.

5. Yao F, Gish RG. Treatment of chronic hepatitis B: new antiviral therapies. Curr Gastro-enterol Rep. Feb-Mar 1999;1(1):20-26. Review.

6. Gish RG, Mason A. Autoimmune liver disease. Current standards, future directions. Clin Liver Dis. May 2001;5(2):287-314. Review.

7. Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am. Mar 2004;33(1 Suppl):S1-9.

8. Gish RG. Clinical trial results of new therapies for HBV: implications for treatment guide-lines. Semin Liver Dis. 2005;25 Suppl 1:29-39. Review.

9. Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in spe-cial populations: patient and treatment considerations. Clin Gastroenterol Hepatol. Apr 2005;3(4):311-8. Review.

10. Gish RG. Current treatment and future directions in the management of chronic hepatitis B viral infection. Clin Liver Dis. Nov 2005;9(4):541-65, v. Review.

11. Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimi-crob Chemother. Jan 2006;57(1):8-13. Epub 2005 Nov 17. Review.

12. Pawlotsky JM, Gish RG. Future therapies for hepatitis C. Antivir Ther. 2006;11(4):397-408. Review.

13. Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol. Mar 2006;4(3):252-61. Review.

14. Chang TT, Gish R, de Man R, Gadano A, Sollano J, Han KH, et al. Management of chronic hepatitis B virus infection: Current perspectives for the nurse practitioner. Jour-nal of the American Academy of Nurse Practitioners. May 2006;18(5):203-215. Review.

15. Gish RG. Entecavir: A Viewpoint by Robert G. Gish. Drugs. 2006;66(12):1623-1624. Re-view.

16. Gish RG. Setting Up an Outreach Clinic and Tertiary-Quaternary Medical Care Program. Gastroenterology and Hepatology. May 2006;2(5): 384-385. Review.

Curriculum Vitae


PUBLICATIONS – REVIEW ARTICLES: Continued

17. Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroen-

terol Hepatol. Jun 2006;4(6):666-676. Review.

18. Gish RG. Current developments in the treatment of hepatitis and hepatobiliary disease. Clin Adv Hematol Oncol. Jul 2006;4(7):511-512.

19. Gish RG, McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl. Nov 2006;12(11 Suppl 2):S54-64. Review.

20. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat. Dec 2006;13(12):787-798. Review.

21. Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol Rep. Mar 2007;9(1):14-22. Review.

22. Gish RG. Improving outcomes for patients with chronic hepatitis B. Hepatol Res. Jul 2007;37(s1):S67-78.

23. Gish RG, Perrillo RP, Jacobson IM. Customizing the management of chronic hepatitis B virus infection. Semin Liver Dis. Aug 2007;27 Suppl 1:9-17. Review.

24. Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin Liver Dis. Nov 200711(4):761-95, viii. Review.

25. Gish RG, Baron A. Hepatocellular carcinoma (HCC): Current and evolving therapies. IDrugs. Mar 2008;11(3):198-203.

26. Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, Wagner PD. The degree of readiness of selected biomarkers for the early detection of hepatocellular car-cinoma: notes from a recent workshop. Cancer Biomark. 2008;4(1):19-33.

27. Gish RG, Hisatake G. Improving clinical trial design for hepatocellular carcinoma treat-ments. Oncology Reviews. May 2007;1(1):45-52.

28. Gish R, Marrero JB, Tong MJ. Medical therapies to extend survival in hepatocellular car-cinoma. Clin Adv Hematol Oncol. Aug 2008;6(8):1-14.

29. Gish RG, Miyashita L. Sorafenib offers a new treatment for liver cancer – new medica-tion shown to improve survival in clinical trials. Liver and GI Review. Winter 2008, No.24.

30. Gish RG. Diagnosis of chronic hepatitis B and the implications of viral variants and mu-tations. Am J Med. Dec 2008;121(12 Suppl):S12-21.

31. Gish RG, Benson AB, Sherman M, Morgan BS. Cases in point: risk factors, surveillance strategies and treatment options for HCC. Gastroenterol Hepatol. Jan 2009;5(1)Suppl 3:1-16.

32. Gish RG. Hepatitis B treatment: current best practices, avoiding resistance. Cleve Clin J Med. May 2009;76(Suppl 3):S14-19.

Curriculum Vitae



33. Gish RG, Gholam PM. Monotherapy vs multiple-drug therapy: the experts debate. Cleve

Clin J Med. May 2009;76(Suppl3):S20-24.

34. Gish RG. Therapy for hepatitis B: la nouvelle vague. Can J Gastroenterol. June 2009;23(6):407-409.

35. Frenette CT, Gish RG. To “be” or not to “be” that is the question. Am Gastroenterol. Aug 2009;104(8):1948-1952.

36. Drug Effectiveness Review Project (DERP) team, Oregon Health & Science University, Grant Funding from Attorney General Consumer, Prescriber Grant Program, and Con-sumer Reports. Gish RG “Consumer Reports Best Buy Drugs.” Consumer Reports. 2010.

37. Gish RG, Marrero JA, Benson AB. A multidisciplinary to the management of hepatocel-lular carcinoma. Gastroenterol Hepatol 2010 Mar:6(3 Suppl 6):1-16. Clinical Roundtable Monograph

38. Gish RG, Abou-Alfa GK, Tong MG. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. Clin Adv Hematol Oncol. 2010 Sep;8(9):2p preceding 4-15. Clinical Roundtable Monograph

39. Frenette C, Gish RG. Hepatocellular Carcinoma: Molecular and Genomic Guide for the Clinician.Clin Liv Dis. 2011 May;15(2):307-321. Review

40. Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers? Clin Liv Dis. 2011 Aug;15(3):627-639. Review

41. Wong R, Frenette C, Gish R. Hepatocellular carcinoma: locoregional and targeted ther-apies. Gastroenterol Clin North Am. 2011 Sept;40(3):599-610. Review

42. Frenette CT, Frederick RT, Gish RG. “Clinical Management and Case Reports for the Treatment of Hepatocellular Carcinoma with Sorafenib”. J Clin Gastroenterol. 2011 Sept;45(8):733-737 Case report

43. Frenette C, Gish R. Targeted Systemic Therapies for Hepatocellular Carcinoma: Clini-cal Perspectives, Challenges And Implications. World J Gastroenterol. 2012 Feb 14;18(6):498-506. Review.

44. Gish RG, Society of interventional radiology critique and commentary on the cochrane report on transarterial (chemo)embolization. American Association for the Study of Liver Disease, Hepatology, HEP-12-0552; March 22, 2012.

45. Gish RG, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012 Apr;12(4):341-353. Review

46. Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Role of the multidiscipli-nary team in the diagnosis and treatment of hepatocellular carcinoms. Expert Rev Gas-troenterol Hepatol. 2012 Apr;6(2):173-185. Review.

Curriculum Vitae



47. Gish, RG, Marrero, J., Finn R. Extending survival with the use of targeted therapy for the

treatment of hepatocellular carcinoma. CAHO/G&H roundtable monograph, Clinical Ad-vances in Hematol/Oncol, Millennium Medical Publishing, Inc. 2013 Feb;4: page num-bers. Review.

48. Gish RG. Strategies for hepatocellular carcinoma surveillance and diagnosis. Gastroen-terol Hepatol. 2013 Apr;V9(4): page numbers. Review.

49. Noureddin M, Gish RG. Hepatitis Delta: Epidemiology, Diagnosis and Management: 36 Years After Discovery. Curr Gastroenterol Rep (2014) 16:365; Springerlink.com, 30 Nov 2013. Review.

PUBLIC POLICY: ORIGINAL MANUSCRIPT

1. Gish RG, Bui TD, Nguyen CT, Nguyen DT, Tran HV, Tran DM, Trinh HN; International Group for Liver Health in Viet Nam. Liver Disease In Viet Nam: Screening, Surveillance, Management And Education: A 5-Year Plan And Call To Action. J Gastroenterol Hepa-tol. 2012 Feb;27(2):238-247.


NEWSLETTERS

1. Gish RG, Osorio R. New Techniques and Devices are Revolutionizing Liver Transplan-

tation and Therapy. Pacific Currents, May 2000. Available at: http://www.cpmc.org/pro-fessionals/research/currents/2000LiverTX.html.

2. Gish RG. The Future of Western Treatment for Hepatitis C. HCV Advocate Medical Writers’ Circle. March 2002. Available at: http://www.hcvadvocate.org/hcsp/board.asp.

3. Gish RG. Overview of Treatment of Hepatitis B. HCV Advocate Medical Writers’ Circle. April 2003. Available at: http://www.hcvadvocate.org/hcsp/board.asp.

4. Gish RG. Minimizing the Impact of Neuropsychiatric Effects During Chronic HCV Dis-ease and Treatment. HCV Advocate Medical Writers’ Circle. April 2004. Available at: http://www.hcvadvocate.org/hcsp/board.asp.

5. Hassanein TI, (Gish RG steering committee). “Managing HCV: Nonresponders to Pegylated Interferon and Ribavirin Therapy.” PHOENIX – Perspectives in Hepatitis C Outcomes: An Educational Network for Improving Options in Treatment Failures. 2005.

6. Gish RG, comment in: LoBuono C. “New drug marks advance in treatment of hepatitis B.” Drug Topics: The News Magazines for Pharmacists. May 2, 2005.

7. Gish RG. Future Therapies for Hepatits C. HCV Advocate Medical Writers’ Circle. Feb 2006. Available at: http://www.hcvadvocate.org/hcsp/board.asp.

8. Gish RG, Miyashita L. Indicators of Hepatitis B Virsus (HBV) Infection – Screening Panel Advocated for At-Risk Populations. California Pacific Liver & GI Re-view. Spring/Summer 2006; Issue 20:2. www.cpmc.org/liver.

9. Gish RG. Multimodality Approach to the Treatment of HCC: The Emerging Paradigm. Newsletter from 58th Annual AASLD, Boston, MA, November 2007.

PUBLICATIONS: BOOK CHAPTER & EDITORIALS

1. Gish RG. “Ischemic and Congestive Liver Disease.” In: Gitnick, G, ed. Principles and Practice of Gastroenterology and Hepatology. New York: Elsevier Science Publishing Co., 1988: 1346-1352.

2. Gish RG. “Ischemic and Congestive Liver Disease.” In: Gitnick, G, ed. Principles and Practice of Gastroenterology and Hepatology. New York: Elsevier Science Publishing Co., 1988: 1346-1352.

3. Gish RG, Keeffe EB. “The Short Bowel Syndrome.” In: Snape, W, ed. Consultations in Gastroenterology. Cambridge, Mass: W.B. Saunders Company, 1995.

4. Gish RG, Keeffe EB. “The Short Bowel Syndrome.” In: Snape, W, ed. Consultations in Gastroenterology. Cambridge, Mass: W.B. Saunders Company, 1995.

5. Gish RG, Keeffe EB. Recent developments in the treatment of chronic hepatitis B virus infection. Expert Opinion on Investigational Drugs. Feb 1995;4(2):95-115.

http://www.hcvadvocate.org/hcsp/board.asp

http://www.cpmc.org/liver

Curriculum Vitae


PUBLICATIONS: BOOK CHAPTERS & EDITORIALS: Continued

6. Gish RG, Keeffe EB. Recent developments in the treatment of chronic hepatitis B virus infection. Expert Opinion on Investigational Drugs. Feb 1995;4(2):95-115.

7. Gish RG. “Evolving therapies for the treatment of viral hepatitis.” Ed. W. C. Bowman, J. D. Fitzgerald and J. B. Taylor. Emerging Drugs: The prospect for improved medicines annual executive briefing. Vol 1. London: Ashley Publications Ltd, 1996.

8. Gish RG, Cox KL, Mizokami M, Ohno T, Lau JY. Vertical transmission of hepatitis C. (letter) J Pediatr Gastroenterol Nutrition. Jan 1996;22(1):118-119.

9. Gish RG. “Evolving therapies for the treatment of viral hepatitis.” Ed. W. C. Bowman, J. D. Fitzgerald and J. B. Taylor. Emerging Drugs: The prospect for improved medicines annual executive briefing. Vol 1. London: Ashley Publications Ltd, 1996.

10. Gish RG. Hepatitis C virus: Seven years old. Viral Hepatitis Reviews. 1997;3(1):17-37.

11. Gish RG, Lau JYN. Hepatitis C Virus: Eight Years Old. Viral Hepatitis Reviews. Mar 1997;3(1):17-37.

12. Gish RG. Liver physiology and pathology. Chapter 20, "Liver." Gastroenterology Nurs-ing: A Core Curriculum. 2nd ed. St.Louis, Missouri: Mosby-Year Book, Inc., Apr 1997.

13. Gish RG. Liver physiology and pathology. Chapter 20, "Liver." Gastroenterology Nurs-ing: A Core Curriculum. 2nd ed. St.Louis, Missouri: Mosby-Year Book, Inc., April 1997.

14. Gish RG and Olden K. Alcohol and liver disease — should transplantation be of-fered? Practical Gastroenterology. Dec1997.

15. Gish RG. Review of computer program "A simplified approach to the management of patients with chronic hepatitis B and C infections." Gastroenterology. Dec 1997.

16. Gish RG, Locarnini S. “Chronic Hepatitis B Viral Infection.” In: Yamada and Alpers, eds. Textbook of Gastroenterology. Vol. 2.;107:2309-2327. Lippincott Williams & Wilkins, 1998.

17. Gish RG, Locarnini S. “Chronic Hepatitis B Viral Infection.” In: Yamada and Alpers, eds. Textbook of Gastroenterology. Vol. 2.;107:2309-2327. Lippincott Williams & Wilkins, 1998.

18. Gish RG. Longer, Longer, Longer. Advances in Gastroenterology, Hepatology and Clini-cal Nutrition. 1998;3:83-85.

19. Gish, RG, Wakil AE. Combination interferon-alfa 2B plus ribavirin for treatment of chronic hepatitis C. Current Practice of Medicine. 1999;2(4-10).

20. Gish RG, Baker EL. Imaging Before and After Liver Transplantation. Imaging in Hepato-biliary and Pancreatic Disease, 1999.

21. Gish RG, Baker EL. Imaging Before and After Liver Transplantation. Imaging in Hepato-biliary and Pancreatic Disease, 1999.

Curriculum Vitae



22. Gish RG. Treatment of Chronic Hepatitis B – Transplant Recipients. Management of Chronic Viral Hepatitis, 1999.

23. Gish RG. Counseling the Patient with Chronic Hepatitis C. Practical Hepatitis Update, 1999.

24. Poordad FF, Gish RG. Development in hepatitis C during 1997 – 1999. Expert Opinion on Therapeutic Patents. Sep 1999;9(9):1249-1262.

25. Cohen MR, Gish RG and Doner K. The hepatitis C help book: a groundbreaking treat-ment program combining Western and Eastern medicine for maximum wellness and healing. 1st ed. New York: St. Martin’s Press, 2000.

26. Gish RG. Current Treatment Options in Gastroenterology. Current Science, 2000.

27. Gish RG. “Treatment of Chronic HBV in Transplant recipients.” In: Stuart Gordon, MD, ed. Management of Chronic Viral Hepatitis. Marcel Dekker, 2001.

28. Gish RG. “HCV: Molecular Tools for Measuring Treatment Responses.” In: American College of Gastroenterology Clinical Guidelines. ACG, 2001.

29. Gish RG. “Prevention and treatment of hepatitis B in liver transplant recipients.” In: Ar-royo, Bosch, Bruix, Gines, Navasa, and Rodes, eds. Therapy in Hepatology. Barcelona: Ars Medica, 2001:183-191.

30. Lok AS, Heathcote EJ, Hoofnagle JH, Gish RG (subauthor). Management of hepatitis B: 2000 – summary of a workshop. Gastroenterology. Jun 2001;120(7):1828-1853.

31. Gish RG. “Approach to the Patient With Hepatomegaly.” In: David Rossman, MD, ed. Best Practice of Medicine. Praxis Press, 2002.

32. Lau G, Gish R, Liang R. Hepatitis B Infection and Immunosuppression. Chapter 12. In: Locarnini S and Lai L, eds. Hepatitis B Virus Guide. London: International Medical Press, 2002.

33. Gish RG, Wakil A. Hepatitis B in liver transplant recipients as a special model of antiviral drug development. Methods Mol Med, Hepatitis B and D Protocols II. 2004;96:319-341.

34. Gish RG, Locarnini S. Studying the treatment of chronic hepatitis B viral infection in spe-cial populations. Methods Mol Med, Hepatitis B and D Protocols III. 2004;96:465-498.

35. Gish RG, Lau J, Fang J, Mizokam M, Wright T. “Hepatitis C.” In: J. Larry Jameson, ed. Principles of Molecular Medicine. Humana Press, March 2004.

36. Gish RG. Maximizing the benefits of antiviral therapy for HCV: the advantages of treat-ing side effects. [editorial] Gastroenterol Clin North Am. Mar 2004;33(1 Suppl):xxiii-xxiv.

37. Gish RG. “Overview of Hepatitis C.” St. John and Sandt, eds. Hepatitis C Choices. 3rd Edition. Hepatitis C Caring Ambassadors Program, 2004:1-6.

38. Gish RG. “Future of Allopathic Hepatitis C Treatment.” St. John and Sandt, eds. Hepati-tis C Choices. 3rd Edition. Hepatitis C Caring Ambassadors Program, 2004:125-134.

Curriculum Vitae



39. Gish RG. Flamm S, Fried M, Pockros P. “Supporting Patients With Chronic Hepattis C During Therapy.” Special Report. January 1, 2005.

40. Gish RG, Briceno J. Factors Affecting Liver Transplantation for Hepatocellular Carci-noma Associated with Hepatitis C Virus Cirrhosis. Transplant International. Manuscript ID TRI-0A-06-0112.

41. Gish RG. Hepatitis C: Current Standards of Care and Future Perspectives. HCV Advo-cate Medical Writers’ Circle. May 2006. Available at: http://www.hcvadvo-cate.org/hcsp/board.asp.

42. Gish RG. Principles of Molecular Medicine. 2nd Ed. Totowa, NJ: Humana Press, 2006. ISBN: 1-58829-202-9.

43. Gish RG. “Risk Factors and Treatment for Hepatocellular Carcinoma.” Advances in Hepatology. Gastroenterology & Hepatology. Volumne 2, Issue 7. July 2006.

44. Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, Wagner PD. The degree of readiness of selected biomarkers for the early detection of hepatocellular car-cinoma: Notes from a recent workshop. Cancer Biomark. 2008;4(1):19-33.

45. Gish RG, Locarnini S. Chronic hepatitis B viral infection. Chapter 81. In: Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW. (Eds) Textbook of Gastroen-terology. Oxford, England. Blackwell Publishing, 2009: 2112-2138.

46. Raymond T. Chung, Robert G. Gish, Stephen A. Harrison. Jounal Options Hepatitis. Clinical Care Options. Volume 4, Issue 1. 2010.

47. Gish R, Martinez A, Western (Allopathic) Medicine: The Future of Allopathic Treatment for Hepatitis C, Hep C Choices.

48. Gish RG, Tam D. Bui MD, PhD, Chuc T.K. Nguyen, Pharm PhD, Duc T. Nguyen, MS,

PhD, Huy V. Tran, MD, PhD, Diem M.T. Tran, Huy N. Trinh, MD, AGAF, International Group for Liver Health in Vietnam (ILFVN), “Liver Disease in Viet Nam: Screening, Sur-veillance, Management and Education – A Five Year Plan and Call To Action,” Septem-ber, 2011.

49. Gish, RG, “HBV Screening in Asians and Pacific Islanders: Interim Cost-effectiveness

Analysis of a Single-center San Francisco Program,” Journal of Epidemiology & Commu-nity Health, January 2012.

Curriculum Vitae



50. Guitierrez JA, Gish, RG. “Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules “.Transl Cancer Res. 25 Nov 2013. Manuscript ID: TCR-13-113 DOI: 10.3978/j.issn.2218-676X.2013.10.01. Pioneer Bioscience Publishing Company. www.thetcr.org

51. Tran B, Yu K, Gish RG, Educational Awareness: Expanding Hepatitis B screening in

Asian Populations in San Diego, chapter presented to World Council for Curriculum and Instruction (WCCI) by Dr. Bihn Tran, San Diego, CA, August 2014.

52. Kwo PY, Gish RG, Nordenson NJ, Emerging Antiviral Agents and Strategies, HCV

Emerging Treatments, 2235-42 , Projects in Knowledge, 1Sept 2014. 53. Gish RG, “Chronic hepatitis B viral infection,” Yamada Textbook of Gastroenterology 5th

edition, update, DOI: 10.1002/9781444303254.ch81, original published date: 17Feb 2009, 5th edition update 15Jan 2015.

CASE REPORTS & LETTERS TO THE EDITOR

1. Huibregtse K, Gish RG, Tytgat GN. A frightening event during endoscopic papillotomy.

[letter] Gastrointes Endosc. Jan-Feb 1988;34(1):67-68. 2. Gish RG, Cox KL, Mizokami M, Ohno T, Lau JY. Vertical transmission of hepatitis C.

(letter) J Pediatr Gastroenterol Nutrition. Jan 1996;22(1):118-119.

3. Savur S, Bonacini M, Bzowej N, Gish R, Wakil A, Osorio R. Erythropoietin is approved for the treatment of anemia associated with renal failure, chemotherapy, preoperative anemia, and human immunodeficiency virus disease. (letter) Liver Transpl. Mar 2005;11(3):366.

4. Gish RG. Do we need to MEND the MELD? [comment] Liver Transpl. Apr 2007;13(4):486-487.

5. Moore L, Gish RG, “PBC: Primary Biliary Cirrhosis, What is in a name?” American Asso-ciation for the Study of Liver Disease (AASLD) eNews online portal, 10Oct 2014.

http://www.thetcr.org/


PUBLICATIONS: EDITOR / REVIEWER

1. Gish RG. Section Editor, “Hepatitis B: Epidemiology, Natural History, Treatment, and

Transplantation.” Current Hepatitis Reports. May 2003;2(2):49-59, 63-87.

2. Schreibman IR, Schiff ER. Entecavir: A Novel Treatment for Chronic Hepatitis B Infec-tion. Gish RG, ed. Future Virology. Sep 2006;1(5):541-552.

3. Gish RG, Reviewer/Editor. “Entecavir Drug Evaluation.” July 4, 2006.

4. Gish RG, Reviewer, The American Journal of Clinical Oncology, 2006. 5. Gish RG, Veenstra D, Iioeje U, Sullivan S, Tafesse E, Clarke L, Di Bisceglie A, Kowdley

K. Cost-Effectiveness of Entecavir versus Lamivudine in HBe-Ag-Positive Chronic Hep-atitis B Based on a 2 Year Clinical Trial. Editorial Manger for Gastroenteroly. Manuscript Draft.

6. Gish RG, Section Editor. Treatment and Antiviral Drug Resistance. Current Hepatitis B Reports. Aug 2007;1(1).

7. Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, Williams R, Lau GK, Schalm SW, Naoumov NV. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. Gish RG, journal editor. J Med Virol. Aug 2007;79(8):1055-63.

8. Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin Liver Dis 2007; 11(4):761-95, viii.

9. Gish RG, Reviewer/Editor. “Gankang Granula Therapy showed Potent Antiviral Activity in Chronic Hepatitis B.” 2007.

10. Gish RG, Reviewer/Editor. “The treatment of chronic hepatitis B – focus on adefovir like antivirals.” 2007.

11. Gish RG, journal reviewer/editor. Manuscript SGAS-2007-0057. Predicition of virologic response in difficult-to-treat chronic hepatitis C patients during high dose interferon in-duction therapy. Scandinavian Journal of Gastroenterology. March 3, 2008.

12. Gish RG, Reviewer/Editor. “Impact of antiviral treatment on noninvasive predictors of liver fibrosis in HIV/HCV co-infected patients: the Fibrovic 2 Study-ANRS HC02.” Journal of Acquired Immune Deficiency Syndromes. May 2008.

13. Ting-Tsung Chang, You-Chen Chao, Vladimir V. Gorbakov, Kwang-hyub Han, Gish RG, Robert de Man, Hugo Cheinquer, Fernando Bessone, Helena Brett-Smith, Ricardo Tamez. “Summary of an International Study of Entecavir for the Management of Nucleo-side-Naïve HBeAg-positive Patients With Chronic Hepatitis B.” Manuscript AJG-08-1370. American Journal of Gastroenterology. Submitted August 2008.

14. Gish, RG, Expert Reviewer, French National Cancer Institute, "Program of comprehen-sive research actions: Hepatocellular Carcinoma." 2008.

15. Gish, RG, Expert Reviewer. Wong, WS and Chan, Henry LY, HCC: Prevention and Control in Low and Middle Income Countries, October 2011.

Curriculum Vitae


PUBLICATIONS – EDITOR / REVIEWER: Continued

16. Gish RG, Reviewer, GUT Journal. 2008.

17. Gish, RG, Reviewer. “Higher baseline transaminases predict cirrhosis while longer time of adherence to antiretroviral therapy is linked to favorable virological outcome in HIV-HBV-co-infected patients.” Manuscript for HIV Clinical Trials. 2008.

18. Gish RG, Reviewer for Grant Application, Deutsche Forschungsgemeinschaft (DFG).

19. Gish RG, Reviewer for Grant Application, National Research Foundation South Africa (NRF).

20. Gish RG, Reviewer. “Abstract Session: Clinical: Allocaton MELD.” 2008.

21. Gish RG, Reviewer. “Cancer Chemotherapy and Pharmacology.” CCP-08-0223. 2008. 22. Gish RG, Section Editor. “Epidemiology and Natural History of Hepatitis B in Vietnam.”

2008. 23. Gish RG, Section Editor. “HBV Prevalence, Natural History, and Treatment in Eastern

Europe, Turkey, and Turkish-Speaking Countries in Central Asia.” 2008. 24. Gish RG, Section Editor. “Hepatitis B Virus Prevalence, Natural History, and Treatment

in Africans in Africa and the United States.” 2008. 25. Gish RG, Section Editor. “HBV Prevalence, Natural History, Treatment, and Resistance:

a 2008 Update with a Special Perspective on Individuals from the Indian Subcontinent.” 2008.

26. Gish RG, Section Editor. “Epidemiology, Presentation, and Treatment of Chronic HBV

Infection in Mainland China, in Taiwan, and in Chinese Americans in the United States.” 2008.

27. Gish RG, Section Editor. “HBV Prevalence, Natural History, and Treatment in Korea and the United States.” 2008.

28. Gish RG, Medical Reviewer. “Understanding HCV – A Patient Pocket Guide.” 2009. 29. Gish RG, Reviewer, Clinical Gastroenterology and Hepatotolgy. Submitted for

publication. 2009. 30. Gish, RG, “The Molecular and Functional Characterization of Hepatitis B Virus (HBV)

Genotypes Isolated from Human Immunodeficiency Virus (HIV) Infected Southern Africans: Part II.” The Medical Research Council (MRC). 2010.

31. Gish RG, Reviewer. “Hepatitus:Treatment and Clinical Trials” The Governing Board of the American Association for the Study of Liver Diseases (AASLD), 2011

32. Gish, RG, Reviewer. “BenhGan.org- Learn About Hepatitusand Liver Diseases”.

Curriculum Vitae



33. Gish, RG, Reviewer.” Evaluation of the merits of the evidence regarding the identification of hepatitis C virus (HCV) and HCV-Related Chronic Disease Among {ersons Born from 1945 to 1965,” Division of Viral Hepatitis at the Centers for Disease Control and Prevention.

34. Gish, RG, Reviewer, “Management of a Case of Obscure Lower-GI Bleeding by

Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Case Report,” October 2011. 35. Gish, RG, Reviewer. “Rationale For Selecting Chronic Hepatitis B Therapy With a High

Barrier to Resistance”, The Lancet Infectious Diseases. Elsevier Ltd., THELANCETID-D-10-00628R1;October 2011.

36. Gish, RG, Reviewer. “Hepatitis B: Treatment and Clinical Trials,” AASLD, San

Francisco, CA. October 2011. 37. Gish, RG, Reviewer. American Journal of Tropical Medicine & Hygiene 38. Gish, RG, Reviewer and Consultant, “Screening for Hepatitis C Virus Infection in

Adults,” Agency for Healthcare Research and Quality (AHRQ) HCV, December 2011.

39. Gish, RG, Reviewer, HBV Abstract submissions, Digestive Disease Week, American Association for the Study of Liver Disease, May 2012.

40. Gish RG, Assessment Reviewer, Chinese University of Hong Kong; January 13, 2013.

41. Gish RG, Hepatitis B: Treatment and Clinical Trials abstract review committee, Ameri-can Association for the Study of Liver Diseases (AASLD) Digestive Disease Week (DDW), January 4, 2013.

42. Gish RG, External Reviewer / Examiner, The University of Hong Kong. May 31, 2013.

43. Gish RG, Technical Review Author, AGA Guidelines for Antiviral Therapy for HBV Reac-

tivation in Setting of Immunosuppressive Therapy, June 2013.

44. Gish RG, Peer Reviewer, Department of Health & Human Services, Agency for Healthcare Research and Quality (AHRQ) Evidence-based Practice Center (EPC) Pro-gram, 2012 – 2013.

45. Gish RG, Reviewer, High Prevalence and Significance of Hepatitis D Virus Infection among Treatment-naïve HBsAg-Positive Patients in Northern Vietnam,” Public Library of Science (PLOS ONE), PONE-D-13-28265R1, August 2013.

46. Gish RG, Abstract Reviewer, Alimentary Pharmacology & Therapeutics - APT-0841-2013, August 2013. 2013:

47. Gish RG, Abstract Reviewer, Digestive Diseases and Sciences, 2013.

Curriculum Vitae



48. Gish RG, Peer Abstract Reviewer, Digestive Disease Week 2014, American Association for the Study of Liver Disease, Janunary 2014.

49. Gish RG, Reviewer, Open Access Public Library of Science, PONE-D-13-44773R1, EMID:ccb2186b7e4e406c, 15Jan 2014.

50. Gish RG, Reviewer, American Journal of Tropical Medicine and Hygiene, AJTMH-14-0068, 5Feb 2014.

51. Gish RG, Reviewer, American Association for the Study of Liver Disease (AASLD), 3Mar 2014.

52. Gish RG, Abstract Reviewer, Liver: Viral Hepatitis, American Transplant Congress, 2May 2015.


UCSD

2011 – 2012 UCSD DOM Residents Rotation Overview: Hepatology, HC

2010 – 2013 U.C. San Diego Medical Director of Center for Hepatobiliary Disease and Abdominal Transplantation (CHAT) Chief of Hepatology Professor of Medicine 350 Dickinson Street, Suite 342 San Diego, California


PUBLICATIONS: ABSTRACTS

1. Gish RG, Kaplowitz N, Langer AB. Calcium compartmentation and exchange rates in

rat hepatocyte monolayers. Hepatology. 1987;7:1128. Presented at the American As-sociation for the Study of Liver Diseases (AASLD) Liver Meeting, 1987.

2. Gish RG, Fernandez C, Kaplowitz N, Langer GA. Isotopic identification of calcium com-partmentation in hepatocyte monolayers. Hepatology. 1988;8:1309. Presented at the AASLD Liver Meeting, 1998.

3. Young SG, Linton MF, Hubl ST, Gish RG, Esquivel CO, Wardell M, Concepcion W, Nakazato P, Hardiman M. APO-E and APO-B phenotypes following liver transplanta-tion. Clin Res. 1990;38:483A. Presented at the American Federation for Clinical Re-search Meeting, 1990.

4. Gish RG, Nakazato P, Concepcion W, Garcia-Kennedy R, Imperial J, Esquivel C. Liver transplantation for hepatitis B-induced cirrhosis using HBIG prophtyaxis. Presented at the International Symposium on Viral Hepatitis and Liver Disease, 1990.

5. Nakazato P, Gish RG, Cox K, Berquist W, Concepcion W, Imperial J, Burns W, Garcia-Kennedy R, Esquivel CO. Incidence of incidental hepatocellular carcinoma in endstage liver disease patients undergoing liver transplantation with pre-transplant hepatitis C an-tibody reactivity. Hepatology. 1991;14:60A. Presented at the AASLD Liver Meeting, 1991.

6. Fry KE, Gish RG, Nakazato P, Reyes GR, Kuramoto RK, Lim J, Yarbough PO, Zeldis JB, Warmerdam M, Moeckli R, Yun-Chae K. Hepatitis C antibody testing in patients with chronic liver disease. Gastroenterology. 1991;100:A742. Presented at the AASLD Liver Meeting, 1991.

7. Gish RG, Fry KE, Concepcion W, Reyes GR, Kuramoto RK, Lim J, Yarbough PO, Zeldis JB, Warmerdam M, Moeckli R, Yun-Chae K. Hepatitis C infections in patients with or-thotopic liver transplantation. Presented at the American Gastroenterology Association (AGA) Meeting, 1991.

8. Gish RG, Fry KE, Concepcion W, Reyes GR, Kuramoto RK, Lim J, Yarbough PO, Zeldis JB, Warmerdam M, Moeckli R, Yun-Chae K. Early seroconversion to non-C100-3 anti-gens in acute HCV hepatitis. Gastroenterology. 1991;100:A747. Presented at the AGA Meeting, 1991.

9. Cox K, Berquist W, Gish RG, Imperial J, Rich E, Baker E. Endoscopic retrograde chol-angiopancreatography in children (ERCP). Gastrointest Endosc. 1992;38:266-267.

10. Cox K, Berquist W, Gish RG, Imperial J, Baker E. Biliary manometry in children. Gas-troenterology. 1992;102:A309. Presented at the AGA Meeting, 1992.

11. Gish RG, Lee AH, Rome H, Concepcion W, Esquivel CO, Keeffe EB. Liver transplanta-tion (OLTx) for patients with alcoholism and endstage liver disease. Hepatology. Octo-ber 1992:A941. Presented at the AASLD Liver Meeting, 1992.

12. Gish RG, Imperial JI, Esquivel CO, Keeffe EB. Ganciclovir treatment of severe hepatitis B virus infection. Gastroenterology. April 1993;104:A908. Presented at the AGA Meet-ing, 1993.


PUBLICATIONS – ABSTRACTS: Continued

13. Gish RG, Concepcion W, So SKS, Esquivel CO, Keeffe EB. Orthotopic liver transplan-tation for hepatitis B virus cirrhosis; potential efficacy of therapy with HBIG. Gastroenter-ology. April 1993;104:A908. Presented at the AGA Meeting, 1993.

14. Gonzales-Peralta RP, Fang JWS, Davis GL, Gish RG, Mizokami M, Kohara M, Mondelli M, Lesniewski R, Phillips I, Lau JYN. Optimization for the detection of viral hepatitis C (HCV) antigens in liver. Gastroenterology. April 1993;104:A909. Presented at the AGA Meeting, 1993.

15. Twu JS, Sherker AH, Fung K, Fernandez J, Yarbough PO, Gish RG, Bradley DW, Rob-inson WS, Reyes GR. Hepatitis E virus infection of primary human hepatocytes and identification of neutralizing antibodies. Presented at the International Symposium on Viral Hepatitis and Liver Disease, Eighth Triennial Congress, Tokyo, Japan, May 1993.

16. Twu JS, Sherker AH, Fung K, Fernandez J, Gish RG, Bradley DW, Robinson WS, Reyes GR. Inhibition of hepatitis E virus replication by Ribavirin, iron and human alpha-Interferon in primary human hepatocyte culture. Presented at the International Sympo-sium on Viral Hepatitis and Liver Disease, Eighth Triennial Congress, Tokyo, Japan, May 1993.

17. Lau JYN, Davis GL, Ohno T, Nakano T, Mizoguchi N, Perrillo R, Lindsay K, Gish RG, Wilber JC, Urdea MS, Tsukiyama-Kohara K, Kohara M, Mizokami M. Application of hep-atitis C virus (HCV) subtyping in chronic hepatitis C in the United States. Hepatology. October 1993;18. Presented at the AASLD Liver Meeting, 1993.

18. Gonzalez-Peralta RP, Fang JWS, Davis GL, Gish RG, Lau GKK, Wu PC, Lau JYN. He-patic Response in chronic hepatitis C virus (HCV) infection. Hepatology. October 1993; 18. Presented at the AASLD Liver Meeting, 1993.

19. Fang JWS, Lau GKK, Marousus C, Gonzalez-Peralta RP, Davis GL, Gish RG, Moyer RW, Kao KJ, Lesniewski R, Mizokami M, Houghton M, Lau JYN. Failure to detect cell surface expression of hepatitis C virus (HCV) structural proteins using a vaccinia expres-sion system. Gastroenterology. April 1994;106:A890. Presented at the AGA Meeting, 1994.

20. Lau GKK, Fang JWS, Davis GL, Gish RG, Wu PC, Lau JYN. Detection of hepatitis C virus (HCV) genome in liver by in-situ reverse transcription polymerase chain reaction (I-RT-PCR). Gastroenterology. April 1994;106:A925. Presented at the AGA Meeting, 1994.

21. Gonzalez-Peralta RP, Fang JWS, Davis GL, Gish RG, Kohara M, Mondelli MU, Mizo-kami M, Lau JYN. Significance of hepatic expression of hepatitis C viral (HCV) antigens in chronic HCV infection. Gastroenterology. April 1994;106:A899. Presented at the AGA Meeting, 1994.

22. Gish RG, Keeffe EB, Fang JWS, Garcia-Kennedy R, Lau JYN. Ganciclovir treatment of recurrent hepatitis B virus (HBV) infection in orthotopic liver transplant (OLT) recipients. Gastroenterology. April 1994;106:A899. Presented at the AGA Meeting, 1994.

23. Gish RG, Krams S, Martinez OM. Interleukin 12 (IL-12): A possible cytotoxic t-lympho-cyte (CTL) differentiation factor in allograft recipients. International Transplantation Meet-ing, Kyoto, Japan, August 1994.

Curriculum Vitae



24. Fang JWS, Gonzalez-Peralta RP, Gottschall JA, Davis GL, Gish RG, Mizokami M, Lau JYN. Hepatic expression of c-FAS and apoptosis in chronic hepatitis C virus (HCV) in-fection. Hepatology. October 1994;20:251A. Presented at the AASLD Liver Meeting, 1994.

25. Gonzalez-Peralta RP, Fang JWS, Davis GL, Gish RG, Mizokami M, Lau JYN. Immuno-pathobiology of chronic hepatitis C virus infection. Hepatology. October 1994;20:232A. Presented at the AASLD Liver Meeting, 1994.

26. Burns W, Gish RG, Berquist W, Severson E, Esquivel C. Glutathione s-transferase as a marker in the diagnosis of rejection in liver transplant recipients: A preliminary report. Hepatology. October 1994;20:335A. Presented at the AASLD Liver Meeting, 1994.

27. Cacciarelli T, Martinez OM, Villaneuva JC, Lau JYN, Gish RG, Krams SM. Immunoreg-ulatory cytokines in hepatitis C virus (HCV) infection pre- and posttreatment with alpha-Interferon. Gastroenterology. April 1995;108:A1042. Presented at the AGA Meeting, 1995.

28. Ghany MG, Ayola B, Villamil FG, Gish RG, Roiter S, Vierling JM, Lok ASF. S Gene es-cape mutants as a cause of HBV reinfection in patients who received HBIG post-OLT. Hepatology. October 1995;22:174. Presented at the AASLD Liver Meeting, 1995.

29. Gish RG, Xu YL, Brooks L, Leung J, Qian KP, Pike I, Lau JYN. Application of a simple serology based genotyping assay in a prospective cohort of patients with chronic hepati-tis C. Hepatology. October 1995;22(4):1258. Presented at the AASLD Liver Meeting, 1995.

30. Ghany MG, Villamil FG, Gish RG, Roiter S, Vierling, JM, Lok ASF. Survival after liver transplantation for HBV-liver failure is unrelated to pre-core stop codon mutation. Hepa-tology. October 1995;22(4):1255. Presented at the AASLD Liver Meeting, 1995.

31. Bhardwai G, Ohno T, Mizokami M, Gish RG, Lau JYN. Host immune response in liver in chronic hepatitis C: Both perforin and FAS-ligard are activated. Presented at the AGA Meeting, May 1996.

32. Ghany MG, Ayola B, Villamil FG, Gish RG, Roiter S, Vierling JM, Lok ASF. HBV reinfec-tion in liver transplant (LT) patients (PTS) who remained HBsAG negative post-LT. Pre-sented at the AASLD Liver Meeting, 1996. Chicago, Illinois.

33. Ayola B, Ghany MG, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok ASF. HBIG-induced gene mutations in liver transplant recipients can revert after withdrawal of HBIG. Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.

34. Perrillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, Dienstag J, Gish RG, Ville-neuve J, Caldwell S, Brown N, Self P. Lamivudine for hepatitis B after liver transplanta-tion. Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.

35. Gish RG, Xu YL, Brooks L, Leung J, Pike I, Qian KP, Lau JYN. Anti-HCV positive sera that were not genotypeable or serologically genotypable—what does it mean? Pre-sented at the AASLD Liver Meeting, 1996. Chicago, Illinois.

Curriculum Vitae



36. Ghardwai G, Ohno T, Gish RG, Lau JYN. In vivo activated of cytotoxic t-lymphocyte pathways in HCV-related cirrhosis—implications on immunopathogenesis. Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.

37. Perrillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, Dienstag J, Gish RG, Ville-neuva J, Caldwell S, Brown N, Self P. Lamivudine for hepatitis B after liver transplanta-tion Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.

38. Bhardwai G, Ohno T, Gish RG, Lau JYN, In vivo activation of cytotoxic t-lymphocyte (CTL) pathways in HCV-related cirrhosis—implications on immunopathogenesis Pre-sented at the AASLD Liver Meeting, 1996. Chicago, Illinois.

39. Gish RG, Lee A, Brooks L, Leung J, Block GD. Long-term follow-up of patients evalu-ated for liver transplantation using a method of risk stratification for estimating recidi-vism. Presented at the American Society for Transplantation Physicians (ASTP) 15th Annual Scientific Meeting, May 1997.

40. Gish RG. Assessment of an immunoblot hepatitis C virus serologic genotyping assay in a large cohort of US patients. Presented at Digestive Diseases Week (DDW), 1997. Washington, DC.

41. Xiang J, Klinzman D, Schmidt WN, Labrecque DR, Gish RG, Stapleton JT. Biophysical characterization of hepatitis G virus. Presented at the 97th American Society for Micro-biology Meeting (ASM), May 1997. Miami Beach, Florida.

42. Xing J, Ghany M, Ayola B, Villamil F, Gish RG, Rojter S, Vierling J, Lok, ASF. HBIG in-duces mutations in the HBV S but not pre-S gene in liver transplant patients. Presented at the AGA Annual Meeting, May 1997.

43. Elkayam O, Hassoba HM, Ferrell LD, Garcia-Kennedy R, Gish RG, Wright TL, Rosen-thal P. Hepatitis GBV-C infection in children pre- and post-liver transplantation. Hepa-tology. October 1997; 94. Presented at the AASLD Liver Meeting, 1997. Chicago, Illi-nois.

44. Terrault NA, Pessoa MG, Singleton S, Kim E, Martin P, Crippin J, Gish RG, Keeffe E, Lake J, Ascher N, Wright TL. Improved survival of hepatitis B patients undergoing liver transplantation: Effects independent of therapeutic interventions. Presented at the AASLD Liver Meeting, October 1997. Chicago, Illinois.

45. Perrillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, Dienstag J, Gish RG, Ville-neuva JP, Caldwell S, Brown N, Self P, and the Lamivudine Transplant Group. Long term Lamivudine therapy of patients with recurrent hepatitis B post-liver transplantation. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

46. Xing J, Ghany M, Villamil F, Roiter S, Gish RG, Vierling J, Lok ASF. Different patterns of HBV S gene mutations in liver transplant (OLT) patients (PTS) with and without HBV reinfection. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

47. Xing J, Hussain M, Roiter S, Gish RG, Villamil F, Vierling J, Lok ASF. Mutations in the HBV pre-S regions are associated with more severe liver disease. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

Curriculum Vitae



48. Perrillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, Gish RG, Dickson R, Adams P, Brown N, Self P, and the Lamivudine Transplant Group. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation (OLT). Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

49. Tung BY, Tabasco-Minguillan J, Bacon BR, Farrell FJ, Gish RG, McCashland TM, Kowdley KV. Long-term follow-up after liver transplantation for hereditary hemochroma-tosis. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

50. Gish RG, Lee A, Brooks L, Leung J, Block GD. Long-term follow-up of patients evalu-ated for liver transplantation using psychiatric risk factors for estimating recidivism. Pre-sented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

51. Fischer L, Müller-Ruchholtz C, Günther S, Gish RG, Will H, Sterneck M. Serial analysis of the complete hepatitis B virus nucleotide sequences in patients with fibrosing choles-tatic hepatitis after liver transplantation. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

52. Perrillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, Dienstag J, Gish RG, Ville-neuva, JP, Caldwell S, Brown N, Self P, and the Lamivudine Transplant Group. Long term Lamivudine therapy of patients with recurrent hepatitis B post-liver transplantation. Presented at the AASLD Annual Meeting, 1997. Chicago, Illinois.

53. Xing J, Ghany M, Villamil F, Rojter S, Gish RG, Vierling J, Lok ASF. Different patterns of HBV S gene mutations in liver transplant patients with and without NBV reinfection. Pre-sented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

54. Xing J, Hussain M, Rojter S, Gish RG, Villamil F, Vierling J, Lok ASF. Mutations in the HBV pre-S regions are associated with more severe liver disease. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

55. Perrillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, Gish RG, Dickson R, Adams P, Brown N, Self P, and the Lamivudine Transplant Group. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post-liver transplantation (OLT). Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

56. Terrault NA, Pessoa MG, Singleton S, Kim E, Martin P, Crippin J, Gish RG, Keeffe E, Lake J, Ascher N, Wright TL. Improved survival of hepatitis B patients undergoing liver transplantation: Effects independent of therapeutic interventions. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

57. Tung BY, Tabasco-Minguillan J, Bacon BR, Farrell RJ, Gish RG, McCashland TM, Kowdley KV. Long-term follow-up after liver transplantation for hereditary hemochroma-tosis. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

58. Elkayam O, Hassoba HM, Ferrell LD, Garcia-Kennedy R, Gish RG, Wright TL, Rosen-thal P. Hepatitis GBV-C infection in children pre- and post-liver transplantation. Pre-sented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

Curriculum Vitae



59. Pessoa MG, Kim E, Martin P, Crippin J, Keeffe E, Gish RG, Ascher N, Wright TL, Ter-rault NA. Dual effects of hepatitis B (HBV) infection and hepatitis B immunoglobulin (HBIG) in educing the incidence of acute rejection post-transplantation. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

60. Dienstag J, Schiff E, Wright T, Perrillo R, Hann H-W, Crowther L, Woessner M, Rubin M, Brown N, and the U.S. Lamivudine Investigator Group (Gish RG). Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients : histologic improvement and hepatitis Be-antigen (HBeAg) seroconversion. Presented at the AGA Meeting, May 1998.

61. Pawlotsky JM, De Gendt S, Beaucourt, S, Lopes Gozclaes F, Butterworth LA, Cooksley WGE, Gish RG, Ganne-Carrie N, Beuaugrand M, Fay O, Gonzalez JE, Brngel Martine RM, Dhumeuax D, Vanderborght B, Stuyver L. Worldwide spread of hepatitis C virus genotype 3a among intravenous drug users. Presented at the AASLD Liver Meeting, 1998.

62. McHutchison J, Gordon S, Schiff E, Shiffman M, Lee W, Rustgi V, Albrecht J for the Hepatitis Interventional Therapy Group (Gish RG). Interferon alpha-2b alone or in com-bination with Ribavirin in naive chronic HCV patients: A US multicenter randomized trial. Presented at the AASLD Liver Meeting, 1998.

63. Cahoon-Young B, Gish RG, Livermore T, Clanon K. Prevalence of hepatitis C anti-body and HIV co-infection in a high-risk female population. Presented at the AASLD Liver Meeting, 1998.

64. Xu I, Guo L, Gish RG, Mason AL. A human endogenous retrovirus as a candidate auto-immune gene in primary biliary cirrhosis. Presented at the AASLD Liver Meeting, 1998.

65. Poordad F, Yao F, Gish RG, Steady S, Osorio R, Roberts J. Post-orthotopic liver trans-plantation antiviral therapy and immunoprophylaxis against recurrent hepatitis B. Pre-sented at the AASLD Liver Meeting, 1998.

66. Gish RG, Yao F, Brooks L, Poordad F, Cain-Schulze G and the North American Rib-aHep study group. A randomized trial of interferon alfa-2b, daily vs. three times a week for one month, followed by three times a week for one year in combination with ribavirin in patients who have failed a previous course of interferon. Presented at the AASLD Liver Meeting, 1998.

67. Yao F, Gish RG, Poordad F, Rodvien R. Hepatocellular carcinoma: data from the Cali-fornia Cancer Registry. Presented at the AASLD Liver Meeting, 1998.

68. Gish RG, Cahoon-Young B, Clanon K, Livermore T, and Wakil A. Epidemiology, diag-nosis and management of hepatitis C in high-risk populations: A community-based ap-proach to developing coordinated services and harm reduction strategies. Journal Sub-stance Abuse, 1999. The American Society of Addiction Medicine, 1999.

69. Gish RG, Leung NWY, Schooley RT, Sykes A, Turner F, Shi H, Wakeford C, Delehanty H, Rousseau F. Emtricitabin (FTC): Activity Against Hepatitis B Virus in a Phase I/II Clinical Study. ICAAC for TRCB-101. May 1999.

Curriculum Vitae



70. Gish RG. Lamivudine for Prevention of Recurrent Hepatitis B After Liver Transplanta-tion: Final Result of U.S./Canadian Multicenter Trial. A2006 Study AASLD 1999.

71. Tanaka A, Prindiville T, Solnick J, Coppel RL, Lake J, Keeffe E, Gish R, Gershwin ME. Molecular identification of infectious agents in primary biliary cirrhosis. Presented at the AASLD Liver Meeting, 1998.

72. Gish R, Leung NWY, Schooley R, Sykes A, Turner F, Shi H, Wakeford C, Delehanty J, Rousseau F, California Pacific Medical Center, San Francisco, CA; Prince of Wales Hos-pital, Hong Kong China; University of Colorado, Denver, CO; Triangle Pharmaceuticals, Durham, NC. Emtricitabine (FTC): Activity against Hepatitis B Virus in a Phase 1/11 Clinical Study. Presented at ASM’s 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 29-29, 1999.

73. Crippin J, Gish R, Prieto M, Bass T, Baker C, Watson J, Hillygus J, Netto G, Alonzo J, Garcia R, Wright TL. Marked Increase In Post-Transplantation (OLT) HCV-Related Fi-brosis Progression in Recent Years. November AASLD 1999.

74. Perrillo R, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Brown N and the Lamivudine Transplant Group. A Mul-ticenter U.S.- Canadian Trial to Assess Lamivudine Monotherapy Before and After Liver Transplantation for Chronic Hepatitis B. DDW AASLD 2000.

75. Renz J, Osorio R, Horan S, Diaz G, Venook A, Gish R, Ascher N, Lake J, Roberts J, Chemo-Embolization for Treatment of Hepatocellular Carcinoma Discovered While Awaiting Liver Transplantation: A Multicenter Experience. Presented at the AGA An-nual Meeting, May 2000.

76. Durr R, Gish R, Brooks L, Williams R, Naoumov NV. Functional Characterization Of Full Length Hepatitis B Virus (Hbv) Genomes From Liver And Serum Of Patients With Fi-brosing Cholestatic Hepatitis. Presented at DDW, 2000.

77. Wright T, Gish R, Teverson G, Mcquire B, Crippin J, Batts K, Brass, C, Ullemeyer V, In-terferon-Alfa2B and Ribavirin Combination Therapy in Liver Transplant Recipients with Recurrent Hepatitis C. Division of Gastroenterology & Hepatology. AASLD 2000.

78. Gish R, Hepatitis C Virus: Evaluation and management. Presented at the Family Prac-tice Re-Certification Meeting, June 2000.

79. Kowdley K, Tung B, Han S, Bass A, Gish R, Brandhagen D, Sterling R, Cotler S, Fon-tana R, McCashland T, Emond M, National Hemochromatosis Transplant Registry In-vestigators. Prevalence of Hepatic Iron Overload and HFE Mutations among orthotopic Liver Transplant Recipients: Preliminary Results from the National Hemochromatosis Transplant Registry. Presented at the AASLD Liver Meeting, October 2000.

80. Gish R, Wright T, Leung NWY, Trinh A, Robertson T, Delehanty J, Rousseau F, and Delehanty J. Emtricitabine (FTC): Results from a 24-week dose-selection trial in pa-tients with chronic HBV infection (FTCB-102). Presented at the AASLD Liver Meeting, October 2000.

Curriculum Vitae



81. Jazayeri M, Sran N, Gish R, Basuni A, Cooksley G, Locarnini S, Carman WF. HBV Core Sequence: Definition of Subtype-Specific Variability and Correlation With Geographic Origin. Presented at the AASLD Liver Meeting, October 2000.

82. Gish R, Wakil A, Brooks L, Schulze G, Leung J. A Randomized Trial of Daily Interferon Alfa-2B in Combination With Ribavirin, vs. Three Times a Week For One Month, Fol-lowed by Three Times a Week for One Year in Relapse or Nonresponder Patients. AASLD 2000.

83. Aschara G, Sadovsky R, Gish R, Paulotsky JM, Sulkowski M. Hepatitis C Virus: Estab-lishing the Standards of Diagnosis and Treatment. Presented at the Family Practice Re-certification Meeting, July 2000.

84. Hadlock K, Gish R, Rowe J, Rajyaguru S, Newsom M, Foung S, Cross Reactivity and Clinical Impact of the Antibody Response to Hepatitis C Virus (HCV) Second Envelope Glycoprotein (E2). AASLD 2000.

85. Hadlock K, Gish R, Rajyagura S, Row J, Newsom M, Dagan S, Foung S. High Levels of Antibodies that can neutralize HCV Infection in the HCV-Trimera Model are rare in HCV infected individuals. AASLD 2000.

86. Berenguer M, Watson J, Crippin R, Gish R, Netto G, Alonzo J, Garcia R, Wright T, Dept. of Medicine VAMC/UCSF, Baylor University (Dallas), California Pacific Medical Center (SF), La Fe-Hosp. (Valencia, Spain). HCV Related Fibrosis Progression Following Liver Transplantation (OLT). AALSD 2000.

87. Shakil A, McGuire B, Crippin J, Conjeevaram H, Teperman L, Gish R, Kwo P, Wright T, Demetris J, Rakela J, Division of Gastroenterology. Hepatology & Nutrition, University of Pittsburgh, PA 15213 and MIRTH Study Group. Interferon-Alpa2B and Ribavirin Combi-nation Therapy in Liver Transplant Recipients with Recurrent Hepatitis C AASLD 2000.

88. Kowdley, Brandhagen, Crippin, Gish RG, Bacon, Keeffe, Sterling, Fontana, Cotler, Emond, NHTR Investigators. Survival after Orthotopic Liver Transplantation Among Pa-tients with Hepatic Iron Overload: Preliminary Results from the National Hemochromato-sis Transplant Registry. Presented at the AASLD Liver Meeting, October 2000.

89. Kowdley, Tung, Han, Bass, Gish RG, Brandhagen, Sterling, Cotler, Fontana, McCash-land, NHTR Investigators. Prevalence of Hepatic Iron Overload and HFE Mutations Among Orthotophic Liver Transplant Recipients: Preliminary Results from the National Hemochromatosis Transplant Registry. Presented at the AASLD Liver Meeting, October 2000.

90. Sanne I, Gish RG. FTC-302 Study Investigators and the FTC-302 Clinical Steering Com-mittee. Severe Liver Toxicity in Patients Receiving Two Nucleoside Analogues and a Non Nucleoside Reverse Transcriptase Inhibitor. Presented at the AIDS and Retroviral meet-ing, December 2000, Glasgow, Scotland, and DDW, May 2001, Atlanta, Georgia.

91. Hadlock, Gish RG, Rowe, Rajyaguru, Newsom, Warford, Foung. Cross Reactivity and Clinical Impact of the Antibody Response to Hepatitis C virus (HCV) Second Envelope Glycoprotein. DDW 2001.

Curriculum Vitae



92. Gish RG, Pawlostky JM, Gendt, Beaucourt S, Lopes F, Goncales, Butterworth, Cooks-ley WGE, Ganne-Carrie N, Beaugrand M, Fay F, Fay O, Gonzalez JE, Martins RM, Dhumeaux D, Vanderborght B, Stuyver J. Molecular Epidemiology of Hepatitis C Virus Genotype 3a In Intravenous Drug Users (IVDUs). 1999. AASLD

93. Gish RG. Severe Liver Toxicity In Patients Receiving Two Nucleoside Analogues and a Non-Nucleoside Reverse Transcriptase Inhibitor. Presented at the AGA Meeting, May 2001.

94. Gish RG, Kowdley, Brandhagen, Bass, Weinstein, Schilsky, Fontana, McCashand, Cotler, Bacon, Keefe and Nayak. Survival after Orthopedic Liver Transplant (OLT) Among Patients With Hepatic Iron Overload: Interim Results from the National Hemo-chromatosis Transplant Registry (NHTR). Presented at the AASLD Liver Meeting, 2001. Dallas, Texas.

95. McHutchison J, Yoffe B, Brown R, Schiff E, Reddy R, Shiffman M, Carrithers R, Wright T, Fried M, Gish RG, Younossi Z, Poulios N. Preliminary Report of the Development of a Hepatitis C Web-based Patient Registry at 11 US Hepatology Units. Presented at the AASLD Liver Meeting, 2001. Dallas, Texas.

96. Gish RG, Larry Corey, Nancy Leung, Amy Rigney, Lei Fang, Elsa Mondou, John Dill-berger, Antiviral Activity of 48 Weeks of Emtricitabine Treatment in Patients with HbeAg Negative DNA Positive Chronic Hepatitis B (CHB). Hepatology 2001; 34: 323A. Pre-sented at the AASLD Liver Meeting, 2001. Dallas, Texas.

97. Gish RG, Leung NEWY, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Sykes A, and Rousseau F. A Dose Ranging Study of the Pharmacokinetics, Safety, and Preliminary Antiviral Activity of Emtricitabine in Adults with HBV Infection. 2001.

98. Gish RG, Fuminaka S, Etsuro O, et al. Recombination of HBV Genotypes. Nagoya City University Medical School, December, 6, 2001.

99. Jazayer M, Basuni A, Sran N, Gish R, Cooklesy G, Locarnini S, Carman WF. HBV Core Sequence: Definition of Genotype-Specific Variability and Correlation with Geographic Origin. Journal of General Virology. 2001.

100. Kato H, Orito E, Sugauchi F, Gish R, Ueda R, Miyakawa Y, Mizokami M. New Detection System for Hepatitis B Virus (HBV) of Genotype G and its Surveillance in Japanese Pa-tients with HBV Infection. Journal of Medical Virology. 2001.

101. Gish R, Wright T, Wang C, Corey L, Leung N, Sykes A, Mondou E, Fang, L, Rousseau F. HBeAg profile in patients with Chronic HBeAg+ hepatitis BV (CHB) treated with emtricitabine (FTC) for 1 year. Presented at the AASLD Liver Meeting, 2001. Dallas, Texas.

102. McHutchison J and the IHIG Study group (Gish RG). Durability of sustained virologic re-

sponse in patients with chronic hepatitis C after treatment with interferon alfa-b alone or in combination with ribavirin. Abstract 281. Presented at the AASLD Liver Meeting, 2001. Dallas, Texas.

Curriculum Vitae



103. Sulkowski M, Wasserman R, Brooks L, Ball L, Gish R. Hemoglobin Changes During In-terferon/Riboviran Treatment. July 23, 2002.

104. Tong M, Shiffman M, Heathcote J, Gish RG, et al. Long-term safety beyond 48 weeks of adefovir dipivoxil (ADV) 10 mg once daily for chronic hepatitis B (CHB): an integrated analysis of two phase III studies. 2002.

105. Javaheri S, Bzowej N, Wakil A, Gish RG, et al. A new clue in HBV fibrosis progression: negative HBV DNA levels in treatment naïve patients are associated with cirrhosis re-gardless of duration of disease. 2002.

106. Bzowej N, Gish RG, Wakil AE, Brooks l, Shaffer M, et al. Comparison of peginterferon Alfa-2B and ribavirin with or without induction therapy for the treatment of chronic hepati-tis C (HCV) nonresponders. 2002.

107. Terrault N, Friesenhahn M, Gish RG, et al. Decline in HCV viral load in chronically-in-fected patients during the first eight weeks of therapy with standard interferon/ribavirin is highly predictive of virologic outcome. Presented at the National Institutes of Health Management of Hepatitis C Meeting, June 10-12 2002.

108. Selmi C, Mayo M, Gish RG, et al. Occurrence of primary biliary cirrhosis in identical twins. 2002.

109. Afdahl N, Flamm S, Gish RG, et al. Analysis of 40 KDA peginterferon Alfa-2A (PEGASYS®) in combination with ribavirin, mycophenolate mofetil, amantadine, or amantadine plus ribavirin in patients that relapsed or did not respond to Rebetron™ ther-apy: a report of two randomized, multicenter, efficacy and safety studies. Abstract 41184. Presented at the AASLD Liver Meeting, 2001. Dallas, Texas.

110. Zarski J, McHutchison J, Bronowicki J, Gish RG, et al. Rate of natural disease progres-sion in patients with chronic hepatitis C. 2002.

111. Kato H, Orito, E, Sugauchi, F, Ueda, R, Gish RG, Usuada, S, Miyakawa, Y, Mizokami, M. . Recombination of HBV genotypes. 2002.

112. Elbeik T, Friesenhahn M, Gish RG, et al. Decline in HCV viral load in chronically-in-fected patients during the first eight weeks of therapy with standard interferon/ribavirin is highly predictive of virologic outcome. Presented at the AASLD Liver Meeting, 2002.

113. Kato H, Orito, E, Sugauchi, F, Ueda, R, Gish RG, Usuada, S, Miyakawa, Y, Mizokami, M. Molecular analysis of hepatisi B virus of genotype G (HBV/G) and development of a new method for detecting HBV/G. APASL J Gastro Hepatology. 2003;17;suppl. abs PI-2-0:A44.

114. Shiffman ML, Angelino A, Gish RG. Side Effects Associated with the Treatment of Hep-atitis C, Infection: Recommendations for Improved Management. 2002.

Curriculum Vitae



115. Gish RG, TT Chang, S Hadziyannis, J Cianciara, M Rizzeto, E Schiff, G Pastore, K Klesczewski, G Denisky J Zhu, D DeHertogh, R Hindes. Sustained Vral Load and ALT Reduction following 48 weeks of Entecavir Treatments in HBeAg Negative and Positive patients with Chronic Hepatitis B Who Have Failed Prior Lamivudine Therapy. Pre-sented at the European Association for the Study of the Liver (EASL) Meeting, 2003.

116. Gish RG. Clinical Significance of Nucleoside Resistance in HBV Antiviral Therapy. Pre-sented at Strategic Implications International, April, 2003.

117. Gish RG. Neuroendocrine Tumor Case Review. Presented at Williams Labadie Commu-nications for Healthcare Conference, January, 2003.

118. Gish RG. HCV side-effect management. Presented at DVC Healthcare Communications Conference, March, 2003.

119. Gish RG. HCV side-effect management. Presented at DVC Healthcare Communications Conference, April, 2003.

120. Gish RG. SGNA – Controversies in Hepatitis C Therapy Presented at Medical Education Collaborative, Inc. (MEC) Conference, May 2003.

121. Gish RG. HCV – “The Case for Selective Treatment.” Nurses CE Symposium, Contro-versies in Hepatitis C Therapy, Does the Patient Really Need Treatment? Does the Pa-tient Really Need a Liver Biopsy? Presented at Medical Education Collaborative Confer-ence, May 18, 2003. Atlanta, GA.

122. Gish RG. HCV side-effect management. Presented at DVC Healthcare Communications Conference, October, 2003.

123. Gish RG. HCV side-effect management. Presented at DVC Healthcare Communications Conference, October, 2003.

124. Gish RG, Sulkowski M, Wasserman R, Brooks L, Ball L. Changes in Hemoglobin During Interferon alfa-2b Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection. October, 2003.

125. Pockros P, Schiff E, Shiffman M, McHutchison J, Muir A, Beth A, Gish RG, Huyghe T, Oltersdorf T, and Shapiro I. The First Caspase Inhibitor of Apoptosis, IDN-6556, Given Orally Lowers Liver Enzymes in HCV Patients. October 2003.

126. Afdhal NH, Gish RG. New Data on Managing Anemia with Growth Factors for Patients on Anti-HCV Therapy: A Case Based Series. October 2002.

127. Study Group 435 International Investigators Group (Gish, RG). Adefovir Dipivoxil Ther-apy for Lamivudine-Resistant Hepatitis B in Pre- and Post- Liver Transplantation Pa-tients. Presented at the AASLD Liver Meeting, 2003.

128. Bzowej N, Gish RG, Newsom, M. Eight Genotypes (A-H) for Hepatits B Virus Infecting Patients from San Francisco and their Demographic Clinical and Virological Characteris-tics. Presented at the AGA Meeting. 2003.

Curriculum Vitae



129. Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am. Decem-ber 2003.

130. Gish RG, Selmi C, Mayo M, Bach N, Ishibashi H, Invernizzi P, Gordon S, Wright H, Podda M, Stastny P, Gershwin E. Primary Biliary Cirrhosis in Monozygotic and Dizygotic Twins, Genetics, Epigenetics and Environment. March 2004.

131. Gish RG, Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, Archarya S, Shrestha S, Khan M, Miyakawa Y, Mizokami M. A Case-control Study for Differences among Hepati-tis B Virus Infections of Genotypes A (Subtypes Aa and Ae)and D. March 2004.

132. Gish RG, Sugauchi F, Kumada H, Acharya S, Shrestha S, Gamutan T, Khan M, Tanaka Y, Kato T, Orito E, Ueda R, Miyakawa Y, Mizokam, M. Epidemiological and virological differences between two subtypes (Ae and Aa) of the hepatitis B virus genotype A. Jour-nal of General Virology. March 2004.

133. Gish RG, Westland W, Delaney W, Huiling Y, Chen S, Marcellin P, Hadziyannis S, Fry J, Brosgart C, Gibbs C, Miller M, Xiong, S. Hepatitis B Virus Genotypes and Virologic Response in 694 Patients in Phase III Studies of Adefovir Dipivoxil. Presented at the AGA Meeting, 2004.

134. Gish RG. Maximizing the Benefits of Antiviral Therapy for HCV: The Advantages of Treating Side Effects, Treating Hepatitis C: State of the Art, March 2004.

135. Gish RG. Hepatitis C Combination Therapy with Virmadine and Peginterferon Alfa-2a Reduces Potential for Ribavirin-Related Hemolytic Anemia. DDW AASLD, 2004.

136. Gish RG, Sanne I, Marin H, Hinkle J, Bartlett J, Lederman M, Maarteens G, Wakeford C, Shaw A, Quinn J, Rousseau F. Severe Hepatotoxicity Associated with Nevirapine Use in HIV-infected Patients, ICAAC 2004.

137. Gish RG. HCV in San Francisco and their demographic, clinical and virologic character-istics. Journal of Medical Virology. March 2004.

138. Gish RG, Chang TT, Hadziyannis S, Cianciara J, Rizzetto M, Schiff E, Pastore G, Jack-son R, Thiry A, Hindes, R. Lamivudine-refactory Hepatitis B can be safely switched di-rectly to Entecavir 1.0mg daily therapy. Presented at the 39th Annual EASL Meeting, 2004.

139. Gish RG, Arora S, Nelson D, Fernandez H, Lamon K. Safety and efficacy of Viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naïve patients. Presented at the 39th Annual EASL Meeting, 2004.

140. Gish RG, Patt Y, Garcia-Vargas J, Gallo J, Suplick G. Demographics from the ETHECC trial: A randomized comparison between Thymitaq and doxorubician for the treatment of unresectable hepatocellular carcinoma (HCC) in terms of survival. 2004.

141. Gish RG, Bzowej N, Phung Y, Bonacini M, Wakil A, Lubliner G, Hassoun A, Rabkin J, Hisatake G, Osorio R. Transplantation of HCV-positive livers in HCV-positive patients: Interaction between donor and recipient virus. 2004.

Curriculum Vitae



142. Lok A, Regev A, Keeffe E, Han SH, Emre, S, Ishitani, M, Luketic V, Brown R, Fung SK, Hussain M, HBV-OLT Study Group (Gish RG). Relation between HBV genotypes and HBV variants and indications for liver transplant (LT) in hepatitis B patients in the US. 2004.

143. Patt Y, Gish RG, Garcia-Vargas J, Gallo J, Suplick G, Senico P. Thymitaq (nolatrexed diihydrochloride) in unresectable HCC. Update of the ETHECC trial, a pivotal random-ized phase III study comparing Thymitaq vs. doxorubicin in terms of survival. Gastroin-testinal Oncology. 2004.

144. Chang T, Gish RG, de Man R, Gadano A, Sollano J, Han KH, Goodman Z, Cross Z, De-hertogh D, Apelian D and the Entecavir study group. Entecavir is Superior to Lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naïve patients. Presented at the AASLD Liver Meeting, 2004. Boston, Mas-sachusetts.

145. Terrault N, Godofsky E, Gish RG. New Hepatitis C Drugs: Can Safety, Efficacy be Im-proved. Gastroenterology and Endoscopy News. 2004.

146. Snow A, Lim SG, Gish R, Sorbel J, Anderson J, Rousseau F. Correlation between base-line genotype and antiviral response to Emtricitabine 200mg QD among HBeAg positive patients with chronic hepatitis B infection. Presented at the AASLD Liver Meeting, 2004. Boston, Massachusetts.

147. Gish RG, et al. ETV Efficacy across Disease-Related Baseline Subgroups. Presented at the EASL Meeting, April 2004. Berlin, Germany.

148. Gish RG, Arora S, Nelson D, Fried M, Reddy KR, Xu Y, Peterson J, Murphy, B. End-of-Treatment (EOT) Response in Therapy-Naïve Patients Treated for Chronic Hepatitis C with Viramidine in Combination with Pegylated Interferon. Presented at the AASLD Liver Meeting, 2004. Boston, Massachusetts.

149. Gish RG, de Man RA, Pedersen C, et al. Sustained response off-treatment to entecavir and lamivudine after 48 weeks of treatment in nucleoside-naïve, HBeAg+ patients: 24-week follow-up results of phase 3 study ETV-022. J Hepatol. 2005; 42(suppl 2):177. Pre-sented at the EASL Meeting, April 2005.

150. Gish RG, Trinh H, Leung N, Chan FKL, Fried MW, Wright TL, Wang C, Anderson J, Mondou E, Snow A, Sorbel J, Rousseau F, Corey L., from Journal of Hepatology. JHE-2004-00980.R1. Safety and Antiviral Activity of Emtricitabine (FTC) for the treatment of Chronic Hepatitis B Infection: A Two Year Study. CAB Abstracts. 2005.

151. Porta C, Gish RG, Patt Y, Suplick G, Garcia-Vargas J, Gallo J. Demographics from the ETHECC© (Evaluation of THYMITAQ ®[nolatrexed dihydrochloride] in the Hepatocellu-lar Carcinoma [HCC]) trial population. June 2005.

152. Porta C, Gish RG, Patt Y, Suplick G, Garcia-Vargas J, Gallo J. Improved safety profile of nolatrexed dihydrochloride (THYMITAQ®) IN THE Phase III Hepatocellular Carcinoma (HCC) trial when compared to the safety of the Phase II program.

Curriculum Vitae



153. Nguyen T, Tong M, Brown R, Columbia, Gish R, Grant G, Viridae, Pico CS, Joshi S, Siegal S, Lin C. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Remo-fovir in Chronic HBV Patients in US and Canada Following Daily Dosing for 28 days. Presented at the EASLMeeting, April 2005. Paris, France.

154. Gish R, N Bzowej N, Brooks L, Brass C, Weng W. Treatment with Pegylated Interferon ALFA-2B in Combination with Ribavirin Improved Health-Related Quality of Life Com-pared with Interferon ALFA-2B Plus Ribavirin in Chronic Hepatitis C. 2005.

155. Sanne I, Marin H, Hinkle J, Bartlett J, Lederman M, Maarteens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F. Severe Hepatotoxicity Associated with Nevirapine Use in HIV-Infected Subjects. 2005.

156. Yurdaydin C, Ciancara J, Gish RG, Chang TT, Sherman M, Apelian D, Fernandes L, Hindes R, Thiry A, Cross A, Wilber R. Alanine Aminotransferase (ALT) Flares are Un-common both On- and Post-treatment in Entecavir-Treated HBeAg-positive Patients. Presented at the 40th Annual EASL Meeting, April 2005.

157. Lurie Y, Manns MP, Gish RG, Chang TT, Yurdaydin C, Lai CL, Shouval D, Brown RS, Jr., Apelian D, Kiescziwski K, Cross A, Wilber R. The Efficacy of Entecavir is Similar Re-gardless of Disease-Related Baseline Subgroups in Treatment of Nucleoside-Naïve, HBeAg(+) Patients with Chronic Hepatitis B. Presented at the 40th Annual EASL Meet-ing, April 2005.

158. Shouval D, Senturk H, Gish RG, Chang TT, Yurdaydin C, Lai CL, Lok A, Brown RS, Jr., Apelian D, Fernandes L, Kiesczewski K, Cross A, Wilber R. Entecavir Demonstrates Consistent Responses Throughout Baseline, Demographic Subgroups for the Treatment of Nucleoside-Naïve, HBeAg(+) and HBeAg(-) Patients, with Chronic Hepatitis B. Pre-sented at the 40th Annual EASL Meeting, April 2005.

159. Gish RG, De Man RA, Pedersen C, Bialkowska J, Chang TT, Apelian D, Fernandes L, Zhu J, Cross A, Wilber R, and the BEHoLd Study Group. Sustained Response Off-treat-ment to ntecavir and lamivaudine After 48 Weeks of Treatment in Nucleoside-naïve, HBeAg(+) Patients: 24-week Follow-Up Results of Phase 3 Study ETV-022. Presented at the 40th Annual EASL Meeting, April 2005.

160. Manns MP, Raptopoulou-Gigi M, Soliano J, Gish RG, Chang TT, Sherman M, Yurdaydin C, Shouval D, Lok A, Cooney E, Hindes R, Yang J, Cross A, Wilber R. Entecavir is Well-tolerated for the Treatment of Nucleoside-Naïve and Lamivudine-Refractory Chronic Hepatitis B Viral Infection: Phase II/III Safety Results. Presented at the 40th Annual EASL Meeting, April 2005.

161. Cianclara J, Yurdaydin K, Gish RG, Chang TT, Sherman M, Goodman Z, Brett-Smith H, Hindes R, Thiry A, Cross A, Wilber R. Alanine Aminotransferase (ALT) Flare are Uncom-mon both On- and Post-treatment in Entecavir (ETV)-treated HBeAg(+) Patients. Pre-sented at the 13th World Congress of Gastroenterology, September 10-14, 2005. Mon-treal, Canada.

Curriculum Vitae



162. Gish R, Chang TT, de Man R, Dadano A, Sollano J, Han KH, Goodman Z, Zhu J, Cross A, Brett-Smith H, the BEHoLD Study Group. Entecavir is Superior to Lamivudine for the Treatment of HBeAg(+) Chronic Hepatitis B: Results of Phase III Study ETV-022 in Nu-cleoside-naïve Patients. Presented at the 13th World Congress of Gastroenterology, September 10-14, 2005. Montreal, Canada.

163. Hillebrand DJ, Pfeifle J, Roberts C, Lo T, Hay K, Bull B, Frederick RT, Gish RG. Anticoagulation for an artificial liver support device, the I.M.P.A.C.T. system™ (In-termittent Modular Plasma Adsorption of Cytokines and Toxins). ASAIO Journal. March/April 2006;52(2):10A. Presented at the American Society for Artificial Internal Or-gans (ASAIO) Meeting, 2006.

164. Behrsing HP, Tam J, Gray B, Do A, Zhao D, Jung J, Bundey R, Gish RG, McGuire BM, Suh D-J, Park S-S. Characterization of a novel porcine liver slice-filled bioartificial liver (BAL) for treatment of liver failure patients. ASAIO Journal. March/April 2006;52(2):10A. Presented at the ASAIO Meeting, 2006.

165. Hillebrand DJ, Pfeifle J, Roberts C, Lo T, Federick T, Gish RG. Intermittent modular plasma adsorption of cytokines and toxins (IMPACT System™) in subjects with cirrhosis hepatic encephalopathy. ASAIO Journal. March/April 2006;52(2):10A. Presented at the ASAIO Meeting, 2006.

166. Hillebrand DJ, Pfeifle J, Roberts C, Lo T, Frederick T, Gish RG. Improvement in sys-temic hemodynamics with the I.M.P.A.C.T. System™ artificial liver support device. ASAIO Journal. March/April 2006;52(2):10A. Presented at the ASAIO Meeting, 2006.

167. Veenstra DL, Iloeje UH, Tafesse E, Sullivan SD, Cross A, Di Bisceglie A, Gish RG. Cost-effectiveness of Antivirals in HBeAg-positive Chronice Hepatitis B: Impact of Sero-conversion and Viral Suppression. Presented at DDW, May 20-25, 2006. Los Angeles, California.

168. Gish R, Behrsing HP, Tam J, Gray B, Do A, Park Y, Yun H, Zhao D, Gropper C, Jung J, McGuire BM, Panoskaltsis-Mortari A, Lau GK, Lim Y-S, Lee HC, Suh D-J, Park S-S. In vivo characterization of a novel procine liver slice-filled bioartificial liver (BAL) for treat-ment of liver failure patients. HepaHope Inc. Presented at the World Tranplant Con-gress, 2006.

169. Gish R, Fischer L, Will H, Sterneck M. Severe Recurrent Hepatitis B: Comparative Analysis of Complete Genomic Sequences Isolated Before and After Liver Transplanta-tion. Presented at the World Transplant Congress, August 2006. Boston, MA.

170. Gish R. Anticoagulation for an Artificial Liver Support Device, The I. M. P. A. C. T. Sys-tem [Trade] (Intermittent Modualr Plasma Adsorption of Cytokines and Toxins). Pre-sented at the Blood Substitutes and Hematology Meeting., June 10, 2006.

171. Gish R, Porta C, Ruff P, Feld R, Feun L, Jeziorski K, Leighton J, Kennealey G. Results of a Phase III randomized controlled study comparing the survival of patients with unre-sectable hepatocellular carcinoma (HCC) treated with nolatrexed (NOL) or doxorubicin (DOX). Presented at the Shanghai-Hong Kong Liver Congress, March 2006. Shanghai, China.

Curriculum Vitae



172. Gish R. A Trial of Zdaxin? (thymalfasin) with Trans Arterial Chemoembolization (TACE) in the treatment of adult patients with unresectable hepatocellular carcinoma: A Phase II trial. Presented at the Shanghai-Hong Kong Liver Congress, March 2006. Shanghai, China.

173. DeMan RA, Mutimer D, Gish RG, Chang T-T, Zhu J, Cross A, Brett-Smith H. Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical im-provement and HBeAg seroconversion in HBeAg(+) chronic patients (Study ETV-022). Presented at the International Association for the Study of the Liver (IASL) Meeting, 2006.

174. Gish R. This Study Compared the Efficacy and Safety of Zadaxin plus TACE with TACE alone in Patients with Unresectable HCC. Final Abstract. EASL 2006.

175. Gish R, Park S-S, Jung J, Zhao D, Yun H, Tam J, Park Y, Gropper C, McGuire B, Panoskaltsis-Mortari A, Han JJ, Lim Y-S, Lee HC, Suh D-J. Assessment of a Novel Po-cine Liver Slice-filled Bio-artificial Liver (BAL) for Dialysis of Liver Failure Patients. Pre-sented at the AASLD Liver Meeting, October 27-31, 2006. Boston, MA.

176. Gish RG, TT Chang, CL Lai, R de Man, A Gadano, F Poordad, J Zhu, H Brett-Smith, R Wilber. Hepatitis B Surface Antigen Loss in Antiviral-Treated Patients with HBeAG(+) Chronic Hepatitis B (CHB) Infection: Observations from Antiviral-Naïve Patients Treated with Entecavir (ETV) or Lamivudine (LVD). Presented at the AASLD Liver Meeting, Oc-tober 27-31, 2006. Boston, MA.

177. Gish RG, TT Chang, YC Chao, J Kuydowicz, S Kaymacoglu, H Cheinquer, M Pessoa, F Poordad, J Yang, H Brett-Smith, R Hindes. Entecavir Maintained Virologic Suppression Through 3 Years of Treatment in Antiviral-Naïve HBeAg(+) Patients (ETV 022/901). Pre-sented at the AASLD Liver Meeting, October 27-31, 2006. Boston, MA.

178. Gish R, Schiff E, Di Bisceglie A, Raptopulou-Gigi M, Hadzyannis S, Kaymakoglu S, Chang TT, Sollano J, Lai CL, Young J, Hindes R, Lopez-Talavera JC. Entecavir is well tolerated for the treatment of nucleoside-naïve and lamivudine-refractory chronic hepati-tis B: safety data through 2 years. 2006. Boston, MA.

179. Hoffman JC, Gish RG. Hepatitis C Associated Systemic Cryoglobulinemia: Successful Treatment with Plasma Exchange. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.

180. Carr C, Hollinger FB Yoffe B, Wakil A, Phillips J, Bzowej N, Leung J, Mirro K, Poordad F, Moore DH, Gish RG. Efficacy of Interferon Alpha-2b Introduction Therapy before Re-treatment for Chronic Hepatitis C. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.

181. Schiff ER, Everson GT, Tsai N, Bzowei NH, Gish RG, McHutchison JG, Jacobson IM, Tong MJ, Jensen DM, Lauer GM, Cruickshank S, Ferraro J, Haller A, Duke R, Rodell T, Apelian D. HCV-Specific Cellular Immunity, RNA Reductions, and Normalization of ALT in Chronic HCV Subjects after Treatment with GI-5005, a Yeast-Based Immunotherapy Targeting NS3 and Core: A Randomized, Double-blind, Pacebo Controlled Phase 1b Study. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.

Curriculum Vitae



182. Gish RG, McGuire M. Acute Liver Failure and Artificial Liver Support. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.

183. Han S, Chang TT, Chao Y, Yoon S, Gish RG, Cheinquer H, Carrillho F, Zhang H, Brett-Smith H, Hindes R. Four-Year Entecavir Treatment in Nucleoside-Naïve HBeAg (+) Pa-tients: Results from Studies ETV-022 and -901. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.

184. Gish R, Hofmann J. Hepatitis C Associated Systemic Cryoglobulinemia: Successful Treatment with Plasma Exchange. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.

185. Chang TT, Caho YC, Lai CL, Yoon SK, Han KH, Tan CK, Gish RG, Cheinquer H, Han S, Zhang H, Smith HB, Hindes R. Four-Year Treatment with Entecavir Results in High Proportions of Nucleoside-Naïve HBeAg-Positive Patients with Undetectable HBV DNA: Results from Studies ETV-022 and -901. Presented at the AASLD Liver Meeting, No-vember 2-6, 2007. Boston, MA.

186. Pachuk C, Gish R. Preclinical and Clinical Development of NUCB1000 – An Expressed Interfering RNA-Based Hepatitis B Antiviral. Presented at HEP DART, December 2007.

187. Schiff E, Everson G, Tsai N, Bzowej N, Gish R, McHutchison J, Jacobson I, Tong M, Jensen D, Lauer G, Cruickshank S, Ferraro J, Haller A, Duke R, Rodell T, Apellian D. HCV-Specfic Cellular Immunity, RNA Reductions, and Normalization of ALT in Chronic HCV Subjects After Treatment with GI-5005, A Yeast-Based Immunotherapy Targeting NS3 And Core: A Randomized, Double-Blind, Placebo Controlled Phase 1B Study. Pre-sented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.

188. Park S-S, Yang Y-K, Lee Y-I, Jung J, Zhao D, Park Y, Yoon H, Tam J, Ganda C, Lee H-T, Park J, Yang S, Groupper C, Gish RG, McGuire BM, Panoskaltsis-Mortair A, Lim Y-S, Lee HC, Suh D-J, Ferguson J. Preclinical Assessment of HepaHope Bioartificial Liver System. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.

189. Gish RG, Satishchandran C. Polyamine-Complexed Plasmid DNA Nanoparticle Deliv-ery of RNAi to Hepatocytes. Meeting on Drug Delivery Boston. 2007.

190. Gish RG. Epidemiology Of Chronic Hepatitis B Patients. Presented at DDW, May 17-22, 2008. San Diego, CA.

191. Frederick RT, Zagorski J, Gish RG, Hofmann JC. Treatment of Hepatitis C Associated Severe Mixed Cryoglobulinemic Syndrome With Plasma Exchange Improves Tolerability and Response to Interferon-Based Therapy. Presented at DDW, May 17-22, 2008. San Diego, CA.

192. Gish R, Frederick T, Hoffman J. Treatment of Hepatitis C Associated Severe Mixed Cryoglobulinemic Syndrome With Plasma Exchange Improves Tolerability and Re-sponse to Interferon-Based Therapy. Poster. DDW, San Diego, CA, May 17-22, 2008.

Curriculum Vitae



193. Sung-Soo Park, Jaeho Jung, Sunny Yang, Sunnie Kim, Sam Lee, Young Park, Hyoung Yoon, Nercy Fernandez, Paul Hernandez, Nick Haman, Daren Cox, Robert Gish, Bren-dan McGuire, Dong-Jin Suh, Han Chu Lee. How to Improve Bioartificial Liver (BAL) System for Clinical Trials? Poster. ILC/ASAIO 2008.

194. Sung-Soo Park, Jaeho Jung, Delai Zhao, Sunny Yang, Sunnie Kim, Sam Lee, Hyoung Yoon, Young Park, Nercy Fernandez, Robert G. Gish, Brendan M. McGuire, Angela Panoskaltsis-Mortari, Han chu Lee, Dong-Jin Suh. Assessment of HepaHope bioartifi-cial liver (BAL) system for treating liver failure patients. Hong Kong, China. ILC 2008.

195. Park S-S, Jung J, Yang S, Kim S, Lee S, Yoon H, Park Y, Fernandez N, Fernandez P, Haman N, Cox D, Gish R, McGuire B, Suh D-J, Lee HC. How to Improve Bioartificial Liver (BAL) System for Clinical Trials. Presented at the 54th Annual ASAIO Conference, 2008.

196. Han S, Chang TT, Chao Y, Yoon S, Gish RG, Cheinquer H, Carrillho F, Zhang H, Brett-Smith H, Hindes R. Four-Year Treatment with Entecavir Results in High Proportions of Nucleoside-Naïve HBeAg-Positive Patients with Undetectable HBV DNA: Results from Studies ETV-022 and ETV-901. Presented at the 18th Conference of the Asian Pacific Association for the Study of Liver (APASL), March 2008. Seoul, Korea.

197. Levy AR, Kowdley KV, Iloege U, Tafesse E, Mukherjee J, Gish R, Bzowej N, et al. “The impact of chronic hepatitis B on quality of life: a multinational study of utilities from in-fected and uninfected persons.” Value Health. 2008 May-Jun; 11(3) :527-38.

198. RT Frederick, J Zagorski, R Courville, Gish RG. Negative tissue PCR does not confer reduced risk of relapse after treatment of HCV in patients. Presented at the European Association for the Study of Liver Disease (EASL), April 2008. Milan, Italy.

199. Han S, Chang TT, Chao Y, Yoon S, Gish RG, Cheinquer H, Carrillho F, Zhang H, Brett-Smith H, Hindes R. Four-Year Treatment with Entecavir Results in High Proportions of Nucleoside-Naïve HBeAg-Positive Patients with Undetectable HBV DNA: Results from Studies ETV-022 and ETV-901. Presented at the Hong Kong-Shanghai ILC Meeting, June 2008. Hong Kong, China.

200. Morris Sherman, Cihan Yurdaydin, Halis Simsek, Marcelo Silva, Yun-Fan Liaw, Vinod K. Rustgi, Hoel Sette, Naoky Tsai, Daniel J. Tenney, James Vaughan, Bruce Kreter, Robert Hindes, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved viro-logic, biochemical, and serology outcomes through 96 weeks. – RG Gish included in BEHoLD Study Group. Hepatology. July 1, 2008.

201. Gish R, Marrero JB, Tong MJ. Medical therapties to extend survival in hepatocellular carcinoma. Clin Adv Hematol Oncol. 2008 Aug;6(8) :1-14; quiz 5.

202. S.Han, TT Chang, YC Chao, SK Yoon, RG Gish, H Cheinquer, G Kitis, H Zhang, U IIo-eje. Five Years of Continuous Entecavir for Nucleoside-Naïve HBeAg(+) Chronic Hepa-titis B: Results from Study ETV-901. Journal of Hepatology. AASLD, November 2008. San Francisco, CA.



203. Sung-Soo Park, RG Gish, Brendan Martin McGuire, Angela Panoskaltsis-Mortari, Chris Stevens. A Novel Acute Liver Failure Large Animal Model Suitable for Testing Extracorpo-real Bioartificial Liver Systems. Poster. AASLD, November 2008. San Francisco, CA.

204. Steven Han, Rajender Reddy, Emmet B. Keeffe, Consuelo Soldevila-Pico, Robert Gish, Raymond Chung, Bulent Degertekin, Anna Lok. Hepatocellular Carcinoma (HCC) is the Main Inidcation for the Liver Transplantation (OLT) among HBV Patients in the Era of Nucleos/Tide Analogue Therapies.

205. Paul Gaglio, Sundeep Singh, Bulent Degertekin, Michael Ishitani, Munira Hussain, Rob-ert Perrillo, Anna S Lok, and the NIH HBV OLT Study Group. Impact of HBV Genotype on Pre- and Post- Liver Transplantation Outcomes.

206. Debbie Hana Yi, Sumbella Baqai, Robert Gish. Characteristics of Hepatitis Delta in Northern CA.

207. Ting-Tsung Chang, You-Chen Chao, Vladimir V. Gorbakov, Kwang-hyub Han, Robert G. Gish, Robert de Man, Hugo Cheinquer, Fernando Bessone, Helena Brett-Smith, Ri-cardo Tamez. “Summary of an International Study of Entecavir for the Management of Nucleoside-Naïve HBeAg-positive Patients With Chronic Hepatitis B.” 2008.

208. Debbie Hanna Yi, Sumbella Baqai, Robert G. Gish. “Characteristics of Delta Hepatitis in Northern California.” Poster presented at AASLD. October 2008.

209. Xu L, Guo L, Shen Z, Loss G, Gish R, Wasilenko S, et al. “Duplication of MER115 on Chromosome 4 in Patients with Primary Biliary Cirrhosis.” Liver Int. 2008 Oct 10.

210. Steven-Huy B. Han, Ting-Tsung Chang, You-Chen Chao, Seung Kew Yoon, Robert G. Gish, Hugo Cheinquer, George E. Kitis, Hui Zhang, Uchenna LLoeje. “Five Years of Continuous Entecavir for Nucleoside-naïve HBeAg(+) chronic hepatitis B: Results from study ETV-901.” 2008.

211. Robert G. Gish, Catherine Frenette. “Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management – Volume 4. Medscape Gastroenterology 2008.

212. Patrick Marcellin, Robert G. Gish, Norman Gitlin, Jamie Heise, Deanine G. Halliman, Eric Chun, Maribel Rodriguez-Torres. “Randomized, Double-Blind, Multicenter Study Comparing the Safety and Efficacy of Viramidine and Ribavirin in Treatment-Naïve Pa-tients With Chronic Hepatitis C: Results of ViSER2.” Manuscript Submitted for Publica-tion. 2008.

213. Robert G. Gish. “Diagnosis of Chronic Hepatitis B and the Implications of Viral Variants and Mutations.” The American Journal of Medicine. September 2008.

214. Maribel Rodriguez-Torres, Robert Gish, Norman Gitlin. “Randomized, Double-Blind, Multicenter Study Comparing the Safety and Efficacy of Viramidine and Ribavirin in Treatment-Naïve Patients with Chronic Hepatitis C: Results of ViSER2.” Poster pre-sented at AASLD. San Francisco, CA. October 2008.



215. Steven-Huy B. Han, Ting-Tsung Chang, You-Chen Chao, Seung Kew Yoon, Robert G. Gish, Hugo Cheinque, George E. Kitis, Hui Zhang, Uchenna IIoeje. “Five Years of Con-tinuous Entecavir for Nucleoside-naïve HBeAg (+) Chronic Hepatitis B: Results from Studies ETV-022/-901.” Poster presented at AASLD. San Francisco, CA. October 2008.

216. Catherine T. Frenette, Robert G. Gish. “Screening At-Risk Individuals for Hepatitis B: What do the Guidelines Say?” Medscape, Expert Column. 2008.

217. Robert Gish. “Hepatitis B: Advances in Screening, Diagnosis, and Clinical Manage-ment.” Medscape – Volume 4. November 2008. http://www.medscape.com/viewpro-gram/17750

218. Catherine T. Frenette, Robert G. Gish. “Review of Selected Liver Cancer Abstracts from the AASLD Meeting in San Francisco 2008 for NATAP – Proteomics, Genomics and Biomarkers.” 2008.

219. Catherine T. Frenette, Robert G. Gish. “Review of Selected Liver Cancer Abstracts from the AASLD Meeting in San Francisco 2008 for NATAP – Hepatitis C and Hepato-cellular Carcinoma.” 2008.

220. Catherine T. Frenette, Robert G. Gish. “Review of Selected Liver Cancer Abstracts from the AASLD Meeting in San Francisco 2008 for NATAP – Hepatitis B and risk for Hepatocellular Carcinoma.” 2008.

221. Catherine T. Frenette, Robert G. Gish. “Review of Selected Liver Cancer Abstracts from the AASLD Meeting in San Francisco 2008 for NATAP – HCC Screening and Sur-veillance.” 2008.

222. Catherine T. Frenette, Robert G. Gish. “Review of Selected Liver Cancer Abstracts from the AASLD Meeting in San Francisco 2008 for NATAP – Risk Factors for Hepato-cellular Carcinoma.” 2008.

223. Catherine T. Frenette, Robert G. Gish. “Review of Selected Liver Cancer Abstracts from the AASLD Meeting in San Francisco 2008 for NATAP – Treatment of Hepatocellu-lar Carcinoma, Treatment Access.” 2008.

224. Catherine T. Frenette, Robert G. Gish. “Review of Selected Liver Cancer Abstracts from the AASLD Meeting in San Francisco 2008 for NATAP – TACE, Radiofrequency Ablation and Other Ablative Therapies.” 2008.

225. Catherine T. Frenette, Robert G. Gish. “Review of Selected Liver Cancer Abstracts from the AASLD Meeting in San Francisco 2008 for NATAP – Multi-Kinase Inhibitor, Oral Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma.” 2008.

226. Catherine T. Frenette, Robert G. Gish. “Review of Selected Liver Cancer Abstracts from the AASLD Meeting in San Francisco 2008 for NATAP – Liver Transplant Patients and Hepatocellular Carcinoma.” 2008.



227. Robert Gish, Catherine Frenette, Michael Schilsky, Dr Wong. “Clinical epidemiology of Wilson Disease in patients with concurrent liver disease.” Hepatology – Manuscript ID HEP-08-1912. 2008.

228. Robert G. Gish. “Diagnosis of Chronic Hepatitis B and the Implications of Viral Variants and Mutations.” The American Journal of Medicine. 121,S12-S21.

229. Robert Gish, Robert Osorio, Kenneth Binmoeller. “New Strategies for Hard-to-Treat Gastrointestinal Cancer.” California Pacific Medical Center Research Institute – Cur-rents 2008.

230. Robert G. Gish. “Chronic Hepatitis B Viral Infection.” Atlas of Gastroenterology, 4th Edition. Page 636-641. 2009.

231. Robert G. Gish, Stephen Locarnini. “Chronic Hepatitis B Viral Infection.” Textbook of Gastroenterology, 5th Edition. Volume 2, Page 2112-2138. 2009.

232. Sumbella Baqai, Robert G. Gish. “High Rate of Core and Precore Mutations in a Pa-tient Population with Chronic Hepatitis B at a Tertiary Referral Center.” 19th Conference of the APASL. Hong Kong Convention and Exhibition Centre. February 13-16, 2009.

233. Sumbella Baqai, Debbie Hanna Yi, Robert G. Gish. “Characteristics of Hepatitis Delta in Northern California.” 19th Conference of the APASL. Hong Kong Convention and Ex-hibition Centre. February 13-16, 2009

234. Robert G. Gish. “What do we know about the Difficult-to-Treat Patient with Chronic Hepatitis C Infection.” 19th Conference of the APASL. Hong Kong Convention and Exhi-bition Centre. February 13-16, 2009.

235. Robert G. Gish, Stuart C. Gordon, David Nelson, Vinod Rustgi, Isreal Rios. “A Ran-domized Controlled Trial of Thymalfasin plus Transartierial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma.” Hepatology International. In press. 2009.

236. Robert G. Gish, Ting-Tsung Chang, ching-Lung Lai, Robert de Man, Adrian Gadano, Fred Poordad, Joanna Yang, Ricardo Tamez, Helena Brett-Smith. “Loss of HBsAg Anti-gen During Treatment With Entecavir or Lamivudine in Nucleoside-Naïve HBeAg-Posi-tive Patients With Chronic Hepatitis B.” Journal of Viral Hepatology. Submitted for publi-cation. 2009.

237. Adrian M. Di Bisceglie, Robert G. Gish, Steven-Huy B. Han, W. Ray Kim, Naoky C.S. Tsai. “HBV Advanced Certificate Program IV Launches with First Course.” Projects In Knowledge. 2009.

238. Robert G. Gish, Catherine Frenette. “To Be or Not to Be: That is the Question.” Ameri-can Journal of Gastroenterology. Submitted for publication. 2009.

239. Robert G. Gish, Steven Locarnini. “Chronic Hepatitis B Viral Infcction.” Gastroenterol-ogy Textbook. 2009.

Curriculum Vitae



240. Adrian Di Bisceglie, Robert G. Gish, Patty Peterson, Elaine Rudell. “HBV Management: Gaps in Clinical Competence and Practice Performance – US Survey Findings.” Ab-stract for EASL 2009.

241. Robert G. Gish. “Update – New Therapies for Hepatitis B and Hepatitis C.” 16th Annual Alimentary Update. South Lake Tahoe. March 27, 2009.

242. Robert G. Gish. “Using a new palette of treatment options to paint the portrait of cure for patients infected with hepatitis C on our clinical canvas.” NATAP/EASL: New HCV Drugs Report. EASL 2009. April 23-26, 2009.

243. Robert G. Gish. “HBV Poster.” DDW poster. May 2009.

244. Adrian Di Bisceglie, Robert G. Gish, Patty Peterson, Elaine Rudell. “HBV Management Among US Clinicians: Gaps in Clinical Competence and Practive Performance-Survey Findings.” DDW Poster. May 2009.

245. Robert G. Gish. “Wilsons Disease Symposium.” California Pacific Medical Center. San Francisco, CA. May 2, 2009.

246. Michele Tana, Kaveh Hoda, Jackson Wong, Yiqiu Wei, Wylie Liu, Nanette Hinojales, Paula Lykins, Germaine Andrews, David Stone, Doug Wong, Grace Estevez, Eddie Cheung, Judy Li, Robert Gish, Stewart Cooper. “DDW 2009 HBV Abstract.” DDW poster. May 30, 2009 – June 3, 2009.

247. Adrian Di Bisceglie, Robert Gish. “Hepatitis B – Combined.” DDW poster. May 30, 2009 – June 3, 2009.

248. Robert Gish. “Advanced Certificate Program IV: Bridging Cultural Differences to Im-porve HBV Treatment in Asian and Other Diverse Communities – Course Title: Case Study: HBeAg-Positive Vietnamese Patient.” Tx Reporter. 2009.

249. Terry Conway, Vernon Smith, Gaylee Morgan, Jack Meyer, Dennis Roberts, Esther Reagan.” Robert Gish, Member of Expert Working Group. “Early Medicaid Coverage of Chronic Hepatitis B May Reduce Medicaid Spending and is Associated with Positive Health Outcomes.” JAMA. 2009.

250. Robert Gish. “Loss of HBsAG antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.” Journal of Viral Hepatitis. 2009.

251. Edward L. Baker, Robert G. Gish. “Imaging in Hepatobiliary and Pancreatic Disease: A Practical Clinical Guide.” 2009.

252. Robert Wong, Robert Gish, Michael Schilsky, Catherine Frenette. “Clinical Epidemiol-ogy of Wilson Disease in Patients With Concurrent Liver Disease.” Poster. APASL 2010. April 2009.

253. Robert Gish. “Hepatitis B treatment: Current best practices, avaoiding resistance.” Cleveland Clinic Jouranal of Medicine. Supplement to Cleveland Clinic Journal of Medi-cine. Supplement 3, Volume 76. May 2009.



254. Robert Wong, Robert Gish, Michael Schilsky, Catherine Frenette. “Clinical Epidemiol-ogy of Wilson Disease in Patients With Concurrent Liver Disease.” Poster. Wilson Dis-ease Meeting. San Francisco, CA. May 2, 2009.

255. R.G. Gish, T.T. Chang, C.L. Lai, R. de Man, A. Gadano, F. Poordad, J. Yang, H. Brett-Smith, R. Tamez. “Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HbeAg-positive patients with chronic hepatitis B.” Journal of Viral Hepatitis, 2009.

256. T.T. Chang, Y.C. Chao, V.V. Gorbakov, K.h. Han, R.G. Gish, R. de Man, H. Cheinquer, F. Bessone, H. Brett-Smith, R. Tamez. “Results of up to 2 years of entecavir vs lamivu-dine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.” Journal of Viral Hepatitis, 2009.

257. Michele Tana, Kaveh Hoda, David Hutton, Jackson Wong, Yiqiu Wei, Wylie Liu, Nanette Hinojales, Paula Lykins, Germaine Andres, David Stone, Doug Wong, Grace Estevez, Eddie Cheung, Judy Li, Robert Gish, Stewart Cooper. “HBV Screening in Asians and Pacific Islanders: An interim cost effectiveness analysis of a single center San Francisco program.” 2009.

258. Adrian M. Di Bisceglie, Robert G. Gish, Steven-Huy B. Han, W. Ray Kim, Nancy C.S. Tsai. “Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Di-verse Communities.” Advanced Certificate Program IV. Projects in Knowledge. 2009.

259. Adrian M. Di Bisceglie, Robert G. Gish,. “Case Study: HBsAg-Positive, Anti-HBe-Nega-tive Black Immigrant from Somalia.” Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse Communities. Advanced Certificate Program IV. Projects in Knowledge. 2009

260. Adrian M. Di Bisceglie, Robert G. Gish, “Case Study: HBsAg-Positive, Anti-HBe-Nega-tive Black Immigrant from Somalia.” Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse Communities. Advanced Certificate Program IV. Volume 4, Issue 5. Projects in Knowledge. 2009

261. Robert Wong, Robert Gish, Michael Schilsky, Catherine Frenette. “Clinical Epidemiol-ogy of Wilson Disease in Patients With Concurrent Liver Disease.” Liver International Journal. Submission. November 2009.

262. Robert Wong, Todd Frederick, Natalie Bzowej, Robert Gish, Catherine Frenette. “Clini-cal Profile of Autoimmune Hepatitis Patients withConcurrent Development of Hepatocel-lular Carcinoma.” Submitted EASL abstract. November 2009.

263. Robert Gish. “A Retrospective Analysis of Tenofovir DF and Entecavir Combination Therapy in Patients with Chronic Hepatitis B (CHB) and Previouse Treatment Failure (PTF).” Submitted EASL Asbstract. November 2009.

264. Robert Gish. “United network for Organ Sharing regional Review Analysis: Heterogene-ity of MELD Upgrade Scores for MELD Exceptions.” Abstract Submission to American Transplant Congress. December 2009.



265. Steven-Huy Han, K. Rajender Reddy, Emmet B. Keeffe, Consuelo Soldevila-Pico, Rob-ert Gish, Raymond Chung, Bulent Degertekin, Anna Lok, NIH-HBV OLT Study Group. “Clinical Outcomes of Liver Transplantation for HBV-Related Hepatocellular Carcinoma: Data from the NIH HBV-OLT Study Group.” Submitted for publication.

266. Adrian M. Di Bisceglie, Robert G. Gish,. “Expert Insight Into: Hepatitis B Testing and Vaccination Among Vietnamese-andCambodian-Americans (Part 2 of Series).” Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse Communi-ties. Advanced Certificate Program V. Projects in Knowledge. 2010.

267. Adrian M. Di Bisceglie, Robert G. Gish,. “Expert Insight Into: Prevalence of Hepatitis B Surface Antigen Among Refugees Entering the United States Between 2006 and 2008 (Part 3 of Series).” Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse Communities. Advanced Certificate Program V. Projects in Knowledge. 2010.

268. Adrian M. Di Bisceglie, Robert G. Gish,. “Expert Insight Into: Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-Up Study (Part 4 of Series).” Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse Communities. Advanced Certificate Program V. Projects in Knowledge. 2010.

269. Adrian M. Di Bisceglie, Robert G. Gish,. “Expert Insight Into: Perinatal Transmission of Hepatitis B Virus: An Australian Experience (Part 6 of Series).” Bridging Cultural Differ-neces to Improve HBV Treatment in Asian and Other Diverse Communities. Advanced Certificate Program V. Projects in Knowledge. 2010.

270. Adrian M. Di Bisceglie, Robert G. Gish. “Expert Insight Into: Incidence and Risk Factors of Progression to Cirrhosis in Inactive Carriers of Hepatitis B Virus (part 5 of Series)” Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse Communities. Projects In Knowledge. 2010.

271. Robert Gish, Ji-Dong Jia, Stephen Locarnini, Fabien Zoulim. “Principles for Selecting Chronic Hepatitis B Therapy with a High Barrier to Resistance.” Submitted for publica-tion. 2010.

272. Robert Wong, Robert Gish, Michael Schilsky, Catherine Frenette. “A Clinical Assess-ment of Wilson Disease in Patients With Concurrent Liver Disease.” Journal of Clinical Hepatology. 2010.

273. Norah A. Terrault, Jennifer L. Dodge, Edward L. Murphy, John E. Tavis, T.R. Levin, Robert Gish, Michael busch, Miriam J. Alter. “Sexual Transmission of HCV Among Mo-nogamous Heterosexual Couples: The HCV Partners Study.” New England Journal of Medicine. 2010.

274. Robert G. Gish. “International and National Priorities for Liver Cancer Control.” John Hopkins Bloomberg School of Public Health IRB. February 2010.

275. Robert G. Gish, Jorge A. Marrero, Al B. Benson. “A Muiltidisciplinary Approach to the Management of Hepatocellular Carcinoma.” Clinical Roundtable Monograph. March 2010.

Curriculum Vitae



276. R.Wong, R.Gish, T.Frederick, N.Bzowej, C.Frenette. “Epidemiology, Staging and Prog-nosis.” Submission for ILCA 2010.

277. Chari Cohen, Scott Holmberg, Joan Block, Carol Brosgart, Brian McMahon, W.T. Lon-don, Robert G. Gish, Timothy Block. “Is Chronic Hepatitis B Being Under Treated in the United States?” JVH. Submitted 6/2010, Published 4/2011

278. Robert Wong, Robert Gish, Todd Frederick, Natalie Bzowej, Catherine Frenette. “De-velopment of Hepatocellular Carcinoma in Autoimmune Hepatitis.” ILCA Poster. Sep-tember 10-12, 2010.

279. Heiner Wedemeyer, Robert Gish, Tuan Nguyen, Ching-Lung Lai, Cyril Llamoso, Ting-Tsung Chang. “Efficacy and Safety of Entecavir in the Older Patient (>50 years of age). Submitted to AASLD – November 2010 Boston Meeting.

280. Sung-Soo Park, Jaeho Jung, Hong Bock Lee, Delai Zhao, Young Park, Hyoung Yoon, Jason Lee, Sunny Yang, Jun Choi, David Goldberg, Vickie Sheckler, Robert G. Gish, Todd Frederick, Brendan M. McGuire, Norman L. Sussman, Angela Panoskaltsis-Mor-tari, Han Chu Lee, Dong Jin Suh. “Acute Liver Failure and Artificial Liver.” Poster. AASLD – November 2010 Boston Meeting.

281. Sung-Soo Park, Jaeho Jung, Hong Bock Lee, Delai Zhao, Young Park, Hyoung Yoon, Jason Lee, Sunny Yang, Jun Choi, David Goldberg, Vickie Sheckler, Robert G. Gish, Todd Frederick, Brendan M. McGuire, Norman L. Sussman, Angela Panoskaltsis-Mor-tari, Han Chu Lee, Dong Jin Suh. “Development of a Canine Acute Liver Failure Model that is Suitable for Evaluating Safety and Efficacy of Bioartificial Liver Systems.” Poster. AASLD – November 2010 Boston Meeting.

282. Catherine Frenette, Robert Gish. “Clinical Management and Case Reports for the Treatment of Hepatocellular Carcinoma with Sorafenib.” Journal of Clinical Gastroenter-ology. Submitted for publication. 2010.

283. Robert G. Gish, Norman Sussman. “The Current Status of Artificial Liver Support (ALS).” The Gastroenterology Exchange. 2010.

284. Robert Gish. “Is Chronic Hepatitis B Being Undertreated in the United States,” Journal of Viral Hepatitis. August 2010.

285. Adrian M. Di Bisceglie, Robert G. Gish. “Severe Lactic Acidosis During Treatment of Chronic Hepatitis B with a Nucleoside Analog in Patients with Impaired Liver Function (Part 8 of Series)” Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse Communities. Advanced Certificate Program V. Projects in Knowledge. 2010.

286. Adrian M. Di Bisceglie, Robert G. Gish, “Case Study: Focus on Reactivation” Projects in Knowledge. 2010.

287. Robert Gish. “UNOS Researchers Contribute to ATC Abstracts. UNOS Magazine. 2010.

Curriculum Vitae



288. Steven Huy Han, K. Rajender Reddy, Emmet B. Keeffe, Consuelo Soldevila-Pico, Robert Gish, Raymond T. Chung, Bulent Degertekin, anna Lok, NIH-HBV OLT Study Group. “Clin-ical Outcomes of Liver Transplantation for HBV-Related Hepatocellular Carcinoma: Data from the NIH HBV-OLT Study.” Clinical Transplantation. 2010. CLTX-10-OA-0087.R1.

289. Robert Gish. “HCC Treatment Options and Their Associated Adverse Events.” Inte-grating Recent Data in Managing Adverse Events in the Treatment of Hepatocellular Carcinoma. Clinical Roundtable Monograph. September 2010.

290. Myron J. Tong, Robert Gish, Ghassan K. Abou-Alfa. “Multidisciplinary Treatment of Pa-tients With HCC.” Integrating Recent Data in Managing Adverse Events in the Treat-ment of Hepatocellular Carcinoma. Clinical Roundtable Monograph. September 2010.

291. Mary Ann Cmunale, Mengjun Wang, Lucy Rodemich-Betesh, Julie Hafner, Anne Lamon-tagne, Andrew Klein, Jorge Marrero, Adrian M. Di Bisceglie, Robert Gish, Timothy Block, Anand Mehta. “Novel Changes in Glycosylation of Serum Apo-J in Patients with Hepatocellular Carcinoma.” 2010.

292. R.G. Gish, S.L. Cooper. “Hepatitis b in the greater san francisco bay area: an integrated programme to respond to a diverse local epidemic.” Journal of Viral Hepatitis. 2010.

293. Heiner Wedemeyer, Robert Gish, Tuan Nguyen, Ching-Lung Lai, Cyril Llamoso, Ting-Tsung Chang. “Efficacy and Safety of Entecavir in the Older Patient (≥50 years of age).” APASL 2010.

294. Robert Gish, Naoki Tsai, Calvin Pan, Kris Kowdley, Ke-Qing Hu, Lai CL, Ting-Tsung Chang, Kwang-Hyub Han, David Coehn, Hong Tang, Myron Tong. “Efficacy and Safety of Entecavir in Nucleos(t)ide Naïve Asians with HBeAg Positive and Negative Chronic Hepatitis B: Results from Studies ETV-022/027.” APASL 2011 - Thailand.

295. Catherine T. Frenette, Richard Todd Frederick, Robert Gish. “Clinical Management and Case Reports for the Treatment of Hepatocellular Carcinoma With Sorafenib.” Journal of Clinical Gastroenterology. 2010.

296. Robert Gish, Pamela Norton, Hongyan Liang, Timothy Block, Mengjun Wang, Ronald Long. “Hepatocellular Carcinoma Biomarker GP73: Effects of IL-6 Family Cytokines and Interferon-α in Human Hepatocytic Cells and in People with Liver Disease (lower case alpha). Cancer Epidemiology, Biomarkers & Prevention. 2010.

297. Kohla M, El-Warraky M, Gish R, Management of a Case of Obscure Lower GI Bleeding by Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Case Report, EUGW2011, Stockholm.

298. Gish R, Sussman N, Park S, McGuire, An In Vitro Demonstration of the HepaPheresisTM

System that can Metabolize 15N-Ammonia and Lidocaine using a Porcine Liver Slice-Filled Bioartificial Liver

299. Gish R, Bu Y, Fang J, Lau J, Hanguar D, KX01,” A Dual-Mechanism Src/Pretubulin in-

hibitor, Is Synergistic With Sorafenib But Not with Doxorubicin Against Liver Cancer Cells,” AASLD

Curriculum Vitae



300. Gish R, DiBisceglie A, Nguyen M, Te H, Tran T, “Testing and Interpretation of Hepatitis B Serologic Markers and Other Markers of Disease Activity”

301. Gish, R, Kohla M, “Spontaneous Regression of HCC: A Case Report,” accepted for Poster Presentation, International Liver Cancer Association, September 2011.

302. Gish, R, Kohla M, “Predictive Factors for Hepatic Decompensation after TACE for Hepa-tocellular Carcinoma (HCC): A Single Center Experience,” accepted for Poster Presenta-tion, International Liver Cancer Association, September 2011.

303. Robert G. Gish MD, Alexander, Colleen Tu BS, Kuo MD, Cyndy Collins NP, Shirley M.

Tsunoda, Pharm.D. “Effect of Sirolimus on Immune Cell Function Assay in Liver Trans-plant Recipients,” September 2011.

304. R. Gish, W.Sievert1, H.Wedemeyer2, T.Nguyen4, C.L.Lai5, C.Llamoso6, T.T.Chang7 , “Entecavir Efficacy and safety in patients ≥50 Years Of Age,” Australian Gastroenterol-ogy Week, Brisbane, Australia, 12-15 September 2011.

305. Gish, Robert G., “HCV In At Risk Populations: Who Can Be Treated And How?,” Cur-

rent Hepatitis Reports, September 2011. 306. Gish, Robert G., “Hepatitis B Surface Antigen Quantification,” Armenia Journal:

BLOOD. September 2011. 307. Gish, Robert G., “Drug-Induced Liver Disease (DILI) and Acute Liver Failure,” Armenia

Journal: BLOOD. September 2011. 308. Gish, Robert G., “Autoimmune Hepatitis and Acute Liver Failure,” Armenia Journal:

BLOOD. September 2011.

309. Gish, Robert G., “Serologic and Virologic Tools For the Workup and Management of Hepatitis B,” Armenia Journal: BLOOD. September 2011.

310. Gish, Robert G., “Wilson Disease,” Armenia Journal: BLOOD. September 2011.

311. Gish, Robert G., “Liver Cancer Biomarkers,” Armenia Journal: BLOOD. September 2011.

312. Gish, Robert G., “Current Management of Liver Cancer,” Armenia Journal: BLOOD. September 2011.

313. Gish, Robert G., “Liver Transplantation in 2011,” Armenia Journal: BLOOD. Septem-ber 2011.

314. Gish, Robert G., “Chronic HBV Infection Outside Treatment Guidelines: Is Treatment Needed?” Journal of Viral Hepatitis, (Submitted for Publication), December, 2011.

Curriculum Vitae



315. Robert G. Gish MD, Heather Patton MD, Michael Misel PharmD., “Acute Liver Failure: An Evidence-Based Management Protocol for Clinicians,” Gastroenterology & Hepatol-ogy, January 2012.

316. Gish, Robert G., Shirley Tsunoda, Pharm D, “Effect of Sirolimus on Immune cell func-tion assay in liver transplant recipients,” January, 2012.

317. Gish, Robert G., Binh Tran, PharmD, “Barriers to Hepatitis B screening and Hepatitis B knowledge among Asian populations in San Diego County,” January 2012.

318. Gish, Robert G., “Serum Albumin and AFP Levels as Predictors of Hepatic Decompen-sation After TACE for Hepatocellular Carcinoma (HCC),” Presented at: APASL, Taipei, Taiwan. February 2012.

319. Gish, Robert G., Frenette, Catherine, “Targeted Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives, Challenges and Implications,” World Journal of Gas-troenterology, February, 2012.

320. Gish, Robert G., Martinez, Anthony D, “HCV In At-Risk Populations: Who Can Be Treated and How?” Current Hepatitis Reports, Volume 8, Number 1, February 2012.

321. Sumbella F. Baqai MD, Debbie H. Yi MD, Michael Mangahas, Robert G. Gish MD, “High Rate of Core Promoter and Precore Mutations in Patients with Chronic Hepatitis B and Their Impact on Liver Disease,” Journal of Viral Hepatitis, (Submitted for Publication), 2012.

322. Norah A. Terrault, Jennifer L. Dodge, Edward L. Murphy, John E. Tavis, Alexi Kiss, T.R.

Levin, Robert Gish, Michael Busch, Arthur L. Reingold, Miriam J. Alter: “Sexual Trans-mission of HCV Among Monogamous Heterosexual Couples: The HCV Partners Study,” study was supported by a cooperative agreement with the Centers for Disease Control and Prevention, U50 CCU915651, U01 DK60345 (J.E.T), ‘Accepted Article,’ doi: 10.1002/hep.26164; November 25, 2012.

323. Maja Kodani, Alyssa Martin, Tonya Mixson-Hayden, Jan Drobeniuc, Robert Gish, and

Saleem Kamili, “One-Step Real-Time PCR Assay for Detection and Quantification of Hepatitis D Virus RNA by Short-Form Paper, Journal of Clinical Microbiology, Virology Section, Control number JCM00554-13; February 26, 2013

324. Robert G. Gish, Ting-Tsung Chang, Ching-Lung Lai, Robert A de Man, Adrian Gadano,

Cyril Llamoso, Hong Tang: “Quantitative Hepatitis B Surface Antigen Analysis in Hepati-tis B e Antigen-Positive, Nucleoside-Naive Patients Treated With Entecavir,” Antiviral Therapy, Manuscript ID AVT-12-OA-2806.R1, doi: 10.3851/IMP2559, International Medi-cal Press Ltd., http://www.intmedpress.com/journals/avt/abstract.cfm?id=2559&pid=48; February 28, 2013.

Curriculum Vitae



325. Maja Kodani, Alyssa Martin, Tonya Mixson-Hayden, Jan Drobeniuc, Robert Gish, Saleem Kamili, “One-Step Real-Time PCR Assay for Detection and Quantification of Hepatitis D Virus RNA One-Step qRT-PCR for HDV Detection,” Journal of Clinical Micro-biology, Virology Section, JCM0054-13, March 2013.

326. Robert B. Gish, Strategies for Hepatocellular Carcinoma Surveillance and Diagnosis,

Gastroenterology & Hepatology, April 2013 Volume 9, Issue 4.

327. “Impact of Entecavir Versus Lamivudine on Hepatic HBV Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepati-tis B Patients,” Robert G. Gish, Scott Bowden, Stephen Locarnini, Ting-Tsung Chang, You-Chen Chao, Kwang-hyub Han, Robert de Man, Cyril Llamoso, Hong Tang, “DDW, Orlando Florida oral presentation,” Funded by Bristol-Myers Squibb; May 2013.

328. Shirley M. Tsunoda, Stephanie Wang, Linda Awdishu, Nina Phak, Alicia Somers, Robert G. Gish, “Utilizing Intracellular ATP Activity as a Biomarker for Predicting Rejection in Hepatitis C Liver Transplant,” submitted to 2013 ATC Conference; May 2013.

329. Robert G. Gish, Shirley M. Tsunoda, Jonathan Hu et al, Effect of Hepatitis C Therapy

on Immune Cell Function Assay in Liver Transplant Recipients, submitted to 2013 ATC Conference; May 2013.

330. Scott Bowden, Stephen Locarnini, Ting-Tsung Chang, You-Chen Chao, Kwang-hyub Han, Robert G. Gish, Robert de Man, Cyril Llamoso7, Hong Tang, “Impact of Entecavir Versus Lamivudine on Hepatic HBV Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients,” e-Poster, Lecture collateral, Digestive Disease Week, Orlando, FL.; May 19–21, 2013.

331. Speaker, Current Insights in to the Management of Hepatic Encephalopathy, Hepatology

Centers of Educational Expertise, San Diego, CA; May 28, 2013.

332. Session Chairman, Transforming Science to Clinical Practice, APASL Liver Week 2013 Singapore: Session Chairman, Singapore; June 6-10, 2013.

333. Dr. Robert Gish, Dr. Lynn Huang, “Hec1 as a Novel Approach to Liver Cancer, submitted

for publication, June 24, 2013.

334. Maja Kodania, Alyssa Martina, Tonya Mixson-Haydena, Jan Drobeniuca, Robert R. Gish, Saleem Kamilia; “One-Step Real-Time PCR Assay for Detection and Quantitation of Hepatitis D Virus RNA,” Journal of Virological Methods 193 (2013), pp. 531-535, Au-gust 2013.

335. Wyles D, Nelson D, Swain M, Gish RG, Ma J, McNally J, Brainard D, Symonds W, McHutchison J, Bernstein D, Thompson A, Mangia A, Jacobson I. “On Treatment HCV RNA as a Predictor of Virologic Response in Sofosbuvir-Containing Regimens for Geno-type 2/3 HCV Infection: Analysis of the FISSION, POSITRON, and FUSION Studies. “American Association for the Study of Liver Disease, “The Liver Meeting.” Washington DC. November 1-5, 2013.

Curriculum Vitae



336. Scott Bowden, Stephen Locarnini, Ting-Tsung Chang, You-Chen Chao, Kwang-hyub Han, Gish RG, Robert de Man, Cyril Llamoso, Hong Tang. “Impact of Entecavir Versus Lamivudine on Hepatic HBV Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients”. Australian Gastroenterology Week 2013. Melbourne, Australia. October 7-9, 2013.

337. Gish RG et al; “Hepatocellular Carcinoma Surveillance: An Inquiry Into Current Prac-tices”, Abstract #ILCA2013-1080, International Liver Cancer Association Seventh Annual Conference, Washington D.C., September 13-15, 2013.

338. Luke Huang; Simon Shih-Hsien Chuang, KJ Kao, Diana Wu; Jinn Wu, Gish, Robert; Johnson Lau; “Inhibition of Hec1 as a Novel Approach to the Treatment of Primary Liver Cancer”, Taivex Therapeutics, 2013.

339. Gish RG, “VIRGIL ((Vigilance Against Viral Resistance) Study Establishes Clinical Ben-efit of Virologic Suppression With Entecavir,” Commentary, Clinical Care Options, Virol-ogy, September, 2013.

340. Gish RG, “Delta Virus Infection: Epidemiology and Initiatives to Intercept It,” Commen-tary, Gastroenterology & Hepatology, September 2013

341. Gish RG, “Global Hepatitis Overview and How to Respond to the Epidemic”, Armenia Liver Conference 2013, September 6-8, 2013.

342. Gish RG, “Current Therapy of Hepatitis B: Planning for 2013 and Beyond”, Armenia Liver Conference 2013, September 6-8, 2013.

343. Gish RG, “Hepatitis E”, Armenia Liver Conference 2013, September 6-8, 2013.

344. Gish RG, “Hepatitis C Virus: The Basics, Current Status and the Future”, Armenia Liver Conference 2013, September 6-8, 2013.

345. Gish RG et al; “Utility of On-Treatment HCV RNA as a Predictor of Response”, American Association for the Treatment of Liver Disease”, The Liver Meeting, Washington D.C., November 1-5, 2013.

346. Gish RG, et al, “On Treatment HCV RNA as a Predictor of Virologic Response in Sofos-buvir-Containing Regimens for Genotype 2/3 HCV Infection,” The Liver Meeting, AASLD 2013, Washington DC, November 1-5, 2013.

347. Gish RG et al, “Impact of Entecavir Versus Lamivudine on Hepatic HBV Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients”. ISGCON 2013 - Indian Society of Gastroenterology Con-ference, Gujarat, Ahmedabad , India; November 28 – December 2013.

348. Sandy Chong et al, “Collaborative Efforts to Screen at-risk Populations for Hepatitis B and C in San Diego County,” abstract approved for HepDart 2013, Kohala, Hawaii, De-cember 10, 2013.

Curriculum Vitae



349. Nguyen CT, Gish RG, et al; “POC Testing for Hepatitis C Screening at Community-Based-Organizations Facilitates Disease Control,” abstract approved for HepDart 2013, Kohala, Hawaii, December 10, 2013.

350. Gish RG, Gutierrez J, Navarro-Cazarez N, Giang K, Adler, D, Tran B, Locarnini S, Ham-mond R, Bowden D. “A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation.” Submitted for publication. Journal of Vir Hep; 2013 Dec, JVH-00600-2013

351. Julio Gutierrez, et al, “Efficacy of Screening for Hepatitis B Infection and Immunity in Low Resource Settings with an Inexpensive Point of Care Immunoassay,” abstract approved for HepDart 2013, Kohala, Hawaii, December 10, 2013.

352. Lillian Nguyen, et al, “Cost-Effectiveness Analysis of Point of Care versus Standard of Care Tests for Hepatitis B in Asian and Pacific Islanders in San Diego County,” abstract approved for HepDart 2013, Kohala, Hawaii, December 10, 2013.

353. Xuan Phan, et al, “Targeting Populations At-Risk for Hepatitis B Using the Research Electronic Data Capture (RED Cap) Program,” abstract approved for HepDart 2013, Ko-hala, Hawaii, December 10, 2013.

354. Lillian Nguyen, et al, “Cost-Effectiveness Analysis of Point of Care versus Standard of Care Tests for Hepatitis B in Asian and Pacific Islanders in San Diego County,” poster submitted to European Association for the Study of Liver Diseases (EASLD); Spring 2014.

355. Sandy Chong et al, “Collaborative Efforts to Screen at-risk Populations for Hepatitis B and C in San Diego County,” poster submitted to European Association for the Study of Liver Diseases (EASLD), Spring 2014.

356. Mitchell, DG, Bruix, J, Sherman, M, Sirlin, CB. Gish, RG. RADS (Liver Imaging Report-ing and Data System): Summary, Discussion, Consensus of the LI-RADS Management Working Group and Future Directions.” Journ of Hep: 30 Mar-2014.

357. Julio Gutierrez, et al, “Efficacy of Screening for Hepatitis B Infection and Immunity in Low Resource Settings with an Inexpensive Point of Care Immunoassay,” poster submitted to European Association for the Study of Liver Diseases (EASLD), Spring 2014.

358. Xuan Phan, et al, “Targeting Populations At-Risk for Hepatitis B Using the Research Electronic Data Capture (RED Cap) Program,” poster submitted to European Associa-tion for the Study of Liver Diseases (EASLD), Spring 2014.

359. Christina Thuy Nguyen, et al; “POC Testing for Hepatitis C Scr eening at Community–Based Organizations Facilitates Disease Control”, poster submitted to European Associ-ation for the Study of Liver Diseases (EASLD), Spring 2014.

360. Kono Y, Gish RG.” HCC Surveillance: An Inquiry into Current Practices in the United States “. Poster submitted for Digestive Disease Week 2014. CID: 1901686. McCormick Place Convention Center, Chicago, IL., 5 May-2014.

Curriculum Vitae



361. Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Hong T, “DNA Reduction With Entecavir Or Lamivudine,” ESPS Manuscript NO: 13924, World Journ of Gaastro, 1Feb 2015. Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. “HCC: Surveillance: An Inquiry into Current Practices in the United States”, American Journ of Gastroentrol, Manuscript ID: AJG-13-2307. May 2014 Volume 146, Issue 5, Supplement 1, Page S-995. DOI: http://dx.doi.org/10.1016/S0016-5085(14)63616-7, 5 May 2014.

362. Chong SI, Gish RG, Nguyen C, Tran BN, Tsunoda S, Navarro-Cazarez N, Gutierrez J, P Taylor P: Collaborative Efforts to Screen At-Risk Populations for Hepatitis B and C in San Diego County: Singapore Hepatitis Conference, 6-7 June-2014.

363. Nguyen L.T., Tran BN, Fontanesi J, Gish RG; “Cost-Effectiveness Analysis of Point-of Care versus Standard of Care Tests for Hepatitis B in Asian and Pacific Islanders”: Sin-gapore Hepatitis Conference, 6-7 June-2014.

364. Given BD, Locarnini A, Schluep T, Lau J, Lewis D, Gish RG, Lickliter J., A Phase I, first in human clinical trial of ARC-520, a siRNA-based therapeutic for the treatment of chronic hepatitis B virus infection, in normal healthy volunteers, submitted for publica-tion, American Association for the Study of Liver Disease 2015., June 2014.

365. Gish, RG, Tran B, Nyguyen C, Pharm D., Cost effectiveness Analysis of Point-of-care versus Standard of Care Tests for Hepatitis B in Asian and Pacific Islanders, Poster Ab-stract presentation, Singapore Hepatitis Conference 2014, Singapore, June 5-7, 2014.

366. Gish, RG, Tran B, Nyguyen C, Pharm D., Point-of-care testing for hepatitis C screening at Community-Based-Organizations facilitates disease control, Poster Abstract presenta-tion, Singapore Hepatitis Conference 2014, Singapore, June 5-7, 2014.

367. Gish, RG, Tran B, Nyguyen C, Pharm D., Targeting populations at risk for hepatitis B us-ing the Research Electronic Data Capture Program (REDCap), Poster Abstract presen-tation, Singapore Hepatitis Conference 2014, Singapore, June 5-7, 2014.

368. Gish, RG, Tran B, Nyguyen C, Pharm D., Pearls gained from hepatitis B screening in the Community setting), Poster Abstract presentation, Singapore Hepatitis Conference 2014, Singapore, June 5-7, 2014.

369. Gish, RG, Tran B, Nyguyen C, Pharm D., Collaborative Efforts to screen at risk popula-tions for hepatitis B and C in San Diego County, Poster Abstract presentation, Singapore Hepatitis Conference 2014, Singapore, June 5-7, 2014.

370. Seetharam A, Perrillo R, Gish RG; “Immunosuppression in Patients with Chronic Hepati-tis B,” Curr Hepatology Rep, DOI 10.1007/s11901-014-0238-2, e-ISSN 2195-9595, also available Springerworks.com; 1Aug, 2014.

371. Wong RJ, Gish RG, Ahmed A; “Hepatic Encephalopathy is Associated with Significantly Increased Mortality among Patients Awaiting Liver Transplantation”, Manuscript ID: LT-14-198.R3; DOI: 10.1002/lt.23981, Wiley Online Library, 2014 Aug 25.

http://dx.doi.org/10.1016/S0016-5085(14)63616-7

Curriculum Vitae



372. Huang LY, Chang CC, Lee YS, Huang JJ, Chuang SH, Chang JM, Kao KJ, Lau GM, Tsai PY, Liu CW, Lin HS, Gish RG, Lau JY; Inhibition of Hec1 as a novel approach for treatment of primary liver cancer. Cancer Chemother Pharmacol. Sept2014;74(3):511-20. doi: 10.1007/s00280-014-2540-7. Epub 20 Ju l2014.

373. Ahn J, Gish RG, “Hepatitis D Virus: A Call to Screening”, Gastroenterology & Hepatol-ogy, 634-640, Gastroenterology & Hepatology Volume 10, Issue 10 Oct 014.

374. Yuen MF, Lewis DL, Chan HLY, Lai CL, Given BD, Locarnini SA, Hamilton J, Lau John-son YN, Schluep T, Gish RG; “Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection”, Abstract Poster Presen-tation Publication Number: LB-21, American Association for the Study of Liver Disease (AASLD), The Liver Meeting 2014, Boston, MA, 10Nov2014.

375. Ramers CB, Wallace D, Gish RG, Lewis R, Wyles DL, Reyes L, Kuo A, “One Year Re-sults of a Community-Based Hepatitis C Testing and Linkage to Care Program”, Ab-stract ID 2094798, 22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015). Washington State Conference Center, Seattle, WA, February 23 - February 26, 2015.

376. Mixson-Hayden T, Kodan M, Gish RG, Perrillo R, Kamili S, “Passive Hepatitis Delta Sur-veillance in the United States: 2012-2014,” Abstract presented at The Liver Meeting, American Association for the Study of Liver Disease, 12Nov 2014.

377. Wong RJ, Cheung R, Gish RG, Ahmed A, “Pre-Transplant Hepatic Encephalopathy is Associated with Significantly Lower Survival Following Liver Transplantation,” poster pre-sented at The Liver Meeting, American Association for the Study of Liver Disease, 12Nov 2014.

378. Reddy KR, Beavers KL, Hammond SP, Lim JK, Lim, Gish, RG, Falck-Ytter YT, American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy, Gastroenterology, online publication Dec. 2014.

379. Wong RJ, Cheung R, Gish RG, Ahmed A, “Pre-Transplant Hepatic Encephalopathy is Associated with Significantly Lower Survival Following Liver Transplantation,” 20:1454–1461, Liver Transplantation, Dec 2014.

Curriculum Vitae ROBERT G. GISH, M.D. 117 CME PRESENTATIONS AND PUBLICATIONS

1. Gish RG et al. The Clinicians Companion: Expert Perspectives on Contemporary Clini-cal Issues in Hepatitis C. 1997.

2. Gish RG. Interferon alfa-2b/Ribavirin Combination Therapy: A Promising Step Toward the Treatment of Chronic Hepatitis C: A CME monograph. Presented at a DDW Sympo-sium. May 12, 1997.

3. Gish RG. Highlights of DDW 1997. Liver Disease Digest 1997.

4. Gish RG. Treating Chronic Hepatitis C: New Strategies for non-responders and relaps-ers. AALSD Meeting Highlights. A CME monograph. Presented at an AALSD Sympo-sium. November 8, 1998.

5. Gish RG. Management of End-Stage Liver Disease from Viral Hepatitis. Placerville CA. April 25, 199.

6. Gish RG. Liver Assist Device. Presented at a California Pacific Specialty Services Con-tinuing Medical Education. February 3, 2000.

7. Gish RG. The Medical/Surgical Aspects of Gastrointestinal Disease. Presented at Sutter Roseville Medical Center. April 1, 2000.

8. Gish RG. Objective Structured Clinical Exercise (OSE). Presented at the University of California, San Francisco. April 15, 2000.

9. Gish RG. Plenary I & Presidential Address I. Presented at the American Society of Transplantation (AST) Meeting. May 13, 2000.

10. Gish RG. Clinical Science Symposium: Transplantation Tolerance. Presented at the AST Meeting. May 13, 2000.

11. Gish RG. Concurrent Communications. Presented at the AST Meeting. May 13, 2000

12. Gish RG. Transplantation Immunobiology Symposium. Presented at the AST Meeting. May 13, 2000.

13. Gish, RG. Concurrent Communications III. Presented at the AST Meeting. May 13, 2000.

14. Gish RG. Clinical Science Symposium: Practice Guidelines. Presented at the AST Meeting. May 13, 2000.

15. Gish RG. Application of Epidmeology and Biostatistics to Clinical Research. Presented at the AASLD symposium. May 20, 2000.

16. Gish RG. Physicians on the Attack against Hepatitis C. Office.com. December 21, 2000.

17. Gish RG. Hepatitis C: Building a Response to the North State Crisis. Sacramento April 28, 2000.

Curriculum Vitae


CME PRESENTATIONS AND PUBLICATIONS: Continued

18. Gish RG. Department of Transplantation: Transplant Tolerance, Living Donor Liver Transplant. December 21, 2000.

19. Gish RG. What is the natural history of Hepatitis C? Treatment Reporter: Gastroenterology. 2002.

20. Gish RG, Afdhal N. New data on managing anemia with growth factors for patients on

anti-HCV therapy: a case-based series. Treatment Reporter: Gastroenterology. September 2002.

21. Gish RG. Optimizing Treatment Response in HCV Infection by Anemia Management.

Presented at the Foundation for better health and DVC. January 24, 2003.

22. Gish RG. Managing Liver Related Challenges. Presented at the AASLD Expert Consen-sus. 2003

23. Gish RG. Autoimmune Liver Disease. Presented at a Special CME Conference. March 18, 2003

24. Gish RG. Hepatitis B. Presented at Sunrise Hospital, April, 2003. Las Vegas, NV.

25. Gish, RG. Optimal Clinical Outcomes: Managing Hepatitis Related Challenges. University of Wisconsin. November 2004.

26. Gish RG, Chronic Hepatitis C, Hepatitis Magazine, May 2004. 27. Gish RG, Surveying the Hepatitis C Landscape: Current Treatment and a Look at New

Options on the Horizon. Medical Media Communications. May 2004.

28. Gish RG. Implications & Management of Anemia in Liver Disease. CME Monograph Se-ries, Volume 2, Issue 2, October 2004.

29. Gish RG. Prevalence and Characterization of HCV-Associated Cognitive Impairment. DDW May 21, 2004.

30. Gish RG. Plan for Success: Effective Side Effect Management in Anti-HCV Therapy. DDW May 16, 2004.

31. Gish RG. Concepts and Controversies in the Management of Hepatitis B – A Debate Among the Experts. DDW May 2004.

32. Gish RG. HBV Infection in Clinical Practice. Tx Reporter: Gastroenterology. March 22, 2005.

33. Gish RG. Phoenix Educational Initiative. Presented at The France Foundation, 2005.

34. Gish RG. New Data on Emerging Therapies for the Treatment of Chronic Hepatitis B Virus. PVI and University of Florida, January 2005.

Curriculum Vitae



35. Gish RG. Implications & Management of Anemia in Liver Disease: Pre-Management of HCV-Infected Patients Before & After Liver Transplantation. CME Monograph Series, V 2, Issue 3, March 2005.

36. Gish RG. Clinical Case Consults in Chronic Hepatitis B: An Interactive Teleconference Program. Bristol-Meyers Squibb. 2005.

37. Gish RG, Benhamou Y, Forns X, Marcellin P. Ribavirin Analogues and Ribavirin-like Molecules: New Directions in Antiviral Therapy. An update on Ribavirin Analogues: Meeting the challenge of anemia in Hepatitis C treatment. April 14, 2005. CME Module for Clinical Care Options.

38. Gish RG. Practical Pathways Towards Improved Management of HCV Treatment Fail-ures. Presented at DDW, May 15, 2005.

39. Gish RG. Therapies for Hepatocellular Carcinoma. Informed, The Newsletter of the Hep-atitis B Foundation. No. 43:Spring, 2005.

40. Gish RG. Controversies in Management of HBV: Lessons from Case Studies. October 12, 2005. CME-CD-ROM for Projects In Knowledge. http://www.pro-jectsinknowledge.com/Init/G/1718/

41. Gish RG. Part I: Diagnosing HBV: Signs, Symptoms, and Diagnostic Tests for Chronic Infection. December 7, 2005.

42. Gish RG. Part 6 of 9: Management of Cirrhosis and Decompensation. HBV Infection in Clinical Practice. The Treatment Reporter: Gastroenterology. September 23, 2005. CME for Projects in Knowledge.

43. Gish RG. Immediately Useful Strategies for Improving Patient Outcomes. The Treat-ment Reporter: Gastroenterology. Volume 1, Issue 6 2006.

44. Gish RG. Part 7 of 9: Management of the HBV Coinfected Patient. The Treatment Re-porter: Gastroenterology. 2006.

45. Gish RG. Part 8 of 9: A Steady Advance: Latest Findings from Anti-HBV Clinical Tri-als. The Treatment Reporter: Gastroenterology. February 17, 2006.

46. Gish RG. Part 9 of 9: Viral Resistance. The Treatment Reporter: Gastroenterology. February 27, 2006.

47. Afdhal N, Gish R. Decreased Resistance and Good Safety With Newer Nucleos(t)ides for Hepatits B. University of Florida/Peer View: Course Director Review. 2006.

48. Afdhal N, Gish R. Nucleos(t)ide Analogues Suppress Hepatitis B Virus, Reverse Dis-ease in Multiple Patient Populations. University of Florida/Peer View: Course Director Review. 2006.

49. Gish RG, Di Bisceglie AM. In-Depth and Timely Response to Pressing Educational Needs. Advanced Certificate Program in the Management of Chronic Hepatitis B: Mem-ber’s Update. 2006;1(7):2.

Curriculum Vitae



50. Gish RG. HBV Review – based on the proceedings from our satellite symposium at AASLD 2006. CME activity for Projects in Knowledge.

51. Gish RG, Newer Nucleos(t)ide Analogues Suppress Hepatitis B Virus, Reverse Disease in Multiple Patient Populations. PeerView Press. February 15, 2006.

52. Gish RG. Selecting Antiviral Therapy for a Treatment-Naive Patient with Hepatitis B—Posting 3. Practical Guidelines for Managing HBV in Special Patient Populations. August 16, 2006. CME activity for Projects in Knowledge.

53. Dusheiko GM, Gish RG, Keeffe EB, Perrillo RP. Latest Findings in HBV Manage-ment. CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA. November 11-15, 2005. Slideset for Clinical Care Options, posted February 1, 2006.

54. Gish RG. Assessing Antiviral Treatment Effect: Recognizing Primary and Secondary Treatment Failure—Posting 9. Practical Guidelines for Managing HBV in Special Patient Populations. February 14, 2007. CME activity for Projects in Knowledge.

55. Gish RG. Managing HBV Infection During Pregnancy—Posting 7. Practical Guidelines for Managing HBV in Special Patient Populations. January 4, 2007. CME activity for Pro-jects in Knowledge.

56. Gish RG. Postoperative Management of Patients with Hepatocellular Carcinoma—Posting 12. Practical Guidelines for Managing HBV in Special Patient Populations. May 11, 2007. CME activity for Projects in Knowledge.

57. Gish RG, expert commentary. Expert Insight Into: Provider Knowledge and Practice Re-garding Hepatitis B Screening in Chinese-Speaking Patients. Advanced Certificate Pro-gram III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Di-verse Communities. October 10, 2007. CME activity for Projects in Knowledge.

58. Gish RG, expert commentary. Expert Insight Into: Why We Should Routinely Screen Asian-American Adults for Hepatitis B: A Cross-Sectional Study of Asians in California. Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treat-ment in Asian and Other Diverse Communities. December 20, 2007. CME activity for Projects in Knowledge.

59. Gish RG, expert commentary. Expert Insight Into: A Randomized Controlled Trial of Lamivudine to Treat Acute Hepatitis B. Advanced Certificate Program III: Bridging Cul-tural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. January 28, 2008. CME activity for Projects in Knowledge.

60. DL Veenstra, DE Spackman, A Bisceglie, KV Kowdley, Gish RG. “Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-ef-fectiveness analysis.” Alimentary Pharmacology & Therapeutics, p1240-1252.

61. Gish RG, Lau GKK. Case Study: Managing Genotype B HBV Infection in an Asian Pa-tient. TX Reporter Newsletter. Advanced Certificate Program III: Bridging Cultural Differ-ences to Improve HBV Treatment in Asian and Other Diverse Communities. November 29, 2007. CME activity for Projects in Knowledge.

Curriculum Vitae



62. Gish R, Jacobson I, Pockros P. Improving HBV Treatment: Early Screening and Sus-tained Control for Improved Outcomes. Clinical Roundtable Monograph. Gastroenterol-ogy and Hepatology. January 2008.

63. Gish RG, Kim RW. Case Study: Managing Confounding Herbal Hepatotoxicity and Fa-milial Hepatocellular Carcinoma Risk in an HBeAg-Negative Vietnamese Immigrant. TX Reporter Newsletter. Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. February 27, 2008. CME activity for Projects in Knowledge.

64. Gish RG. Update on Hepatitis C Virus: epidemiology, natural history and treatment. Saint Mary’s Regional Medical Center. July 24, 2008. 2 AMA Physician’s Recognition Award Category 1 Credits.

65. Gish RG, Terry Baker, Misha Cohen, Stewart Cooper, Randy Dietrich, Gregory T. Ever-son, Sylvia Flesner, Peter Hauser, Randy Horwitz, David W. Indest, Jessica Irwin, Julia Jernberg, Joyce S. Kobayashi, Douglas R. LaBrecque, Lark Lands, Shri K. Mishra, Sha-ron D. Montes, Julie Nelligan, J. Lyn Patrick, Bharathi Ravi, Aparna Roy, Lorren Sandt, Kathleen B. Schwarz, Tina M. St. John, Amy E. Smith, Diana L. Sylvestre, Norah Ter-rault, Sivarama Prasad Vinjamury, Qing Cai Zhang, Susan L. Zickmund. “Hepatitis C Choices, 4th Edition – Diverse Viewpoints and Choices for Your Hepatitis C Journey.” Caring Ambassordors Program. 2008.

66. Gish RG, Al B. Benson III, Morris Sherman, Barbara Sigler Morgan. “Cases in Point: Risk Factors, Surveillance Strategies and Treatment Options for HCC.” Gastroenterol-ogy and Hepatology. Volume 5, Issue 1, Supplement 3. January 2009.

67. Gish RG. “Hepatocellular Carcinoma Screening in Patients with Hepatitis C Cirrhosis.” Medscape CME. 2009.

68. Gish RG. “Hepatitis B treatment: Current best practices, avaoiding resistance.” Cleve-land Clinic Journal of Medicine. Supplement to Cleveland Clinic Journal of Medicine. Supplement 3, Volume 76. May 2009.

69. Gish RG, “Update in Hepatocellular Carcinoma - The Latest Information on Pathogene-sis, Screening and Treatment” (Course HCC01.07). The Advanced Certificate Program in Heptocellular Carcinoma – Projects in Knowledge, Feb.2010.

70. Gish RG, Hepatitis B Testing and Vaccination Among Vietnamese- and Cambodian-Americans (Part 2 of Series) (Course HBV5.03), Advanced Certificate V, Bridging cul-tural Differences to Improve HBV Treatment in Saian and Other Diverse Communities, Project of Knowledge, March 2010.

71. Robert Gish, USA Co-author White Letter “A Plan of Action for Liver Disease in Viet Nam” March 2010.

72. Wong, Robert, Robert Gish, “A Clinical Assessment of Wilson Disease in Patients With Concurrent Liver Disease" JCG9314 Accepted for publication. March 2010.

Curriculum Vitae



73. Robert Gish. “Staying the Course: Patient Adherence Strategies in the Era of New Frontline HBV Therapies – Barriers to Treatment, Adherence in Asian Americans.” Clini-cal Care Options CME/CE Certified Treatment Update. 2010.

74. Robert Gish, The Secret Epidemic: Hepatitis C Affects Between Four and Six Million Americans, , Bottom Line’s Daily Health News, www.bottomlinesecrets.com, Feb, 7, 2006.

75. Robert Gish, New Drug for Hepatitis C, Bottom Line’s Daily Health News, www.bottomli-nesecrets.com, May 19, 2011.

76. Robert Gish, Hepatocellular Carcinoma: Locoregional and Targeted Therapies, Gastro-enterology Clinics of North America, June 7, 2011.

77. Robert Gish, 35th Annual CAPA Conference, September 22- 25, 2011. 78. Gish, Robert., “Learn About Hepatitis and Liver Diseases”, www.BenhGan.org.; 2011.

79. Robert Gish, AASLD Annual Meeting, November 2011.

80. Robert Gish, Best Practice in Advanced Liver Disease, Chicago, Illinois, August 13, 2011. 81. Robert G. Gish, “Risk Assessment and Clinical Management of Patients with CHB,” Fullerton, CA Speaker, August 15, 2011 82. Robert Gish, The Pacific Health Foundation Presents: Fourteenth Annual Liver Symposium, Speaker, San Jose, CA, September 17, 2011. 83. Robert Gish, Viral Hepatitis and Hepatocellular Carcinoma Symposium, La Jolla, CA, October 2011. 84. Robert Gish, Moores Cancer Center, San Diego, CA. November 2011. 85. Robert Gish, Center for Biomedical Continuing Education, HCC Local CME Speaker Program, 2011 – 2012. 86. Robert Gish, University of Nevada, School of Medicine Grand Rounds, 2011 – 2012 87. Robert Gish, “Chronic HBV,” Clinics in Liver Disease (Accepted for Publication),

May 2012.

88. Speaker, “Hepatitis Hot Topics” GR’S (?) (Short notice). Scripps Mercy Hospital San Di-ego, February 22, 2013.

89. International Liver Cancer Association Meeting, Washington, DC 2013. 90. Speaker, Treatment of Viral Hepatitis Circa 2013. Advances in Gastroenterology and

Hepatology, San Diego Omni Hotel, San Diego, CA. March 2, 2013.

Curriculum Vitae



91. Wide Spread Hepatitis B screening and treatment in Vietnam CME meetings in Ha Noi and HCMC, March 3-5, 2013.

92. Current Insights in to the Management of Hepatic Encephalopathy, Hepatology Centers

of Educational Expertise, San Diego, CA; May 28, 2013. 93. Speaker, Current Insights into the Management of Hepatic Encephalopathy. The Chronic

Liver Disease Foundation, 2013 Hepatology Centers of Educational Expertise Lecture Series. Ruth’s Chris Steak House, San Diego, CA. May 28, 2013.

94. Speaker. Hepatitis D and E: The Forgotten Viruses. UCSD AntiViral Research Center,

San Diego, CA. June 21, 2013. 95. HCV Update. Sponsored by Duke University School of Medicine & the Chronic Liver Dis-

ease Institute. Phoenix, AZ. January 20, 2014. 96. Speaker & Educator, Viral Hepatitis Action Plan Webinar, Office of HIV/AIDS and Infec-

tious Disease Policy, Department of Health and Human Services, December 13, 2013. 97. Speaker, Surveillance for Hepatocellular Carcinoma in the At-Risk Population in associa-

tion with Bayer Healthcare and Onyx Pharmaceuticals. Philadelphia, PA. January 14, 2014. 98. Instructor, State of the Art Therapy for HCV, University of Washington, University of Ala-

bama Birmingham, IAS-USA online training module, Funded by a grant from the Centers for Disease Control and Prevention. March 15, 2014. http://hepati-tisc.uw.edu/browse/all/lectures#page/featured/lectures/state-art-therapy

Curriculum Vitae ROBERT G. GISH, M.D. 124 FEDERAL AND STATE LEGAL HEARINGS

October 28th, 1997: Senate Interim Hearing, Public Safety Subcommittee on Prison Construction and Operation (Senator Polanco, Chairman).

June 9th, 1998: Advisory Group on Hepatitis C, for the California Assembly Health Committee on merits of Senate Bill 694 introduced by Senator Polanco (Public education and screening for hepatitis C virus)

April 14, 2000: Coalition Members, Deparment of Health and Human Services (DHHS) Task Forced On Hepatitis C.

May 22, 2000: Coalition Members, Senate Bill 1256 (Polanco).

June 6th, 2000: Advisory Group on Hepatitis C for the California Assembly Health Committee on merits of Senate Bill 1256 introduced by Senator Polanco (Public education and screening for hepatitis C virus)

May 4, 2001. CASG HCV/Civacir protocol re: NIAID Collaborative Antiviral Study Group (CASG) clinical trial “A Randomized Open-label, Phase I/II Study to Evaluate the Safety and Pharmacokinetics of Hepatitis C Immune Globulin (Human) Civacir™ in Liver Transplant Recipients”

2002: Center for Policy Reform Senate Bill AB 2529 (Hep C prevention education for prisoners).

March 26, 2014: Liver Capitol Hill Day in association with the American Association for the Study of Liver Diseases, Washington, D.C.

Meeting Participant, The White House Initiative on Asian Americans and Pacific Islanders (AAPI); Data.gov & AAPI Stakeholder Conference Call, September 30, 2014.

Curriculum Vitae


EDUCATIONAL EVENTS

X550 Dinner Program with Temecula-Area Group of Heptologists, Temecula, CA. October, 2011.

Facilitator, “Academic Health Centers & Health Reform: Re-establishing the Social Con-tract,” University of California, San Diego Department of Medicine Grand Rounds, February 8, 2012.

EASL, The International Liver Congress 2013, 48th Annual Meeting of the European Associ-ation for the Study of the Liver. Amsterdam, Netherlands. 24 hours. April 26, 2013

Tools in Waitlisted Patient Management, Xyn Management, May 2013.

Grand Rounds, Internal Medicine Residents & Fellows, Penn State University Medical Cen-ter, Hershey, PA, October 18, 2013.

Facilitator, HBV Task Force, St Joseph’s Medical Center, Phoenix, AZ March 19, 2014. SPECIAL COURSES ATTENDED

Therapeutic Biliary Endoscopy. Kees Huibregtse, M.D., Academic Medical Center. Amsterdam, Netherlands, April 9-June 6, 1987.

Liver Transplantation Strategies. Baylor Medical Center, May 1988.

Endoscopic Ultrasound: Lok Tio M.D., and Therapeutic Biliary Endoscopy: Kees Huibregtse, M.D. Academic Medical Center, Amsterdam, Netherlands, June 1-30, 1989.

AASLD Annual Postgraduate Course and Research Meeting, Chicago, Illinois, 1984-present.

DDW Annual Postgraduate Course and Research Meeting. Various 1985, 1988, 1991, 1992, 1993, 1994.

Laparoscopy and Liver Biopsy. Under the direction of Lennox Jeffers, M.D., University of Miami, Miami, Florida, 1992.

Liver Transplantation and Viral Hepatitis. NIH, AASLD Symposium, Reston, Virginia, March 25, 1993.

The Psychiatric Effects of Interferon: Theories and Therapeutic Approaches, Integrated Therapeutics, Short Hills, Virginia, May 31, 1996.

Liver Transplantation for Alcoholic Liver Disease, ASTP/AASLD Forum, Bethesda, Maryland, December 3, 1996.

Curriculum Vitae


SPECIAL COURSES ATTENDED: Continued

Liver Transplantation for Alcoholic Liver Disease, The National Institute of Diabetes and Digestive and Kidney Diseases, Washington, DC, December 6, 1996.

International Hepatology Symposium, Beijing, China August 8-16, 1997.

Testing for Hepatitis C: New Technologies for Optimal Therapy. Trevose, PA. November 14, 2001; December 13, 2001; December 17, 2001.

HCV Side Effects Consensus Conference. San Francisco, CA. May 18, 2002.

Controversies in Hepatitis C Therapy. Boston, MA. November 3, 2002.

AASLD Annual Meeting and Postgraduate Course, Boston, MA October 24-28, 2003.

Evolving Concepts in Liver Allocation in the MELD/PELD Era. Washington DC, December 8, 2003.

New Directions in the Treatment of Hepatitis B. Chicago, IL, March 2004.

1st Internation Conference of Armenian Hepatological Forum-participated as Moderator of event. Yerevan, Armenia, September 2011.

Armenian Hepatological Forum. Yerevan, Armenia. September 2011.

Attendee, PBC: Past, Present & Future, The Royal College of Physicians, London, United Kingdom, April 8. 2014.

Attendee, “Towards HCV elimination in Georgia: epidemiology, care and treatment options, and evidence based control strategies.” International Liver Congress 2014, European Asso-ciation for the Study of the Liver, London. United Kingdom, April 9, 2014.

Attendee, Hepatitis Delta International Network, International Liver Congress 2014, Euro-pean Association for the Study of the Liver, London. United Kingdom, April 9, 2014.

Curriculum Vitae


COMMUNITY SERVICE and MEDIA APPEARANCES Hepatitis B Prevention and Transplantation. Viacom Cable Channel 6, City Lights. June, 1992.

Hepatitis B Prevention and Transplantation. Nationally televised program hosted by Dr. Dean Edell. June, 1992.

The Three H's: Headaches, High Blood Pressure, and Hepatitis B. Presentation to the Liver Transplant Recipient Support Group, California Pacific Medical Center. San Francisco, California. July 8, 1992,

Organ Donation. Kaiser Permanente Medical Center. Walnut Creek, California. November 10,

1993.

Organ Transplantation. BBC television. Nightline.

Hepatitis B. Glamour Magazine, 1994.

Hepatic Hotline. Moderator, American Liver Foundation patient and community conference on hepatitis, St. Mary's Hospital. San Francisco, California. October 29, 1994.

Liver Disease. Liver Disease Support Group. Modesto, California. January 22, 1995.

Viral Hepatitis: Vaccination and Prevention. San Francisco Veteran's Administration Medical Center. San Francisco, California. October 17, 1995.

Your Liver, Your Life. Public Education workshop. American Liver Foundation, San Francisco, California. October 7, 1995.

Liver Disease, Liver Transplantation and Organ Donation. Moderator, Public Round Table Forum, American Liver Foundation. San Francisco, California. October 25, 1995.

Chronic Hepatitis. Public questions and answer period. Eureka, California. December 13, 1995.

Evaluation of Patients with Elevated Liver Enzymes and Viral Hepatitis. Shasta Community Health. Redding, California. May 14, 1996.

Recurrent Disease after Liver Transplantation. American Liver Foundation, San Francisco, California. May 18, 1996.

Future Careers in Organ Transplantation. National Youth Leadership Conference. August 2, 1996.

Treatment of Chronic Viral Hepatitis in the Department of Corrections. Chowchilla State Prison. August 3, 1996.

Organ Transplantation and its Psychosocial Implications. Chico Support Group. Chico, California. September 13, 1996.

Treatment of Chronic Viral Hepatitis in the Department of Corrections. Crescent City, California. September 18, 1996.

Curriculum Vitae


COMMUNITY SERVICE and MEDIA APPEARANCES: Continued

Hepatitis C in the Correction System. Folsom State Prison. Folsom, California. October 8, 1996.

Hepatitis A-Z. North Coast Society of Health System Pharmacists. Santa Rosa, California. January 22, 1997.

Patient Support Group Lectures. John Muir Hospital. Walnut Creek, California. January 30, 1997.

Patient Support Group Lectures. Roseville Liver Transplant at Sutter-Roseville Hospital. February 9, 1997.

Nutrition for the Liver. Support Group Lecture. Sutter General Hospital. Sacramento, California. February 19, 1997.

Patient Support Group Lecture. Sacramento Support Group. Sacramento, California. March 1, 1997.

HVC Support Group. Sutter General Hospital., Sacramento, California. March 19, 1997.

Hepatitis C Results. National Morning-Drive Radio Tour. March 27, 1997.

The ABC's of Hepatitis. East County (Contra Costa) Times. May 6, 1997.

Dialogue on Digestive Health Awareness. DDW Telephone Program. May 15, 1997.

Gastroesophageal Reflux Disease.CBS Radio News Show: Diagnosis and Management. December 20, 1997.

Hepatitis C: An Epidemic in the Prison System. National Radio News Show: 14 Radio Interviews between October 23-24, 1997.

“Hepatitis C: Setting up and continuing support groups, ALF effort,” San Francisco, California, 5/6/98.

Hepatitis C: New treatment options. American Liver Foundation North California Chapter newsletter, San Francisco, California. June 13, 1998.

Patient Support Group Lecture. San Francisco Veterans Administration Hospital. April 14, 1998.

Hepatitis C Increasing public awareness. Radio America interview with 19 national radio shows. June 10, 1998.

Hepatitis C screening of inmates proposed. Interview with the Riverside Press-Enterprise. June 13, 1998.

Curriculum Vitae



Alternatives in the treatment of chronic hepatitis C infection. American Liver Foundation, Liver Lifeline. June, 1998

National Youth Leadership Conference: Forum on Medicine. Berkeley, California. July 16, 1998.

The silent epidemic: Hepatitis C. San Jose, California. August 21, 1998

Updates in research, treatment, and understanding Hepatitis C. Yuba-Sutter Hepatitis C Support Group Meeting. November, 1999.

I Will Survive. Sacramento Area Support Group. Sacramento, CA. March 15, 2000.

Hepatitis Central guest speaker, questions and answers on line. San Francisco, California. January 27, 2000.

Is Hepatitis an Epidemic? What are current treatments? KSUF Radio Interviews, San Francisco, California. April 22, 2000.

Dark to dawn: A lesson in living: Liver Transplant patient Wendy Marx. San Francisco Examiner. San Francisco, California. May 7, 2000.

China Digest Interview. June 2008.

Hepatitis: Cases of disease rising, and it could get worse. Santa Barbara News. Santa Barbara, CA. January 18, 2001.

Hepatitis Neighborhood Town Hall hosted chat sessions. San Francisco, California. March 7, 2001.

HCV Advocate Medical Writers Circle. Online community service. 9/2001-current

Galileo High School Students discussion on cirrhosis and liver failure. December 13, 2001.

Herbal Medicine and HCV. KRON news. February 1, 2002.

Hepatitis C education: The Need at the Professional Level. The First inter-county California Statewide HSC Task Force Conference. Sacramento, California. March 13, 2002

Managing Treatment Outcomes for HCV-Related Anemia. AdvancMed. May 29, 2002

2002 Laguna Development Meeting for Clinician’s Companion VI. Secaucus, NJ. August 2002.

Advances in the Care of Patients with Autoimmune Liver Disease. AXCAN Scandipharm. Honolulu, HI. September 17, 2002.

Liver Transplant Symposium. September 25, 2002.

Hepatitis C Community Health Update. San Francisco, CA. October 24, 2002.

Curriculum Vitae



Alameda County Health Care Services Agency. Oakland, CA. November 14, 2002.

Hepatitis B provider’s event. NICOS Chinese Health Coalition. May 28, 2003.

HCV Workshop. San Francisco, California. June, 2004.

AWARE Talk Radio. Interview with Dr. Robert Gish. November 9, 2004.

The Q&A Series – Liver Cancer., American Liver Foundation. 2006.

Liver Disease – Hepatitis B & C. KCBS Radio. 2007.

CPMC & San Francisco Hep B Program – 1 in 10 Hepatitis B in the API/Chinese Community. Imperial Palace Restaurant. San Francisco, CA. May 4, 2008.

The 4th Annual Asian Heritage Street Celebration. Japantown. San Francisco, CA. May 17, 2008.

CP#384 event launching on the West side of the City. Picture and comments listed. Ming Pao News Reporting. November 27, 2008.

HBV Free Physicians Honor Roll 2009 – 2010

Vietnamese Federation of San Diego, San Diego, October 2011.

“Consult to the Commission on Viral Hepatitis.” State of Nevada – Department of Business and Industry Athletic Commission. April 8, 2010.

“Robert Gish takes the helm of hepatitis B prevention.” San Francisco Examiner Newspaper. Article by: Andrea Koskey. May 27, 2010.

A National Strategy for Viral Hepatitis Control. AASLD 2010.

Facilitator, La Jolla High School Organ Tour, University of California, La Jolla, CA, 2011.

Free Screening for Diabetes and Hep B, UCSD 2011

Hepatitis Screening Education with Asian Pacific Health Foundation, Wesley First United Methodist Church, San Diego, CA May 29, 2011.

Hepatitis B: Current Epidemiology, UCSD May 19, 2011.

Spring Community Health Fair, Wesley First United Methodist Church, May 22, 2011

FAIR Foundation Support Group, Rancho Mirage, CA, June 27, 2011.

Clinical Care Options, “Bringing into Focus: A Practical Guide to Using Virologic and Sero-logic Tests in the Management of Hepatitis B” June 2011.

Community Health Outreach; Hep B & C Screening, San Diego, June 26, 2011.

Curriculum Vitae



Hepatitis Screening Education with Asian Pacific Health Foundation, Chinese Evangelical Church, San Diego, CA July 31, 2011.

Update on the Treatment of Liver Cancer, CancerCare Teleconference, August 18, 2011.

World Hepatitis Day 2011, San Francisco, CA, August 2011.

UDW 2nd Annual San Diego County Health and Resource Fair (hosted by Skaggs School of Pharmacy and the Asian Pacific Health Foundation), San Diego, CA August 2011.

“Domino liver transplants treats two rare diseases,” Donate Life, features Allan Hemming, MD and Robert Gish, MD. CBS 8, KPBS, NBC-SanDiego, 10News, The La Jolla Light, Fox 5, 760AM and BioPortfolio, September 2011.

Hepatitis Screening Education with Asian Pacific Health Foundation, Tzu Chi, San Diego, CA September 11, 2011.

Hepatitis Screening Education with Asian Pacific Health Foundation, Hzi Fang Temple, San Diego, CA September 25, 2011.

HBV Chinese Community Event held at the office of the Asian Pacific Health Foundation. October 2011.

Health Fair for the Vietnamese Federation of San Diego, San Diego, presented topic: Up-dates on Hepatitis B, October 2011.

Hepatitis Screening Education with Asian Pacific Health Foundation, Vietnamese Federa-tion, San Diego, CA October 14, 2011.

Hepatitis Screening Education with Asian Pacific Health Foundation, La Jolla Country Day, San Diego, CA November 6, 2011.

Hepatitis Screening Education with Asian Pacific Health Foundation, Middlebrook Middle School, San Diego, CA , December 3, 2011.

Asian Journal-Los Angeles, San Francisco, Las Vegas, New York, November 2011.

Facilitator, La Jolla High School Organ Tour, University of California, La Jolla, CA, 2012

Participant: Buddhist Tzu Chi Foundation San Diego Service Center: Lunar New Year Blessing Ceremony, San Diego, CA, January 2012.

Facilitator, Vietnamese Federation of Sa Diego in conjunction with the Vietnamese Elderly Associaton and the Vietnamese Veterans Association, San Diego, CA January 14, 2012.

Event Organizer, 2nd Annual Symposium, 2012 Controversies in Inflammatory Bowel Dis-ease, San Diego, CA January 28, 2012.

Curriculum Vitae



Event Organizer, Hepatitis Free San Diego Introductory Meeting, Skaggs School of Phar-macy, Sponsored by Merck Co, La Jolla, CA January 31, 2012.

Bottom Line Personal (Home of America’s Top Experts in Everything), “Everyone born be-tween 1945 and 1965 should be tested for Hepatitis C,” Volume 33, Number 3, February 1, 2012.

The Doctors TV program, Topic: “Nail Salon Dangers,” featuring Robert Gish, MD. Febru-ary 2012.

Facilitator, Asian Pacific Health Foundation Training Session: Handling and Disposal of Sup-plies and Barriers Study Surveys, Asian Pacific Health Foundation, San Diego, CA Febru-ary 14, 2012.

Hepatitis Screening Education with Asian Pacific Health Foundation, Wesley First United Methodist Church, San Diego, CA April 4, 2012.

Hepatitis Screening Education with Asian Pacific Health Foundation, Thai Temple (New Year), San Diego, CA April 19, 2012.

Hepatitis Screening Education with Asian Pacific Health Foundation, Taiwanese American Community Center, San Diego, CA May 19, 2012

Hepatitis Screening Education with Asian Pacific Health Foundation, Vietnamese Federa-tion, San Diego, CA June 10, 2012.

Hepatitis Free San Diego, Family Health Day Hepatitis B and C screening Organized by the Tzu-Chi, St. Peters Church, Fallbrook, CA; June 29, 2012.

Hepatitis Free San Diego, Participant, 2012 Annual Convention of the Vietnamese American Medical Association, Orlando, FL; August 5, 2012.

Hepatitis Free San Diego Community Outreach, Union of Homecare Workers (UDW), Joan Kroc Community Center, San Diego, CA; August 25, 2012.

Hepatitis Free San Diego Hepatitis B and C pilot run Wesley First Methodist Church, San Diego, CA; August 27-29, 2012.

Hepatitis Free San Diego Hepatitis C screening at the UCSD HERE Initiative (Health + Education + Research = Empowerment), Jacobs Center, San Diego, CA; September 8, 2012.

Hepatitis B Screening with Dr. Julio Gutierrez, Asian Pacific Health Foundation targeting Laotian and Cambodians in East San Diego, Colina Park, San Diego, CA; December 16, 2012.

Facilitator, La Jolla High School Organ Tour, University of California, La Jolla, CA, 2013.

Curriculum Vitae



Hepatitis B Screening, Asian Pacific Health Foundation, Good Shepherd Church, San Di-ego, CA; January 12, 2013.

Feature Article, “A Hep B Free San Diego,” Discoveries Magazine, Innovations in Research, Health Care and Education Volume 3 / 2012.

Tzu-Chi Family Health Day, Asian Pacific Health Foundation, Asian Hepatitis B Screening for Asians, Saint Peter’s Church, Fallbrook, CA.; January 13, 2013.

Hepatitis B Screening with Dr. Julio Gutierrez, Asian Pacific Health Foundation, Our Lady of Sacred Heart Church, San Diego, CA; January 20, 2013.

Hepatitis B Screening with Dr. Julio Gutierrez, Asian Pacific Health Foundation, Coolidge Park, San Diego, CA; January 27, 2013.

32nd Annual Advanced Nephrology: Nephrology for the Consultant, San Diego, CA; January 31, 2013 – February 02, 2013.

National AIDS Treatment Advocacy Project, Sexual Transmission of HCV Among Monoga-mous Heterosexual Couples: The HCV Partners Study, Abstract by: Norah A. Terrault, Jen-nifer L. Dodge, Edward L. Murphy, John E. Tavis, Alexi Kiss, T.R. Levin, Robert Gish, Mi-chael Busch, Arthur L. Reingold, Miriam J. Alter, (Center for Disease Control and Preven-tion); February 22, 2013.

Liver Cancer Webinar: “Liver Cancer and Hepatitis B: What You Need to Know,” Presented by the Hepatitis B Foundation, Doylestown, PA; March 6, 2013.

Successful Domino Liver Transplantation From A Patient With Methylamalonic Acidemia, First Ever Report, American Association for the Study of Liver Diseases (AASLD); March 8, 2013.

Hepatitis B Consultative Meeting: National Viral Hepatitis Task Force (NVHTF) and Viral Hepatitis Foundation (VHF) a public private partnership to formulate a “Road Map” for Viral Hepatitis Control and Prevention in the Philippines, Manila Philippines; March 11, 2013.

Hepatitis B and C screenings: presented by Asian Pacific Health Foundation San Diego Chi-nese School, San Diego, CA; March 16, 2013.

Robert Gish, “Baby Boomers & Hepatitis C Test”, UCSD Online Content, March 2013.

Hepatitis Screening Education with Asian Pacific Health Foundation, San Diego Chinese School, San Diego, CA March 16, 2013

Hepatitis B and C screenings: presented by Asian Pacific Health Foundation Health Fair: Wesley First United Methodist Church, San Diego, CA; March 17, 2013.

Curriculum Vitae



Hepatitis B Screening, Asian Pacific Health Foundation with Dr. Binh Tran, Nhu Lai Temple, San Diego, CA, March 19, 2013.

Hepatitis Screening Education with Asian Pacific Health Foundation Vietnamese Federation of San Diego, San Diego, CA. April 14, 2013.

Gish RG, Alain, Litwin, An Evolving Therapeutic Landscape for Chronic Hepatitis C Virus: Optimizing the Linkage to Care. MD Magazine, Peers & Perspectives Special Issue. May 2013.

International Conference on Continuous Renal Replacement Therapies (CRRT) 2013, Ad-vances in Critical Care, San Diego, CA; May 4-7, 2013.

Hepatitis B screening, Asian Cultural Festival, Naval Training Center Liberty Station, San Di-ego, CA; May 11, 2013.

Attendant, Representing Coalition for the Eradication of Viral Hepatitis in Asia Pacific (CEVHAP) and National Viral Hepatitis Roundtable (NVHR) Organizations, Viral Hepatitis Action Coalition, Atlanta, GA.; May 17, 2013.

Hepatitis B screening with Dr. Binh Tran, Asian Pacific Health Foundation, Nhu Lai Temple , San Diego, CA May 19. 2013.

Current Insights in to the Management of Hepatic Encephalopathy, Hepatology Centers of Educational Expertise, San Diego, CA, May 28, 2013

Hepatitis Screening Education with Asian Pacific Health Foundation, Mabuhay Filippino-American Festival, National City, CA. June 8, 2013.

Speaker. Hepatitis D and E: The Forgotten Viruses. UCSD AntiViral Research Center, San Diego, CA. June 21, 2013.

Hepatitis B and C screenings with Yi Liu, PhD: presented by Asian Pacific Health Founda-

tion, Zion Market, San Diego, CA; June 29, 2013.

Guest Speaker, PBS Television, PBS radio and NPR; Hepatitis B Prevalent in San Diego's AsianCommunities, Global update, July 1, 2013.

Hepatitis B and C screenings with Yi Liu, PhD: presented by Asian Pacific Health Founda-

tion, Zion Market, San Diego, CA; June 29, 2013.

Health Fair & Hepatitis B Screening in association with Binh Tran & Asian Pacific Health Foundation; San Diego Lantern Festival; San Diego CA, July 20-21, 2013.

Health Fair & Hepatitis B Screening in association with Binh Tran & Asian Pacific Health Foundation; Vietnamese Catholic Center; July 27, 2013.

Curriculum Vitae



Hepatitis Screening Education with Asian Pacific Health Foundation, Tzu Chi Foundation, San Diego, CA, October 19, 2013.

Hepatitis Screening Education with Asian Pacific Health Foundation Nov 2 Health Wellness Fair at Paradise Valley Hospital, San Diego, CA, November 2, 2013.

Hepatitis B Special Interest Group: SIG Business Meeting, Washington D.C., November 3, 2013.

Sponsor & Supervisor, Hepatitis B Screening, Asian Pacific Health Foundation with Dr. Binh Tran, Tet Festival, San Diego, CA; February 1, 2014.

Asian Pacific Health Foundation with Dr. Binh Tran, Spring Health Fair at Vietnamese Fed-eration, San Diego, CA; February 9, 2014.

Hepatitis B screening and Bone densitometry Asian Pacific Health Foundation with Dr. Binh Tran, Living Water Church, San Diego, CA; March 9, 2014.

Liver Capitol Hill Day in association with the American Association for the Study of Liver Dis-eases, Washington, D.C., March 26, 2014.

Video Interview, “HBV treatment and reactivation,” Center for Liver Disease (CLD) Journal, European Association for the Study of the Liver, London, United Kingdom, April 10, 2014.

Public Service Announcement for National Viral Hepatitis Testing Day. Produced by CBS local affiliate KPIX-TV and KBCW-TV, San Francisco for national distribution, April 18, 2014.

La Jolla High School, Anatomy and Physiology class, Organ tour of cadaveric organs 2 hours, April 28, 2014.

Boy Scout Troop 4, La Jolla, CA, Organ tour of cadaveric organs, 1 hour, April 28, 2014.

Community Outreach and Screening, Asian Pacific Health Foundation, Wesley First United Methodist, San Diego CA, May 18, 2014.

Guest Speaker, (HELP!) Community Event, Speaker; “Hepatitis C Today & Tomorrow: Tri-age or Treatment?,” Santa Cruz Bible Church, Santa Cruz, CA. July 21, 2014.

Community Outreach and Screening, Asian Pacific Health Foundation, Vietnamese Alliance Church of North San Diego , San Diego, CA, July 20, 2014.

Community Outreach and Screening, Asian Pacific Health Foundation, Holy Family Church, San Diego, CA; August 10, 2014.

Community Outreach and Screening, Asian Pacific Health Foundation, Wesley First United Methodist, San Diego CA, August 23, 2014.

Curriculum Vitae ROBERT G. GISH, M.D. 136 INTERNATIONAL COMMUNITY PROGRAMS

Robert Gish, Nguyen Tien Duc, Bui Duy Tam. “Detection, Prevention, Control and Treatment of Viral Hepatitis, Liver Cancer and Other Liver Disease in Viet Nam.” February 11, 2010.

Robert Gish, Huy Trinh. “Overview of US Medical Schools and comparison to the Viet Nam

and University of Ha Noi programs” Ha Noi Medical University, Ha Noi, Viet Nam 8 30 10 Robert Gish, Yerevan, Armenia – Yerevan Hepatology Days, Aug 31 – Sep 4, 2011.

Mohamed Kohla, Mohamed El-Warraky, Sayed Solaiman, Robert Gish, Management of a

Case of Obscure Lower GI Bleeding by Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Case Report. Poster for Asian Pacific Digestive Week (APDW 2012), Bangkok, Thailand; December 5-8, 2012.

Mohamed Kohla, Mohamed El-Warraky, Robert Gish, “Unilateral Sensori-neural Hearing Loss Induced by Pegylated Interferon α2a: A Case Report. Poster, Asian Pacific Digestive Week (APDW 2012), Bangkok, Thailand; December 5-8, 2012.

Robert De man and Robert G Gish, et al (INCOMPLETE AUTHORS), Abstract A-533-0019-01294 entitled: Impact of Entecavir Versus Lamivudine on Hepatic Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients. Both ePoster and Paper poster, International Liver Congress 2013 (ILC), Amsterdam, Netherlands; April 26, 2013.

Robert Gish, Binh Tran, John Fontanesi, Lilly Nguyen Co-Author, Cost Efficiency Analysis of Point-of-Care versus Standard of Care Tests for Hepatitis B in Asian Americans in San Diego Count. Asian Pacific Health Foundation, UCSD. Summer 2013.

Robert Gish, Binh Tran, John Fontanesi, Thuy Nguyen, Co-Authors. Cost-Effectiveness of Hepatitis C Screening: Point of Care (POC) vs. Standard of Care Tests. Hepatitis Free San Diego, UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, Summer 2013.

Robert Gish, Binh Tran, John Fontanesi, Xuan Phan. Co-Authors Viral Hepatitis: Early Identification and Linkage to Care for Persons with Chronic HBV and HCV infections Hepati-tis Free San Diego. UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, Sum-mer 2013.

Participant, Hepatitis B Prevention PLAN for HCMC University of Health, San Francisco-HCMC Sister City Committee & International Liver Foundation for Viet Nam. Hepatobiliary Hospital. Bach Mai, Hanoi, Viet Nam. 2013 – Present.

Curriculum Vitae ROBERT G. GISH, M.D. 137 INTERNET SITE and PUBLICATIONS

HealthLink (www.healthlink.com): 1998 New and Evolving Therapies for Hepatitis C. Sponsored by the Canadian Digestive Disease Week Forum, Banff, Canada.

Sapient (www.sapient.com): 1997-1998 Hepatitis C: Diagnosis Treatment and Management.

Thrive: The Cutting Edge: New Therapies for Hepatitis B and C. 1998.

CPMC (www.cpmc.org): Liver Disease and Liver transplant program.

Contributor, Blog on Liver Transplantation for UCSD, Blog website: http://ucsdhealthsciences.tumblr.com/; September 2011.

Speaker, “Liver Cancer and Hepatitis B - What You Need to Know,” 2013 Liver Cancer Webinar Series, Hepatitis B Foundation, March 6, 2013.

Speaker, www.MeetTheHCVExpert.com/Gish, online presentation, July 9, 2014.

Speaker, “HCV Advances”, www.chronicliverdisease.org, November 19, 2014.

“Effect of t-Butyl hydroperoxide on calcium transport,” USC-UCLA Colloquium on Oxygen, USC Medical School, Los Angeles, California, 7/8/87.

“Liver transplantation in the United States”: Lichtenberg Hospital, Netherlands, 6/12/89; Gronengen University, Gronengen, 6/14/89; Dizkzigt, Rotterdam University, 6/16/89; Amsterdam Medical Center, 6/18/89.

“Liver transplantation state of the art,” Division of Gastroenterology, University of California at Irvine, Irvine, California, 4/5/89.

“Liver transplantation for malignancy,” and “The use of databases in the management of a liver transplant program,” in Spanish, Associacion Andaluza de Cirujanos, Cordoba, Spain, 12/13/90.

“Acute and chronic liver disease,” Straub Clinic, Honolulu, Hawaii, 1/30/91.

“FK506: a new immunosuppressant,” University of Florida at Gainesville, Gainesville, Florida, 1/21/92.

“Gallstones,” Utah Academy of Family Physicians, Centerville, Utah, 2/29/92.

“Liver cancer,” Sixth International Conference on Health Problems Related to the Chinese in North America, San Francisco, California, 6/19/92.

“Liver transplantation for patients with alcoholism and endstage liver disease,” American Society of Addiction Medicine, Los Angeles, California, 5/1/93.

“Liver transplantation for alcoholic liver disease,” University of Nebraska, Omaha, Nebraska, 4/29/94.

http://ucsdhealthsciences.tumblr.com/

Curriculum Vitae ROBERT G. GISH, M.D. 138 INVITED LECTURES – NATIONAL AND INTERNATIONAL

“Hepatitis B – issues related to liver transplantation,” University of Alabama, Birmingham, Alabama, 9/23/94.

“Hepatitis C — current diagnostic techniques,” World Congress of Gastroenterology, Los Angeles, California, 10/1/94.

“Medical aspects of liver transplantation,” University California at Davis, Sacramento, California, 10/11/94.

“Therapeutic options in decompensated hepatitis B,” American Association for the Study of Liver Disease, Chicago, Illinois, 11/4/94.

“HCV workup meeting,” Tufts University School of Medicine, Boston, Massachusetts, 3/23/96-3/24/96.

“Hepatitis A-Z and its relationship to organ transplantation,” National Association of Transplant Coordinators, San Diego, California, 8/5/96.

“Combined kidney/liver transplantation roundtable,” University of Washington, Seattle, Washington, 8/9/96.

“Hepatitis A through G: an alphabet soup,” Hilo, Hawaii, 1/1/97 to 1/4/97.

“Consensus conference,” University of Pennsylvania Department of Medicine, Philadelphia, Pennsylvania, 2/97.

“Viral hepatitis and liver transplantation,” Ochsner Medical Clinic, New Orleans, Louisiana, 3/23/97.

“Diagnosis and treatment of chronic hepatitis,” Alaska Regional Medical Center, Anchorage, Alaska, 5/7/97.

“Hepatitis B & C,” Alaska Public Health Hospital, Anchorage, Alaska, 5/8/97.

“Controversies in Liver Transplantation,” UCLA Medical Center, Los Angeles, California, 10/21/97

“Diagnosis and treatment of elevated liver enzymes,” Providence Hospital, Anchorage, Alaska, 5/9/97.

“Update on Ribavirin treatment of chronic hepatitis C,” Washington, DC, 5/12/97.

“The outpatient management of patients with chronic viral hepatitis,” Washington, DC, 5/15/97.

“Diagnosis and treatment of hepatitis C,” Summary of the NIH Conference, St. Louis, Missouri, 5/16/97.

“Hepatitis A through G: an alphabet soup,” Honolulu, Hawaii, 5/97.

Curriculum Vitae ROBERT G. GISH, M.D. 139 INVITED LECTURES – NATIONAL AND INTERNATIONAL: Continued

“Diagnosis and treatment of liver cancer,” Las Vegas Gastroenterology Group, Las Vegas, Nevada, 6/2/97.

“Post-transplant complications of hepatitis B infection,” Hepatitis Awareness Program, Hong Kong, China, 8/12/97.

“Liver transplantation for hepatitis B and C,” International Symposium on Hepatology, Beijing, China, 8/13/97.

“Treating relapsers and nonresponders: a clinical Challenge,” AASLD Satellite Symposium, Chicago, Illinois, 11/8/97.

“New and Emerging Therapy for Hepatitis C,” Canadian Digestive Disease Week, Banff, Canada, 3/5/98.

“U.S. Combination Trials in NR patients: Review of Preliminary Data,” US investigator meeting, San Puerto Rico, 1/31/98.

“Selection of patients for liver transplantation with liver cancer,” NIH/AASLD Single Topic Conference, Saint Louis, Missouri, 3/28/98.

“Beyond monotherapy: Treatment of Hepatitis C: New options for relapsers and nonresponders. Satellite symposium, DDW/AALSD New Orleans, Louisiana, 5/17/98

“Treatment of Hepatitis C: Poster Review Session, AASLD/DDW,” DDW, New Orleans, Louisiana, 5/17/98

“Interferon Treatment for Chronic Hepatitis B: An Update,” 8th International Congress on Infectious Disease, International Society of Infectious Disease, Boston, Massachusetts, 5/14/98

“Interferon and ribavirin treatment for chronic hepatitis C: A review of recent data,” Cheng Si Yuan, Conference on Viral Hepatitis, Shenzen, China, 9/14/98

“The Therapeutic Standard Strategy for Chronic Hepatitis C,” Luncheon Seminar, DDW Japan 1999.

“Hepatitis C new therapies, Interferon and Ribavirin” Japanese DDW, invited lecture, 9/2000.

“HCV Research and Prevention, An immunomodulatory approach to HCV therapy” HCV Global Foundation, San Francisco, CA 08/10/00.

“Hepatitis C,” WFTC World Conference, 09/00.

“FTC,DAPD, and L-FMAU Nucleoside Candidates for Treatment of Chronic HBV,” Management of Hepatitis B: 2000 National Institutes of Health, Bethesda, MD 09/09/00.

Curriculum Vitae


INVITED LECTURES – NATIONAL AND INTERNATIONAL: Continued

“HCV Research and Prevention, New approaches to HCV therapy” HCV Global Foundation, San Francisco, CA 08/10/01.

“Hepatitis B and Liver Transplantation” Beijing Friendship University, Beijing, China, 8/30/2001.

“Interferon and ribavirin treatment for chronic hepatitis C: A review of recent data,” ‘Autoimmune Hepatitis,’ Primary Biliary Cirrhosis’, Primary Sclerosing Cholangitis,” Conference of Science and Technology, Conference on Liver Disease, Beijing, China, 8/13/2001

“Hepatitis and liver transplant, current standards of therapy,” Barcelona Liver Disease Symposium, Barcelona Spain, 9/24/2001

“Interferon and ribavirin, importance of dosing and compliance” Japanese DDW, Osaka and Tokyo, Japan 10/24/2001

“Hepatitis C: 2001, a virus odyssey,” New Horizons in Hepatology, UCSD Liver Center 2001, San Diego, California 9/15/2001

“Testing for Hepatitis C: Satellite Symposium. AASLD. Dallas Texas. 11/14/2001

“Testing for Hepatitis C: New Technologies for Optimal Therapy. US teleconference. CME accredited 11/14/2001, 12/3/2001, 12/17/2001.

“Managing Hematologic Dysfunction During hepatitis C Therapy. AASLD satellite symposium. Dallas Texas, 11/5/2001

“The workup and evaluation of liver tumors” Early AM workshop, AASLD 11/5/2001

CSY China Itl Hepatitis Research Foundation. Hong Kong, China 10/20/2001

“Hepatitis C management advances in therapy.” William Earl Clark Society. April 30, 2002

“Treating Chronic Hepatitis B”: Gilead Sciences DDW Interactive Consultants Forum on Treating Chronic Hepatitis B. San Francisco, CA. 05/19/2002

“Management of Hepatitis C” NIH/FAES CME Committee. Bethesda, MD. 6/10-6/12/2002. Earned 13.5 hours CME credit toward the AMA Physician’s Recognition Award

“Treatment and the HCV Patient including the role of Alternative and Complimentary Medicine” Hepatitis Foundation International. Los Angeles, CA. July 18, 2002

“Living Longer, Living Stronger: Maintaining the Quality of Life for Patients with Anemia & HIV Infection.” Institute for Continuing Healthcare Education. Las Vegas, NV. September 4, 2002. Earned CME credit.

“Autoimmune hepatitis, PSC and PBC.” U-Japan Meeting on Autoimmune Liver Diseases. Oahu, HI. 9/12-14/2002

Curriculum Vitae



“Retransplantation of patients with recurrent hepatitis C—update.” MCAT. San Francisco Ca. 9/17/2002

“Advances in the use of molecular testing for HCV: Diagnosis and treatment.” Bayer Diagnostics. Taipeo, Taiwan. 9/27/02

“Parallel Session XXXIV Primary Biliary Cirrhosis. ILTS Transplant Course. AASLD. Dallas Texas. 10/27/2002

“Cholestatic and Autoimmune Liver Diseases”: ILTS Transplant Course. AASLD. Dallas Texas. 10/27/2002

“Hepatitis C: Mechanisms & other treatment issues”: ILTS Transplant Course. AASLD. Dallas Texas. 10/27/2002

“Hepatitis C: Treatment”: ILTS Transplant Course. AASLD. Dallas Texas. 10/27/2002

“Hepatitis B: Treatment”: ILTS Transplant Course. AASLD. Dallas Texas. 10/27/2002

“106-Optimal Use of Lamivudine before & after liver transplantation? When should Lamivudine be initiated in patients awaiting liver transplantation?.” Liver Transplantation for Viral Hepatitis. AASLD. 11/01/2002

“Point/Counterpoint: Controversies in Hepatitis C Therapy.” AASLD Annual Meeting. Boston, MA. November 3, 2002.

“Advances in the management of chronic hepatitis.” AASLD. Boston, MA. 11/4/02.

“Information exchange”-conference call. ACG Liver Disease Expert Information Exchange. ACG Institute for Clinical Research & Education. 12/10/02.

“Controversies in Transplantation,” Beaver Run Resort and Conference Center, University of Colorado, CME program, Adefovir for the Management of the Transplant Patient. 3/6-8 2003

“Treatment of HCV Infection, Managing side-effects during therapy”2/3-5 2003.

University of Colorado School of Medicine. March 9, 2003.

Adefovir treatment of post-transplant HBV.

“Hepatitis B and C Are Curable, How to Do It” Infectious Diseases Symposium, Emerging Clinical Issues, Sacramento, CA 5/8-9/2003.

“Maximizing the Benefits of Antiviral Therapy for HCV, The Advantages of Treating Side Effects,” Orlando, FL 5/20/03.

Curriculum Vitae



“Liver Diseases in Functional-Genomic Era,” Third Scientific Meeting of Cheng Si Yuan (China-International) Hepatitis Research Foundation), Hong Kong-Shanghai International Liver Congress 2004, 2/14-17/2004.

“HVC Side-Effect Management Medical Education Program” Phone Conference 8/6/2003.

“HVC Disease Update: Diagnosis and Management,” Las Vegas, Nevada, 8/25/2003.

“Case Histories in the Management of Patients Chronically-Infected with HBV” Hong Kong, China, 2/17/04.

“Surveying the Hepatitis C Landscape, Emerging Treatment Options on the Horizon,” Berlin, Germany, 4/14/04.

“Future Alternatives to Ribavirin,” Berlin, Germany, 4/14/04.

“Liver Diseases,” Napa CA, 11/30/04.

“ACT-HBV-Entecavir Phase III Clinical Trial Results,” San Francisco, CA 12/03/04.

“HBV Hardball-An in-dept Analysis and Fiery Debate on Optimizing Outcomes in the Treatment of Hepatitis B Virus” Nov. 9, 2004, New York.

“Face B- Bristol Myers Squibb Hepatitis B Speakers Bureau Conference : Facing a New Future,” Washington, D.C., April 2005.

“Virologic Response and Safety Outcomes in Therapy-Naïve Patients Treated for Chronic Hepatitis C with Virmadine in Combination with Pegylated Interferon ALFA-2A,” DDW Chicago, IL, May 2005.

“Entecavir Leads to Sustained Response Off-Treatment in Nucleoside-Naïve, HBEAGE(+) Patients Who Met On-Treatment Response Endpoints at 48 Weeks of Therapy in Phase 3 Study ETV-022,” DDW Chicago, IL, May 2005.

“Entecavir is Well Tolerated for the Treatment of Nucleoside-Naïve and Lamivudine-Refractory Chronic Hepatitis B: Phase 2/3 Safety Results,” DDW Chicago, IL May 2005.

“Opening Remark - Practical Pathways Towards Improved Management of HCV Treatment Failures,” DDW Chicago, IL May 2005.

“Alanin Aminotrasferease (ALT) Flares are les Frequent with Entecavir than Lamivudine

Treatment Both On- and Off- Treatment in HBeAg(+) Patients,” DDW Chicago, IL, May 2005.

“Entecavir Demonstrates Consistent Responses Among Baseline Subgroups in the Treatment of Nucleoside-Naïve, HBeAg(-) Patients with Chronic Hepatitis B” DDW Chicago, IL, May 2005.

Curriculum Vitae ROBERT G. GISH, M.D. 143 INVITED LECTURES – NATIONAL AND INTERNATIONAL: Continued

“Current Diagnostics and Management of HBV Drug Resistant.” Saigon, Vietnam. August 29, 2010.

“NAT/PCR Role as a Decisions Tool for the Management of Chronic Hepatitis B.” Saigon, Vietnam. August 29, 2010.

“Current Diagnostics and Management of HBV Drug Resistant.” Hanoi, Vietman. September 1, 2010.

“NAT/PCR Role as a Decisions Tool for the Management of Chronic Hepatitis B.” Hanoi, Vietnam. September 1, 2010.

“New Hepatitis B Treatments: Long-Term Therapy: Balancing the Risk and Benefits as We Pursue Sustained Viral Clearance.” Viral Hepatitis Conference 2010. Melbourne, Australia. September 6, 2010.

“The Shifting Focus of Hepatitis B Supported by the Australian Government Department of Health and Ageing.” Viral Hepatitis Conference 2010. Melbourne, Australia. September 6, 2010.

“Delivery of Hepatitis B Care & Management – A San Francisco Perspective.” Melbourne, Australia. September 6, 2010.

“CHB Treatments, Endpoints & Stopping Rules. New Agents, Better Outcomes.” Viral Hepatitis Conference 2010. Melbourne, Australia. September 7, 2010.

“Boceprevir in Practice”; MSD Singapore. MSD Hepatitis Advisory Board Meeting, October 2011.

Hepatobiliary Neoplasia Special Interest Group Leadership, Hepatobiliary Neoplasia Special Interest Group Leadership, San Francisco, CA. November, 2011.

AASLD, “The Liver Meeting,” San Francisco, CA. November 2011.

Speaker, “Advancing Hepatology in New Era: Milestones and Perspectives”, 67TH Annual Conference of the Association of Physicians of India, Science City, Kolkata, India, January 12 – 15, 2012.

Speaker, Asian Pacific Association for the Study of the Liver (ASPASL), Taipei, Taiwan, February 15, 2012.

Participant, “Polaris Group Lunch and Investigator Meeting on: “A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy”, The Intercontinental San Francisco Hotel, , San Francisco, CA January 19, 2012.

Curriculum Vitae



Speaker, “Simply Speaking, HBS: An Expert Educator’s CME Lecture Series,” Grand Hyatt, San Antonio, TX, January 21, 2012.

Facilitator, Guest Lecture Series, M. Bishr Omary, Chair, Department of Molecular & Integrative Physiology, University of Michigan, Ann Arob, “Keratins: Genetic Modifiers of Liver disease and Required Components of Mallory-Denk Bodies,” January 26. 2012.

Speaker, “Nexavar Unresectable Heptocellular Carcinoma ,” Webcast NAXAVAR Concert Series sponsored by Onyx and Bayer Pharmaceuticals, February 7, 2012.

Asian Pacific Association for the Study of the Liver. Taipei. February 12-19, 2012.

Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP). Taipei, February 19, 2012.

Speaker, Gilead GS09620 Protocols Investigators’ Meeting, St Francis Hotel, San Fran-cisco, CA., March 3, 2012.

Speaker, “Advanced Curriculum in Chronic HBV Management VII., Presented by Projects in Knowledge., Tele-Conference, March 5, 2012.

Speaker, Management of Chronic Hepatitis C Infection, One Patient at a Time, Merck March Talks, Reno, NV, March 15, 2012.

Speaker, Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, Merck March Talks, San Diego, CA, March 20 - 21, 2012.

Speaker, American Transplant Congress, Boston, MA, June 2-6, 2012.

Speaker, “Coagulopathy in Cirrhosis and Associated Vascular Complications,” NEED NAME OF EVENT, September 29, 2012.

Speaker, HBV update, Moderator, Panel Discussion, National Liver Conference 2012, San Antonio, TX, September 22, 2012.

Speaker, Liver Transplantation, University of Nevada, School of Medicine, Las Vegas, NV, January 30, 2013.

“Presentation on Liver Disease, Digestive Disease Forum”. Patient Case Conference, Good Samaritan Regional Medical Center, 3600 NW Samaritan Drive, Corvallis, OR. February 22, 2013.

Speaker, Hepatitis B World Advocacy Meeting, Philadelphia, PA, March 16, 2013.

Speaker, “Part 2: Review of HCV Data from AASLD; Liver Journal Club, NEED CITY, March 5, 2013.

Curriculum Vitae



Speaker, “Liver Cancer and Hepatitis B? What You Need to Know,” 2013 Liver Cancer Webinar Series, Hepatitis B Foundation, March 6, 2013.

Moderator & Speaker, National Viral Hepatitis Task Force and Viral Hepatitis Foundation Convention, Makati, Philippines, March 11-12, 2013.

Speaker, “Chronic Viral Hepatitis: Epidemiology, Who to Screen, How to Screen and Link-age to Care – A Focus on Viral Hepatitis B and C in Viet Nam,” Bach Mai Hospital, Hanoi, Viet Nam, March 15, 2013.

“Impact of Entecavir versus Lamivudine on Hepatic Covalently Closed-Circular DNA and To-tal Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients,” AASLD, Digestive Disease Week. Orange County Convention Center. Orlando, FL. May 18, 2013.

Speaker, World Federation of Chinese Medicine Societies Hepatology Conference. “West-ern Medicine and the Potential role for TCM in Partnership or the Use of TCM in the West”. Shen Zhen, China. May 31, 2013.

“Chronic Hepatitis C Therapy: Current and Future Perspectives”. St. Luke’s 4th Liver and 2nd Gastroenterology International Symposium. St. Luke’s Medical Center, Global City, Phil-ippines. June 2, 2013.

“Clinical Challenge: Management of Chronic Hepatitis B in Special Populations,” St. Luke’s 4th Liver and 2nd Gastroenterology International Symposium, St. Luke’s Medical Center, Global City, Philippines; June 2, 2013.

“Meet the Expert 2: Individualized Therapy in Chronic Hepatitis B”. St. Luke’s 4th Liver and 2nd Gastroenterology International Symposium. St. Luke’s Medical Center, Global City, Philippines. June 2, 2013.

Speaker, Improvement in Diagnosis and Treatment of HCV Infection. Scientific Symposium on Hepatitis. Manila, Philippines. June 3, 2013.

Speaker, Summary of the Viral Hepatitis Action Committee Meeting May 16-17 in Atlanta, GA, CEVHAP General Meeting, Singapore. June 2013.

Speaker, “The Histologic Improvement due to the Oral Anti Viral Treatment Treatment in CHB Patients”, 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2013), Seoul 120-752,Korea; July 5, 2013.

Speaker, “Combination TDF + ETV Therapy in Chronic Hepatitis B Patients with Previous Treat-ment Failure”, 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2013), Seoul 120-752, Korea; July 5, 2013.

Panelist, 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2013), Seoul 120-752,Korea; July 6, 2013.

Curriculum Vitae



Robert Gish, “Hepatitis A” National Viral Hepatitis Roundtable (NVHR), www.nvhr.org; Au-gust 2013.

Robert Gish, “Hepatitis D” National Viral Hepatitis Roundtable (NVHR), www.nvhr.org; Au-gust 2013.

Robert Gish, “Hepatitis E” National Viral Hepatitis Roundtable (NVHR), www.nvhr.org; Au-gust 2013.

“Management of Chronic Hepatitis B in Asian Americans,” Vietnamese Physicians Associa-tions of America (VAMA), Seattle, WA; August 8-11, 2013.

Speaker, Viral Hepatitis E The 2nd Biannual International Conference of Armenian Hepato-logical Forum, September 6, 2013.

Chairman, The 2nd Biannual International Conference of Armenian Hepatological Forum, September 6, 2013.

Honored Guest and Meeting with President of the Artsakh Republic President Bako Sa-hakyan, (officially Nagorno-Karabakh Republic), Stepanakert, Nagorno-Karabakh Republic, September 4, 2013.

Chair and Speaker, “Global Hepatitis Overview,” The 2nd Biennial International Conference of Armenian Hepatological Forum, Yerevan, Armenia, September 6, 2013.

Speaker, “Current Therapy of Hepatitis B. Planning for 2013 and Beyond,” Where East Meets West, Search for a Cure, The 2nd Biennial International Conference of Armenian Hepatological Forum, Yerevan, Armenia, September 7, 2013.

Speaker, “Hepatitis E,” The 2nd Biennial International Conference of Armenian Hepatologi-cal Forum, Yerevan, Armenia, September 7, 2013.

Oral Presentation, Hepatocellular Carcinoma Surveillance: An Inquiry Into Current Practices, Abstract #ILCA2013-1080, International Liver Cancer Association Seventh Annual Confer-ence, Washington D.C., September 13-15, 2013.

“Impact of Entecavir Versus Lamivudine on Hepatic Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients," Australian Gastroenterology Week 2013, Melbourne, Australia, October 9, 2013.

Speaker, “The Liver Meeting,” Hepatitis Delta International Network Meeting, Participant, Washington, D.C., November 2, 2013.

Moderator, The Liver Meeting, Liver Cancer Roundtable in Association with Caring Ambas-sadors, Robert Gish moderator. Washington, D.C., November 5, 2013.

http://www.nvhr.org/



Curriculum Vitae



Facilitator, The Liver Meeting, Panel Discussion, HCC Surveillance Protocol Utilizing Bi-omarkers, Robert Gish, MD; Facilitator, Walter E. Washington Convention Center, Washing-ton, D.C. (in association with Wako Life Sciences, Inc.), November 3, 2013.

Speaker, “Complications of Cirrhosis in the Age of Quality Health Measures,” Presented by Salix Pharmaceuticals, Inc. Elements Restaurant, Paradise Valley, AZ; November 14 2013.

Speaker and Partner, “International Collaboration on Viral Hepatitis Advocacy,” Viral Hepati-tis in the Philippines: Hepatology Society of the Philippines, Launching the National Viral Hepatitis Task Force, Makati City, Philippines, November 20, 2013.

Speaker, “Treatment of HIV-Coinfected Patients in the Era of the DAAs”. 3rd Annual Asian Pacific Study of the Liver(APASL) Conference, 21 November 2013. Cebu Philippines.

Speaker, “HBV: State of the Art”. 3rd Annual Asian Pacific Study of the Liver Conference (APASL). November 22, 2013. Cebu, Philippines.

Speaker, “Novel Approaches for the Treatment of Hepatitis B,” Viral Hepatitis Grand Rounds, Perelman School of Medicine, University of Pennsylvania CME; January 15, 2014. Speaker, Viral Hepatitis Grand Rounds from the University of Pennsylvania, Philadel-phia, PA; January 15, 2014.

Speaker, State of the Art Therapy for HCV, University of Washington, University of Alabama Birmingham, IAS-USA online training module, Funded by a grant from the Centers for Dis-ease Control and Prevention. March 15, 2014. http://hepatitisc.uw.edu/browse/all/lec-tures#page/featured/lectures/state-art-therapy

Speaker, “Clinical considerations in unresectable Hepatocellular Carcinoma & the role of Nexavar (sorafenib) tablets,” Cibo Wine Bar, Coral Gables, FL., April 23, 2014.

Co-Presenter & Speaker, Asian Pacific Health Foundation in collaboration with UCSD to screen at-risk individuals in San Diego County for hepatitis B. Cost-effective point-of-care testing expands pharmacist screening activities in pharmacies, optimizing linkage-to-care, 16th World Conference on Education, San Diego, CA June 16, 2014.

Speaker, “Viral Hepatitis – HCV,” 1st Transcaucasus International Conference on Liver Dis-ease 2014; Presented by Georgian, Armenian and Azerbaijani Hepatology Associations, Tibilisi, Georgia; September 5, 2014.

Speaker, “Viral Hepatitis - HBV,HDV, HEV,” 1st Transcaucasus International Conference on Liver Disease 2014; Presented by Georgian, Armenian and Azerbaijani Hepatology Associa-tions, Tibilisi, Georgia; September 5, 2014.

Speaker, “Hepatitis E,” 1st Transcaucasus International Conference on Liver Disease 2014; Presented by Georgian, Armenian and Azerbaijani Hepatology Associations, Tibilisi, Geor-gia; September 5, 2014.

http://hepatitisc.uw.edu/browse/all/lectures#page/featured/lectures/state-art-therapy

http://hepatitisc.uw.edu/browse/all/lectures#page/featured/lectures/state-art-therapy

Curriculum Vitae



Speaker, “Case Study,” 1st Transcaucasus International Conference on Liver Disease 2014; Presented by Georgian, Armenian and Azerbaijani Hepatology Associations, Tibilisi, Geor-gia; September 6, 2014.

Speaker, “HCV Discussion,” 1st Transcaucasus International Conference on Liver Disease 2014; Presented by Georgian, Armenian and Azerbaijani Hepatology Associations, Tibilisi, Georgia; September 6, 2014.

Speaker, “Post-OLT Complications and a Focus on Long Term Management,” 1st Transcau-casus International Conference on Liver Disease 2014; Presented by Georgian, Armenian and Azerbaijani Hepatology Associations, Tibilisi, Georgia; September 6, 2014.

Speaker, Closing Remarks, 1st Transcaucasus International Conference on Liver Disease 2014; Presented by Georgian, Armenian and Azerbaijani Hepatology Associations, Tibilisi, Georgia; September 6, 2014.

Speaker, “Disease Management Interventions for Patients with Cirrhosis”, National Liver Conference 2014; Austin, TX. September 19, 2014.

Speaker, “Clinical and Research Trials in Liver Cancer,” University of Buffalo, Buffalo NY, October 5, 2014.

Speaker, “Direct Acting Antiviral Therapies,” The Liver Meeting 2014, Single Interest Group (SIG), American Association for the Study of Liver Disease, November 14, 3014.

Curriculum Vitae ROBERT G. GISH, M.D. 149 INVITED LECTURES – REGIONAL: Continued

1988

“Liver transplantation,” Sutter-Solano Medical Center, Vallejo, California, 9/23/88.

“Occupational liver disease,” Western Occupational Health Conference, Monterey, California, 10/13/88.

“Liver transplantation: state of the art,” Kaweah Delta Hospital, Visalia, California, 10/22/88.

“The organization of a liver transplantation program,” Scripps Clinic, La Jolla, California, 10/28/88.

“Controversies in liver transplantation,” University of California at Davis, Davis, California, 11/7/88.

1989

“Liver transplantation: a case presentation,” Gastroenterology Grand Rounds, Stanford University, Palo Alto, California, 1/5/89.

“Indications and controversies in liver transplantation,” Queen of the Valley Hospital, Napa, California, 1/28/89.

“Liver transplantation: research opportunities,” University of New Mexico, Albuquerque, New Mexico, 2/1/89.

“Update on peptic ulcer disease,” Mather Air Force Base, California, 2/6/89.

“Treatment of peptic ulcer disease and reflux esophagitis,” Mercy General Hospital, Denver, Colorado, 2/23/89.

“Advances in the treatment of liver disease: liver transplantation,” Alameda Hospital, Alameda, California, 2/27/89.

“Liver transplantation: indications and timing,” House Staff Noon Conference, Santa Teresa/Kaiser Hospital, San Jose, California, 3/16/89.

“Advances in liver transplantation,” Medical Grand Rounds, Seton Medical Center, San Francisco, California and Hawaii, 3/17/89.

“Liver transplant symposium,” Honolulu and Maui, Hawaii, 4/24/89-4/27/89.

“Treatment of gallstone disease,” Tri-County Pharmacists Association, Santa Cruz, California, 9/10/89.

“Treatment of chronic liver disease,” Ukiah Valley Medical Center, Ukiah, California, 9/17/89.

“Peptic ulcer disease: an update,” Columbia, California, 9/19/89.

Curriculum Vitae


INVITED LECTURES – REGIONAL: Continued

“Rounds on liver disease” and “Peptic ulcer disease,” Scenic General Hospital, Modesto, California, 10/4/89.

“Diagnosis and treatment of chronic pancreatitis,” Peninsula Hospital, Burlingame, California, 10/26/89.

“New treatment for PUD,” Killeen Hospital Medical Staff, Killeen, Texas, 11/13/89.

“Peptic esophagitis: new treatments,” Andrews Air Force Base, Tempe, Arizona, 11/17/89.

“New treatment for esophagitis and PUD,” Regional Conference, Sun Valley, Idaho, 12/2/89.

“Omeprazole: proton pump blockers,” University of California at Irvine Pharmacy School, Irvine, California, 12/6/89.

1990

“Organ transplantation,” Auburn Faith Community Hospital, Auburn, California, 1/3/90.

“Management of acid peptic disease,” Highland General Hospital, Department of Medicine, Oakland, California, 1/26/90.

“Advances in therapy for acid related disorders,” Kaiser Permanente, Roseville, California, 2/20/90.

“Advances in therapy for acid related diseases,” Brookside Hospital, San Pablo, California, 2/27/90.

“Orthotopic liver transplantation state of the art,” Tripler Medical Center, Honolulu, Hawaii, 4/18/90.

“Liver transplantation for Wilson’s disease,” Community Hospital, Santa Rosa, California, 4/25/90.

“Current advances in the management of gallstones,” Dominican Hospital, Santa Cruz, California, 4/27/90.

Management of peptic ulcer disease in the multi-risk patient,” Saint Mary’s Medical Center,

Long Beach, California, 5/11/90.

“Liver disease: an update on treatment and liver transplantation,” Redding Medial Center, Redding, California, 5/25/90.

“Advances in the management of liver disease,” Western Medical Center, Santa Ana, California, 6/4/90.

Curriculum Vitae



“Acid pump inhibitor — a new option,” Ralph K. Davies Medical Center, San Francisco, California, 6/22/90.

“Controversies in ulcer management in the intensive care unit,” Good Samaritan Hospital, San Jose, California, 7/3/90.

“Current advances in the treatment of gallstones,” Bellwood General Hospital, Bellflower, California, 8/27/90.

“Acid pump inhibitor—a new option,” Delta Memorial Hospital, Antioch, California, 8/28/90.

“Hepatitis C,” Sutter Solano Medical Center, Vallejo, California, 9/4/90.

“Hepatitis C,” Highland Hospital, Oakland, California, 9/21/90.

“Advances in therapy for acid-related disorders,” Children’s Hospital, San Francisco, California, 10/9/90.

“Management of peptic ulcer in the multi-risk patient,” Santa Barbara GI Symposium, Santa Barbara, California, 10/20/90.

“Orthotopic liver transplantation for alcoholic liver disease,” American College of Gastroenterology, San Francisco, California, 10/29/90.

“Hepatitis C,” Medical Grand Rounds, Seton Medical Center, Daly City, California, 11/16/90.

“Liver transplantation,” Kaiser Permanente, Sacramento, California, 11/20/90.

1991

“Liver transplantation and life after liver transplantation,” Ukiah Valley Medical Center, Ukiah, California, 4/4/91.

“Acute and chronic liver failure,” Highland Hospital, Oakland, California, 8/16/91.

“Endstage liver disease,” Mills-Peninsula Hospital, San Mateo and Burlingame, California, 9/10/91.

“Management of pancreatic disease,” Kaiser Permanente, Richmond, California, 9/16/91.

“Multiple organ failure, cytokines,” Sequoia Hospital, Redwood City, California, 11/12/91.

“Liver transplantation state of the art,” San Jose Medical Center, San Jose, California, 11/14/91.

Curriculum Vitae



1992

“Gastroenterology and liver disease in the elderly,” Internal Medicine Department, Spokane, Washington, 2/19/92.

“Diagnosis and treatment of hepatoma,” Asian Health Services Provider Conference, Asian Health Services, Oakland, California, 3/3/92

“Diagnosis and treatment of chronic liver disease,” Kaiser Permanente Richmond, Richmond, California, 3/3/92.

“Update on treatment of chronic liver disease,” University of Nevada, Reno, Nevada, 4/21/92.

“Management of the patient with endstage liver disease,” L.D.S. Hospital, Salt Lake City, Utah, 5/2/92.

“Controversies in orthotopic liver transplantation,” Central Valley Club, Fresno, California, 7/28/92.

“State of the art: chronic hepatitis,” Mercy Medical Center, Redding, California, 8/12/92.

“Endstage liver disease in liver transplantation,” Queen’s Health Care Plan and Physicians, Honolulu, Hawaii, 9/28/92.

“Hepatitis B infection and treatment,” Kuakini Medical Center, Honolulu, Hawaii, 9/28/92.

“Patient selection for liver transplantation,” Queens Hospital, Honolulu, Hawaii, 9/28/92.

“Hepatitis B infection and treatment,” Hawaii/Honolulu Gut Club, Honolulu, Hawaii, 9/29/92.

“Case presentations, endstage liver disease,” Tripler Army Medical Center, Honolulu, Hawaii, 9/30/92.

“Duodenal Ulcers – Current Treatment,” Lecture Teleconference, California Pacific Medical Center, 10/21/92.

“Chronic hepatitis B,” Association of Asian Pacific Community Health Organizations, San Francisco, California, 10/22/93.

“Hepatitis serology,” American Liver Foundation, St. Mary's Medical Center, San Francisco, California, 10/24/92.

“Evaluation of elevated liver tests,” Kansas City Southwest Clinical Society, Kansas City, Missouri, 11/06/92.

Curriculum Vitae



“Evaluation of abnormal liver tests” and “Helicobacter — Is This A Real Disease,” 19th Annual Gastroenterology Symposium, Enloe Hospital, Chico, California, 11/11/92.

1993

“Hepatitis A, B and C: an update,” Tahema County Medical Society, Tahema County Medical Facility, California, 4/26/93.

“Interferon and hepatitis,” Queen of the Valley Hospital, Napa, California, 7/16/93.

“What's new in hepatitis,” Mercy Medical Center, Redding, California, 8/31/93.

“Chronic hepatitis: what's new,” Kaiser Permanete, Napa, California, 9/1/93.

“Chronic viral hepatitis,” Sequoia Hospital, Redwood City, California, 9/18/93.

“Endstage liver disease,” University of California at Davis, Family Practice Program, Merced, California, 9/22/93.

“Hepatitis update,” Travis Air Force Base Medical Center, Travis, California, 9/24/93.

“Medical aspects of liver transplantation,” California Pacific Medical Center, San Francisco, California, 10/23/93.

“Metabolic liver disease,” University of California at Davis, Family Practice Program, Merced, California, 10/27/93.

“Chronic hepatitis,” Marshall Hospital, Placerville, California, 12/15/93.

“The workup and evaluation of patients with chronic liver disease,” University of California at Davis, Family Practice Program, Merced, California, 12/29/93.

1994

“Chronic liver disease and viral hepatitis,” California Pacific Teleconference, 1/12/94.

“Current treatment of viral hepatitis,” Highland General Hospital, Oakland, California, 1/15/94

“NSAID induced GI injury,” Maui Memorial Hospital, Wailuku, Maui, Hawaii, 1/22/94.

“Current diagnosis and treatment of chronic viral hepatitis,” St. Francis Medical Center, Honolulu, Hawaii, 1/24/94.

“Treatment of endstage liver disease and portal hypertension,” University of Hawaii, Honolulu, Hawaii, 1/25/94.

Curriculum Vitae



“Fulminant liver failure in a kidney transplant recipient,” Department of Transplantation, California Pacific Medical Center, San Francisco, California, 2/25/94.

“Diagnosis and treatment of hepatitis C,” San Quentin State Prison, San Quentin, California, 2/28/94.

“Portal hypertension, part I,” University of Nevada, Reno, Washoe Medical Center, Reno, Nevada, 3/4/94.

1994

“Post-liver transplant patient management for nurses,” Mercy Medical Center, Redding, California, 3/15/94.

“The diagnosis and treatment of chronic hepatitis,” Highland General Hospital, Oakland, California, 3/21/94.

“Update on hepatitis C,” Palomar Medical Center, Escondido, California, 3/24/94.

“Alcoholic liver disease,” University of California Davis, Medical School, 2nd Year Lecture, Davis, California, 3/31/94.

“Portal hypertension, part II,” University of Nevada, Reno, Veterans Hospital, Reno, Nevada, 4/1/94.

“The epidemiology of viral hepatitis,” Merced Community Medical Center, Grand Rounds, Merced, California, 5/2/94.

“Liver cancer update,” Merced Community Medical Center, Grand Rounds, Merced, California, 6/29/94.

“Histopathology of chronic hepatitis C,” St. Mary's Medical Center, Reno, Nevada, 6/30/94.

“Hepatocellular carcinoma,” University of Nevada, Reno, Nevada, 7/1/94.

“Hepatitis C: management in the primary care setting,” San Francisco Public Health Department, Wadell Clinic, San Francisco, California, 7/6/94.

“Hepatitis C: diagnosis, management and prognosis,” Las Vegas Gut Club, Las Vegas, Nevada, 7/11/94.

“Update on the diagnosis and treatment of hepatitis C,” Rideout Hospital, Marysville, California, 7/19/94.

“The diagnosis and treatment of chronic liver diseases,” Fremont-Rideout Health Group, Peachtree Clinic, 7/19/94.

Curriculum Vitae



“Hepatitis B treatment — past, present and future,” California Pacific Medical Center, 8/4/94.

“Hepatitis C and alpha-Interferon: questions and answers,” Tuolumne County Medical Society, Sonora, California.

“Hepatitis C-revisited,” Alexian Brothers Hospital, San Jose, California, 9/6/94.

“Hepatitis C diagnosis and treatment,” Visalia Primary Care Group, Visalia, California, 9/8/94.

“Liver disease pathology conference,” Fresno Gut Club, Fresno, California, 9/8/94.

“Liver transplantation,” University of California at Davis, Sacramento, California, 10/11/94.

“Reflux disease,” Merced Community Medical Center, University of California at Davis Affiliate, Merced, California, 10/12/94.

“Liver enzymes and liver function tests,” Kansas City Southwest Clinical Society Annual Meeting, Kansas City, Missouri, 11/3/94.

“Diagnosis and treatment of hepatitis C,” San Quentin State Prison, San Quentin, California, 11/8/94.

“Update on viral hepatitis: testing, diagnosis, treatment,” American College of Osteopathic Family Physicians, San Francisco, California, 11/17/94.

“Hepatitis-grand rounds,” St Agnes Medical Center, Fresno, California, 12/13/94.

1995

“Liver pathology rounds,” Liver Biopsy Conference moderator, St. Mary's Hospital, Reno, Nevada, 1/6/95, 3/95, 5/95, 7/95, and 9/95.

“Hepatitis B and C,” Sequoia Hospital, Redwood City, California, 1/17/95.

“Liver biopsy diagnosis,” Mercy San Juan Hospital, Sacramento, California, 1/24/95.

“Basic science of hepatitis,” Mercy General Hospital, Sacramento, California, 1/24/95.

“Treatment of hepatitis C,” Sacramento Gut Club, Sacramento, California, 1/24/95.

“Hepatitis update and histopathology conference,” Redding Gut Club, Redding, California, 1/25/95.

“Hepatitis diagnosis and treatment,” Tracy Prison System, Tracy, California, 1/25/95.

“Hepatitis and hemochromatosis,” Las Vegas Gut Club, Las Vegas, Nevada, 1/26/95.

Curriculum Vitae



“New drugs & modern concepts in pharmacotherapy,” VA Northern California System of Clinic, 2/10/95 - 2/12/95, Lake Tahoe and 3/3/95 - 3/5/95, San Francisco, California.

“Hepatitis: drugs that cause and drugs that treat,” Northern California System of VA Clinics, Martinez, VA Hospital, N. Lake Tahoe Conference, Incline Village, Nevada, 2/11/95.

“Hepatitis C, a silent disease,” St. Francis Medical Center, Primary Care conference, Honolulu, Hawaii, 2/11/95.

“The virology of hepatitis C infection,” Kaiser Medical Center, Honolulu, Hawaii, 2/15/95.

“The liver in systemic disease,” Maui Memorial Hospital, Wailuku, Maui, Hawaii, 2/17/95.

“Fulminant liver failure,” Sequoia Medical Center, Redwood City, California, 2/28/95.

“Hepatitis: drugs that cause and drugs that treat,” Northern California System of VA Clinics, Martinez, VA Hospital, San Francisco, California, 3/2/95.

“Fulminant hepatitis: when to refer,” UCSF/Fresno, Hanford-Kings County Medical Society, Hanford, California, 3/18/95.

“An educational conference on chronic hepatitis C and B,” Northwest R.N. Symposium, San Francisco, California, 3/23/95.

“Hepatitis viruses: the alphabet soup, diagnosis and treatment,” Petaluma Valley Hospital, Petaluma, California, 3/27/95.

“Hepatitis C: evaluation of patients,” San Joaquin General Hospital, French Camp, California, 3/29/95.

“Alcoholic liver disease,” University of California at Davis Medical School, 2nd Year Lecture, Davis, California, 3/31/95.

“Hepatitis,” Dominican Santa Cruz Hospital, Santa Cruz, California, 6/23/95.

“Liver update: alcoholic liver disease, selection criteria for transplantation,” Therapeutic and Diagnostic Pancreaticobiliary Endoscopy Course, California Pacific Medical Center, San Francisco, California, 7/22/95.

“Hepatitis: an alphabet soup,” Queen of the Valley Hospital, Napa, California, 8/18/95.

“Evaluation of patients for Wilson's disease,” St. Mary's Hospital, San Francisco, California, 8/29/95.

Curriculum Vitae



1995

“Wilson's disease,” GI Conference, St. Mary's Hospital, San Francisco, California, 8/29/95.

“Evaluation of acute and chronic liver disease,” San Quentin State Prison, San Quentin, California, 8/30/95.

“An update on liver transplantation,” Wadsworth VA Hospital, Los Angeles, California, 9/1/95.

“Recurrent disease after liver transplantation,” USC Medical Center, Los Angeles, California, 9/22/95.

“Recurrent hepatitis C infection after liver transplantation,” Honolulu Regional GI Program, Honolulu, Hawaii, 10/10/95.

“New forms of viral hepatitis,” Honolulu Gut Club, St. Francis Hospital, 10/10/95.

“Update on managed care in northern California,” Maui, Hawaii, 10/12/95.

“Acute and chronic hepatitis: the alphabet soup,” Napa State Hospital, Napa, California, 10/20/95.

“Hepatitis issues for correctional facilities,” San Francisco STD-HIV Prevention Training Center, 2nd Annual Infectious Disease Conference, California Department of Corrections, Natoma, California, 11/1/95.

“The evaluation of elevated liver enzymes in acute and chronic liver disease,” and “The role of medication in the cause of acute and chronic liver disease,” 21st GI Symposium, Chico, California, 11/15/95.

“AASLD 1995 review,” Sacramento Gut Club, University of California at Davis, Sacramento, California, 11/15/95.

“Workup of elevated liver enzymes,” Merced Community Hospital, Merced, California, 11/15/95.

“Controversies in chronic liver disease,” Sacramento Valley Gut Club, Sacramento, California, 11/15/95.

“Controversies in the management of hepatitis,” Indian Health Clinic, Trinidad, California, 12/13/95.

“Controversies in the management of chronic hepatitis,” Pelican Bay Prison, Pelican Bay, California, 12/14/95.

“Autoimmune hepatitis,” UCSF, Fresno Valley Gut Club/UCSF, Fresno, California, 12/16/95.

Curriculum Vitae



“Autoimmune liver disease,” Merced Community Hospital, Merced, California, 12/19/95.

1996

“Viral hepatitis: the alphabet soup,” California Pacific Medical Center Teleconference Network, San Francisco, California, 1/23/96.

“National leadership conference on chronic hepatitis C,” University of Medicine and Dentistry of New Jersey, 1/29/96.

1996

“Overview of treatment of hepatitis,” Dameron Hospital, Stockton, California, 2/23/96.

“Hepatitis A-G: diagnosis, natural history and epidemiology,” Dameron Hospital, Stockton, California, 2/23/96.

“Evaluation of patients with chronic viral hepatitis B and C,” University of California at Berkeley, Berkeley, California, 2/29/96.

“Hepatitis A-G: diagnosis, natural history and epidemiology,” Infectious Diseases Symposium, Sacramento, California, 3/23/96.

“Hepatitis A-G: diagnosis and treatment,” Medical Grand Rounds, California Pacific Medical Center, San Francisco, California, 2/27/96.

“Hepatitis A-G: prevention, vaccination and therapy,” Infectious Diseases Symposium, Sacramento, California, 3/23/96.

“Hepatitis A-G: diagnosis and treatment,” Sutter Community Hospitals, Sacramento, California, 4/12/96.

“Metabolic and autoimmune liver disease,” Gastroenterology Club of Las Vegas, Las Vegas, 4/15/96.

“Endstage liver disease and cirrhosis,” San Quentin State Prison, San Quentin, California, 5/1/96.

“Hepatitis A-G,” Sutter Health Conference, Sacramento, California, 5/4/96.

“Primary care for the '90s,” University of Nevada School of Medicine, Reno, Nevada, 5/10-11/96.

“Viral hepatitis: the alphabet soup,” University of Reno, Reno, Nevada, 5/11/96.

“Hepatitis C and Interferon,” California Department of Corrections, Las Vegas, Nevada, 5/17/96.

Curriculum Vitae



“Laboratory tests in hepatitis C in diagnosis and in monitoring therapy,” Controversies and Challenges in Viral Hepatitis C Conference, San Francisco, California, 5/20/96.

“Hepatitis A, B and C,” San Jose Pharmacy Group, Santa Clara, California, 5/22/96

“Liver transplantation III: immunosuppression,” Chaired 1996 ASTP Scientific Session, Dallas, Texas, 5/28/96.

“Update on hepatitis C,” Santa Rosa Gut Club, Santa Rosa, California, 5/29/96.

“The treatment of chronic hepatitis B and C in the prison system of California,” Department of Corrections, Sacramento, California, 5/96.

“Overview of hepatitis C,” Schering-Plough, 6/5/96.

“Point/counterpoint — hepatitis C,” Ukiah Hospital, Ukiah, California, 6/20/96.

“Diagnosis of hepatitis,” University of Nevada, Las Vegas, Nevada, 6/27/96.

“Hepatitis C lecture,” California Pacific Medical Center, San Francisco, California, 7/3/96.

“An insider's perspective of a specialist,” National Youth Forum on Medicine, San Francisco, California, 7/15/96.

“The diagnosis and treatment of hepatitis A through G,” Placerville General Hospital, Placerville, California, 7/17/96.

1996

“Hepatitis A-G: evaluation, diagnosis and prognosis,” Mt. Diablo Hospital, Concord, California, 8/8/96.

“Hepatitis — diagnosis & treatment,” California Women's Facility, Chowchilla, California, 8/15/96.

“Chronic hepatitis: an alphabet soup,” CPMC Teleconference, produced by Annenberg Center for Health Sciences, Rancho Mirage, California, 8/17/96.

“Metabolic causes of chronic liver disease,” Merced Community Medical Center, Merced, California, 8/15/96.

“Molecular diagnosis and treatment of hepatitis C infection,” Phoenix Basin Gastroenterology Club, Phoenix, Arizona, 9/13/96.

“Case studies in chronic viral liver disease,” Eureka, California, 9/18/96.

“Hepatitis A-G: diagnosis, prognosis and treatment,” Redding Medical Center, Redding, California, 9/19/96.

Curriculum Vitae



“Hepatitis A-G: diagnosis and treatment,” Merrithview Memorial/Contra Costa Hospital, 9/22/96.

“The diagnosis and treatment of chronic hepatitis C infections,” Kaiser Permanente, South Sacramento, California, 9/26/96.

“Current trends in hepatitis treatment,” Marin Consortium's Grand Rounds, Marin General Hospital, Larkspur, California, 10/1/96.

“Viral hepatitis and liver transplantation,” Dept. of Internal Medicine, University of Iowa, Iowa City, Iowa, 10/3/96.

“Viral hepatitis and the immune system,” Case Conference on Infectious Disease, University of Iowa, Iowa City, Iowa, 10/3/96.

“Chronic viral hepatitis C: immunology,” University of Iowa, Iowa City, Iowa, 10/3/96.

“Portal hypertension,” Merced Community Medical Center, Merced, California, 10/9 & 10/16, 1996.

“Evaluation and treatment of helicobacter pylori,” Primary Care Physicians, Sacramento, California, 10/12/96.

“State-of-the-art Interferon therapy for chronic viral hepatitis,” Chronic Viral Hepatitis (CVH) in the era of Managed Care, AASLD, Chicago, Illinois, 10/17/96.

“Should we offer renal transplantation to patients with hepatitis B? What, if any, role is there for Lamivudine,” Grand Rounds, California Pacific Medical Center, San Francisco, California, 10/18/96.

“Non-response to treatment with Interferon alfa,” Chronic Hepatitis C: Strategies for Difficult Management Cases Conference, ACG, Seattle, Washington, 10/20/96.

“Evaluation and treatment of chronic hepatitis C,” Round Table Discussion, American College of Gastroenterology, Seattle, Washington, 10/20/96.

“Hepatitis A-G,” Santa Rosa Community Hospital, Santa Rosa, California, 10/23/96.

“Hepatitis A-G: diagnosis and treatment,” Veteran's Administration Hospital, Reno, Nevada, 10/24/96.

1996

“Hepatitis A-G: evaluation and treatment,” Nevada Academy of Family Physicians, Reno, Nevada, 10/24/96.

“Hepatitis B and C” Sacramento Methadone Program, Sacramento, CA 10/30/1996

Curriculum Vitae



“Hepatitis overview to Stockton prison,” Northern California Women's Facility, Stockton, California, 10/31/96.

“Hepatitis A-G: the alphabet soup,” Lassen Hospital, Susanville, California, 11/12/96.

“Hepatitis B & C: liver disease in organ transplant recipients,” Advances in Transplantation, 8th Annual Conference, San Francisco, California, 11/19/96.

“Hepatitis C: current diagnosis and treatment,” Mad River Hospital, Arcata, California, 11/21/96.“Chronic liver disease and hepatitis A-G,” St. Joseph's Hospital, Eureka, California, 11/21/96.

“Evaluation of the abnormal liver in alcoholism/drug dependency,” Academy of Addiction Psychiatry Meeting, Medical Complications of Substance Abuse, 12/7/96.

“Evaluation of the abnormal liver enzymes in alcoholism and drug dependency. Conference: Medical Complications of substance abuse and treatment of chronic hepatitis,” Academy of Addiction Psychiatry Meeting, Medical Complications of Substance Abuse, 12/7/96.

“Liver transplantation,” House Staff Conference, California Pacific Medical Center, San Francisco, California, 12/9/96.

1997

“Hepatitis C update,” Santa Rosa Memorial Hospital, Santa Rosa California, 1/16/97

“Pharmacological management of chronic viral infections,” North Coast Pharmacy Association, 1/22/97.

“Chronic hepatitis A-G: an alphabet soup,” San Ramon Regional Medical Center, San Ramon, California, 1/23/97.

“Round table,” Sacramento Valley GI Gut Club, Sacramento, California, 1/28/97.

“Diagnosis and treatment of hepatitis C,” Mill Creek Prison, Ione, California, 1/29/97.

“GI conference,” California Pacific Medical AASLD Abstract Review, (AASLD) Meeting 1996, 1/30/97.

“Current treatment of hepatitis C,” Lake Tahoe, California, 2/5/97.

“Elevated liver tests: when is it hepatitis C and what do you do?,” Lake Tahoe, California, 2/6/97.

“Hepatitis C as a systemic disease,” Fresno Gut Club, Fresno, California, 2/27/97.

Curriculum Vitae



“Diagnosis and treatment of hepatitis A-G,” Eden Hospital, Castro Valley, California, 2/28/97.

“The role of the primary care physician's diagnosis & treatment of hepatitis,” Eden Medical Center, Castro Valley, California, 2/28/97.

“Hepatitis A-G,” Northern California Society of Gastroenterology Nurses and Associates, Larkspur, California, 3/15/97.

“Hepatitis C update,” Santa Rosa Memorial Hospital Grand Rounds, Santa Rosa, California, 3/21/97.

1997

“Hepatitis C: new issues,” Sutter North Medical Foundation, Marysville, California, 3/27/97.

“Hepatitis A-Z: a review,” Grand Rounds, Department of the Air Force, 60th Medical Operations Squadron (AMC), Travis Air Force Base, Travis, California, 5/2/97.

“Hepatitis C casebook development,” Laguna Nigel, California, 6/5/97.

“Medication-induced chronic liver disease,” Merced, California, 6/18/97.

“Update on chronic hepatitis B & C,” Chinese Hospital, San Francisco, California, 6/25/97.

“Hepatitis as a systemic disease,” John Muir Medical Center, Walnut Creek, California, 6/26/97.

“Hepatitis A-G, who, what, when,” GI Nurses of Sacramento, Sacramento, California, 9/4/98.

“Hepatitis C, the exploding epidemic, medical management, initial diagnosis, pre- and post-liver

Transplant management,” San Francisco, California, 8/22/97.

“Chronic liver disease update,” Symposium Moderator, San Francisco, California, 9/9/97.

“New and evolving issues in acute and chronic liver disease: the evaluation of elevated liver enzymes and liver function tests.” Sacramento, California, 9/11/97.

“Hepatitis B and C: who and when to treat” Alexian Brothers Hospital. San Jose, California, 9/16/97.

“Why and how hepatitis B and C should be part of an infectious disease practice,” IDSA Symposium, San Francisco, California, 9/15/97.“Chronic liver disease - focus on hepatitis B and C,” Providence Medical Center. Kansas City, Kansas, 10/16/97.

Curriculum Vitae



“Chronic hepatitis: Case Presentations,” Olathe Medical Center, Olathe, Kansas, 10/17/97.

“Hepatitis: who, when and where. Resuscitation 5,” Redding Medical Center, Redding, California, 10/25/97.

“The management of hepatitis C patients in a county medical clinic setting,” County of Sacramento Clinics, Sacramento, California, 11/21/97.

“Chronic hepatitis: A - Z, diagnosis and treatment,” California Pacific Medical Center.

1998

“Liver enzymes and liver function,” CPMC GI nurse organization, California Pacific Medical Center, San Francisco, California, 2/7/98.

“AASLD Review,” Las Vegas Gut Club, Las Vegas, Nevada, 2/5/98.

“AASLD Review,” Sacramento Gut Club, Sacramento, California, 2/11/98.

“Hepatitis C: an epidemic of awareness,” Enloe Hospital, Chico, California, 2/26/98.

“New Interferons,” Sutter Hospital Roseville, GI Symposium 1998,” Sacramento, California, 2/28/98.

“Alcohol and Liver Cancer,” Mercy Regional Cancer Center, Redding, California, 4/18/98.

1998

“Hepatitis C: Third World Disease in a Developed Country,” River City Medical Group, Mercy Hospital Sacramento, Sacramento, California, 4/23/98.

“Hepatitis C: Current Evaluation and Management,” National Acupuncture and Oriental Medicine Alliance Annual Meeting, San Francisco, California, 5/2/98.

“Chronic hepatitis C: nine years old,” San Jose, California 6/8/98.

“Treatment of hepatitis C: new options,” North State Practitioners Society, Chico, California, 6/12/98.

“Treatment of hepatitis C: Epidemiology and treatment; Applications to the Department of Corrections,” California Department of Corrections, 7/14/98.

“Hepatitis C infection in women and minorities, a collaborative approach to research and intervention,” Oakland, California, 7/30/98.

Curriculum Vitae



“An Epidemic of Awareness: New tests and treatments for hepatitis B and C,” Conference: New Technologies and current trends in infectious disease, Mercy General Hospital, Sacramento, California 8/8/98.

“Treatment of patients with hepatitis C,” Sacramento Blood Center, Sacramento, California 8/6/98.

“Combination therapy for relapser and nonresponder patients with hepatitis C, cost effectiveness of therapy,” Hepatitis C Global, Oakland, California 8/24/98.

“Combination therapy for, Panel presentation,” Hepatitis C Global, Oakland, California 8/24/98.

“Hepatitis C update,” Alta Bates Medical Center, Berkeley, California 8/26/98.

“Hepatitis B: Current treatment options and HIV interactions,” Davies Campus of California Pacific Medical Center, San Francisco, California 9/6/98.

“Hepatitis B: Current Treatment Options and HIV Interactions,” University of California, San Francisco, San Francisco, CA 9/14/98.

“Update on the Treatment of Hepatitis C,” Sacramento Valley Society of Health-System Pharmacists, Sacramento, CA 10/8/98.

“Acute and Chronic Liver Disease,” Sacramento, CA 11/3/98.

“Hepatitis C,” TAP Pharmaceuticals, Carson City, NV 12/3/98.

“Hepatitis C: Epidemiology, Diagnosis and New Treatments,” San Francisco State University, San Francisco, CA 12/5/98.

“Optimizing Outcomes in Difficult Cases: Relapsers,” Boston, MA 10/11/98.

“New Treatments for Hepatitis C,” Davies Campus of California Pacific Medical Center, San Francisco, CA 11/20/98.

1999

“An Update on Hepatitis C from AASLD,” AMGEN, Las Vegas, NV 1/18/99.

“Medications Used for Organ Transplantation,” Santa Rosa, CA 1/20/99.

“Liver Transplantation: Who, When, and Why,” Napa, CA. 02/14/99.

“Elevated Liver Enzymes & the Diagnosis of Liver Disease,” College of Osteopathic Medicine, San Francisco, CA 2/16/99.

“Hepatitis C Update: New Treatment Options,” GUT Conference, Reno, NV 3/4/99.


“Interferon/Ribavirin Combination Therapy of Hepatitis C, 67th Annual Postgraduate Convention, San Bernardino, CA 03/99.

1999

“Hepatitis B Infection,” Sutter Roseville Medical Center, Roseville, CA 4/3/99.

“Rebetron, Combination Therapy,” Boyes Hot Springs, CA 4/16/99.

“Current Approaches to Viral Hepatitis Management,” San Francisco, CA 4/17/99.

“Hepatitis Update,” UNOS Region 5 OPO and Clinical Forum, San Francisco, CA 04/08/99.

“Hepatitis C” Nineteenth Annual Infectious Diseases Symposium, Sacramento, CA 4/30/99

“Hepatology Case Conference,” Schering Oncology/Biotech, Fresno, CA 6/3/99

“Viral Hepatitis and the Surgeon,” California Pacific Medical Center, San Francisco, CA 6/4/99

“Hepatitis C Support Group,” Sutter General Hospital, Sacramento, CA 6/16/99

“Present and future therapies for Hepatitis C,” University of California, San Francisco, CA 6/21/99

“What’s Your Specialty?” San Francisco Medical Forums, National Youth Leadership Forum, San Francisco, CA 6/30 and 7/14/99.

“Hepatitis C,” Amgen Medical Education Services, David Grant USAF Medical Center, Travis Air Force Base, CA 07/02/99

“The Best of DDW,” Orlando, CA 07/08/99

“Hemochromatosis Study,” Future of Hepatitis C, UCSF, San Francisco, CA 07/14/99

“Rebetron” Medical TAR CE Program, Schering Plough, Stockton, CA 7/7/99

“The Best of Liver,” The Best of DDW, Phoenix, AZ 07/8/99

“Research and Treatment,” HCV Global Foundation, Oakland, CA 08/21/99

“The Role of the ID Physician in the Treatment of Chronic Hepatitis,” Laguna, CA 08/28/99

“Viral Hepatitis,” Gastroenterology, Liver Transplantation, Sutter Solano Medical Center, Vallejo, CA 09/14/99

“Liver Disease and The Veterans Health Administration: New Advances in the Management of Hepatitis C,” Dover Communications Inc., Scottsdale, AZ 09/17/99

Curriculum Vitae



“Hepatitis C Overview,” American Liver Foundation, Sacramento, CA 10/16/99.

“Hepatology for the ID Specialist” and “Treatment of Hepatitis C,” Hepatitis for the New Millennium, IDSA Annual Conference, Philadelphia, PA 11/18/99

2000

“HCV Epidemiology,” Virology Symposium, Sacramento, CA 01/29/00

“Managing Fulminate, Acute and Chronic Liver Disease,” CPSS Liver Disease Symposium, San Francisco, CA, 02/03/00

“Hepatitis C,” Sutter Medical Center, Sacramento, CA 02/25/00

“Viral Hepatitis: Into the New Millennium,” Sutter Medical Center of Santa Rosa, Santa Rosa, CA 03/07/00

“Health Sciences,” UC Davis Health System Leadership Council, Sacramento, CA 03/08/00.

“Hepatitis C,” I will survive Hepatitis C Support Group, Sacramento, CA 03/10/00

Sutter Health Family Practice Residency Program, 03/14/00

“Therapy of Viral Hepatitis Including Alternative Therapies Panel, Sutter Roseville Medical Center, Roseville, CA 04/01/00.

“Autoimmune Liver Disease,” Sutter Roseville Medical Center, Roseville, CA 04/01/00.

“Objective Structured Clinical Exercise” University of CA, San Francisco, CA. 04/08/00.

“Current Issues Regarding Transmission & Prevention Current Standards for Diagnosis & Medical Management” Hepatitis C: Building a Response to the Northstate Crisis, Red Bluff, CA 04/28/00

“New Trends in Treatment and Long Term Survival” Hepatitis C: Building a Response to the Northstate Crisis, Red Bluff, CA 04/28/00

“Living With Hepatitis C” Panel Discussion, Hepatitis C: Building a Response to the Northstate Crisis, Red Bluff, CA 04/28/00

“Hepatitis C Part 2: Liver Transplants and Hepatitis C:, Eden Medical Center, Castro Valley, CA 05/05/00

“Acute Hepatic Failure,” Critical Care Training Program, California Pacific Medical Center, San Francisco, CA 05/11/00

“Application of Epidemiology and Biostatistics to Clinical Research,” San Diego, CA 05/20/00.


“Liver Transplant,” Gilead Sciences, Foster City, CA 05/31/00.

“New Perspectives in the Diagnosis and Management of Hepatitis C,” Bayer Diagnostics Hepatitis C Satellite Symposium, San Francisco, CA 07/25/00

“NYLF/MD’s Specialist Seminars,” National Youth Leadership Forum, San Francisco, CA 07/27/99

2001

“Update of HCV Diagnosis and Management” Sutter Community Hospitals, Sacramento, CA 1/26/01.

“Portal hypertension management,” Merced Community Hospital, Merced California 2/3/2001

“Metabolic liver diseases,” Merced Community Hospital, Merced California. 4/13/2001

“Hepatitis C diagnosis and treatment,” Merced Community Hospital, Merced California 6/12/2001

“Department of Transplantation Hep-C and HIV” Cal Pacific Medical Center 5/14/01

“Hepatitis C: Treatment II,” Georgia World Congress Center 5/22/01

“Current Issues in HIV and Hepatitis C co-infection” Institute for Continuing Health Care Ed-ucation, CME program, San Francisco CA, 6/27/2001

“Liver Transplantation: Update 2001,” Feather River Hospital, Paradise, CA 06/25/01

“Living Longer, Living Stronger: Maintaining the Quality of Life for Patients with Anemia and HIV Infection; Current Issues in HIV and Hepatitis C Coinfection,” Le Colonial, San Fran-cisco, CA 7/16/01

“Hepatitis A, B, C: New Strategies in Management,” Dominican Hospital, Santa Cruz, CA 07/20/01

“Management of the complex GI patient,” Merced Community Hospital, Merced California 8/10/2001

2001

“Hepatitis C on the Front Line of Community Health,” 5th International HCV Conference, San Francisco, CA 8/2/01

“Management of the complex GI patient,” Merced Community Hospital, Merced California 10/10/2001.


“Start of the art treatment of viral hepatitis” Chico GI Community Lecture, Chico California, 10/8/2001.

“A comprehensive Overview of hepatitis C” Merced Community Physicians, 11/14/2001.

“Liver Cancer Abstract Review, Post AASLD Review Course” Southern California Society of Gastroenterology, 11/17/2001.

“Interpretation of liver function tests and new therapies in hepatitis C” Sacramento Valley Society of Health-System Pharmacists, Sacramento California 12/4/2001.


2002

“State of the Art Treatment of Viral Hepatitis,” Redding CA, 1/24/2002

“Management of the complex GI patient,” Merced Community Hospital, Merced California 2/10/2002, 4/6/02, 6/10/02, 8/1/02,10/3/02

“Update on Immunosuppressive Therapy”

“Advances in the treatment of Viral Hepatitis

“Diagnosis and Management of Benign and Malignant Liver Tumors

The Ninth Annual Alimentary Update. 2002. Univ. of Nevada School of Medicine. Lake Tahoe, Nevada. 3/7-9/2002

“Therapy of Chronic Viral Hepatitis: An Update.” The Medical and Surgical Aspects of Gastrointestinal Disease… A One Day Course. Roseville CA, 4/6/2002


“Current Issues in HIV and Hepatitis C Coinfection.” Institute for Continuing Healthcare Edu-cation. San Mateo, CA. 5/15/02.

“Managing Treatment Outcomes for HCV - Related Anemia.” Advancmed. Santa Barbara, CA. 5/29/02.

“Anemia Management in HCV.”HCV Regional Advisory Board- Symbiotix. San Francisco, CA. 5/31/02.

CME audio tape/CD Review of the NIH Consensus Conference on Management of Hepatitis C: 2002. 6/10-12/2002.

Curriculum Vitae



“Hepatitis C.” St. Elizabeth Community Hospital CME Meeting. Redding, CA. August 2, 2002.

“PPI’s: Welcome to the Liver”; AstraZeneca. San Francisco, CA. 10/08/02.

Enloe Medical Center Noon Conference. Chico, CA. 10/10/02.

HCV Provider Training. Alameda County. Oakland, CA. 11/14/02.

“Updates in the Treatment of Hepatitis B.” East Bay Gut Club, Berkeley, CA. 12/12/02.

“Hepatology Care Conference.” Schering Onc/Biotech. San Francisco, CA. 12/19/02.

2003

“Hepatitis B Therapy advances in Treatment” GI gut club, Sacramento, CA. 1/16/2003.

Liver Transplant Grand rounds, Department of Surgery faculty, University of California, Los Angeles 4/8/03.

“Patients with ESLD and Decompensated Cirrhosis,” HCV Summit Meeting, Mandarin Hotel, San Francisco, CA 4/12/03.

“Hepatitis B,” Sunrise Hospital and Medical Center, Las Vegas, April, 2003.

“Natural History and Global Epidemiology of HBV Disease,” Bayer Diagnostics-sponsored symposium, EAST 2003, 7/4/03.

“Trends in Hepatitis Testing and Treatment,” Bayer HealthCare, Grand Hyatt, San Francisco, 6/17/2003.

“Hepatitis B and C are Curable,” Infectious Diseases Symposium, Emerging Clinical Issues, May, 2003.

“Hepatitis C Update, 2003, Community Health Resource Center, June, 2003.

“Treating and Managing Chronic Viral Hepatitis in Patients Living in the Pacific Rim,” The Lodge at Sonoma, CA July, 2003.

“NASH” July

“Managing Treatment Outcomes for Hepatitis C Virus Related Anemia,” AdvancMed. August 2003.

“Hepatitis C” for Schering Oncology in Stockton and Modesto, August, 2003.

“Update on the Treatment of Hepatitis C, Schering Oncology, August, 2003.

Curriculum Vitae



“Advancing Hepatitis C Education (AHE),” Scott’s Seafood Grill & Bar, Sacramento, CA, August,

conferences at Sunrise Hospital Las Vegas Nevada.

“Portal HTN” August.

“Autoimmune Liver Disease” September.

“Liver Transplant,” Galileo High School, San Francisco, CA. September 2003.

“From Diagnosis to Treatment: The Full Spectrum of Care in Hepatitis C,” Sheraton Boston Hotel, October 2003.

“Hepatitis C Treatment 2003,” Sequoia Hospital, October 2003.

“Tailoring Hepatitis C Therapy: Treatment Decisions in Select Patient Populations,” Boston, Massachusetts. October 2003

“Optimal Clinical Outcomes: Managing Hepatitis Related Challenges,” Atlanta, Georgia. October 2003.

“From Diagnosis to Treatment: The Full Spectrum of Care in Hepatitis C,” AASLD Satellite Symposium, Boston, Massachusetts. October 2003.

“Molecular Testing in the Diagnosis and Management of Chronic HBV and HCV,” Liver and Digestive Health Medical Clinic and Stanford University Medical Center, October 2003.

“Provider Update: Hepatitis C,” Alexis Park Resort, Las Vegas. November 2003

“Patient Update: Hepatitis C & Liver Transplantation,” Alexis Park Resort, Las Vegas. November 2003.

2003

“Liver Transplant: Complications & When to be Evaluated: The MELD System and Living Related,” Reno Hilton, November 2003.

“Issues Related to HCV Treatment in Patients Co-infected with HCV and Management of Anemia Associated with Combination Therapy for Patients Co-infected with HCV,” San Diego, California. November 2003.

“Treatment Options for Patients with HCV,” San Bernadino County of Public Health, November 2003.

“Hepatitis B disease” November.

“MELD,” Sunrise Hospital and Medical Center, Las Vegas, Nevada. December 2003.

Curriculum Vitae



“Liver Biopsy Conference,” St. Mary’s Hospital, San Francisco, CA, December 2003.

2004

“Recent Advances in Gastroenterology and Hepatology 2004” Squaw Valley, CA January 2004.

“Update n Depression Management” DDW Faculty Conference Call, San Francisco, CA. February 2004.

“New Directions in the Treatment of Hepatitis B” Chicago, IL, March 2004.

“Controversies in HBV: What is on the Horizon for Clinical Management of HBV Infections” Rochester, MN, January 2004.

“Strength to Thrive” Phoenix and Tucson, AZ, March 2004.

“Reaching out to Communities” San Jose, CA, March 2004.

“Hepatitis C: Side Effect Profiles and Current Treatment Paradigms,” Las Vegas, NV, June 2004.

“Hepatitis C Update and Treatment Options,” Chico, CA March 2004.

“Hepatitis B,” San Jose, CA, March 2004.

“Treatment of Hepatitis C,” Monterey, CA, June 2004.

“Update on the NIH conference on HBV and HCC” Las Vegas, NV, June 2004.

“Hepatitis C-SFDPH Provide Update,” San Francisco, CA, July 2004.

“Schering Hepatitis Meeting,” Sacramento, CA, October, 2004.

“Liver Disease: From: Bench to Bedside” Boston, MA, October, 2004.

“What is the Prognosis for HBV?,” October, 2004.

“Diagnostics and New Drugs,” Boston, MA, October -November, 2004.

“10th Annual Princeton Workshop,” Princeton, NJ, November, 2004.

“2nd Annual UC Davis Conference on Primary Care for Hepatitis C & Other Liver Diseases,” Napa, November 20-21, 2004.

“Hepatitis B: Evolving Treatment Strategies @ 5th International Annual Hot Topics in Lever Disease Conference,” October, 2004.

Curriculum Vitae



2005

“Hepatitis C – A Public Health Concern: the Role of Pharmacists,” San Rafael, CA July 11, 2005 “Sunrise Hospital and Medical Center Continuing Medical Education,” Las Vegas, NV, January –May 2005.

“UNOS Committee Meeting: Liver and Intestine Committee.”

“University of Florida PeerView CME – Medical Accuracy Review,” January 2005

“Treatment Approaches for Hepatitis B: A Critical Appraisal,” San Francisco January, 2005

“Drugs and the Live: What the primary care physician should know,” Honolulu, HI, January 2005

“Treatment of Chronic Viral Hepatitis,” San Francisco, January 2005

“Reno-Sparks Community Wide Liver Conference,” Reno, NV, January 6, 2005

“Gastroenterology Case Conference,” San Francisco, CA. January 13, 2005.

“Liver Diseases: An Update for the Primary Care Provider,” Honolulu, HI, January 15, 2005

“Improving Outcomes for Asians and Pacific Islanders at Risk for Hepatitis B.” Washington Hospital. Fremont, CA. January 25, 2005.

“Gastroenterology Case Conference,” San Francisco, CA. January 27, 2005.

“HCV Treatment Modalities, Dosage and Duration,” South Lake Tahoe, February 2005

“Sunrise Hospital & Medical Center: Heavy Metal: Wilson’s Disease & Hemochromatosis,” Las Vegas, February 1, 2005.

“Gastroenterology Case Conference,” San Francisco, CA. March 17, 2005.

“Gastroenterology Case Conference,” San Francisco, CA. March 24, 2005.

“Gastroenterology Case Conference,” San Francisco, CA. April 21, 2005.

“GI Cancer Board,” San Francisco, CA. May 2, 2005.

“Recognition & Management of Shock: New Standard of Care,” San Francisco, CA. May 6, 2005.

“Gastroenterology Case Conference,” San Francisco, CA. June 2, 2005.

“GI Cancer Board,” San Francisco, CA. June 7, 2005.

Curriculum Vitae



“Gastroenterology Case Conference,” San Francisco, CA. June 23, 2005.

“Gastroenterology Case Conference,” San Francisco, CA. July 7, 2005.

“Gastroenterology Case Conference,” San Francisco, CA. August 18, 2005.

“Gastroenterology Case Conference,” San Francisco, CA. August 25, 2005.

“Therapy of Hepatitis B” AASLD, September 14, 2005

“Emerging Treatments for Liver and Complex GI Diseases,” Omni Hotel, San Francisco. September 16-17, 2005.

“Gastroenterology Case Conference,” San Francisco, CA. September 29, 2005.

“Gastroenterology Case Conference.” San Francisco, CA. October 10, 2005.

“Adult Donor Liver Transplantation,” San Francisco, CA. October 21, 2005.

“Clinical Case Consults in Chronic Hepatitis B” September 26, 2005, October 24, 2005.

“Hot Topics in Liver Disease” St. Luke’s Episcopal Hospital. October 7-8, 2005.

“Update on HBV” Sunrise Medical Center, Las Vegas October 18 05.

2005

“Hepatitis B: Identifying the Issues and Improving Patient Outcomes.” University of Wisconsin Medical School, Office of Continuing Medical Education. San Francisco, CA. October 20, 2005.

“GI Cancer Board,” San Francisco, CA. November 1, 2005.

“Treating HCV – Maximizing Response and Minimizing Injury.” University of Wisconsin Medical School, Office of Continuing Medical Education. Las Vegas, NV. November 7, 2005.

“Where Do We Go From Here? - Emerging Strategies in the Management of HCV Treatment Failures.” AASLD, November 13, 2005.

“Early Morning Workshops” – AASLD, November 13-15, 2005.

“Entecavir (ETV) Treatment Through 96 Weeks Results in Substantial Virologic and Biochemical Improvement and HBeAg Seroconversion in HBeAg (+) Chronic Hepatitis B (CHB) Patients (Study ETV-022). AASLD. San Francisco. 2005.

“Presentation at Brick’s Restaurant,” Reno November 17, 2005.

Curriculum Vitae



“Treatment Strategies for the HCV Nonresponder.” InterMune. Roseville, CA. November 28, 2005.

“Expert Council Meeting,” ACT-HBV. The Clift Hotel, San Francisco. December 2, 2005.

“General Session,” ACT-HBV. The Clift Hotel, San Francisco. December 3, 2005.

“Primary Care Special Committee” ACT-HBV, The Clift Hotel, San Francisco. December 3, 2005.

“AASLD Update.” Mountain View Hospital. Las Vegas, NV. December 6, 2005.

“HBV Resistance Roundtable Meeting” The Fairmont Orchid, Kona, HI December 9-10, 2005.

“New Date on Hepatitis Drug Development,” HEP DART, Kohala Coast, Big Island, Hawaii. December 11-15, 2005.

“A Rising Tide: The Next Wave of Treatment Options in HBV and HCV.” AdvancMed. The Fairmont Orchid. Kona, Hawaii. http://www.advancmed.org/807. December 11, 2005.

“Clevudine Advisory Board.” Pharmasset. The Fairmont Orchid. Kona, Hawaii. December 12, 2005.

“Next Generation of HBV/HCV Inhibitors.” HEP DART, The Fairmont Orchid. Kona, Hawaii. www.ihlpress.com/gaj_120605. December 13, 2005

“HCC: Future Therapies,” HEP DART, The Fairmont Orchid. Kona, Hawaii. December 13, 2005.

“Hepatitis B Treatment: 2005 and beyond: an overview,” HEP DART, The Fairmont Orchid. Kona, Hawaii. www.ihlpress.com/gaj_120605. December 13, 2005.

2006

“Reno-Sparks Community Wide Liver Conference.” Saint Mary’s Regional Medical Center. Reno, NV. January 19, 2006.

“2006 CLDF Steering Committee Meeting” Tampa, FL January 20-21, 2006.

“Improving Outcomes for Asians and Pacific Islanders at Risk for Hepatitis B,” Washington Hospital. Fremont, CA. January 25, 2005.

“GI Grand Rounds.” Sunrise Hospital, Las Vegas. February 1, 2006.

“Hot Topics in Hepatology: Updates, Strategies and Future Trends” Hyatt Regency Monterey, CA. February 4, 2006.

http://www.advancmed.org/807

http://www.ihlpress.com/gaj_120605

http://www.ihlpress.com/gaj_120605

Curriculum Vitae



“Reno-Sparks Community Wide Liver Conference.” Saint Mary’s Regional Medical Center. Reno, NV. February 16, 2006.

“Support Group Lecture.” Champions of Organ Sharing. A Southern Nevada Transplant Support Group. March 2006.

“MELD Exception Study Group Meeting” Westin O’Hare Hotel. Chicago, IL. March 1-2, 2006.

“New and Future Treatments for Hepatitis.” Controversies in Transplantation, University of Colorado School of Medicine. Breckenridge, Colorado. March 3-5, 2006.

“COS – Shampions of Organ Sharing.” Clark County Library. March 14, 2006.

“Major Advances in Treating HCV: entering a new era targeted therapy and immunotherapy,” SciClone Pharmaceuticals. Shanghai, China. March 25, 2006.

“A Trial of Zadaxin (thymalfasin) with Trans Arterial Chemoembolization (TACE) in the Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma: A Phase II Trial,” Shanghai-Hong Kong International Liver congress 2006. Shanghai, China. March 26, 2006.

“Application of Viral Load Measurement in HCV Patients on Antiviral Therapy,” Shanghai-Hong Kong International Liver Congress 2006. Shanghai, China. March 26, 2006.

“Overview of Global and China.” Shanghai-Hong Kong International Liver Congress 2006. Shanghai-China. March 26, 2006.

“Management of Chronic Hepatitis B: Entecavir – The Global Experience,” Shanghai-Hong Kong International Liver Congress 2006. Shanghai, China. March 26, 2006.

“Nucleos(t)ide Analogue as First-line Therapy (Pro),” Shanghai-Hong Kong International Liver Congress 2006. Shanghai, China. March 27, 2006.

“Has Antiviral Therapy Altered the Natural History of HBV,” Shanghai-Hong Kong International Liver Congress 2006. Shanghai, China. March 27, 2006.

“Changing paradigm in the Treatment of HBV Infection,” Shanghai-Hong Kong International Liver Congress 2006. Shanghai, China. March 28, 2006.

“Medical need for a prophylactic vaccine against HCV,” Shanghai-Hong Kong International Liver Congress 2006. Shanghai, China. March 28, 2006.

“Region 5 Meeting.” Las Vegas, NV. March 31, 2006.

“Hepatitis Alphabet.” Fresno-Madera Medical Society – 55th Annual Yosemite Postgraduate Institute. Yosemite National Park. March 31-April 2, 2006.

Curriculum Vitae



2006

“Primary Care Approach to Abnormal Liver Function Tests.” Fresno-Madera Medical Society – 55th Annual Yosemite Postgraduate Institute. Yosemite National Park. March 31-April 2, 2006.

“A Case Based Approach to the Modern Management of HCV,” San Francisco, CA. Meet the HCV Masters. April 3, 2006.

“A Partnership Between Primary Care and Specialty Physicians.” Syllabus. 2006.

“Management of Hepatitis B Virus.” Bethesda, MD. April 6-8, 2006.

“Results of a Phase III Randomized Controlled Study Comparing the Survival of Patients with Unresectable Hepatocellular Carcinoma (HCC) Treated with Nolatrexed (NOL) or Doxorubicin (DOX), EASL, Vienna. April 27, 2006.

“Complication of Cirrhosis,” EASL, Vienna. April 27, 2006.

“Therapeutic Strategies for Liver Disease: Hepatitis B, Hepatitis C, and Hepatocellular Carcinoma Treatment Regimens Using Thymalfasin, An Immune System Enhancer.” Austria Center. Vienna. April 27, 2006.

“Hepatitis B, C and Liver CA Update,” Sunrise Hosptial and Medical Center. Cili’s Restaurant. Las Vegas, NV. May 8, 2006. 1.0 AMA PRA Category Credit.

“Cost-effectiveness of Antivirals in HBeAg-positive Chronic Hepatitis B: Impact of Seroconversion and Viral Suppression.” DDW poster. May 2006.

“Advanced Certificiate Program II: Management of Chronic Hepatitis B.” May 2006.

“CLDF Content Development Meeting on HCV Treatment Failures.” Hyatt Regency Century Plaza. Los Angeles, CA. May 19, 2006.

“Refining the HBV Treatment Paradigm.” Westin Bonaventure Hotel. Los Angeles, CA. May 20, 2006.

“Scientific Advisory Panel at DDW.” Wilshire Grand Hotel. Lost Angeles, CA. May 20, 2006.

“International Symposium on HBV.” Kyotot International Conference Hall. Kyoto, Japan. May 27, 2006.

“BARACLUDE (entecavir) as a First-Line Treatment Option in Chronic Hepatitis B Patients and Hypothetical Case Studies.” Campagnia Restauarant. Fresno, CA. June 6, 2006.

“What’s New in the Treatment of Hepatitis B & C.” Double Tree Hotel. Modesto, CA. June 7, 2006.

Curriculum Vitae



“Idenix/Novartis HCV Clinical Expert Panel.” Las Vegas, NV. June 9-10, 2006.

“Treating HCV – Maximizing Response and Minimizing Injury.” Wild Ginger Restaurant. Seattle, WA. June 12, 2006.

“Treatment Strategies for the HCV Nonresponder.” Fifth Floor Restaurant. San Francisco, CA. June 13, 2006.

“Chronic Hepatitis B National Advisory Board Meeting.” New Haven, CT. June 15-17, 2006.

“Reno Sparks Community Wide Liver Conference: Medical & Surgical Aspects of Liver Transplantation 2006.” Reno, NV. June 22, 2006.

“Focus on the Virus: A New Paradigm for the Management and Treatment of HBV,” Sheraton Boston Hotel, Boston, MA. October 30, 2006.

“The NCSCG Yosemite GI Retreat 2006.” Yosemite, CA. November 3-5, 2006.

2007

“Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities – Expert Insight Intro: Provider Knowledge and Practice Regarding Hepatitis B Screening in Chinese-Speaking Patients.” Course HBV3:03. 2007.

“ESLD and ICU Care Lecture.” University of Nevada School of Medicine. February 12, 2007.

“New Therapies in Liver Cancer and Hepatitis.” Spain, Barcelona. April 12, 2007.

“Liver Pathology Rounds.” Fresno, CA. April 25, 2007.

“Care of Pre and Post Transplant Patients.” Medical/Surgical Aspects of Gastrointestinal Disease – A One Day Course. Sutter Roseville Medical Center. Sacramento, CA. April 21, 2007.

“Panel Discussion: Challenges in Therapy of Hep C.” Medical/Surgical Aspects of Gastrointestinal Disease – A One Day Course. Sutter Roseville Medical Center. Sacramento, CA. April 21, 2007.

“American Transplant Congress.” San Francisco, CA. May 5-9, 2007 (CME Credit)

“Molecular Tests for HBV: Genotype, Core and Precore Testing, Quatification Tests.” San Francisco, CA. May 7, 2007.

“Molecular Tests for HBV: Genotype, Core and Precore Testing, Quantification Tests. Seattle, WA. May 9, 2007

“Strategies for the Treatment of the HCV Refractory Patient.” Seattle, WA. May 9, 2007

Curriculum Vitae



“Viral Hepatitis.” San Jose, CA. May 16, 2007

“April 07 Advanced Issues in the Management of Chronic Hepatitis B.” San Francisco, CA. May 17, 2007.

“The Next Steps in Viral Eradication for HCV Treatment Failures.” Sacramento, CA. May 23, 2007

“The Next Steps in Viral Eradication for HCV Treatment Failures.” Reno, NV. May 24, 2007

“Metabolic Liver Disease.” University of Nevada, School of Medicine, Las Vegas. June 11, 2007.

“Hepatology in the ICU.” CPMC. San Francisco, CA. June 26, 2007.

“Vertex Pharmaceuticals Physician Advisory Forum.” Chicago, IL. June 30, 2007.

“Case 1 - Patient RD: Management of HCV genotypes 2/3.” CARES. July 2007.

“Case 4 – Patient AR: Hematologic Toxicities in Patients Undergoing Treatment for HCV.” CARES. July 2007.

“Hepatology in the ICU.” CPMC. San Francisco, CA. July 17, 2007.

“Evaluation of Abnormal Liver Tests.” University of Nevada School of Medicine. July 23, 2007.

“April 07 HCP Guide.” Las Vegas, NV. July 24, 2007.

“April 07 Advanced Issues in the Management of Chronic Hepatitis B.” Reno, NV. July 26, 2007.


“Evolving Strategies in the Management of HCV.” San Jose, CA. July 31, 2007.

“Case 2 – Patient FN: Management of HCV Genotype 1.” CARES. August 2007.

“Case 5 – Patient KM: Psychiatric Issues in Patients Undergoing Treatment for HCV.” CARES. August 2007.

2007

“Update on Hepatitis.” University of Nevada School of Medicine. Las Vegas, NV. August 22, 2007.

“Management of CHB in the era of Ptent Antivirals.” Workerhill Hotel, Korea. August 29, 2007.

Curriculum Vitae



“Management of CHB in the era of Ptent Antivirals.” Asan Hospital, Korea. August 30, 2007.

“Management of CHB in the era of Ptent Antivirals.” Samsung Hospital, Korea. August 30, 2007.

“HBV Treatment, do we need a compass, roadmap or GPS? (or a seeing eye dog?)” September 1, 2007.

“Targeting the RAS/Raf Signaling Pathway: Implications in the Management of Hepatocellular Carcinoma.” Faculty Teleconference. September 6, 2007.

“Emerging Data in the Management of HBV.” Morton’s Steakhouse. San Francisco, CA. September 6, 2007.

“April 07 HCP Guide.” Tarpy’s Roadhouse. Monterey, CA. September 17, 2007.

“Liver Pathology Rounds.” Community Medical Center. Fresno, CA. September 18, 2007.

“HEP B Free – 2007 CME.” Tommy Toy’s. San Francisco, CA. September 19, 2007.

“Overview of Antiviral Drug Resistance in Chronic Hepatitis B (CHB): Focus on BARACLUDE (entecavir). Brennan’s. Houston, TX. September 20, 2007.

“HEP B Free – 2007 CME with Dr Eddie Cheung.” Griffin Room – St Luke’s Campus. September 25, 2007.

“ILCA’s First Annual Conference.” Barcelona-Spain. October 5-7, 2007.

“Evaluation of a Liver Mass.” University of Nevada School of Medicine. October 17, 2007.

“Managing the Patient with Advanced Liver Disease.” Spencer’s – Spokane, WA. October 26, 2007.

“Optimal Clinical Outcomes: Managing Hepatitis Related Challenges.” PlumpJack Café. San Francisco, CA. October 29, 2007.

“Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities.” Projects In Knowledge/AASLD. November 2007.

“Hepatitis Medicaid Expansion Project.” Expert Working Group Meeting – Boston, MA. November 1, 2007.

“Multimodality Approach to the Treatment of HCC: The Emerging Paradigm.” AASLD. Boston, MA. November 4, 2007

Curriculum Vitae



“Pharmasset/Roche HCV polymerase Clinical Expert Meeting.” AASLD. Boston, MA. November 4, 2007.

“Frontiers in Drug Development for Viral Hepatitis.” Emory University. December 9-13, 2007.

“Fund Raising Study Task Force Conference Call.” AASLD. December 18, 2007.

2008

“GI Cancer Board,” San Francisco, CA. January 1, 2008.

“Aug 07 Resistance.” BMS. Mitchell’s Steak House - Columbus, OH. January 8, 2008.

“Aug 07 Resistance.” BMS. Ohio State University Medical Center - Columbus, OH. January 9, 2008.

“Simply Speaking – HBV.” The Westin Casuarina. Las Vegas, NV. January 12, 2008.

“Drug Induced Liver Disease.” University of Nevada School of Medicine. Las Vegas, NV. January 14, 2008.

“Retreatment of Relapsers and Non-Responders.” The First Annual Hepatitis C Conference. Reno, NV. January 18, 2008.

“Hepatology in the ICU.” CPMC. San Francisco, CA. January 22, 2008.

“GI Fellow Teaching.” CPMC. San Francisco, CA. January 23, 2008.

“Therapeutical strategies and advances on HBV.” Shanghai Westin Hotel. Chinese Medical Association. Shanghai, China. February 2, 2008.

“Therapeutical strategies and advances on HBV.” Shanghai Hilton Hotel. Chinese Medical Association. Shanghai, China. February 3, 2008.

“GI Cancer Board,” San Francisco, CA. February 5, 2008.

“Conquering Contemporary Challenges – New Hope with Targeted Therapy for Hepatocellular Carcinoma.” Osake Restaurant. Santa Rosa, CA. February 5, 2008.

“GI Fellow Teaching.” CPMC. San Francisco, CA. February 6, 2008.

“GI Fellow Teaching.” CPMC. San Francisco, CA. February 7, 2008.

“HBV New Therapies.” St Mary’s Hospital Grand Rounds. San Francisco, CA. February 8, 2008.


“Clinical Drug Assessment, A Clinician’s View of the Development and Assessment of Drugs to Treat Hepatitis.” Road Map to Drug Discovery, Development and Approval. February 12, 2008.

“Session 5: Management of HBV Resistance – Case Presentation and Discussion.” EASL-AASLD-APASL-ALEH-IASL Conference: Hepatitis B and C Virus Resistance to Antiviral Therapies. Paris, France. February 14-16, 2008.

“LT, Referral and Indications, pre/post transplant care.” Sunrise Hospital. Las Vegas, NV. February 26, 2008.

“American Association for the Study of Liver Disease Update.” Saint Mary’s Regional Medical Center. Reno, NV. February 28, 2008.

“Evolving Treatment Options for Chronic HCV Infection Optimizing Current Treatment Options.” Palm’s Restaurant. Fresno, CA. March 3, 2008.

“GI Cancer Board,” San Francisco, CA. March 4, 2008.

“HBV Resistance and the Role of Baraclude in CHB.” Rice Bowl Restaurant. Sacramento, CA. March 5, 2008.

“Hepatitis B Liver Symposium.” Cathedral Hill Hotel. San Francisco, CA. March 15, 2008.

“NASH and Fatty Liver.” University of Nevada School of Medicine. Las Vegas, NV. March 17, 2008.

“Hepatitis C Questions? We have answers.” Sunrise Medical Center. Las Vegas, NV. March 17, 2008.

2008

“GI Cancer Board,” San Francisco, CA. April 1, 2008.

“Healthcare Provider’s Guide to Chronic Hepatitis B.” BMS. Las Vegas, NV. April 14, 2008.

“Portal hypertension and treatment.” Renown. Reno, NV. April 17, 2008.

“Medical Overview of Hepatitis C.” Hepatitis C Community Outreach Event. Las Vegas, NV. April 19, 2008.

“Treatment of Hepatocellular Carcinoma with TACE plus Thymalfasin.” Sciclone - New Therapies in Liver Cancer and Hepatitis. EASL - Milan, Italy. April 24, 2008.

“HCV.” Silk’s Restaurant. San Francisco, CA. April 29, 2008.

“HCV Update.” Schering-Plough. Rhema Restaurant. Fresno, CA. April 30, 2008.

Curriculum Vitae



“UNOS Regional 5 Meeting.” Las Vegas, NV. May 1, 2008.

“Overview Slide Presentation.” BMS Advisory Board Meeting. Los Angeles, CA. May 3, 2008.

“Questions and Answers.” BMS Advisory Board Meeting. Los Angeles, CA. May 3, 2008.

“GI Cancer Board,” San Francisco, CA. May 6, 2008.

“Autoimmune liver disease, including PSC and PBC/PBH.” Nevada School of Medicine. Las Vegas, NV. May 13, 2008.

“European Association for the Study of Liver Disease Update.” Reno Sparks Community – Wide Liver Conference. Beaujulais Bistro. Reno, Nevada. May 15, 2008.

“2008 Expert Working Group Meeting.” Gilead. San Diego, CA. May 16, 2008.

“Editorial Advisory Board – DDW Breakfast.” Gastroenterology and Hepatology. San Diego, CA. May 19, 2008.

“AASLD Clinical Symposium.” DDW-San Diego, CA. May 20, 2008.

“An Updated Review of Management Strategies for the HCV Non-Responder.” Three Rivers Pharmaceuticals. Roy’s Restauarnt. Las Vegas, NV. May 28, 2008.

“Alcoholic Hepatitis.” Alameda County Medical Center. Oakland, CA. May 30, 2008.

“Treatment End Points: Translating Clinical Trials into Clinical Practice.” Hong Kong-Shanghai International Liver Congress – BMS Satellite Symposium. Hong Kong, China. June 14, 2008.

“Management of acute liver failure – Biological and nonbiological liver support methods.” Hong Kong-Shanghai International Liver. Hong Kong, China. June 14, 2008.

“Liver Support System Workshop – What Do You Need to Know about Liver Support System in 2008.” Hong Kong-Shanghai International Liver Congress Hong Kong, China. June 14, 2008.

“Nucleic acid testing: role in HBV and HCV management.” Hong Kong-Shanghai International Liver. Hong Kong, China. June 14, 2008.

“Combination therapy for CHB: Are we focusing too much on viral suppression rather than on antiviral ressistance as a sign of efficacy? (Pro).” Hong Kong-Shanghai International Liver. Hong Kong, China. June 15, 2008.

“Road map to long term treatment success.” Hong Kong-Shanghai International Liver. Hong Kong, China. June 15, 2008.

Curriculum Vitae



“IX International Symposium on Viral Hepatitis.” Barcelona, Spain. June 20-21, 2008.

“2008 Post Conference Update: EASL.” Simply Speaking. San Francisco, CA. June 23, 2008.

“An Updated Review of Management Strategies for the HCV Non-responder.” Three Rivers Pharmacueticals. Garibaldis Restaurant. Oakland, CA. June 24, 2008.

“Strategies for Optimizing Successful Outcomes in the Management of HCV Difficult-to-Treat Population.” Three Rivers Pharmaceuticals. Bricks Restaurant. Reno, Nevada. June 26, 2008.

“Keynote Speaker.” Hepatitis B Foundation – B Informed Patient Conference. St. Vincent Medical Center. Los Angeles, CA. June 28, 2008.

“Ask the Experts Roundtable.” Hepatitis B Foundation – B Informed Patient Conference. St. Vincent Medical Center. Los Angeles, CA. June 28, 2008.

“GI Cancer Board,” San Francisco, CA. July 1, 2008.

“New Concepts in the Treatment of HCV.” Schering-Plough. July 1, 2008.

“HBV.” GI Noon Conference. CPMC. San Francisco, CA. July 3, 2008.

“HBV Update.” APAC Quarterly Meeting. Four Seas Restaurant. July 9, 2008.


“How do healthcare providers teach about hepatitis b? With the goals, prevelance, natural history treatment – testing.” BMS. E&O Trading. San Francisco, CA. July 15, 2008.

“Clinical Implications of HBV Resistance.” Ruth Cris Steak House. Honolulu, Hawaii. July 17, 2008.

“The Future of Hepatitis B and C.” Fourth Annual Liver Update Seminar. Queen’s Conference Center. July 19, 2008.

“Updates on the Management & Treatment of Hepatitis B.” Fourth Annual Liver Update Seminar. Queen’s conference Center. July 19, 2008.

“Panel Discussion.” Fourth Annual Liver Update Seminar.” Queen’s conference Center. July 19, 2008.

“LFTs.” Nevada School of Medicine. Las Vegas, NV. July 23, 2008.

“Liver Enzyme Elevation.” Renown – Nevada School of Medicine. Reno, NV. July 24, 2008.

Curriculum Vitae



“Update of Hepatitis C Virus: epidemiology, natural history and treatment.” Saint Mary’s Regional Medical Center. 4th Street Bistro. Reno, NV. July 24, 2008.

“Management of the Advanced Liver Disease Patient.” Roche Pharmaceuticals. Lodi, CA. August 18, 2008.

“Management of the HCV Patient.” Schering-Plough. Daily Grill. Fresno, CA. August 19, 2008.

“Hepatology in the ICU.” CPMC. San Francisco, CA. August 21, 2008.

“GI Cancer Board,” San Francisco, CA. September 2, 2008.

“Clinical Implications of HBV Resistance.” BMS. Chicago, IL. September 4, 2008.

“Advances in Managing Patients with Hepatitis B.” Duke Liver Disease Update and Symposium. Duke Clinical Research Institute. Durham, North Carolina. September 6, 2008.

“Gilead Speaker Training.” San Francisco, CA. September 8, 2008.

“Hepatology in the ICU.” CPMC. San Francisco, CA. September 9, 2008.

“Addressing Real World Challenges in the Treatment of Chronic Hepatitis C.” Roche. Ruth Cris Steak House. Kansas City, MO. September 11, 2008.

“Management of the Advanced Liver Disease Patient.” Roche. University of Kansas. Kansas City, KS. September 12, 2008.

“Clinical Implications of HBV Resistance.” BMS. Il Fornaio Restaurant. San Jose, CA. September 16, 2008.

“Treating the Hospitalized Liver Patient.” University of Nevada School of Medicine. Las Vegas, NV. September 22, 2008.

“HCV Update.” Schering-Plough. Cheese Board Restaurant. Reno, NV. September 22, 2008.

“CME Talk.” Renown – Nevada School of Medicine. Reno, NV. September 23, 2008.

“Current Perspectives on Chronic Liver Disease.” CLDF. Scott’s Seafood. Sacramento, CA. September 23, 2008.

“2008 Post Conference Update: EASL.” HRL Communications. El Paseo Restaurant. Mill Valley, CA. September 24, 2008.

“GI Cancer Board,” San Francisco, CA. October 7, 2008.

Curriculum Vitae



“GI Fellow Teaching.” CPMC. San Francisco, CA. October 7, 2008.

“Hepatology in the ICU.” CPMC. San Francisco, CA. October 9, 2008.

“2008 Pegasys Hep B Regional Advisory Board.” San Francisco, CA. October 9, 2008.

“Biliary Disease Work Up of Jaundice.” Nevada School of Medicine. Las Vegas, NV. October 13, 2008.

“Healthcare Provider's Guide to Chronic Hepatitis B.” BMS. Del Frisco’s Restaurant. Las Vegas, NV. October 14, 2008.

“Fatty Liver Evaluation.” Renown – Nevada School of Medicine. Reno, NV. October 16, 2008.

“Update on Liver Cancer from EASL, ILC, and DDW.” CME – Saint Mary’s Continuing Medical Education. 4th Street Bistro. Reno, NV. October 16, 2008.

“Management of Hepatitis B.” Canadian Speaker Tour. On the Fork Restaurant. London, Ontario. October 21, 2008.

“Views on Living Donor Transplants, Hepatocellular Carcinoma Pre and Post Transplant.” Canadian Speaker Tour. London Health Sciences. London, Ontario. October 22, 2008.

“Hepatitis B: Implications of Resistance in End Stage Liver Disease and Liver Transplantation.” Canadian Speaker Tour. Toronto General Hospital. October 22, 2008.

“Viral Resistance.” Canadian Speaker Tour. Toronto Western Hospital. October 23, 2008.

“Chronic Hepatitis B.” Canadian Speaker Tour. Hotel Intercontinental, Salon Maisonneuve. Montreal, Quebec. October 23, 2008.

“Consequences of Antiviral Resistance.” Canadian Speaker Tour. Vancouver Hospital and Health Sciences Centre. October 24, 2008.

“Cases in Point: Risk Factors, Surveillance Strategies and Treatment Options for Hepacellular Carcinoma.” Marriott. San Francisco, CA. November 1, 2008.

“Models for Hepatitis B Screening and Linkage to Care.” Gilead Medical Affairs dinner. Town Hall Restauarnt. San Francisco, CA. November 2, 2008.

“Approved Agents for HBV Treatment.” Clinical Care Options. Le Meridien. San Francisco, CA. November 3, 2008.

“GI Cancer Board,” San Francisco, CA. November 4, 2008.

“Approved Agents for HBV Treatment.” Clinical Care Options. Le Meridien. San Francisco, CA. November 4, 2008.

Curriculum Vitae



“GI Fellow Teaching.” CPMC. San Francisco, CA. November 7, 2008.

“New Concepts in the Treatment of HCV.” Schering-Plough. Plumed Horse Restaurant. October 10, 2008.

“Standard of Care for the Treatment of Hepatitis B & C.” Update in Gastroenterology and Hepatology. Las Vegas Symposium. November 15, 2008.

“Hepatitis C.” Las Vegas Symposium. November 15, 2008.

“Debate Monotherapy is Suitable for HBV.” Las Vegas Symposium. November 15, 2008.

“GI Cancer Board,” San Francisco, CA. December 2, 2008.

“HBV Highlights from CCO’s Coverage of the 2008 AASLD Meeting,” Grand Café. San Francisco, CA. December 2, 2008.

“CARES – Roundtable.” Farallon Restaurant. San Francisco, CA. December 4, 2008.

“Launching of Hepatitis-B Education and Awareness Campaign.” South Seafood Restaurant. San Francisco, CA. November 25, 2008.

“VIREAD: A New Treatment Option for Chronic Hepatitis B in Adults.” Gilead. Fifth Floor Restaurant. San Francisco, CA. December 8, 2008.

“GI Fellow Teaching.” CPMC. San Francisco, CA. December 9, 2008.

“HBV.” Nevada School of Medicine. Las Vegas, NV. December 15, 2008.

“Chronic Hepatitis B.” BMS. Roy’s Restaurant. Las Vegas, NV. December 15, 2008.

“VIREAD: A New Treatment Option for Chronic Hepatitis B in Adults.” Gilead. Las Vegas, NV. December 16, 2008.

“Nexavar in the Treatment of Patients With Unresectable HCC.” Onyx. Beaujolais Bistro. Las Vegas, NV. December 18, 2008.

2009

“NASH = Non-alcoholic Fatty Liver Disease.” CME Talk. Reno, NV. January 8, 2009.

“HBV Screening and Linkage to Care.” Simply Speaking. Scottsdale, AZ. January 10, 2009.

“Guidelines to Screen for and Treat Chronic Viral Hepatitis B and C Infections.” Department of Medicine. Grand Rounds at CPMC. San Francisco, CA. January 13, 2009.

“VIREAD: A First-Line Treatment Option for Chronic Hepatitis B in Adults.” Gilead. Tanglewood Restaurant. San Jose, CA. January 14, 2009.

Curriculum Vitae



“Nexavar in the Treatment of Patients with Unresectable HCC.” Le Papillon Restaurant. Onyx. San Jose, CA. January 15, 2009.

“Speaker Training.” 2009 Pegasysm Speaker Training. Estancia. La Jolla, CA. January 16-17, 2009.

“Current Management Strategies in CHB.” 2nd St Lukes International Liver Conference Scientific Program. Manilla, Philippines. January 19, 2009.

“Treatment Approach of a Patient with CHB.” 2nd St Lukes International Liver Conference Scientific Program. Manilla, Philippines. January 19, 2009.

“Treat to Succeed: A Case by Case Study of Hepatitis B (Discussing current trends and challenges in the treatment of Chronic Hepatitis B).” BMS – Edinburgh and Birmingham. UK and Netherlands Roadshow. January 20, 2009.

“Treat to Succeed: A Case by Case Study of Hepatitis B (Discussing current trends and challenges in the treatment of Chronic Hepatitis B).” BMS – Newcastle and Manchester. UK and Netherlands Roadshow. January 21, 2009.

“Treat to Succeed: A Case by Case Study of Hepatitis B (Discussing current trends and challenges in the treatment of Chronic Hepatitis B).” BMS – London. UK and Netherlands Roadshow. January 22, 2009.

“Treat to Succeed: A Case by Case Study of Hepatitis B (Discussing current trends and challenges in the treatment of Chronic Hepatitis B).” BMS – Utrecht. UK and Netherlands Roadshow. January 23, 2009.

“Current Perspectives in the Treatment of Chronic Hepatitis C.” Slates Restaurant. Roche. Frenso, CA. January 28, 2009.

“VIREAD: A First-Line Treatment Option for Chronic Hepatitis B in Adults.” Gilead. Nola Restaurant. Palo Alto, CA. February 4, 2009.

“CHB Hypothetical Case Studies.” BMS. Tommy Toy’s Restaurant. San Francisco, CA. February 5, 2009.

“Hepatitis B & C Update.” Grand Rounds Talk. Highland Hospital. Oakland, CA. February 6, 2009.

“Strategies for Improved Response in the Treatment of Hep B: Patient Case Approach.” Roche. Tanglewood Restaurant. San Jose, CA. February 9, 2009.

“Liver Transplant.” APASL Meeting. Hong Kong, China. February 12, 2009.

“Hepatitis C.” APASL Meeting. Hong Kong, China. February 12, 2009.

“Chinese American Physicians Association Joint Symposium – What Do You Need to Know about Liver Support System in 2009.” APASL Meeting. Hong Kong, China. February 13,

Curriculum Vitae



2009.

“Long-term treatment goals: Reflections on HBsAg seroconversion.” APASL Meeting. Hong Kong, China. February 13, 2009.

“Postgraduate Course V – Liver Transplantation.” APASL Meeting. Hong Kong, China. February 13, 2009.

“Approach to difficult-to-treat patients.” APASL Meeting. Hong Kong, China. February 14, 2009.

“Improving Patient Quality of Life: Preventing CHB disease progression with Baraclude.” APASL Meeting. Hong Kong, China. February 14, 2009.

“Update on Hepatitis Viral B.” Hue College of Medicine and Pharmacy. Hue, Vietnam. February 18, 2009.

“Update on Hepatitis Viral C.” Hue College of Medicine and Pharmacy. Hue, Vietnam. February 18, 2009.

“Update on the Treatment of Liver Cancer.” Hue College of Medicine and Pharmacy. Hue, Vietnam. February 18, 2009.

“Liver Transplant.” Hue College of Medicine and Pharmacy. Hue, Vietnam. February 18, 2009.

“Nexavar in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC).” Onyx. Nove Italiano Restaurant. Las Vegas, NV. February 23, 2009.

“Nexavar in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC).” Onyx. Rapscallion Seafood House. Reno, NV. February 26, 2009.

“VIREAD: A First Line Treatment Option for Chronic Hepatitis B in Adults.” Oliveto. Oakland, CA. March 3, 2009.

“Be a Hero Dinner.” South Seafood Restaurant. San Francisco, CA. March 5, 2009.

“Autoimmune and metabolic diseases: genetic.” Nevada School of Medicine. Las Vegas, NV. March 10, 2009.

“Roundtable Discussion.” Three Rivers. Ruth Chris Restaurant. Las Vegas, NV. March 10, 2009.

“Nexavar in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC).” Onyx. Rapscallion Seafood House. Reno, NV. March 12, 2009.

Curriculum Vitae



“ALF Salute to Excellence.” San Francisco, CA. March 14, 2009.

“Resistance: “Resistance: The Role of Baraclude.” BMS. Sasso Restaurant. Boston, MA. March 16, 2009.

“Resistance: The Role of Baraclude.” BMS. Jianan Comprehensive Care. Brooklyn, New York. March 17, 2009.

“Nexavar in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC).” Onyx. Hyatt at Olive 8. Seattle, WA. March 19, 2009.

“Nexavar in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC).” Onyx. El Gaucho Restaurant. Seattle, WA. March 19, 2009.

“New Therapies for Hepatitis B and Hepatitis C.” University of Nevada School of Medicine. 16th Annual Alimentary Update. Harveys Resort. Lake Tahoe, CA. March 27, 2009.

“Advances in the Treatment of HCV/HIV Coinfection With Pegasys and Copegus.” Roche. The Grand Café. San Francisco, CA. March 30, 2009.

“Hepatocellular Carcinoma: Current Epidemiology & Management.” Good Samaritan Hospital. CME talk. San Jose, CA. April 1, 2009.

“New Paradigm in Treatment of Chronic Hepatitis B.” South Bay Gut Club/BMS. Amber India Restaurant. San Jose, CA. April 1, 2009.

“Management of Long Term Sequale of Hepatitis B such as Cirrhosis and Hepatoma.” South Bay Gut Club/BMS. Amber India Restaurant. San Jose, CA. April 1, 2009.

“HCV.” GLG Roundtable Meeting. Silks Restaurant. San Francisco, CA. April 8, 2009.

“Viral hepatitis over view B and C.” Renown Medical Center. Reno, NV. April 29, 2009.

“Clinical Implications of Hepatitis B Virus Resistance.” BMS. Rapscallion Seafood House. Reno, NV. April 29, 2009.

2009

“Management of Hepatitis B.” BMS. Scott's Seafood Restaurant. Sacramento, CA. April 30, 2009.

“Wilsons Disease.” CPMC. San Francisco, CA. May 2, 2009.

“Hepatitis C Fight.” Roche. Town Hall Restaurant. San Francisco, CA. May 4, 2009.

“Nexavar in the Treatment with Unresectable HCC.” Onyx. Scott’s Seafood. May 5, 2009.

Curriculum Vitae



“VIREAD: A First-Line Treatment Option for Chronic Hepatitis B in Adults.” Gilead. La Folie Restaurant. San Francisco, CA. May 6, 2009.

“2009 Post Conference Update: EASL.” Simply Speaking. El Paseo Restaurant. Mill Valley, CA. May 13, 2009.

“HCC.” Renown Medical Center. Reno, NV. May 14, 2009.

“HCV and Cryoglobulinemia: How Cool Can You Get.” Saint Mary’s Regional Medical Center. Reno, NV. May 14, 2009.

“Unbranded Professional Programs Program.” Gilead. Nove Italiano at The Palms. Las Vegas, NV. May 19, 2009.

“Fatty Liver.” Nevada School of Medicine. Las Vegas, NV. May 20, 2009.

“Case 6: Patient With HBV Infection: When to Treat and How to Treat.” CARES. McCormick & Kuleto's Restaurant. San Francisco, CA. June 4, 2009.

“Nexavar in the Treatment of Patients with Unresectable HCC.” Onyx. Renown Hospital. Reno, NV. June 30, 2009.

“Weekly Emergency Medicne Conference.” CME talk. Alameda County Medical Center, Highland Hospital. Oakland, CA. July 1, 2009.

“Faculty of John Hopkins University School of Medicine CME Program.” Kuleto Trattoria Restaurant. Burlingame, CA. July 14, 2009.

“HCV and Cryoglobulinemia: How Cool Can You Get?” Saint Mary’s Regional Medical Center. Reno, NV. July 27, 2009.

“Chronic Hepatitis B (CHB_: Screening, Diagnosis and Patient Considerations.” BMS talk. Kings Winery Clinic. Fresno, CA. August 5, 2009.

“VIREAD An Overview Including Safety and Efficacy.” Gilead. Palms Restaurant. Fresno, CA. August 5, 2009.

“An Updated Review of Management Strategies for the HCV Treatment Failure Patient.” Three Rivers. Gordon Biersch Brewing Company. Las Vegas, NV. August 18, 2009.

“Work up of Elevated Liver Tests.” Las Vegas, NV. August 19, 2009.

“Liver Enzyme Elevation.” Renown. Reno, NV. August 20, 2009.

“CHB Hypothetical Case Studies.” BMS talk. Scott’s Seafood. Oakland, CA. August 26, 2009.

“GI Journal Club Presentation.” University of Alberta. Edmonton, Canada. November 10, 2009.

Curriculum Vitae



2010

“HCC Diagnosis and Treatement.” Sonoma Valley Gut Club. Santa Rosa, CA. January 11, 2010.

“State of the Art Liver Transplantation for Hepatocellular Carcinoma: Recurrence of primary and secondary disease; what is more important?” VIVA Restaurant. Los Gatos, CA. February 25, 2010.

“GI Fellow Teaching.” CPMC. March 2, 2010.

“One Therapy From Day One – 5 Year Resistance Update.” Oak Brook, IL. March 5, 2010.

“Advances in Hepatocellular Carcinoma: 2010 Update.” Loyola University. Maywood, IL. March 6, 2010.

“Viral Hepatitis and Hepatocellular Carcinoma.” March 6, 2010.

“VIREAD Case Vignettes: An Examination of Patient Profiles.” Galletto Ristorante. Modesto, CA. March 10, 2010.

“Updates on Viral Hepatitis and Liver Diseases.” Hue college of Medicine and Pharmacy. Vietnam. March 22-23, 2010.

“Liver Suport System for the Management of Liver Failure.” APASL. Beijing, China. March 25, 2010.

“New Concepts in the Treatment of HCV.” Plumed Horse Restaurant. Saratoga, CA. March 29, 2010.

“HBV.” Kaiser. San Jose, CA. March 31, 2010.

“Nexavar in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC).” E&O Trading. San Jose, CA. March 31, 2010.

“CHB Resistance: Role of Baraclude in CHB Therapy for Nucleoside-naïve Patients.” Northwestern Memorial Hospital. Chicago, IL. April 5, 2010.

“The Clinical Implications of Managing Cirrhotics.” CLDF. San Francisco, CA. April 12, 2010.

“VIREAD Case Vignettes: An Examination of Patient Profiles.” Harrahs Steakhouse. Reno, NV. April 28, 2010.

“Overview of HBV and Liver Transplantation: Why is There a Controversy?” Sunrise Symposium: Controversies in Management of HBV after Liver Transplantation. May 2, 2010.

Curriculum Vitae



“Concurrent Session9: Liver:Allocation Issues.” 2010 American Transplant Congress. San Diego, CA. May 2, 2010.

“One Therapy From Day One – 5 Year Resistance Update.” San Francisco, CA. May 3, 2010.

“Chronic Viral Hepatitis: Can we “C” our way to “B” cured?” CME Talk. St Luke’s Grand Rounds. San Francisco, CA May 5, 2010.

“New Advances in the Management of Hepatocellular Carinoma (HCC).” Regional Medical Center of San Jose. May 8, 2010.

“Newest Multi-Disciplinary Treatment Modalities for Liver and locally advanced Pancreatic Cancer.” Renown. Reno, NV. May 11, 2010.

2010

“VIREAD: An Overview Including Safety and Efficacy.” Ritz Carlton Hotel. San Francisco, CA. May 12, 2010.

“Long Term Considerations in Chronic Hep B (CHB) Therapy.” Tommy Toy’s Restaurant. San Francisco, CA. May 17, 2010.

“VIREAD Case Vignettes: An Examination of Patient Profiles.” Alexander’s Steakhouse. Cupertino, CA. May 18, 2010.

“+Bay Area Non-Doc (BAND).” LePapillion Restaurant. San Jose, CA. May 19, 2010.

“The Clinical Implications of Managing Cirrhotics.” Ruth Chris Steakhouse. San Francisco, CA. May 25, 2010.

“Long-Term Considerations in Chronic Hepatitis B (CHB) Therapy.” LePeppillion Restaurant. San Jose, CA. May 26, 2010.

“Long Term Considerations in Chronic Hep B Therapy – Lecture w/HBV Treaters.” Ounce Steakhouse. San Antonio, TX. June 10, 2010.

“2010 National Hepatitis B&C – Training Program & Treatment Update.” Omni Hotel. San Francisco, CA. June 12, 2010.

“Hepatitis C: What is the current diagnostic and treatment paradigm?” Community Hospital of Monterey. Monterey, CA. June 16, 2010.

Coming to your area: Case3: On the Cusp of Change: New Therapeutic Modalities for HCV.” Sienna Restaurant. El Dorado Hills, CA. June 16, 2010.

“Chronic Hepatitis B (CHB) – Screening, Diagnosis and Patient Considerations.”

Curriculum Vitae



Pleasanton, CA. June 29, 2010.

“Remarks from CPMC.” Health Forum. Southeast Asian Community Center. San Francisco, CA. June 13, 2010.

“Hepatitis C: What is the Current Diagnostic and Treatment Paradigm?” Community Hosptial of Monterey. Monterey, CA. June 16, 2010.

“Coming to your area: Case 3: On the Cusp of Change: New Therapeutic Modalities for HCV.” El Dorado Hills, CA. June 16, 2010.

“Chronic Hepatitis B (CHB)-Screening, Diagnosis and Patient Considerations.” Pleasanton, CA. June 29, 2010.

“CHB Hypothetical Case Studies.” Las Vegas, NV. July 28, 2010.

“Use only the “A” Team to Beat Hepatitis “B.”” Chinese Hosptial. San Francisco, CA. August 3, 2010.

“Nexavar in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC).” Las Vegas, NV. August 17, 2010.

“The Clinical Implications of Managing Cirrhotics.” San Jose, CA. September 13, 2010.

“VIREAD Professional Program.” Oakland, CA. September 20, 2010.

“Use Only the “A” Team to Beat Hepatitis “B.”” Saint Francis Memorial Hospital. September 21, 2010.

“VIREAD Professional Program.” Fresno, CA. September 21, 2010.

“HBV Unbranded.” San Jose, CA. September 28, 2010.

“Risk Assessment and Clinical Management of Patients with CHB.” Reno, NV. September 29, 2010.

“Risk Assessment and Clinical Management of Patients with CHB.” Sacramento, CA. September 30, 2010.

“Clinical Update 2010: Chronic Liver Disease and Hepatocellular Carcinoma.” Sutter Roseville Medical Center. Roseville, CA. October 2, 2010.

“Viral Hepatitis Treatment and HCC.” Roseville, CA. October 2, 2010.

“Hepatocellular Carcinoma Current Trends in Diagnosis and Management: What all Healthcare Providers Need to Know.” Hartford Hospital Grand Rounds. Hartford, CT. October 4, 2010.

Curriculum Vitae



“One Therapy From Day One – 5 year Resistance Update.” Hartford, CT. October 4, 2010.

“Chronic Hepatitis B (CHB) – Screening, Diagnosis and Patient Considerations.” Hartford, CT. October 4, 2010.

“One Therapy from Day One: Considerations in Long-Term Hepatitis B Management.” Trumbell, CT. October 5, 2010.

“HCC Update.” Hartford Hospital Grand Rounds. Hartford, CT. October 5, 2010.

“VIREAD Professional Program.” Kansas University Medical Center. Kansas City, KS. October 11, 2010.

“VIREAD: Examing the Clinical Studies.” Kansas City, KS. October 11, 2010.

“Managing HBV in the At-Risk Community.” San Francisco, CA. October 12, 2010.

“Management of Chronic Hepatitis B.” Burlingame, CA. October 15, 2010.

“Chronic Hepatitis B Hypothetical Case Studies.” San Jose, CA. October 18, 2010.

“Chronic Hepatitis B Hypothetical Case Studies.” Fremont, CA. October 19, 2010.

“Hepatitis B & C.” Las Vegas, NV. October 25, 2010.

“Treat or No Treat: An Educational Case-Based Discussion Considering Evidence and Expert Insights in Treatment Decisions for CHB.” Boston, MA. October 30, 2010.

“Viral Hepatitis Treatment and HCC.” 2010 Clinical Update: New Advances in the Management of Hepatocellular Carcinoma. Las Vegas, NV. November 13, 2010.

“Addressing Important Factors in HCV Treatment Today: Insulin resistance/Steatosis.” Hexagone. San Diego, CA. November 15, 2010.

“HBV and Liver Transplantation.” Northwestern. November 19, 2010.

“Hepatitis B and Hepatitis B/HIV Co-Infection.” Northwestern. November 20, 2010.

“Key Developments in Hepatology.” Northwestern. November 20, 2010.

2011

“Hepatitis C: The New Dynamic of HCV treatment,” UCSD Medical, March 2011

Evaluating Use of Hepatitis B Immunoglobulin in Patients after Liver Transplantation, UCSD Medical May 2011

Free Screening for Diabetes and Hep B, UCSD 2011

Curriculum Vitae



Hepatitis B: Current Epidemiology, UCSD May 19, 2011

International Convention of Vietnamese Physicians, Dentists, and Pharmacists. Toronto, August 2011.

Salix Best Practice in Advanced Liver Disease Faculty Meeting, Chicago, IL. August 2011.

“Diverse Aspects of Hepatitis B,” Hepatitis B Outreach Program at Hsi Fang Temple, San Diego. September 2011

“Comparative Effectiveness of Hepatitis C Treatment,” Panel Expert, Oregon Health & Science University, October 2011

Facilitator, CME Roundtable Series, Current Advances in the Management of Cirrhotics, ” Palm Restaurant, San Diego, CA October 7, 2011.

DDW 2011

Lecturer. AASLD: The Liver Meeting, San Francisco, CA, November, 2011.

Faculty: 2011 Hepatology Associates Course, San Francisco, CA. “Point Counterpoint: Complex Patient Case Management Issues.” November 2011.

Expert Panelist: Comparative Effectiveness of Hepatitis C Treatment,” October 2011.

Panelist: “2011 Chronic Liver Disease Foundation (HCEE) HE Webcast Tapings,” San Francisco, CA. November 2011.

Speaker, “Tripe Therapy Advanced: Evolution of HCV Treatment: Telaprevir with PEGASYS/RB; Genetec Speaker Series, Palm Restaurant, San Diego, CA December 20, 2011.

2012

Vietnamese Federation of San Diego, Event- Vietnamese Elderly Association and the Vietnamese Veterans Association on the occasion of Lunar New Year; San Diego, CA. January 14, 2012.

Participant, “Effective Teaching Skills for Faculty & Fellows, VA Hospital, Grand Rounds, Clinical Case Conference, San Diego, CA., January 19, 2012.

Polaris Group; Investigators’ Meeting in conjunction with the American Society for Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA. January 19, 2012.

Speaker, “Multidisciplinary Strategies for the Management of Hepatic Carcinoma,” Presented by Bayer Healthcare Pharmaceuticals, Onyx Pharmaceuticals, and Abbott Pharmaceuticals, Morton’s Steakhouse, San Francisco, CA, January 20, 2012.

Curriculum Vitae



Speaker, “Multidisciplinary Strategies for the Management of Hepatocellular Carcinoma: Paths to Progress, CME Speaker Dinner Series, San Diego, CA. January 21, 2012.

Baldwin Park Lecture for Salix Pharmaceuticals; Los Angeles, CA. January 24, 2012.

CLDF Focus Med Event: San Diego, CA. January 25, 2012.

UCSD Division of Gastroenterology Endowed Jon I. Isenberg Lecture, “Keratins: Genetic Modifiers of Liver Disease and Required Components of Mallory-Denk Bodies,” San Diego, CA. January 26, 2012.

UCSD School of Medicine 2nd Annual Symposium-Controversies in Inflammatory Bowel Disease; San Diego, CA. January 28, 2012.

UCSD Annual Cancer Center Scientific Retreat, “Trandisciplinary Research,” San Diego, CA. January 28, 2012.

Hepatitis Free San Diego Introductory Meeting, La Jolla, CA. January 31, 2012

HCC Web Speaker Training (Bayer/Onyx Pharmaceuticals, 2012 Nexavar Concert Series). Conference Title: Nexavar Unresectable Heptocellular Carcinoma Web Speaker Training, San Diego, CA. Feb.7, 2012.

Nexavar Concert Series (Bayer Healthcare and Onyx Pharmaceuticals-2012) Conference Title: Nexavar in the Treatment of Patients with Unresectable Hepatocellular Carcinoma. Anaheim, CA. February 8, 2012.

Nexavar Concert Series (Bayer Healthcare and Onyx Pharmaceuticals-201 2) Title: Clinical Consideration in Unresectable Hepatocellular Carcinoma. San Diego, CA. February 9, 2012.

2012 INCIVEK Professional Speaking Bureau Training Meeting; Santa Monica, CA. February 11, 2012.

Asian Pacific Health Foundation Training Session: Handling, Disposal of Supplies, Barriers and Study Surveys. San Diego, CA. February 14, 2012.

Speaker, “Metabolic and Autoimmune Liver Disease: What the Primary Care Provide Needs to Know,” Scripps Mercy Hospital Grand Rounds, San Diego, CA, February 14, 2012.

Speaker, “HCV Therapeutics,” Brio Restaurant, Las Vegas, NV., February 23, 2012.

Speaker, “HCV Therapeutics,” 888 Seafood Restaurant, Rosemead, CA., February 24, 2012.

Speaker, UCSD AIDS Clinical Rounds, University of California, San Diego., San Diego, CA, March

2, 2012.

Curriculum Vitae



Speaker, “Clinical Roundtable Discussion: Adult Patients with Chronic Hepatitis B,” Ruth’s Chris Steak House, Anaheim, CA, March 22, 2012.

Speaker, “Variceal Bleeding,” University of California, San Diego, GI Division, July 24, 2012.

“Management of HCC,” Community Liver Event, Redlands, CA; December 6, 2012.

2013

Speaker, “Advancing the Standard of Care: Identification, Deciding Whether to Initiate Ther-apy, and Contemporary Management Strategies for Patients With Hepatitis C, ” Roy’s Res-taurant, Anaheim, CA, January 9, 2013.

“Understanding Hyponatremia: Treating Beyond the Primary Diagnosis,” Otsuka Pharma-ceutical America, Palm Springs, CA; January 28, 2013.

“Managing HCV Disease,” Liver Disease Support Group, Presented by Avella. Specialty Pharmacy, Valley Hospital Medical Center, Las Vegas, NV. January 30, 2013.

Facilitator, Liver Disease Support Group, Avella Specialty Pharmaceutical Event, Las Ve-gas, NV., February 20, 2013.

Speaker, “Management of Chronic Hepatitis B in Asian Americans, Vietnamese Physicians Association of San Diego, San Diego, CA March 1, 2013.

Speaker, “HBV,” Main Conference, Scripps Clinic’s 28th Annual New Treatments in Chronic Liver Disease Conference, La Jolla, CA; March 23, 2013.

Speaker, “Controversy: Warrehouse vs. Treat Now, HBV,” Main Conference, Scripps Clinic’s 28th Annual New Treatments in Chronic Liver Disease Conference, La Jolla, CA; March 23, 2013.

“Hepatocellular Carcinoma”. Clinical Simulation Center of Las Vegas, University of Nevada, School of Medicine, Las Vegas, NV. March 27, 2013.

“Surveillance for Hepatocellular Carcinoma in the At-Risk Population,” Bayer Onyx Oncology Speaker Program, Phoenix, AZ; May 14, 2013.

Current Insights in to the Management of Hepatic Encephalopathy, Hepatology Centers of Educational Expertise, San Diego, CA, May 28, 2013.

“Chronic Hepatitis C Therapy: Current and Future Perspectives,” and “Clinical Challenge: Management of Chronic Hepatitis B in Special Populations,” St Luke’s, Manila, Philippines; June 2, 2013

Curriculum Vitae



Session Chairman, Transforming Science to Clinical Practice, APASL Liver Week 2013 Singapore: Session Chairman, Singapore, June 6-10, 2013.

Speaker, Treatment of Viral Hepatitis Circa 2013. Advances in Gastroenterology and Hepa-tology, San Diego Omni Hotel, San Diego, CA. March 2, 2013.

Speaker, Current Insights into the Management of Hepatic Encephalopathy. The Chronic Liver Disease Foundation, 2013 Hepatology Centers of Educational Expertise Lecture Se-ries. Ruth’s Chris Steak House, San Diego, CA. May 28, 2013.

Guest Speaker, “Management of Chronic Hepatitis B in Asian Americans”, Hogue Hospital Gut Club, Laguna Beach, CA; Tuesday, June 18, 2013

Speaker, Hepatitis D and E: The Forgotten Viruses. UCSD AntiViral Research Center, San Diego, CA. June 21, 2013.

Speaker, ““Hepatitis D and E: The Forgotten Viruses,” AIDS Clinical Rounds San Diego Pro-viders, June 21, 2013. Speaker, “GI Conference & HBV Management,” Rady Children’s Hospital, San Diego, CA, September 12, 2013.

Guest Educator, New and Emerging Strategies to Simplify the Cure of Chronic HCV Infec-tion, Ruth Chris Steakhouse, Walnut Creek, CA; Sponsored by Rush University Medical Center & Gilead Sciences, October 24, 2013.

Speaker, “Advances in HCV Treatment: The Potential for Hepatitis C Clinical Management and Treatment in Primary Care and Other Health Care Settings,” California Forum on Hepa-titis C Screening and Treatment, California Endowment Conference Center, Oakland, CA, November 8, 2013.

Speaker, “Evidence for Baraclude: Clinical Findings,” Sponsored by AHM, Magnones Res-taurant, Riverside, CA; November 14 2013.

Speaker, Complications of Cirrhosis in the Age of Quality Health Measures, Paradise Valley, AZ. November 14, 2013.

2014

Speaker, HCV Update CME , sponsored by Duke University School of Medicine & the Chronic Liver Disease Foundation. Phoenix, AZ. January 20, 2014.

Speaker, “NASH and Fatty Liver, Scripps Health, La Jolla, CA, March 29, 2014 - March 30, 2014

Speaker, HBV update, Scripps Health, La Jolla, CA, March 29, 2014 - March 30, 2014

Speaker, HEV update, Scripps Health, La Jolla, CA, March 29, 2014 - March 30, 2014

Speaker, Presenter; Hepatobiliary & Pancreas Tumor Conference, St. John’s Hospital & Medical Center, April 2014

Curriculum Vitae



Speaker, EASL liver updates 2014, Digestive Disease Week (DDW) 2014 Highlights Dinner Program, Overland Park, Kansas, May 7, 2014.

Speaker, HBV and HCC linkage, sponsored by BNS, Gilead, Onyx and Bayer, Chinese Hos-pital, San Francisco, CA, May 6, 2014.

Speaker, Current Perspectives into the Management of Hepatic Encephalopathy, Presented by Hepatology Center for Educational Expertise, Ruth’s Chris Steak House, May 13, 2014.

Speaker, GI Tumor Conference, cCare & Associates, Fresno, CA, May 22, 2014.

Speaker, Vietnam and the growing Hepatitis problem in the Asian community, Ho Chi Minh City Sister City Committee, Marines’ Memorial Hotel, San Francisco, CA, May 29, 2014.

Speaker, HCV update, UCLA Ground Rounds, University of California, Los Angeles, Medi-cal Center, Westwood, CA, June 11, 2014.

Ground Rounds Speaker, Liver Failure: How to Have your Patients Survive until Liver Trans-plant: A Roadmap to Life, Scripps Center for Organ Transplantation, Timken Amphitheater, Scripps Green Hospital, La Jolla, CA; Friday, July 18 2014.

Speaker, Presenter; Hepatobiliary & Pancreas Tumor Conference, St. John’s Hospital & Medical Center, June 12, 2014 Fellows Speaker, Department of Internal Medicine, School of Medicine, University of Nevada. Las Vegas, NV; July 30, 2014.

Speaker, “Educational Awareness – Expanding Hepatitis B screening among Asian popula-tions in San Diego County”, Presented by the Asian Pacific Health Foundation, Town & Country Hotel, San Diego, CA; August 22, 2014.

Speaker, 3rd Annual Current Trends in Liver Disease. Symposium and Gastroenterology Board Review, St. Joseph’s Hospital and Medical Center, Phoenix, AZ; September 26, 2014.

Speaker, Cirrhosis Overview, St. Joseph’s Hospital and Medical Center, Phoenix, AZ; Octo-ber 6, 2014.

Speaker, Liver Imaging and Disease Staging, Phoenix Baptist Hospital, Phoenix AZ, Octo-ber 14, 2014.

Speaker, “Current Perspectives into the Management of Hepatic Encephalopathy,” Pre-sented by Hepatology Centers of Educational Expertise, San Diego, CA, October 27, 2014.

Speaker, “Current Perspectives into the Management of Hepatic Encephalopathy,” Pre-sented by Hepatology Centers of Educational Expertise, San Diego, CA, October 27, 2014.

Speaker, “Hepatitis B,” Internal Medicine Residency Conference Series, University of Ne-vada, School of Medicine, Las Vegas, NV, December 2, 2014.

Curriculum Vitae



Speaker, “State-of-the-Art Lecture: Liver Biopsy vs. Non-Invasive Tests of Fibrosis,” 2014 Post-AASLD Conference Program, Southern California Gastroenterology Association, Dana Point, CA; December 13, 2014

Speaker, “ HCV treatment”,” 2014 Post-AASLD Conference Program, Southern California Gastroenterology Association, Dana Point, CA; December 14, 2014.

Curriculum Vitae ROBERT G. GISH, M.D. 201 AWARDS, CERTIFICATES AND HONORS

1. Castle Connolly America’s Top Doctor’s award 2000 2. In appreciation United Network for Organ Sharing – certificate in recognition of outstanding

service as an At Large Member on the Liver/Intestine Transplantation Committee, July 1, 2003- June 30, 2005

3. Outstanding Physician Fundraising Team. Circle of Giving 2007. California Pacific

Medical Center. September 20, 2007. 4. Best Doctors in America 2007-2008. http://www.bestdoctors.com/bd/index.php 5. American Society of Transplantation. Certificate of Appreciation. Nominating Committee.

2008-2009. 6. American Liver Foundation (ALF) Salute to Excellence – Honoring Robert Gish. 7. Marin Magazine Best Doctors Issue 2009-2010. February 2010. 8. Certificate of Attendance. 19th Conference of the Asian Pacific Association for the Study

of the Liver (APASL). February 13-16, 2009. 9. Certificate of Appreciation. University of Nevada School of Medicine. Department of

Internal Medicine. 2009-2010.

10. Humanitarian of the Year. San Francisco Ho Chi Minh City Sister City Committee. May 27, 2010. http://www.sfexaminer.com/local/Robert-Gish-takes-the-helm-of-hepatitis-B-prevention-94976469.html

11. America’s Top Doctors for Cancer. 2010. 12. Humanitarian of the Year- 2010 13. Alliance for CME, “Outstanding CME Enduring Material,” 2010 CaseLine: HCC Program 14. San Diego County Medical Society, “2011 Top Doctors – Gastroenterology.” Award is

voted by peers within and outside of specialty. 15. Asian Heritage Awards Gala 2011, Presenter, September, 2011 16. $50,000 Grant from Gilead Foundation, “Barriers to Hep B Screening.” October 2011. (R.

Gish-Full Approver). 17. $100,000 Grant (submitted) from Bristol Myers Squibb, “Point of Care HVB.” October

2011.

18. 2,000 HCV Kits (received) from Merck, “Point of Care HCV For All ‘At-Risk’ Persons. October 2011.

http://www.bestdoctors.com/bd/index.php

http://www.sfexaminer.com/local/Robert-Gish-takes-the-helm-of-hepatitis-B-prevention-94976469.html

http://www.sfexaminer.com/local/Robert-Gish-takes-the-helm-of-hepatitis-B-prevention-94976469.html

Curriculum Vitae


AWARDS, CERTIFICATES AND HONORS: Continued

19. $250,000 Grant (submitted) from Vertex, “POC HCV + Operations Cost Savings.” October 2011

20. America’s Top Doctors – San Diego. November 2011. 21. Diversity Pioneer Award – 2012

22. American Registry, Top Doctor of 2013.

23. San Diego’s Top Doctors Annual List, San Diego County Medical Society, 2013.

24. National Top Doctors List, U.S. News & World Report ; 2012-2013.

25. Diversity Pioneer Honoree & Presenter, Asian Heritage Awards, San Diego, CA, September 14, 2013.

26. Certification of Appreciation, for member of the Organizing Committee, 1st Transcaucasus

International Conference on Liver Disease 2014; Presented by Georgian, Armenian and Azerbaijani Hepatology Associations, Tibilisi, Georgia; September 5-6 2014

Curriculum Vitae ROBERT G. GISH, M.D. 203 CONSULTANT / ACKNOWLEDGEMENT AS A CONTRIBUTOR / CME ACTIVITIES

1998 – 2004 1. Wong J, Bennett W, Koff R, Pauker S. Pretreatment Evaluation of Chronic Hepatitis.

JAMA December 23/30. 1998 Vol 260, No. 24. 2. Louise I. Bertman, Compliance, Noncompliance, and Comparative MMPI-2 Profiles of

Alcohol- Dependent and Non-alcohol Dependent Patients Evaluated for Orthotopic Live Transplantations. Thesis.

3. Lau G, Carman W, Locarnini S, Okuda K, Lu Z, Williams R. Treatment of Chronic

Hepatitis B Virus Infection: An Asia-Pacific Perspective. Special Report, Journal of Gastroenterology and Hepatology. (1999) 14, 3-12.

4. Lok AS, Heathcote, EJ, Hoofnagle, JH. Management of Hepatitis B: 2000- summary of a Workshop. Gastroenterology. 2001;120:1828-1853.

5. McHutchison J and the IHIT Study group (Gish RG). Hepatic HCV RNA before and after

treatment with interferon alone or combined with ribavirin. Hepatology 2002;35:688-693. 6. Pollack, Andrew, F.D.A. Panel Recommends Approval of Hepatitis B Drug. NY Times.

August 7, 2002. 7. AASLD Expert Consensus: Managing Liver Related Challenges. Testing and vaccination

for viral hepatitis. Miami Florida 2003.

8. Christopher Westland, Huiling Yang, William E. Delaney IV, Craig S. Gibbs, Michael D. Miller, Michael Wulfsohn, John Fry, Carol L. Brosgart, Shelly Xiong, Week 48 Resistance Surveillance in Two Phase 3 Clinical Studies of Adefovir Dipivoxil for Chronic Hepatitis B, Acknowledgments include R. Gish.

9. CME Monograph: Side Effect Management in HCV Infection. 2002-2003 with DVC Health Care Communications. 1) Optimizing Treatment response in HCV Infection by Anemia Management.

10. CME: Implications & Management of Anemia in Liver Disease. “Prevalence and

Characterization of HCV-Associated Cognitive Impairment,” CME Monograph Series, V2, Issue 1, June 2004

11. CME: “Hot Topics in Hepatology: Updates, Strategies, and Future Trends,” The Institute

for Medical Education’s CME Program, September, 2004 12. CME: “Chronic Hepatitis B Infection: Re-evaluating Targets for Drug Therapy,” CME

Consultants, Inc. BMS Company, September 2004 13. CME: “Building New Strategies in Chronic Hepatitis B,” BMS & UAB School of Medicine,

October 2004

Curriculum Vitae


CONSULTANT / ACKNOWLEDGEMENT AS A CONTRIBUTOR / CME ACTIVITIES: Cont’d

14. CME: “Implications & Management of Anemia in Liver Disease,” CME Monograph Series, V 2; Issue 2, October 2004

15. CME: Implications & Management of Anemia in Liver Disease “Impact of Side Effect

Management and Adherence in HCV-Infected Patients,” CME Monograph Series, V2, Issue 1, November 2004

2005 16. CME: “Efficacy and Safety Data on Newer Oral and Injectable Agents for Chronic

Hepatitis B Virus Infection,” January 2005 17. CME: Implications & Management of Anemia in Liver Disease “Implications &

Management of Anemia in Liver Disease,” CME Monograph Series, January 2005 18. CME: Sunrise Hospital & Medical Center, Diet, Nutrition and the Liver. January 2005 19. CME: “Treatment of Chronic Viral Hepatitis,” HCA Bay Area Healthcare Network,

January 2005

20. CME: “Gastroenterology Case Conference,” January 13, 2005. 1 Hour CME credit. 21. CME: “Gastroenterology Case Conference,” January 27, 2005. 1 Hour CME credit. 22. CME : UC Davis , “1st Annual Sierra Tahoe Hepatitis C Outreach Conference,” February

2005 23. CME: Sunrise Hospital and Medical Center: “Heavy Metal: Wilson’s Disease and

Hemochromatosis,” Las Vegas, February 1, 2005

24. CME: University of Florida College of Medicine & PVI. “Efficacy and Safety Data on New Oral and Injectable Agents for Chronic Hepatitis B Virus Infection,” February 2, 2005

25. CME: Implications & Management of Anemia in Liver Disease. “Pre-management of

HCV-Infected Patients Before and After Liver Transplantation.” V 2, Issue 3;3-13. February 2005

26. CME: Mayo Clinic College of Medicine. “Update in Liver Disease & Transplantation,”

Scottsdate, AZ, March 2005 27. CME: “Gastroenterology Case Conference,” March 17, 2005. 1 Hour CME credit. 28. CME: “Gastroenterology Case Conference,” March 24, 2005. 1 Hour CME credit. 29. CME: Sunrise Hospital & Medical Center, “Should That Patient Die? The Ethics of Liver

Transplantation,” April 5, 2005 30. CME: “Gastroenterology Case Conference,” April 21, 2005. 1 Hour CME credit.

Curriculum Vitae



31. CME: Sunrise Hospital and Medical Center, “Hepatitis C and Substance Abuse Conference” April 25, 2005, Las Vegas, NV

32. CME: “An Update on Ribavirin Analogues: Meeting the Challenge of Anemia in Hepatitis

C Treatment,” Paris, France, April 2005

33. CME: “Advanced Certificate Program in the Management of Chronic Hepatitis B” Projects in Knowledge.

34. CME: “Practical Pathways Towards Improved Management of HCV Treatment Failures,”

DDW, Chicago, IL May 2005 35. CME: “GI Cancer Board,” May 2, 2005. 1 Hour CME credit. 36. CME: “Recognition & Management of Shock: New Standard of Care,” May 6, 2005.

One Hour CME credit. 37. CME: Digestive Disease Week 2005 , Chicago, IL May 15 and 16, 2005 38. CME: American Transplant Congress, May 21-25, 2005 Seattle Washington 39. CME: Reno-Sparks Community Wide Liver Conference, May 26, 2005 Reno, Nevada 40. CME: “Gastroenterology Case Conference,” June 2, 2005. 1 Hour CME credit. 41. CME: “GI Cancer Board,” June 7, 2005. 1 Hour CME credit. 42. CME: “Gastroenterology Case Conference,” June 23, 2005. 1 Hour CME credit. 43. CME: “Gastroenterology Case Conference,” July 7, 2005. 1 Hour CME credit. 44. CME: “Expanding Options for Chronic Hepatitis B: New Opportunities to Control

Viremia,” University of Florida College of Medicine, PVI, Aug 2. 2005 45. CME: “Gastroenterology Case Conference,” August 18, 2005. 1 Hour CME credit. 46. CME: “Gastroenterology Case Conference,” August 25, 2005. 1 Hour CME credit. 47. CME: “Advanced Certificate Program in the Management of Chronic Hepatitis B,” Vol. 1,

Issue 2, Projects in Knowledge

48. CME: “Nucleos(t)ide Analogs in the Treatment of Hepatits B: Update on Recent Data, Hepatic & Biliary Disorder,” PeerView in Session

49. CME: “Emerging Treatments for Liver and Complex GI Diseases” San Francisco, CA

Sept 16 to Sept 17, Omni Hotel 6hrs

Curriculum Vitae



50. CME: “Gastroenterology Case Conference,” September 29, 2005. 1 Hour CME credit.

51. CME: “Where Do We Go From Here,” InterMune, San Francisco, CA 52. CME: “Treating HVC with Ribavirin Analogues and Ribavirin-like molecules. Journal of

Antimicrobial Chemotherapy” In Press. 53. CME: “Hot Topiex in Liver Disease.” October 7-8,2005 - 1 credit. 54. CME: “Gastroenterology Case Conference,” October 10, 2005. 1 Hour CME credit.

55. CME: “Adult Donor Liver Transplantation,” October 21, 2005. 1 Hour CME credit. 56. CME: “ACT HBV” San Francisco, CA 10 20 05, San Francisco, Marriott 1.75 Units 57. CME: “Clinical Case Consults in Chronic hepatitis B,” an interactive teleconference

program, UAB School of Medicine, Sept26, Oct. 24 2005 58. CME: “Controversies in Management of HBV: Lessons from Case Studies.” October

2005. 59. CME: “GI Cancer Board,” November 1, 2005. 1 Hour CME credit. 60. CME: “Treating HCV – Maximizing Response and Minimizing Injury.” November 7, 2005

– 1 credit toward the AMA Physician’s Recognition Award.

61. CME: “56th Annual Meeting and Postgraduate Course.” American Association for the Study of Liver Diseases, San Francisco, CA. November 11-15, 2005 – 26 hours.

62. CME: “HBV Infection in Clinical Practice.” Treatment Reporter: Gastroenterology. 63. CME: “Hepatitis B: Identifying the Issues and Improving Patient Outcomes.” University

of Wisconsin Medical School, Office of Continuing Medical Education. San Francisco, CA. October 20, 2005.

64. CME: “Treating HCV – Maximizing Response and Minimizing Injury.” University of

Wisconsin Medical School, Office of Continuing Medical Education. Las Vegas, NV. November 7, 2005.

65. CME: Presentation at Brick’s Restaurant. Reno, NV. November 17, 2005. 66. CME: “AASLD Update.” Mountain View Hospital. Las Vegas, NV. December 6, 2005. 67. CME: “A Rising Tide: The Next Wave of Treatment Options in HBV and HCV.” HEP

DART. http://www.advancmed.org/807. December 2006.

68. CME: “Immediately Useful Strategies for Improving Patient Outcomes.” TX Reporter Gastroenterology (Volume 1; Issue 6).

http://www.advancmed.org/807

Curriculum Vitae



2006 69. CME: “Reno-Sparks Community Wide Liver Conference.” Saint Mary’s Regional

Medical Center. Reno, Nevada. January 19, 2006. 70. CME: “Improving Outcomes for Asians and Pacific Islanders at Risk for Hepatitis B,”

Washington Hospital. Fremont, CA. January 25, 2005. 71. CME: “HOT Topics in Hepatology: Updates, Strategies and Future Trends,” Hyatt

Regency Monterey, CA. February 4, 2006. 6.5 CME credits. 72. CME: “Newer Nucleos(t)ide Analogues Suppress Hepatitis B Virus, Reverse Disease in

Multiple Patient Populations.” PeerView Press. February 15, 2006.

73. CME: “Treating Hepatitis B With Nucleos(t)ide Analogues: A Review of New Science.” PeerView Press.

74. CME: “Course 1 - Current and Evolving Therapeutic Strateies in HBV,” Advanced

Certificate Program in the Management of Chronic Hepatitis B. Regional Meeting. 2006.

75. CME: “Course 2 - Natural History and Selection of Patients for Treatment of HBV,”

Advanced Certificate Program in the Management of Chronic Hepatitis B. Audio conference. 2006.

76. CME: “Course 3 - HBV Treatment: Viral Resistance and Clinical Implications,” Advanced Certificate Program in the Management of Chronic Hepatitis B. Webcast. 2006.

77. CME: “Course 4 - Controversies in Management of HBV: Lessons from Case Studies,”

Advanced Certificate Program in the Management of Chronic Hepatitis B. CD-ROM. 2006

78. CME: “Course 5.1 – Diagnosis of Hepatitis B,” Advanced Certificate Program in the

Management of Chronic Hepatitis B. TX Reporter 1. 2006 79. CME: “Course 5.2 – Pretreating Evaluation,” Advanced Certificate Program in the

Management of Chronic Hepatitis B. TX Reporter 2. 2006. 80. CME: “Course 5.3 – Selecting Among Therapeutic Options,” Advanced Certificate

Program in the Management of Chronic Hepatitis B. TX Reporter 3. 2006. 81. CME: “Course 5.4 – Monitoring Therapy,” Advanced Certificate Program in the

Management of Chronic Hepatitis B. TX Reporter 4. 2006. 82. CME: “Course 5.5 – Natural History and Impact of Therapy,” Advanced Certificate

Program in the Management of Chronic Hepatitis B. TX Reporter 5. 2006.

Curriculum Vitae



2006

83. CME: “Course 5.6 – Management of Chirrhosis and Decompensation,” Advanced Certificate Program in the Management of Chronic Hepatitis B. TX Reporter 6. 2006.

84. CME: “Course 5.7 – Management of the HBV-Coinfected Patient,” Advanced Certificate

Program in the Management of Chronic Hepatitis B. TX Reporter 7. 2006. 85. CME: “Course 5.8 – A Steady Advance: Latest Findings from Anti-HBV Clinical Trials,”

Advanced Certificate Program in the Management of Chronic Hepatitis B. TX Reporter 8. 2006.

86. CME: “Course 5.9 – Viral Resistance,” Advanced Certificate Program in the

Management of Chronic Hepatitis B. TX Reporter 9. 2006. 87. CME: “In-Depth and Timely Response to Pressing Educational Needs.” Member’s

Update – Advanced Certificate Program in the Management of Chronic Hepatitis B. Volume 1, Issue 7. 2006.

88. CME: “GI Grand Rounds.” Sunrise Hospital, Las Vegas. February 1, 2006. 89. CME: “Reno-Sparks Community Wide Liver Conference.” Saint Mary’s Regional

Medical Center. Reno, Nevada. February 16, 2006. 90. CME: “Treating Hepatitis B with Nucleos(t)ide Analogues: A Review of New Science.”

PeerView in Session, Webcast Lecture. www.peerviewpress.com/t1/idoct05a. March 2006.

91. CME: “New and Future Treatments for Hepatitis.” Controversies in Transplantation,

University of Colorado School of Medicine. Breckenridge, Colorado. March 3-5, 2006. 92. CME: “Application of Viral Load Measurement in HCV Patients on Antiviral Therapy.”

Shanghai-Hong Kong Liver Congress. Shanghai, China. March 26, 2006. 93. CME: “Nucleos(t)ide Analogue as First-line Therapy (Pro).” Shanghai-Hong Kong Liver

Congress. Shanghai, China. March 27, 2006. 94. CME: “Changing Paradigm in the Treatment of HBV Infection.” Shanghai-Hong Kong

Liver Congress. Shanghai, China. March 28, 2006. 95. CME: “Hepatitis Alphabet.” Fresno-Madera Medical Society – 55th Annual Yosemite

Postgraduate Institute. Yosemite National Park. March 31-April 2, 2006. 96. CME: “Primary Care Approach to Abnormal Liver Function Tests.” Fresno-Madera

Medical Society – 55th Annual Yosemite Postgraduate Institute. Yosemite National Park. March 31-April 2, 2006.

97. CME: “A Case Based Approach to the Modern Management of HCV,” Meet the HCV

Masters Meeting. San Francisco. April 3, 2006.

http://www.peerviewpress.com/t1/idoct05a

Curriculum Vitae



98. CME: “Hepatitis B, C, and Liver CA Update,” Sunrise Hospital and Medical Center. Cili’s Restaurant. Las Vegas, NV. May 8, 2006. 1 AMA PRA Category 1 credit.

99. CME: “Refining the HBV Treatment Paradigm.” Westin Bonaventure Hotel. Los

Angeles, CA. May 20, 2006. 100. CME: “What’s New in the Treatment of Hepatitis B & C.” Double Tree Hotel. Modesto,

CA. June 7, 2006. 101. CME: “Treating HCV – Maximizing Response and Minimizing Injury.” Wild Ginger

Restauarant. Seattle, WA. June 12, 2006. 102. CME: “A Partnership Between Primary Care and Specialty Physicians.” Syllabus. 2006. 103. CME: “Reno-Sparks Community Wide Liver Conference: Medical & Surgical Aspects of

Liver Transplantation 2006.” Reno, NV. June 22, 2006. 104. CME: “The NCSCG Yosemite GI Retreat 2006.” Yosemite, CA. November 3-5, 2006. 1

credit. 105. CME: “Focus on the Virus: A New Paradigm for the Management and Treatment of

HBV.” Sheraton Boston Hotel, Boston , Massachusetts – October 30, 2006. 1 credit 2007 106. CME: Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV

Treatment in Asian and Other Diverse Communities. “Expert Insight Intro: Provider Knowledge and Practice Regarding Hepatitis B Screening in Chinese-Speaking Patients.” Course HBV3.03. 2007.

107. CME: “Molecular Tests for HBV: Genotype, Core and Precore Testing, Quantification

Tests.” Seattle, WA. May 9, 2007 108. CME: “Viral Hepatitis.” San Jose, CA. May 16 2007 109. CME: “Free Hepatitis B Testing Campaign.” San Francisco, CA. 110. CME: “Educational slide set on Understanding Antiviral Resistance” BMS Resistance

Roundtable. 2007. 111. CME: “Case 2 – Patient FN: Management of HCV Genotype 1.” CARES. August 2007. 112. CME: “Case 5 – Patient KM: Psychiatric Issues in Patients Undergoing Treatment for

HCV.” CARES. August 2007.

113. CME: “Case Debates with the Experts: Applying the Updated Practice Guidelines to the Management of Hepatitis B.” 2nd International Symposium. Boston, MA. November 3, 2007.

Curriculum Vitae



114. CME: “Multimodality Approach to the Treatment of HCC: The Emerging Paradigm.” AASLD. Boston, MA. November 4, 2007.

115. CME: “Expert Insight Into: Why We Should Routinely Screen Asian American Adults for Hepatitis B: A Cross-Sectional Study of Asians in California.” Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. Course HBV3.08. 2007.

116. CME: “San Francisco Hospital to Help Sick in Vietnam.” Bay City News in San

Francisco. December 16, 2007.

117. CME: “Course 9 - Case Study: Evaluating HBV Infection Status in a Previously Diagnosed HBeAg-Positive Patient from the Asian and Pacific Islander Community.” HBV TX Reporter NL #2.

2008 118. CME: “GI Cancer Board,” January 1, 2008. 1 Hour CME credit. 119. CME: “GI Cancer Board,” February 5, 2008. 1 Hour CME credit. 120. CME: “Conquering Contemporary Challenges – New Hope with Targeted Therapy for

Hepatocellular Carcinoma.” Osake Restaurant. Santa Rosa, CA. February 5, 2008 121. CME: “Clinical Drug Assessment, A Clinician’s View of the Development and

Assessment of Drugs to Treat Hepatitis.” Road Map to Drug Discovery, Development and Approval. February 12, 2008 – 1 credit hour.

122. CME: American Association for the Study of Liver Disease Update.” Saint Mary’s Regional Medical Center. Reno, NV. February 28, 2008. 2 AMA Physician Recognition Award Category 1 Credits.

123. CME: “GI Cancer Board,” March 4, 2008. 1 Hour CME credit. 124. CME: “GI Cancer Board,” April 1, 2008. 1 Hour CME credit. 125. CME: “GI Cancer Board,” May 6, 2008. 1 Hour CME credit

126. CME: “European Association for the Study of Liver Disease Update.” Reno Sparks

Community-Wide Liver Conference. Saint Mary’s Continuing Medical Education. May 15, 2008. CME awarded 2 AMA Physician’s Recognition Award Category 1 Credits.

127. CME: “AASLD Topic Forum.” DDW-San Diego, CA. May 19, 2008.

128. CME: “AASLD Clinical Symposium.” DDW-San Diego, CA. May 20, 2008.

129. CME: “Alcoholic Hepatitis.” Alameda County Medical Center. Oakland, CA. May 30,

2008.

Curriculum Vitae



130. CME: “American Transplant Congress 2008.” Toronto, Canada. May 31, 2008 – June 4, 2008. 15 AMA PRA Category 1 credits.

131. CME: “Strategies for Optimizing Successful Outcomes in the Management of HCV

Difficult-to-Treat Population.” Bricks Restaurant. Reno, Nevada. June 26, 2008. 132. CME: “GI Cancer Board,” July 1, 2008. 1 Hour CME credit 133. CME: “The Future of Hepatitis B and C.” Fourth Annual Liver Update Seminar. Queen’s

Conference Center. Honolulu, Hawaii. July 19, 2008. 134. CME: “Evidence-Based Treatment of Intermediate- to Advanced-Stage Hepatocellular

Carcinoma: Improving Outcomes With Modern Therapies.” www.peerviewpress.com/p145. PeerView 2008.

135. CME: “Case Study: Managing Drug-Resistant Chronic Hepatitis B Infection.” TX

Reporter. 2008. 136. CME: “GI Cancer Board,” September 2, 2008. 1 Hour CME credit. 137. CME: “6th Annual Liver Disease Symposium,” The Duke University School of Medicine.

September 5, 2008. 2.00 AMA PRA Category 1 credits. 138. CME: “GI Cancer Board,” October 7, 2008. 1 Hour CME credit. 139. CME: “AASLD,” October 31, 2008 to November 4, 2008. 21.5 hours of AMA PRA

Category 1 credits. 140. CME: “GI Cancer Board,” November 4, 2008. 1 Hour CME credit. 141. CME: “Standard of Care for Treatment of Hepatitis B & C,” Update in Gastroenterology &

Hepatology Symposium. Renaissance Hotel. Las Vegas, NV. November 15, 2008. 142. CME: “Hepatitis C,” Update in Gastroenterology & Hepatology Symposium.

Renaissance Hotel. Las Vegas, NV. November 15, 2008. 143. CME: “Debate Monotherapy is Suitable for HBV,” Update in Gastroenterology &

Hepatology Symposium. Renaissance Hotel. Las Vegas, NV. November 15, 2008. 144. CME: “Screening At-Risk Individuals for Hepatitis B: What do the Guidelines Say?”

Medscape, Expert Column. Novmeber 2008.

145. CME: “Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management.” Med-scape – Volume 4. November 2008. http://www.medscape.com/viewprogram/17750

146. CME: “GI Cancer Board,” December 2, 2008. 1 Hour CME credit.

147. CME: “HBV Highlights from CCO’s Coverage of the 2008 AASLD Meeting,” Grand Café.

http://www.peerviewpress.com/p145.%20PeerView%202008

Curriculum Vitae



San Francisco, CA. December 2, 2008. 148. CME: “CARES-Roundtable Meeting,” Farallon Restaurant. San Francisco, CA.

December 4, 2008. 2009 149. CME: “Cases in Point: Risk Factors, Surveillance Strategies and Treatment Options for

HCC.” Gastroenterology and Hepatology. Vol 5, Issue 1, Supplement 3. January 2009. 1.0 AMA PRA Category 1 Credit.

150. CME: “Nash” (Non-alcoholic Fatty Liver Disease).” Reno, NV. January 8, 2009. 1 AMA Physician’s Recognition Award Category 1 Credits.

151. CME: “Hepatitis B&C Update.” Grand Rounds Talk. Highland Hospital. Oakland, CA. February 6, 2009.

152. CME: “Update – New Therapies for Hepatitis B and Hepatitis C.” 16th Annual Alimentary

Update. South Lake Tahoe. March 27, 2009. 153. CME: “Hepatocellular Carinoma: Current Epidemiology & Management.” CME talk.

Good Samaritan Hospital. San Jose, CA. April 1, 2009. 154. CME: “2010 American Transplant Congress – Physician & Physician Assistants.”

Institute for the Adavancementof Human Behavior and Amedco. May 1-5, 2010. 15.00 hours.

155. CME: “Wilson Disease Symposium.” California Pacific Medical Center. San Francisco,

CA. May 2, 2009. 4 CME program hours. 156. CME: “HCV and Cryoglobulinemia.” Saint Mary’s Regional Medical Center. Reno, NV.

May 14, 2009. 1 AMA Physician’s Recognition Award Category 1 Credits. 157. CME: “2009 American Transplant Congress – Physicians.” Certificate of Completion –

The American Society of transplant Surgeons. May 30, 2009 – June 3, 2009. 16 Hours Awarded.

158. CME: “Weekly Emergency Medicne Conference.” CME talk. Alameda County Medical Center, Highland Hospital. Oakland, CA. July 1, 2009.

159. CME: “Faculty of John Hopkins University School of Medicine CME Program.” Kuleto

Trattoria Restaurant. Burlingame, CA. July 14, 2009.

160. CME: “HCV and Cryoglobulinemia: How Cool Can You Get?” Saint Mary’s Regional Medical Center. Reno, NV. July 27, 2009. 1 AMA Physician’s Recognition Award Category 1 Credits.

161. CME: “Bridging Culturaly Differences to Improve HBV Treatment in Asian and Other

Curriculum Vitae



Diverse Communities.” Projects in Knowledge. Advanced Certificate Program IV. 2009.

2010

162. CME: “Managing Hepatitis B in the Primary Care Setting.” PeerView CME. February

2010. 163. CME: “Clinical Concepts in Pain and Aging: A Case-Based CME Monograph.” John

Hopkins University School of Medicine. Febraury 20, 2010. 1.00 AMA PRA Category 1 credit.

164. CME: “Viral Hepatitis and Hepatocellular Carcinoma.” March 6, 2010. 165. CME: “Advances in Hepatocellular Carcinoma: 2010 Update.” Loyola University.

Maywood, IL. March 6, 2010. 166. CME: Clinical roundtable Monograph, moderator “A Mulitdisciplinary approach ot the

Management of Hepatolcellular Carcinoma” 1.0 AMA PRA Category 1 credits, Mar 2010 167. CME: “HBV.” Kaiser. San Jose, CA. March 31, 2010. 168. CME: “The Clinical Implications of Manging Cirrhotics.” CLDF. San Francisco, CA.

April 12, 2010.

169. CME: “Chronic Viral Hepatitis: Can we “C” our way to “B” cured?” ST Luke’s Grand Rounds. San Francisco, CA. May 5, 2010.

170. CME: “New Advances in the Management of Hepatocellular Carcinoma (HCC).”

Regional Medical Center of San Jose. May 8, 2010. 171. CME: “2010 National Hepatitis B&C – Training Program & Treatment Update.” Omni

Hotel. San Francisco, CA. June 12, 2010. 7.75 AMA PRA Category 1 Credit. 172. CME: “Hepatitis C: What is the current diagnostic and treatment paradigm?” Community

Hospital of Monterey. Monterey, CA. June 16, 2010. 173. CME: “Coming to your area: Case3: On the Cusp of Change: New Therapeutic

Modalities for HCV.” Sienna Restaurant. El Dorado Hills, CA. June 16, 2010. 174. CME: “Use only the “A” Team to beat Hepatitis “B.” Chinese Hospital. San Francisco,

CA. August 3, 2010.

175. CME: “Overview of INCIVEK: Phase III Clinical Trial Data and Prescribing Information,” San Diego, CA. Instructor of Program. August, 2011.

176. CME: “HBV Update.” Saint Francis Hospital Grand Rounds. San Francisco, CA. Sep-tember 21, 2010.

Curriculum Vitae



177. CME: “Staying the Course: Patient Adherence Strategies in the Era of New Frontline HBV Therapies – Barriers to Treatment, Adherence in Asian Americans.” Clinical Care Options CME/CE Certified Treatment Update. 2010.

178. CME: “Expert Insight Into: Perinatal Transmission of Hepatitis B Virus: An Australian Ex-perience (Part 6 of Series).” Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse Communities. Advanced Certificate Program V. Projects in Knowledge. 2010.

179. CME: “Clinical Update 2010: Chronic Liver Disease and Hepatocellular Carcinoma.” Sutter Roseville Medical Center. Roseville, CA. October 2, 2010. 4 AMA PRA Cate-gory 1 credit.

180. ME: “Hepatocellular Carcinoma Current Trends in Diagnosis and Management: What all Healthcare Providers Need to Know.” Hartford Hospital Grand Rounds. Hartford, CT. October 4, 2010. 1 AMA PRA Category 1 credit.

181. CME: “HCC Update.” Hartford Hospital Grand Rounds. Hartford, CT. October 5, 2010.

182. CME: “Managing HBV in the At-Risk Community.” San Francisco, CA. October 12, 2010.

183. CME: “Treat or No Treat: An Educational Case-Based Discussion Considering Evidence and Expert Insights in Treatment Decisions for CHB.” Boston, MA. October 30, 2010.

184. CME: “Clinical Viewpoints,” Oct. 2010. Rush University Medical Center, Chicago, Illi-nois.

2011

185. CME: " 2011 American Transplant Congress Meeting -Physicians & Transplant Coordi-nators” April 30- May 4, 2011

186. CME: Hepatitis C: The Expanding Role of the Physician Assistant, Teacher of this

Breakfast Symposium. CME Credit: 1.25 credits. A part of the “Education Initiative in Gastroenterology” series.

187. CME: GUTS (Gastroenterology Universal Training Symposium, June 25, 2011. CME Credits: 8 Hour.

188. CME: “Liver Journal Club at UCSDMC,” July 1, 2010-June 30, 2011. CME Credits: 6 AMA PRA Category 1 Credits.

189. CME: Advances in HCV: New Challenges and Hope, Hanford, CA, June 29, 2011, 2 CME Credits, AMA PRA Category 1 Credits™

190. CME: University of California San Diego Health System SPA Time Study 2011, June 29, 2011.

Curriculum Vitae



191. CME: UCSD GI Division Weekly Conferences (Thursday AM VAMC), July 1, 2010 to June 30, 2011, CME Credits: 19.5 AMA PR Category 1.5 Credits™

192. CME Roundtable Series, “2011 CME Roundtable Series – Current Advances in the Man-agement of Cirrhotics,” Palm Springs, CA. October 2011.

193. CME: “The Role of the Hepatologist,” HCC Los Angeles Dinner, October 2011.

194. CME: “Managing a Medical Malpractice Case,” CME Credits: 2. October 2011.

195. CME: “Coordination of Patient Care,” CME Credits: 2. October 2011.

196. CME: 2011 Southern California Chapters 1 & 3 Scientific Meeting. CME Credits: 4.75 AMA PRA Category 1 Credits. October, 2011.

197. CME: “GI Conference: Hepatobiliary Case Presentations,”CME Credit: 1 AMA PRA Cat-egory 1 Credit. October 2011.

198. CME: 2011 Northern California Chapter Scientific Meeting. American College of Physi-cians (ACP)-Internal Medicine. CME credit: 14.75 AMA PRA Category 1 credits.

199. CME: GI Conference-Hepetobiliary,” San Diego, October 2011.

200. “Xifaxan550 for Reducing the Risk of Overt Hepatic Encephalopathy Recurrence in Pa-tients (equal or greater than) 18 Years of Age,” Temecula, CA. October, 2011.

201. CME: Hepatology Associates Course, San Francisco. CME Credits: 1.0 hr. Teacher of CME Course to Nephrology Physicians, November 2011.

202. CME: Heptaology Associates Course, AASLD Certified: The Liver Meeting 2011. CME Credits: 38.5 AMA PRA Category 1 Credits. San Francisco, November 2011.

203. AASLD Annual Meeting, San Francisco, November 2011.

204. CME: “General Medicine Practices for Hepatitis B,” CME Credits: 1 AMA PRA Category 1 Credit, November, 2011.

205. CDLF (Chronic Liver Disease Foundation): 2011 Hepatology Centers of Educational Ex-pertise (HCEE), HE Webcast Tapings, Topic: Point Counterpoint: Complex Patient Case Management Issues, November, 2011.

206. CME: HCC Dinner Program, “Strategies for the Management of Hepatocellular Carci-

noma: Paths to Progress.” San Francisco. January 2012

Curriculum Vitae



2012 207. CBCE (Center for Biomedical Continuing Education): Multidisciplinary Strategies for the

Management of Hepatocellular Carcinoma: Paths to Progress. January, 2012. CME Credits: 1.0 AMA PRA Category 1 Credit. San Francisco, CA.

208. CME, Liver Club Journal Meeting with Dr. Zarrinpar, San Diego, CA, January 10, 2012.

209. CME, Liver Club Journal Meeting with Dr. McTigue, San Diego, CA, January 17, 2012.

210. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; January 18, 2012.

211. CME, Liver Club Journal Meeting with Dr. Shah, San Diego, CA, January 24, 2012.

212. CME, Liver Club Journal Meeting, Roundtable, San Diego, CA, January 31, 2012.

213. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD, and Kiarash M., Fa-cilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; Febru-ary 1, 2012.

214. CME: UCSD GI Conference, “Changing the Management Paradigm in Non-Alcoholic Steatohepatitis (NASH), VA Hospital, San Diego, CA; February 2, 2012.

215. CME, Liver Club Journal Meeting with Dr. Shah, San Diego, CA, February 7, 2012.

216. CME: CHB Mentorship Hub Program (CHIP), Purdue University & Asian Health Commu-nications, Roy’s Restaurant, Anaheim, CA, February 9, 2012.

217. CME, Liver Club Journal Meeting with Dr. Zarrinpar, San Diego, CA, February 14, 2012.

218. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; February 15, 2012.

219. CME, Liver Club Journal Meeting with Dr. Kuo, San Diego, CA, February 21, 2012.

220. CME, Liver Club Journal Roundtable, San Diego, CA, February 28, 2012.

221. CME, Liver Club Journal Meeting with Dr. Gish, San Diego, CA, March 6, 2012. 222. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD, and Kiarash M., Fa-

cilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; March 7, 2012.

223. CME, Liver Club Journal Meeting with Dr. Nourredin, San Diego, CA, March 13, 2012.

224. CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, March 20, 2012.

Curriculum Vitae



225. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; March 21, 2012.

226. CME, Liver Club Journal Meeting with Dr. Shah, San Diego, CA, March 27, 2012.

227. CME, Liver Club Journal Meeting with Dr. Patton, San Diego, CA, April 3, 2012.

228. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD & K. Mirkia, MD, Facil-itators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; April 4, 2012.

229. CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, April 10, 2012.

230. CME, Liver Club Journal Meeting with Dr. McTigue, San Diego, CA, April 17, 2012.

231. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD & K. Mirkia, MD, Facil-itators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; April 18, 2012.

232. CME, Liver Club Journal Meeting with Dr. Philo, San Diego, CA, April 24, 2012.

233. CME: Liver Club Journal Meeting with Dr. McTigue, San Diego, CA, May 1, 2012.

234. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; May 2, 2012.

235. CME: Liver Club Journal Meeting with Dr. Nourredin San Diego, CA, May 8, 2012.

236. CME, Liver Club Journal Meeting with Dr. Loomba, San Diego, CA, May 15, 2012.

237. CME: 2012 Spring Postgraduate Course, American Gastroenterology Association, May 19 – 20, 2012; 10.75 AMA PRA Category 1 Credits

238. CME: Digestive Disease Week 2012. San Diego, CA. May 19 - 22, 2012. 15 PMA cred-its.

239. CME: Liver Club Journal Meeting with Dr. Nourredin, San Diego, CA, June 5, 2012.

240. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; June 6, 2012.

241. CME: Liver Club Journal Meeting with Dr. Kowng, San Diego, CA, June 12, 2012.

242. CME: Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, June 19, 2012.

243. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD & K. Mirkia, MD, Facil-itators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; June 20, 2012.

Curriculum Vitae



244. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; July 18, 2012.

245. CME: Liver Club Journal Meeting with Dr. Peterson, Hep Series; Basics of Hepato-pathology, San Diego, CA, July 24, 2012.

246. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; August 01, 2012.

247. CME, Liver Club Journal Meeting with Dr. Marie Csete, Hep Series; Anesthesia for Liver Transplantation, San Diego, CA, July 31, 2012.

248. CME, Liver Club Journal Meeting with Dr. Misel/Kerr, Overview of Immunosuppressant Management (Induction, Maintenance,& Acute Cellular Rejection), San Diego, CA, Au-gust 7, 2012.

249. CME: Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, August 14, 2012.

250. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; August 15, 2012.

251. CME: Liver Club Journal Meeting with Dr. Kicak, Hep Series; Risk Management, San Di-ego, CA, August 21, 2012.

252. CME: Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, August 28, 2012.

253. CME: Liver Club Journal Meeting with Dr. Gish, Hep Series; Management of Hepatitis B, San Diego, CA, September 4, 2012.

254. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; September 5, 2012.

255. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, September 11, 2012.

256. CME: Liver Club Journal Meeting with Dr. Mendler, Hep Series; Evaluation of the Liver Transplant Candidate, San Diego, CA, September 18, 2012.

257. CME: HCV Community TeleEcho Clinic, Project Echo., Albuquerque, NM, September 18, 2012; 6 hours.

258. CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, September 25, 2012.

259. CME, Liver Club Journal Meeting with Dr. Loomba, Hep Series; Critical Assessment Of

Medical Literature, San Diego, CA, October 2, 2012.

Curriculum Vitae



260. CME: American College of Clinical Pharmacology 2012 Annual Meeting Education Sym-posia, October 2012.

261. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD & K. Mirkia, MD, Facil-itators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; October 3, 2012.

262. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, October 9, 2012.

263. CME: Liver Club Journal Meeting with Dr. Kuo, Hep Series; HCV Management in Cirrho-sis and Post-Transplant Population, San Diego, CA, October 16, 2012

264. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; October 17, 2012.

265. CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, October 23, 2012.

266. CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, October 30, 2012

267. CME: Liver Club Journal Meeting with Dr. Kono, Hep Series; Screening and Manage-ment of Hepatocellular Carcinoma, San Diego, CA, November 6, 2012.

268. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD & K. Mirkia, MD, Facil-itators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; Novem-ber 7, 2012.

269. CME: The Liver Meeting, American Association for the Study of Liver Diseases (AASLD), Boston, MA, 38.5 AMA PRA Category 1 Credits; November 9-13, 2012.

270. CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, November 13, 2012.

271. CME: Liver Club Journal Meeting with Dr. Patton, Hep Series; Nutritional Assessment and Management in Chronic Liver Disease, San Diego, CA, November 20, 2012.

272. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; November 21, 2012.

273. CME: Liver Club Journal Meeting with Dr. Sohail & Muhammad, San Diego, CA, Novem-ber 27, 2012.

274. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, December 4, 2012.

275. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; December 5, 2012.

276. CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, December 11, 2012.

Curriculum Vitae



277. CME: Liver Club Journal Meeting with Dr. Abbas Fehmi, Hep Series; Overview & after liver transplant management of biliary complications, San Diego, CA, December 18, 2012.

278. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; December 19, 2012.

279. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, January 28, 2013.

280. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, January 15, 2013.

281. CME: Liver Club Journal Meeting with Dr. Sohail & Muhammad, San Diego, CA, January 22, 2013.

282. CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, January 29, 2013.

283. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, February 5, 2013.

284. CME: Liver Club Journal Meeting with Dr. Noureddin & Mazen; San Diego, CA, February 12, 2013.

285. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, February 19, 2013.

286. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, February 26, 2013.

287. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, March 5, 2013.

288. Asian Pacific Association for the Study of the Liver Conference, Singapore, March 7-10, 2013. 24 hours.

289. CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, March 12, 2012.

290. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, March 19, 2013

291. CME: Liver Club Journal Meeting with Dr. Sohail & Muhammad, San Diego, CA, March 26, 2013.

292. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, April 2 2013.

293. CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, April 9, 2013.

294. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, April 16, 2013.

295. CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, April 23, 2012.

Curriculum Vitae



296. EASL, The International Liver Congress 2013, 48th Annual Meeting of the European As-sociation for the Study of the Liver. Amsterdam, Netherlands. 24 hours. April 26, 2013.

297. CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, April 30, 2013. 298. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, May 7, 2013

299. CME: Tools in Waitlisted Patient Management, Xyn Management, May 2013.

300. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, May 14, 2013.

301. CME Digestive Disease Week 2013. Orlando, FL. 18–21 May 2013. 15 PMA credits.

302. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, May 21, 2013.

303. CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, May 28, 2013

304. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, June 4, 2013.

305. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, June 11, 2013.

306. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, June 18, 2013.

307. CME: Liver Club Journal Meeting with DrSohail & Muhammad, San Diego, CA, June 25, 2013.

308. CME: Critical Care Summer Session, Catamaran Hotel, San Diego, CA, 3 Credits, July 25-27, 2013.

309. CME: New and Emerging Strategies to Simplify the Cure of Chronic HCV Infection, Ruth Chris Steakhouse, Walnut Creek, CA; Sponsored by Rush University Medical Center & Gilead Sciences; October 24, 2013, 1 credit.

310. CME: Guest Physician, Educator, GI Tumor Conference, Presented by cCare, St. Agnes Medical Center, Fresno, CA; November 12, 2013. AMA PRA Category 1 credit

311. CME: HEP DART 2013: Frontiers in Drug Development for Viral Hepatitis 6, sponsored by Emory University School of Medicine. Kailua-Kona, Hawaii, December 8-12, 2013.

312. CME Hepatitis B and Reducing Perinatal Transmission: An Overview and Discussion of New Tools, Association of Asian Pacific Community Health Organizations (AAPCHO), Webinar. December 19, 2013. 2 hours.

313. CME: Hepatitis B and Reducing Perinatal Transmission: An Overview and Discussion of

New Tools Confirmation, Association of Asian Pacific Community Health Organiza-tions (AAPCHO) Webinair and Meeting. Thu, Dec 19, 2013. 2 hours.

Curriculum Vitae



314. CME: State of the Art Therapy for HCV, University of Washington, University of Alabama Birmingham, IAS-USA online training module, Funded by a grant from the Centers for Disease Control and Prevention. March 15, 2014

315. CME: New Treatments in Chronic Liver Disease 2014, Scripps Health, La Jolla, CA’ March 29, 2014 - March 30, 2014; 8.00 AMA PRA Category 1™ credits.

316. CME: International Liver Congress 2014, European Association for the Study of the Liver, London. United Kingdom, April 9-13, 2014; 20 hours CME accredited credits.

317. CME: Gastro Cancer Case Conference, Sunrise Medical Center, Las Vegas, NV, 1 hour, 1 AMA PRA Category 1 Credit, March 5, 2014.

318. CME: Gastro Cancer Case Conference, Sunrise Medical Center, Las Vegas, NV, 1 hour, PRA 1 credit, March 19, 2014.

319. CME: Digestive Disease Week (DDW) 2014 Highlights, University of Kansas Medical Center, Overland Park, Kansas, 2.5 hours, 2.5 AMA PRA Category 1 Credits, May 7, 2014.

320. CME: WFA-20 Wilderness First Aid, 20 hours, Wilderness Medicine Outfitters, June 7, 2014. CME: The American Society of Transplant Surgeons & World Transplant Con-gress, Moscone West Convention Center, San Francisco, CA; July 26 - 31, 2014, 31.25 AMA PRA Category 1 Credit(s)

321. CME: “Current Perspectives into the Management of Hepatic Encephalopathy,” Pre-sented by Dr. W. Ray Kim, MD, San Jose, CA; August 4, 2014. 1.5 category 1 CME credits.

322. CME: Public Forum on Redesigning Liver Distribution ", Attendee, Webinar presented by United Network for Organ Sharing (UNOS.org); September 16, 2014.

323. CME: 3rd Annual Current Trends in Liver Disease. Symposium and Gastroenterology Board Review, St. Joseph’s Hospital and Medical Center, Phoenix, AZ; September 26, 2014, 6.25 AMA PRA Category 1 Credits.

324. CME: “HCV Advances”, Catherine Frennette – Speaker, online attendee, www.chroni-cliverdisease.org, November 5, 2014.

325. CME: “Current Perspectives into the Management of Hepatic Encephalopathy,” Pre-sented by Hepatology Centers of Educational Expertise, San Diego, CA, October 27, 2014. 2 hours PRA credit.

326. CME: “3rd Annual Current Trends in Liver Disease and Gastroenterology Board Re-view,” St. Joseph’s Hospital and Medical Center, September 26, 2014, 6.25 AMA PRA Category 1 Credits.

Curriculum Vitae ROBERT G. GISH, M.D. 223 CHARITABLE AND PHILANTHROPIC ACTIVITIES

Contributor, American Association for the Study of Liver Disease Foundation Research Fund. Viral Hepatitis Association Yellow Warriors of the Philippines Vietnam Viral Hepatitis Alliance Asia Pacific Health Foundation Fair Foundation Nationa Viral Hepatitis Roundtable Hepatitis B Foundation

Curriculum Vitae ROBERT G. GISH, M.D. 224 HISTORICAL PRACTICE ADDRESSES and OUTREACH SITES ARIZONA St. Joseph’s Hospital

Director of Liver Transplantation

350 W Thomas Rd, Phoenix, AZ 85013

CALIFORNIA Community Physician's Center Fresno Liver Clinic Clovis, California Enloe Hospital W. 5th & The Esplanade Chico, California 95926 Gould Medical Group 6000 Coffee Road Modesto, CA 95355 Highland Clinic 1411 E. 31st St. Oakland, California 94602 Liver Clinic 2900 Harris Street Eureka, California 95501 McHenry Medical Group 1541 Florida Ave. #200 Modesto, California 95355 Merced Liver Clinic 3605 Hospital Rd. Atwater, California 95301-5173 Oakland East Bay Liver Clinic Doctor’s Medical Building 400 - 30th Street, Suite 200 Oakland, California 94609-3305 Redding Liver Clinic 2225 Court St Redding, California 96001

Sacramento Liver Clinic 1020 29 St. 5th fl #580 Sacramento, California 95816-5119 San Luis Obispo Liver Clinic Pacific Hepatology & Gastroenterology 1250 Peach Street, Suite M San Luis Obispo, California 93401-2877 Santa Cruz Liver Clinic 1595 Soquel Drive, Suite 350 Santa Cruz, California 95065 Santa Rosa Liver Clinic Ukiah Liver Clinic c/o Harold Matossian, M.D. 234 Hospital Drive, A Ukiah, California 95482 Clinical Professor of Medicine Medical Director of Center for Hepatobiliary and Disease and Abdominal Transplantation (CHAT) Chief of Hepatology University of California, School of Medicine San Diego, California Medical Director, Staff Physician Stanford Hospital and Medical Center Stanford, California 94305 NEVADA

Curriculum Vitae


HISTORICAL PRACTICE ADDRESSES and OUTREACH SITES

Desert Gastroenterology 3150 N. Tenaya, Ste. 630 Las Vegas, NV 89128 Digestive Health Associates 5250 Kietzke Lane Reno, NV 89511 Gastroenterology Consultants 880 Ryland Reno, NV 89502 Sunrise Liver Clinic 3006 S Maryland Parkway Las Vegas, Nevada


RESEARCH SUMMARY In his historical roles as Co-Director of the Center for Hepatobiliary Disease and Abdominal Trans-plantation and Chief of Clinical Hepatology, Dr. Gish was both overseeing and personally partici-pating in cutting edge research on viral hepatitis, liver transplant, bio-artificial liver, and liver can-cer. He is currently working to expand clinical trials for a variety of antiviral therapies (including the latest-generation therapies for hepatitis B and for hepatitis C), end-stage liver disease, auto-immune hepatitis, and new bio-artificial liver systems. He was also directing the development of a state-of-the-art biorepository to support future scientific investigation. Under his direction, UCSD researchers are using databases to help uncover associations between liver cancer and certain cancer biomarkers that may ultimately help to guide treatment decisions and choice of therapies. He is currently working toward building a multidisciplinary liver cancer program that will include models of HCC signaling. Dr. Gish has an extensive background in viral hepatitis clinical trials and liver cancer trials, with a quarter century of experience as a clinical investigator on many aspects of liver disease, liver transplant and liver cancer. In addition, Dr. Gish is actively involved, both nationally and internationally, in shaping public policy that relates to liver transplantation and viral hepatitis screening, vaccination, and treatment that should ultimately have an impact on liver cancer rates in the region, nationally and interna-tionally. He recently developed and published a five-year plan for a comprehensive approach to liver disease in Viet Nam, a country that has a very high prevalence of liver disease due to the high prevalence of chronic infection with hepatitis B (12%) and C (at least 2%) along with heavy alcohol consumption by men, but which to date has had no nationwide approach to the disease and no systematic screening of at-risk individuals. The program that Dr. Gish developed in col-laboration with colleagues in Viet Nam, Australia, and the United States includes nationwide ed-ucation for healthcare providers, health educators, and the public; expansion of nationwide screening for hepatitis B and C followed by HBV vaccination or treatment of chronic HBV and/or HCV; education about alcoholic liver disease; long-term surveillance for liver cancer; and reduc-tion of infection transmission related to medical, commercial, and personal re-use of contaminated needles, syringes, sharp instruments, razors, and inadequately sterilized medical equipment. The program has already received the full support of the Vietnamese government and several other countries have now expressed interest in working with Dr. Gish to develop similar programs. He is currently working on development of a liver program for Armenia. Dr. Gish has lectured in China, Viet Nam, and a dozen other countries, and has ongoing long-term research collaborations with colleagues in Australia, Japan, Viet Nam and China. In addition, Dr. Gish is currently working in collaboration with the Asian Pacific Health Foundation on development of a major hepatitis B and C screening program in the greater San Diego area with the goal of ultimately screening at least 10,000 individuals, followed by provision of vaccina-tion and linkage to care, as appropriate. As part of this program, cutting edge research on the use of point-of-care rapid results testing for both hepatitis B and C will be carried out. A unique aspect of this program will be the integration of viral hepatitis screening with broad-based healthcare screening for other disease states such as metabolic syndrome both of which are leading causes of liver cancer.


RESEARCH SUMMARY: Continued Dr. Gish is also involved in important research that could help effect changes in public policy on liver transplant in the United States. His research on the inconsistencies among Regional Review Boards (RRBs) in the assignment of points for MELD/PELD exception patients has shown a large, highly significant regional variation in denial rates for appeals by these patients. This variation gives strong support for replacing the current RRB system with an alternate system, one important possibility for which would be a national review board that would use current clinical knowledge, expertise, peer review literature, expert opinion and data to assign priority on a consistent basis, thus reducing regional inequities and moving toward the goal of equitable allocation of organs and further compliance with the HHS Final Rule.


Role as Director of California Pacific’s Liver Disease Management & Transplant Program

Clinic sites established during my tenure at CPMC 1988 to 2010

Santa Rosa

Modesto

Merced

Fresno

San Luis Obispo

Las Vegas 1 and 2

Chico

Redding

Santa Cruz

RenoUkiah


Disclosures

(Updated March 2013)

PHARMACEUTICAL COMPANY RELATIONSHIPS

Dr. Robert Gish: Financial Disclosure relative to the pharmaceutical industry up to cur-rent for the last 2 years. Robert Gish, MD, has a financial interest/relationship or affilia-tion in the form of:

Grants/Research Support, Bristol-Myers Squibb Company, Gilead, Polairs. Directed to funds at UCSD until August of 2013

Payments from selected companies are directed Dr Gish’s LLC and his research and global policy programs. Dr. Gish has performed as Consultant and/or Advisor to (in the last two years): Bayer AG, Bristol-Myers Squibb Company, Hoffmann-LaRoche Ltd., Genentech, Gil-

ead Sciences, Onyx, Janssen. Consultant Payments are made directly to Dr Gish: Abbott, Merck, Arrowhead, Isis Pharmaceuticals, Janssen Advisory Board: Isis, Janssen, Genentech Chair Clinical Advisory Board: Arrowhead: Chair of CAB

SPEAKERS BUREAU

These speaker bureau activities focus on HBV, HCV, and liver cancer; specifically, epi-demiology, diagnosis, and treatment. In addition, program presentations on vaccination for HBV and management of complications of cirrhosis. Dr. Gish has an active speakers contract to do promotional talks for Bayer, Gilead Sci-ences Inc., AbbVie, Onyx, Salix, Minor Stock Shareholder – Kinex, Arrowhead (options) Other Financial Support or Material Support – None Full details of all Research Grant Support – See CV Leadership Position, Other than Employment other than at St Josephs Hospital and Med-ical Center and Stanford University – None Expert Testimony for Pharma, patent cases, IP– BMS, ICN Other Remuneration from Pharma – None

DSMB: Tekmira 2011 – 2013 DSMB: Novira 2013 - 2014

Date post:	26-Dec-2015
Category:	Documents
Upload:	robert-g-gish-md
View:	171 times
Download:	0 times

Robert G. Gish, MD Full Curriculum Vitae & Biography - Updated January 2015

Documents